id	sid	tid	token	lemma	pos
admet-331	1	1	manuscript	manuscript	PROPN
admet-331	1	2	doi	doi	PROPN
admet-331	1	3	:	:	PUNCT
admet-331	1	4	10.5599	10.5599	NUM
admet-331	1	5	/	/	SYM
admet-331	1	6	admet.4.4.331	admet.4.4.331	PROPN
admet-331	1	7	280	280	NUM
admet-331	1	8	admet	admet	X
admet-331	1	9	&	&	CCONJ
admet-331	1	10	dmpk	dmpk	PROPN
admet-331	1	11	4(4	4(4	NUM
admet-331	1	12	)	)	PUNCT
admet-331	1	13	(	(	PUNCT
admet-331	1	14	2016	2016	NUM
admet-331	1	15	)	)	PUNCT
admet-331	1	16	280	280	NUM
admet-331	1	17	-	-	SYM
admet-331	1	18	301	301	NUM
admet-331	1	19	;	;	PUNCT
admet-331	1	20	doi	doi	NOUN
admet-331	1	21	:	:	PUNCT
admet-331	1	22	10.5599	10.5599	NUM
admet-331	1	23	/	/	SYM
admet-331	1	24	admet.4.4.331	admet.4.4.331	CCONJ
admet-331	1	25	open	open	ADJ
admet-331	1	26	access	access	NOUN
admet-331	1	27	:	:	PUNCT
admet-331	1	28	issn	issn	PROPN
admet-331	1	29	:	:	PUNCT
admet-331	1	30	1848	1848	NUM
admet-331	1	31	-	-	SYM
admet-331	1	32	7718	7718	NUM
admet-331	1	33	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-331	1	34	review	review	NOUN
admet-331	1	35	rock	rock	NOUN
admet-331	1	36	inhibitors	inhibitor	NOUN
admet-331	1	37	in	in	ADP
admet-331	1	38	ocular	ocular	ADJ
admet-331	1	39	disease	disease	NOUN
admet-331	1	40	éva	éva	NOUN
admet-331	1	41	halász	halász	NOUN
admet-331	1	42	,	,	PUNCT
admet-331	1	43	ellen	ellen	PROPN
admet-331	1	44	townes	townes	PROPN
admet-331	1	45	-	-	PUNCT
admet-331	1	46	anderson	anderson	PROPN
admet-331	1	47	*	*	PROPN
admet-331	1	48	rutgers	rutgers	PROPN
admet-331	1	49	new	new	PROPN
admet-331	1	50	jersey	jersey	PROPN
admet-331	1	51	medical	medical	PROPN
admet-331	1	52	school	school	PROPN
admet-331	1	53	,	,	PUNCT
admet-331	1	54	department	department	NOUN
admet-331	1	55	of	of	ADP
admet-331	1	56	pharmacology	pharmacology	NOUN
admet-331	1	57	,	,	PUNCT
admet-331	1	58	physiology	physiology	NOUN
admet-331	1	59	and	and	CCONJ
admet-331	1	60	neuroscience	neuroscience	NOUN
admet-331	1	61	,	,	PUNCT
admet-331	1	62	185	185	NUM
admet-331	1	63	.	.	PUNCT
admet-331	2	1	s.	s.	PROPN
admet-331	2	2	orange	orange	PROPN
admet-331	2	3	ave	ave	PROPN
admet-331	2	4	,	,	PUNCT
admet-331	2	5	newark	newark	PROPN
admet-331	2	6	,	,	PUNCT
admet-331	2	7	new	new	PROPN
admet-331	2	8	jersey	jersey	PROPN
admet-331	2	9	,	,	PUNCT
admet-331	2	10	07103	07103	NUM
admet-331	2	11	*	*	PUNCT
admet-331	2	12	ellen	ellen	PROPN
admet-331	2	13	townes	townes	PROPN
admet-331	2	14	-	-	PUNCT
admet-331	2	15	anderson	anderson	PROPN
admet-331	2	16	:	:	PUNCT
admet-331	2	17	e	e	X
admet-331	2	18	-	-	NOUN
admet-331	2	19	mail	mail	NOUN
admet-331	2	20	:	:	PUNCT
admet-331	2	21	andersel@njms.rutgers.edu	andersel@njms.rutgers.edu	PROPN
admet-331	2	22	;	;	PUNCT
admet-331	2	23	tel	tel	PROPN
admet-331	2	24	.	.	PUNCT
admet-331	2	25	:	:	PUNCT
admet-331	3	1	+1	+1	PROPN
admet-331	3	2	-	-	PUNCT
admet-331	3	3	973	973	NUM
admet-331	3	4	-	-	PUNCT
admet-331	3	5	972	972	NUM
admet-331	3	6	-	-	PUNCT
admet-331	3	7	7392	7392	NUM
admet-331	3	8	;	;	PUNCT
admet-331	3	9	fax	fax	NOUN
admet-331	3	10	:	:	PUNCT
admet-331	3	11	+1	+1	PROPN
admet-331	3	12	-	-	PUNCT
admet-331	3	13	973	973	NUM
admet-331	3	14	-	-	PUNCT
admet-331	3	15	972	972	NUM
admet-331	3	16	-	-	SYM
admet-331	3	17	5059	5059	NUM
admet-331	3	18	received	receive	VERB
admet-331	3	19	:	:	PUNCT
admet-331	3	20	july	july	PROPN
admet-331	3	21	29	29	NUM
admet-331	3	22	,	,	PUNCT
admet-331	3	23	2016	2016	NUM
admet-331	3	24	;	;	PUNCT
admet-331	3	25	revised	revise	VERB
admet-331	3	26	:	:	PUNCT
admet-331	3	27	november	november	PROPN
admet-331	3	28	30	30	NUM
admet-331	3	29	,	,	PUNCT
admet-331	3	30	2016	2016	NUM
admet-331	3	31	;	;	PUNCT
admet-331	3	32	published	publish	VERB
admet-331	3	33	:	:	PUNCT
admet-331	3	34	december	december	PROPN
admet-331	3	35	26	26	NUM
admet-331	3	36	,	,	PUNCT
admet-331	3	37	2016	2016	NUM
admet-331	3	38	abstract	abstract	ADJ
admet-331	3	39	rho	rho	ADJ
admet-331	3	40	kinases	kinase	NOUN
admet-331	3	41	(	(	PUNCT
admet-331	3	42	rocks	rock	NOUN
admet-331	3	43	)	)	PUNCT
admet-331	3	44	have	have	VERB
admet-331	3	45	a	a	DET
admet-331	3	46	crucial	crucial	ADJ
admet-331	3	47	role	role	NOUN
admet-331	3	48	in	in	ADP
admet-331	3	49	actin	actin	NOUN
admet-331	3	50	-	-	PUNCT
admet-331	3	51	cytoskeletal	cytoskeletal	ADJ
admet-331	3	52	reorganization	reorganization	NOUN
admet-331	3	53	and	and	CCONJ
admet-331	3	54	thus	thus	ADV
admet-331	3	55	are	be	AUX
admet-331	3	56	involved	involve	VERB
admet-331	3	57	in	in	ADP
admet-331	3	58	broad	broad	ADJ
admet-331	3	59	aspects	aspect	NOUN
admet-331	3	60	of	of	ADP
admet-331	3	61	cell	cell	NOUN
admet-331	3	62	motility	motility	NOUN
admet-331	3	63	,	,	PUNCT
admet-331	3	64	from	from	ADP
admet-331	3	65	smooth	smooth	ADJ
admet-331	3	66	muscle	muscle	NOUN
admet-331	3	67	contraction	contraction	NOUN
admet-331	3	68	to	to	PART
admet-331	3	69	neurite	neurite	VERB
admet-331	3	70	outgrowth	outgrowth	NOUN
admet-331	3	71	.	.	PUNCT
admet-331	4	1	the	the	DET
admet-331	4	2	first	first	ADJ
admet-331	4	3	marketed	market	VERB
admet-331	4	4	rock	rock	NOUN
admet-331	4	5	inhibitor	inhibitor	NOUN
admet-331	4	6	,	,	PUNCT
admet-331	4	7	called	call	VERB
admet-331	4	8	fasudil	fasudil	NOUN
admet-331	4	9	,	,	PUNCT
admet-331	4	10	has	have	AUX
admet-331	4	11	been	be	AUX
admet-331	4	12	used	use	VERB
admet-331	4	13	safely	safely	ADV
admet-331	4	14	for	for	ADP
admet-331	4	15	treatment	treatment	NOUN
admet-331	4	16	of	of	ADP
admet-331	4	17	cerebral	cerebral	ADJ
admet-331	4	18	vasospasm	vasospasm	NOUN
admet-331	4	19	since	since	SCONJ
admet-331	4	20	1995	1995	NUM
admet-331	4	21	in	in	ADP
admet-331	4	22	japan	japan	PROPN
admet-331	4	23	.	.	PUNCT
admet-331	5	1	during	during	ADP
admet-331	5	2	the	the	DET
admet-331	5	3	succeeding	succeed	VERB
admet-331	5	4	decades	decade	NOUN
admet-331	5	5	rock	rock	NOUN
admet-331	5	6	inhibitors	inhibitor	NOUN
admet-331	5	7	have	have	AUX
admet-331	5	8	been	be	AUX
admet-331	5	9	applied	apply	VERB
admet-331	5	10	in	in	ADP
admet-331	5	11	many	many	ADJ
admet-331	5	12	pathological	pathological	ADJ
admet-331	5	13	conditions	condition	NOUN
admet-331	5	14	from	from	ADP
admet-331	5	15	central	central	ADJ
admet-331	5	16	nervous	nervous	ADJ
admet-331	5	17	system	system	NOUN
admet-331	5	18	disorders	disorder	NOUN
admet-331	5	19	to	to	ADP
admet-331	5	20	cardiovascular	cardiovascular	ADJ
admet-331	5	21	disease	disease	NOUN
admet-331	5	22	as	as	ADP
admet-331	5	23	potential	potential	ADJ
admet-331	5	24	therapeutic	therapeutic	ADJ
admet-331	5	25	agents	agent	NOUN
admet-331	5	26	or	or	CCONJ
admet-331	5	27	experimental	experimental	ADJ
admet-331	5	28	tools	tool	NOUN
admet-331	5	29	to	to	PART
admet-331	5	30	help	help	VERB
admet-331	5	31	understand	understand	VERB
admet-331	5	32	the	the	DET
admet-331	5	33	underlying	underlying	ADJ
admet-331	5	34	(	(	PUNCT
admet-331	5	35	patho)mechanisms	patho)mechanism	NOUN
admet-331	5	36	.	.	PUNCT
admet-331	6	1	in	in	ADP
admet-331	6	2	2014	2014	NUM
admet-331	6	3	,	,	PUNCT
admet-331	6	4	a	a	DET
admet-331	6	5	fasudil	fasudil	NOUN
admet-331	6	6	derivate	derivate	NOUN
admet-331	6	7	named	name	VERB
admet-331	6	8	ripasudil	ripasudil	NOUN
admet-331	6	9	was	be	AUX
admet-331	6	10	accepted	accept	VERB
admet-331	6	11	for	for	ADP
admet-331	6	12	clinical	clinical	ADJ
admet-331	6	13	use	use	NOUN
admet-331	6	14	in	in	ADP
admet-331	6	15	glaucoma	glaucoma	NOUN
admet-331	6	16	and	and	CCONJ
admet-331	6	17	ocular	ocular	ADJ
admet-331	6	18	hypertension	hypertension	NOUN
admet-331	6	19	.	.	PUNCT
admet-331	7	1	since	since	SCONJ
admet-331	7	2	rock	rock	NOUN
admet-331	7	3	kinases	kinase	NOUN
admet-331	7	4	are	be	AUX
admet-331	7	5	widely	widely	ADV
admet-331	7	6	expressed	express	VERB
admet-331	7	7	in	in	ADP
admet-331	7	8	ocular	ocular	ADJ
admet-331	7	9	tissues	tissue	NOUN
admet-331	7	10	,	,	PUNCT
admet-331	7	11	they	they	PRON
admet-331	7	12	have	have	AUX
admet-331	7	13	been	be	AUX
admet-331	7	14	implicated	implicate	VERB
admet-331	7	15	in	in	ADP
admet-331	7	16	the	the	DET
admet-331	7	17	pathology	pathology	NOUN
admet-331	7	18	of	of	ADP
admet-331	7	19	many	many	ADJ
admet-331	7	20	ocular	ocular	ADJ
admet-331	7	21	conditions	condition	NOUN
admet-331	7	22	such	such	ADJ
admet-331	7	23	as	as	ADP
admet-331	7	24	corneal	corneal	ADJ
admet-331	7	25	dysfunction	dysfunction	NOUN
admet-331	7	26	,	,	PUNCT
admet-331	7	27	glaucoma	glaucoma	NOUN
admet-331	7	28	,	,	PUNCT
admet-331	7	29	cataract	cataract	NOUN
admet-331	7	30	,	,	PUNCT
admet-331	7	31	diabetic	diabetic	ADJ
admet-331	7	32	retinopathy	retinopathy	NOUN
admet-331	7	33	,	,	PUNCT
admet-331	7	34	age	age	NOUN
admet-331	7	35	-	-	PUNCT
admet-331	7	36	related	relate	VERB
admet-331	7	37	macular	macular	ADJ
admet-331	7	38	degeneration	degeneration	NOUN
admet-331	7	39	,	,	PUNCT
admet-331	7	40	and	and	CCONJ
admet-331	7	41	retinal	retinal	ADJ
admet-331	7	42	detachment	detachment	NOUN
admet-331	7	43	.	.	PUNCT
admet-331	8	1	this	this	DET
admet-331	8	2	paper	paper	NOUN
admet-331	8	3	aims	aim	VERB
admet-331	8	4	to	to	PART
admet-331	8	5	provide	provide	VERB
admet-331	8	6	an	an	DET
admet-331	8	7	overview	overview	NOUN
admet-331	8	8	of	of	ADP
admet-331	8	9	the	the	DET
admet-331	8	10	most	most	ADV
admet-331	8	11	recent	recent	ADJ
admet-331	8	12	status	status	NOUN
admet-331	8	13	/	/	SYM
admet-331	8	14	application	application	NOUN
admet-331	8	15	of	of	ADP
admet-331	8	16	rock	rock	NOUN
admet-331	8	17	inhibitors	inhibitor	NOUN
admet-331	8	18	in	in	ADP
admet-331	8	19	the	the	DET
admet-331	8	20	field	field	NOUN
admet-331	8	21	of	of	ADP
admet-331	8	22	eye	eye	NOUN
admet-331	8	23	disease	disease	NOUN
admet-331	8	24	.	.	PUNCT
admet-331	9	1	keywords	keyword	NOUN
admet-331	9	2	rho	rho	ADJ
admet-331	9	3	kinase	kinase	NOUN
admet-331	9	4	;	;	PUNCT
admet-331	9	5	corneal	corneal	ADJ
admet-331	9	6	endothelial	endothelial	ADJ
admet-331	9	7	wound	wound	NOUN
admet-331	9	8	healing	healing	NOUN
admet-331	9	9	;	;	PUNCT
admet-331	9	10	glaucoma	glaucoma	NOUN
admet-331	9	11	;	;	PUNCT
admet-331	9	12	diabetic	diabetic	ADJ
admet-331	9	13	retinopathy	retinopathy	NOUN
admet-331	9	14	;	;	PUNCT
admet-331	9	15	retinal	retinal	ADJ
admet-331	9	16	detachment	detachment	NOUN
admet-331	9	17	introduction	introduction	NOUN
admet-331	9	18	in	in	ADP
admet-331	9	19	the	the	DET
admet-331	9	20	past	past	ADJ
admet-331	9	21	few	few	ADJ
admet-331	9	22	years	year	NOUN
admet-331	9	23	,	,	PUNCT
admet-331	9	24	rock	rock	NOUN
admet-331	9	25	inhibitors	inhibitor	NOUN
admet-331	9	26	have	have	AUX
admet-331	9	27	undergone	undergo	VERB
admet-331	9	28	considerable	considerable	ADJ
admet-331	9	29	structural	structural	ADJ
admet-331	9	30	,	,	PUNCT
admet-331	9	31	physico	physico	NOUN
admet-331	9	32	-	-	PUNCT
admet-331	9	33	chemical	chemical	NOUN
admet-331	9	34	and	and	CCONJ
admet-331	9	35	pharmacokinetic	pharmacokinetic	ADJ
admet-331	9	36	development	development	NOUN
admet-331	9	37	.	.	PUNCT
admet-331	10	1	a	a	DET
admet-331	10	2	summary	summary	NOUN
admet-331	10	3	from	from	ADP
admet-331	10	4	last	last	ADJ
admet-331	10	5	year	year	NOUN
admet-331	10	6	listed	list	VERB
admet-331	10	7	more	more	ADJ
admet-331	10	8	than	than	ADP
admet-331	10	9	170	170	NUM
admet-331	10	10	different	different	ADJ
admet-331	10	11	compounds	compound	NOUN
admet-331	10	12	used	use	VERB
admet-331	10	13	in	in	ADP
admet-331	10	14	various	various	ADJ
admet-331	10	15	research	research	NOUN
admet-331	10	16	areas	area	NOUN
admet-331	10	17	from	from	ADP
admet-331	10	18	cancer	cancer	NOUN
admet-331	10	19	to	to	ADP
admet-331	10	20	respiratory	respiratory	ADJ
admet-331	10	21	disease	disease	NOUN
admet-331	10	22	[	[	X
admet-331	10	23	1	1	NUM
admet-331	10	24	]	]	PUNCT
admet-331	10	25	,	,	PUNCT
admet-331	10	26	and	and	CCONJ
admet-331	10	27	since	since	SCONJ
admet-331	10	28	then	then	ADV
admet-331	10	29	the	the	DET
admet-331	10	30	number	number	NOUN
admet-331	10	31	of	of	ADP
admet-331	10	32	substances	substance	NOUN
admet-331	10	33	has	have	AUX
admet-331	10	34	only	only	ADV
admet-331	10	35	increased	increase	VERB
admet-331	10	36	.	.	PUNCT
admet-331	11	1	in	in	ADP
admet-331	11	2	the	the	DET
admet-331	11	3	case	case	NOUN
admet-331	11	4	of	of	ADP
admet-331	11	5	ocular	ocular	ADJ
admet-331	11	6	disease	disease	NOUN
admet-331	11	7	,	,	PUNCT
admet-331	11	8	ripasudil	ripasudil	PROPN
admet-331	11	9	was	be	AUX
admet-331	11	10	approved	approve	VERB
admet-331	11	11	in	in	ADP
admet-331	11	12	2014	2014	NUM
admet-331	11	13	for	for	ADP
admet-331	11	14	the	the	DET
admet-331	11	15	treatment	treatment	NOUN
admet-331	11	16	of	of	ADP
admet-331	11	17	glaucoma	glaucoma	NOUN
admet-331	11	18	and	and	CCONJ
admet-331	11	19	ocular	ocular	ADJ
admet-331	11	20	hypertension	hypertension	NOUN
admet-331	11	21	(	(	PUNCT
admet-331	11	22	oht	oht	PROPN
admet-331	11	23	)	)	PUNCT
admet-331	12	1	[	[	X
admet-331	12	2	2	2	NUM
admet-331	12	3	]	]	PUNCT
admet-331	12	4	.	.	PUNCT
admet-331	13	1	there	there	PRON
admet-331	13	2	are	be	VERB
admet-331	13	3	other	other	ADJ
admet-331	13	4	promising	promising	ADJ
admet-331	13	5	candidates	candidate	NOUN
admet-331	13	6	for	for	ADP
admet-331	13	7	ocular	ocular	ADJ
admet-331	13	8	disease	disease	NOUN
admet-331	13	9	in	in	ADP
admet-331	13	10	phase	phase	NOUN
admet-331	13	11	ii	ii	NOUN
admet-331	13	12	or	or	CCONJ
admet-331	13	13	phase	phase	VERB
admet-331	13	14	iii	iii	NUM
admet-331	13	15	clinical	clinical	ADJ
admet-331	13	16	trials	trial	NOUN
admet-331	13	17	;	;	PUNCT
admet-331	13	18	however	however	ADV
admet-331	13	19	,	,	PUNCT
admet-331	13	20	a	a	DET
admet-331	13	21	number	number	NOUN
admet-331	13	22	of	of	ADP
admet-331	13	23	drugs	drug	NOUN
admet-331	13	24	have	have	AUX
admet-331	13	25	also	also	ADV
admet-331	13	26	already	already	ADV
admet-331	13	27	failed	fail	VERB
admet-331	13	28	[	[	X
admet-331	13	29	1,3	1,3	NUM
admet-331	13	30	]	]	X
admet-331	13	31	(	(	PUNCT
admet-331	13	32	see	see	VERB
admet-331	13	33	table	table	NOUN
admet-331	13	34	1	1	NUM
admet-331	13	35	)	)	PUNCT
admet-331	13	36	.	.	PUNCT
admet-331	14	1	most	most	ADJ
admet-331	14	2	rock	rock	NOUN
admet-331	14	3	inhibitors	inhibitor	NOUN
admet-331	14	4	target	target	VERB
admet-331	14	5	the	the	DET
admet-331	14	6	atp	atp	NOUN
admet-331	14	7	-	-	PUNCT
admet-331	14	8	binding	bind	VERB
admet-331	14	9	site	site	NOUN
admet-331	14	10	of	of	ADP
admet-331	14	11	the	the	DET
admet-331	14	12	kinase	kinase	NOUN
admet-331	14	13	in	in	ADP
admet-331	14	14	its	its	PRON
admet-331	14	15	active	active	ADJ
admet-331	14	16	conformation	conformation	NOUN
admet-331	14	17	and	and	CCONJ
admet-331	14	18	thereby	thereby	ADV
admet-331	14	19	reversibly	reversibly	ADV
admet-331	14	20	compete	compete	VERB
admet-331	14	21	with	with	ADP
admet-331	14	22	atp	atp	PROPN
admet-331	14	23	[	[	X
admet-331	14	24	4	4	NUM
admet-331	14	25	]	]	PUNCT
admet-331	14	26	.	.	PUNCT
admet-331	15	1	the	the	DET
admet-331	15	2	classic	classic	ADJ
admet-331	15	3	rock	rock	NOUN
admet-331	15	4	inhibitors	inhibitor	NOUN
admet-331	15	5	are	be	AUX
admet-331	15	6	isoquinoline	isoquinoline	ADJ
admet-331	15	7	-	-	PUNCT
admet-331	15	8	derived	derive	VERB
admet-331	15	9	fasudil	fasudil	NOUN
admet-331	15	10	or	or	CCONJ
admet-331	15	11	pyridinebased	pyridinebase	VERB
admet-331	15	12	y27632	y27632	PROPN
admet-331	15	13	or	or	CCONJ
admet-331	15	14	y39983	y39983	PROPN
admet-331	15	15	.	.	PUNCT
admet-331	16	1	fasudil	fasudil	PROPN
admet-331	16	2	’s	’s	PART
admet-331	16	3	specificity	specificity	NOUN
admet-331	16	4	for	for	ADP
admet-331	16	5	rock	rock	NOUN
admet-331	16	6	was	be	AUX
admet-331	16	7	reported	report	VERB
admet-331	16	8	to	to	PART
admet-331	16	9	be	be	AUX
admet-331	16	10	less	less	ADJ
admet-331	16	11	than	than	ADP
admet-331	16	12	y27632	y27632	PROPN
admet-331	16	13	,	,	PUNCT
admet-331	16	14	however	however	ADV
admet-331	16	15	both	both	DET
admet-331	16	16	compounds	compound	NOUN
admet-331	16	17	also	also	ADV
admet-331	16	18	inhibit	inhibit	VERB
admet-331	16	19	other	other	ADJ
admet-331	16	20	kinases	kinase	NOUN
admet-331	16	21	including	include	VERB
admet-331	16	22	protein	protein	NOUN
admet-331	16	23	kinase	kinase	PROPN
admet-331	16	24	c	c	X
admet-331	16	25	,	,	PUNCT
admet-331	16	26	protein	protein	NOUN
admet-331	16	27	kinase	kinase	NOUN
admet-331	16	28	a	a	PRON
admet-331	16	29	,	,	PUNCT
admet-331	16	30	and	and	CCONJ
admet-331	16	31	myosin	myosin	PROPN
admet-331	16	32	light	light	PROPN
admet-331	16	33	chain	chain	PROPN
admet-331	16	34	kinase	kinase	PROPN
admet-331	16	35	(	(	PUNCT
admet-331	16	36	mlck	mlck	NOUN
admet-331	16	37	)	)	PUNCT
admet-331	17	1	[	[	X
admet-331	17	2	5	5	NUM
admet-331	17	3	]	]	PUNCT
admet-331	17	4	.	.	PUNCT
admet-331	18	1	because	because	SCONJ
admet-331	18	2	of	of	ADP
admet-331	18	3	these	these	DET
admet-331	18	4	broader	broad	ADJ
admet-331	18	5	interactions	interaction	NOUN
admet-331	18	6	,	,	PUNCT
admet-331	18	7	and	and	CCONJ
admet-331	18	8	especially	especially	ADV
admet-331	18	9	in	in	ADP
admet-331	18	10	the	the	DET
admet-331	18	11	case	case	NOUN
admet-331	18	12	of	of	ADP
admet-331	18	13	in	in	ADP
admet-331	18	14	vivo	vivo	ADJ
admet-331	18	15	studies	study	NOUN
admet-331	18	16	using	use	VERB
admet-331	18	17	higher	high	ADJ
admet-331	18	18	concentrations	concentration	NOUN
admet-331	18	19	,	,	PUNCT
admet-331	18	20	it	it	PRON
admet-331	18	21	is	be	AUX
admet-331	18	22	not	not	PART
admet-331	18	23	always	always	ADV
admet-331	18	24	possible	possible	ADJ
admet-331	18	25	to	to	PART
admet-331	18	26	determine	determine	VERB
admet-331	18	27	whether	whether	SCONJ
admet-331	18	28	the	the	DET
admet-331	18	29	results	result	NOUN
admet-331	18	30	obtained	obtain	VERB
admet-331	18	31	are	be	AUX
admet-331	18	32	due	due	ADJ
admet-331	18	33	to	to	ADP
admet-331	18	34	the	the	DET
admet-331	18	35	on	on	ADP
admet-331	18	36	-	-	PUNCT
admet-331	18	37	target	target	NOUN
admet-331	18	38	or	or	CCONJ
admet-331	18	39	the	the	DET
admet-331	18	40	off	off	ADJ
admet-331	18	41	-	-	PUNCT
admet-331	18	42	target	target	NOUN
admet-331	18	43	effects	effect	NOUN
admet-331	18	44	.	.	PUNCT
admet-331	19	1	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-331	19	2	mailto:andersel@njms.rutgers.edu	mailto:andersel@njms.rutgers.edu	PROPN
admet-331	19	3	admet	admet	PROPN
admet-331	19	4	&	&	CCONJ
admet-331	19	5	dmpk	dmpk	PROPN
admet-331	19	6	4(4	4(4	NUM
admet-331	19	7	)	)	PUNCT
admet-331	19	8	(	(	PUNCT
admet-331	19	9	2016	2016	NUM
admet-331	19	10	)	)	PUNCT
admet-331	19	11	280	280	NUM
admet-331	19	12	-	-	SYM
admet-331	19	13	301	301	NUM
admet-331	19	14	rock	rock	NOUN
admet-331	19	15	inhibitors	inhibitor	NOUN
admet-331	19	16	in	in	ADP
admet-331	19	17	ocular	ocular	ADJ
admet-331	19	18	disease	disease	NOUN
admet-331	19	19	doi	doi	NOUN
admet-331	19	20	:	:	PUNCT
admet-331	19	21	10.5599	10.5599	NUM
admet-331	19	22	/	/	SYM
admet-331	19	23	admet.4.4.331	admet.4.4.331	PROPN
admet-331	19	24	281	281	NUM
admet-331	19	25	table	table	NOUN
admet-331	19	26	1	1	NUM
admet-331	19	27	.	.	PUNCT
admet-331	19	28	potential	potential	ADJ
admet-331	19	29	rock	rock	NOUN
admet-331	19	30	inhibitors	inhibitor	NOUN
admet-331	19	31	for	for	ADP
admet-331	19	32	human	human	ADJ
admet-331	19	33	ocular	ocular	ADJ
admet-331	19	34	disease	disease	NOUN
admet-331	19	35	(	(	PUNCT
admet-331	19	36	n	n	CCONJ
admet-331	19	37	/	/	SYM
admet-331	19	38	a	a	PRON
admet-331	19	39	:	:	PUNCT
admet-331	19	40	not	not	PART
admet-331	19	41	available	available	ADJ
admet-331	19	42	)	)	PUNCT
admet-331	19	43	.	.	PUNCT
admet-331	20	1	compound	compound	NOUN
admet-331	20	2	synonyms	synonym	NOUN
admet-331	20	3	structure	structure	NOUN
admet-331	20	4	company	company	NOUN
admet-331	20	5	ic50	ic50	PROPN
admet-331	20	6	values	value	NOUN
admet-331	20	7	and	and	CCONJ
admet-331	20	8	[	[	X
admet-331	20	9	ref	ref	NOUN
admet-331	20	10	.	.	PUNCT
admet-331	20	11	]	]	X
admet-331	21	1	therapeutic	therapeutic	ADJ
admet-331	21	2	application	application	NOUN
admet-331	21	3	clinical	clinical	ADJ
admet-331	21	4	trials	trial	NOUN
admet-331	21	5	fasudil	fasudil	PROPN
admet-331	21	6	*	*	PROPN
admet-331	21	7	ha-1077	ha-1077	PROPN
admet-331	21	8	asahi	asahi	PROPN
admet-331	21	9	kasei	kasei	PROPN
admet-331	21	10	rock	rock	PROPN
admet-331	21	11	i	i	PROPN
admet-331	21	12	:	:	PUNCT
admet-331	21	13	330	330	NUM
admet-331	21	14	nm	nm	NOUN
admet-331	21	15	[	[	X
admet-331	21	16	5	5	NUM
admet-331	21	17	]	]	X
admet-331	21	18	rock	rock	PROPN
admet-331	21	19	ii	ii	PROPN
admet-331	21	20	:	:	PUNCT
admet-331	21	21	330	330	NUM
admet-331	21	22	nm	nm	NOUN
admet-331	21	23	[	[	X
admet-331	21	24	1	1	NUM
admet-331	21	25	]	]	X
admet-331	21	26	cerebral	cerebral	ADJ
admet-331	21	27	vasospasm	vasospasm	NOUN
admet-331	21	28	approved	approve	VERB
admet-331	21	29	(	(	PUNCT
admet-331	21	30	china	china	PROPN
admet-331	21	31	,	,	PUNCT
admet-331	21	32	japan	japan	PROPN
admet-331	21	33	)	)	PUNCT
admet-331	21	34	raynaud	raynaud	PROPN
admet-331	21	35	syndrome	syndrome	PROPN
admet-331	21	36	;	;	PUNCT
admet-331	21	37	scleroderma	scleroderma	NOUN
admet-331	21	38	phase	phase	NOUN
admet-331	21	39	iii	iii	PROPN
admet-331	21	40	(	(	PUNCT
admet-331	21	41	nct00498615	nct00498615	NOUN
admet-331	21	42	)	)	PUNCT
admet-331	21	43	atherosclerosis	atherosclerosis	NOUN
admet-331	21	44	hypercholesterolemia	hypercholesterolemia	NOUN
admet-331	21	45	phase	phase	NOUN
admet-331	21	46	ii	ii	PROPN
admet-331	21	47	(	(	PUNCT
admet-331	21	48	nct00120718	nct00120718	ADJ
admet-331	21	49	)	)	PUNCT
admet-331	21	50	amyotrophic	amyotrophic	ADJ
admet-331	21	51	lateral	lateral	ADJ
admet-331	21	52	sclerosis	sclerosis	NOUN
admet-331	21	53	phase	phase	NOUN
admet-331	21	54	ii	ii	PROPN
admet-331	21	55	(	(	PUNCT
admet-331	21	56	nct01935518	nct01935518	ADJ
admet-331	21	57	)	)	PUNCT
admet-331	21	58	diabetic	diabetic	ADJ
admet-331	21	59	macular	macular	ADJ
admet-331	21	60	edema	edema	NOUN
admet-331	21	61	phase	phase	NOUN
admet-331	21	62	iii	iii	PROPN
admet-331	21	63	(	(	PUNCT
admet-331	21	64	nct01823081	nct01823081	NOUN
admet-331	21	65	)	)	PUNCT
admet-331	21	66	ripasudil	ripasudil	PROPN
admet-331	21	67	*	*	PROPN
admet-331	21	68	k-115	k-115	PROPN
admet-331	21	69	kowa	kowa	PROPN
admet-331	21	70	company	company	PROPN
admet-331	21	71	rock	rock	NOUN
admet-331	22	1	i	i	PRON
admet-331	22	2	:	:	PUNCT
admet-331	22	3	51	51	NUM
admet-331	22	4	nm	nm	NOUN
admet-331	23	1	[	[	X
admet-331	23	2	6	6	NUM
admet-331	23	3	]	]	X
admet-331	23	4	rock	rock	PROPN
admet-331	23	5	ii	ii	PROPN
admet-331	23	6	:	:	PUNCT
admet-331	23	7	19	19	NUM
admet-331	23	8	nm	nm	NOUN
admet-331	23	9	[	[	X
admet-331	23	10	6	6	NUM
admet-331	23	11	]	]	PUNCT
admet-331	23	12	glaucoma	glaucoma	NOUN
admet-331	23	13	approved	approve	VERB
admet-331	23	14	(	(	PUNCT
admet-331	23	15	japan	japan	PROPN
admet-331	23	16	)	)	PUNCT
admet-331	23	17	diabetic	diabetic	ADJ
admet-331	23	18	retinopathy	retinopathy	ADJ
admet-331	23	19	phase	phase	NOUN
admet-331	23	20	ii	ii	PROPN
admet-331	23	21	(	(	PUNCT
admet-331	23	22	japan	japan	PROPN
admet-331	23	23	,	,	PUNCT
admet-331	23	24	cti:142456	cti:142456	NOUN
admet-331	23	25	)	)	PUNCT
admet-331	23	26	chronic	chronic	ADJ
admet-331	23	27	obstructive	obstructive	ADJ
admet-331	23	28	pulmonary	pulmonary	ADJ
admet-331	23	29	disease	disease	NOUN
admet-331	23	30	(	(	PUNCT
admet-331	23	31	nct02219360	nct02219360	PROPN
admet-331	23	32	)	)	PUNCT
admet-331	23	33	y27632	y27632	PROPN
admet-331	23	34	*	*	PROPN
admet-331	23	35	university	university	PROPN
admet-331	23	36	of	of	ADP
admet-331	23	37	kyoto	kyoto	PROPN
admet-331	23	38	rock	rock	PROPN
admet-331	23	39	i	i	PRON
admet-331	23	40	:	:	PUNCT
admet-331	23	41	140	140	NUM
admet-331	23	42	nm	nm	NOUN
admet-331	23	43	[	[	X
admet-331	23	44	5	5	NUM
admet-331	23	45	]	]	X
admet-331	23	46	rock	rock	PROPN
admet-331	23	47	ii	ii	PROPN
admet-331	23	48	:	:	PUNCT
admet-331	23	49	54	54	NUM
admet-331	23	50	nm	nm	NOUN
admet-331	23	51	[	[	X
admet-331	23	52	8	8	NUM
admet-331	23	53	]	]	X
admet-331	23	54	corneal	corneal	ADJ
admet-331	23	55	endothelial	endothelial	ADJ
admet-331	23	56	disorders	disorder	NOUN
admet-331	23	57	phase	phase	NOUN
admet-331	23	58	i	i	PRON
admet-331	23	59	/	/	SYM
admet-331	23	60	ii	ii	PROPN
admet-331	23	61	(	(	PUNCT
admet-331	23	62	japan	japan	PROPN
admet-331	23	63	)	)	PUNCT
admet-331	23	64	y39983	y39983	PROPN
admet-331	23	65	*	*	PUNCT
admet-331	23	66	rki-983	rki-983	ADJ
admet-331	23	67	,	,	PUNCT
admet-331	23	68	snj-1656	snj-1656	NOUN
admet-331	23	69	senju	senju	PROPN
admet-331	23	70	/	/	SYM
admet-331	23	71	novartis	novartis	PROPN
admet-331	23	72	rock	rock	NOUN
admet-331	23	73	i	i	PROPN
admet-331	23	74	:	:	PUNCT
admet-331	23	75	n	n	CCONJ
admet-331	23	76	/	/	SYM
admet-331	23	77	a	a	DET
admet-331	23	78	rock	rock	NOUN
admet-331	23	79	ii	ii	NOUN
admet-331	23	80	:	:	PUNCT
admet-331	23	81	3.6	3.6	NUM
admet-331	23	82	nm	nm	NOUN
admet-331	23	83	[	[	X
admet-331	23	84	1,8	1,8	NUM
admet-331	23	85	]	]	X
admet-331	23	86	glaucoma	glaucoma	NOUN
admet-331	23	87	phase	phase	NOUN
admet-331	23	88	ii	ii	PROPN
admet-331	23	89	(	(	PUNCT
admet-331	23	90	discontinued	discontinued	ADJ
admet-331	23	91	)	)	PUNCT
admet-331	23	92	ar13324	ar13324	PROPN
admet-331	23	93	rhopressa	rhopressa	PROPN
admet-331	23	94	aerie	aerie	PROPN
admet-331	23	95	pharmaceuticals	pharmaceuticals	PROPN
admet-331	23	96	rock	rock	PROPN
admet-331	23	97	i	i	PROPN
admet-331	23	98	-	-	PUNCT
admet-331	23	99	ii	ii	PROPN
admet-331	23	100	:	:	PUNCT
admet-331	23	101	n	n	CCONJ
admet-331	23	102	/	/	SYM
admet-331	23	103	a	a	DET
admet-331	23	104	glaucoma	glaucoma	NOUN
admet-331	23	105	phase	phase	NOUN
admet-331	23	106	iii	iii	NUM
admet-331	23	107	pg324	pg324	PROPN
admet-331	23	108	roclatan	roclatan	NOUN
admet-331	23	109	(	(	PUNCT
admet-331	23	110	ar13324	ar13324	PROPN
admet-331	23	111	+	+	SYM
admet-331	23	112	latanoprost	latanoprost	ADJ
admet-331	23	113	)	)	PUNCT
admet-331	23	114	n	n	CCONJ
admet-331	23	115	/	/	SYM
admet-331	23	116	a	a	DET
admet-331	23	117	aerie	aerie	ADJ
admet-331	23	118	pharmaceuticals	pharmaceutical	NOUN
admet-331	23	119	rock	rock	NOUN
admet-331	23	120	i	i	PROPN
admet-331	23	121	-	-	PUNCT
admet-331	23	122	ii	ii	PROPN
admet-331	23	123	:	:	PUNCT
admet-331	23	124	n	n	CCONJ
admet-331	23	125	/	/	SYM
admet-331	23	126	a	a	DET
admet-331	23	127	glaucoma	glaucoma	NOUN
admet-331	23	128	phase	phase	NOUN
admet-331	23	129	iii	iii	NUM
admet-331	23	130	ar12286	ar12286	PROPN
admet-331	23	131	*	*	PROPN
admet-331	23	132	aerie	aerie	PROPN
admet-331	23	133	pharmaceuticals	pharmaceuticals	PROPN
admet-331	23	134	rock	rock	PROPN
admet-331	23	135	i	i	PROPN
admet-331	23	136	-	-	PUNCT
admet-331	23	137	ii	ii	PROPN
admet-331	23	138	:	:	PUNCT
admet-331	23	139	n	n	CCONJ
admet-331	23	140	/	/	SYM
admet-331	23	141	a	a	DET
admet-331	23	142	glaucoma	glaucoma	NOUN
admet-331	23	143	phase	phase	NOUN
admet-331	23	144	ii	ii	PROPN
admet-331	23	145	(	(	PUNCT
admet-331	23	146	discontinued	discontinue	VERB
admet-331	23	147	)	)	PUNCT
admet-331	23	148	pg286	pg286	ADJ
admet-331	23	149	(	(	PUNCT
admet-331	23	150	ar12286	ar12286	PROPN
admet-331	23	151	+	+	CCONJ
admet-331	23	152	travoprost	travoprost	ADJ
admet-331	23	153	)	)	PUNCT
admet-331	23	154	n	n	CCONJ
admet-331	23	155	/	/	SYM
admet-331	23	156	a	a	DET
admet-331	23	157	aerie	aerie	ADJ
admet-331	23	158	pharmaceuticals	pharmaceutical	NOUN
admet-331	23	159	rock	rock	NOUN
admet-331	23	160	i	i	PROPN
admet-331	23	161	-	-	PUNCT
admet-331	23	162	ii	ii	PROPN
admet-331	23	163	:	:	PUNCT
admet-331	23	164	n	n	CCONJ
admet-331	23	165	/	/	SYM
admet-331	23	166	a	a	DET
admet-331	23	167	glaucoma	glaucoma	NOUN
admet-331	23	168	(	(	PUNCT
admet-331	23	169	discontinued	discontinue	VERB
admet-331	23	170	)	)	PUNCT
admet-331	23	171	ar13154	ar13154	PROPN
admet-331	23	172	*	*	SYM
admet-331	23	173	n	n	CCONJ
admet-331	23	174	/	/	SYM
admet-331	23	175	a	a	DET
admet-331	23	176	aerie	aerie	ADJ
admet-331	23	177	pharmaceuticals	pharmaceutical	NOUN
admet-331	23	178	rock	rock	NOUN
admet-331	23	179	i	i	PROPN
admet-331	23	180	-	-	PUNCT
admet-331	23	181	ii	ii	PROPN
admet-331	23	182	:	:	PUNCT
admet-331	23	183	n	n	CCONJ
admet-331	23	184	/	/	SYM
admet-331	23	185	a	a	DET
admet-331	23	186	choroidea	choroidea	NOUN
admet-331	23	187	neovascularisation	neovascularisation	NOUN
admet-331	23	188	animal	animal	NOUN
admet-331	23	189	model	model	NOUN
admet-331	23	190	ama0076	ama0076	NOUN
admet-331	23	191	structure	structure	NOUN
admet-331	23	192	not	not	PART
admet-331	23	193	disclosed	disclose	VERB
admet-331	23	194	amakem	amakem	PROPN
admet-331	23	195	rock	rock	PROPN
admet-331	23	196	i	i	PRON
admet-331	23	197	:	:	PUNCT
admet-331	23	198	3.7	3.7	NUM
admet-331	23	199	nm	nm	NOUN
admet-331	23	200	[	[	X
admet-331	23	201	8	8	NUM
admet-331	23	202	]	]	X
admet-331	23	203	rock	rock	PROPN
admet-331	23	204	ii	ii	PROPN
admet-331	23	205	:	:	PUNCT
admet-331	23	206	2.3	2.3	NUM
admet-331	23	207	nm	nm	NOUN
admet-331	23	208	[	[	X
admet-331	23	209	8	8	NUM
admet-331	23	210	]	]	PUNCT
admet-331	23	211	glaucoma	glaucoma	NOUN
admet-331	23	212	phase	phase	NOUN
admet-331	23	213	ii	ii	PROPN
admet-331	23	214	ama0428	ama0428	PROPN
admet-331	23	215	*	*	NOUN
admet-331	23	216	structure	structure	NOUN
admet-331	23	217	not	not	PART
admet-331	23	218	disclosed	disclose	VERB
admet-331	23	219	amakem	amakem	PROPN
admet-331	23	220	rock	rock	PROPN
admet-331	23	221	i	i	PROPN
admet-331	23	222	-	-	PUNCT
admet-331	23	223	ii	ii	PROPN
admet-331	23	224	:	:	PUNCT
admet-331	23	225	n	n	CCONJ
admet-331	23	226	/	/	SYM
admet-331	23	227	a	a	DET
admet-331	23	228	amd	amd	ADJ
admet-331	23	229	animal	animal	NOUN
admet-331	23	230	model	model	NOUN
admet-331	23	231	ats907	ats907	PROPN
admet-331	23	232	altheos	altheo	VERB
admet-331	23	233	rock	rock	NOUN
admet-331	23	234	i	i	PRON
admet-331	23	235	:	:	PUNCT
admet-331	23	236	36	36	NUM
admet-331	23	237	nm	nm	NOUN
admet-331	23	238	[	[	X
admet-331	23	239	1	1	NUM
admet-331	23	240	]	]	X
admet-331	23	241	rock	rock	PROPN
admet-331	23	242	ii	ii	PROPN
admet-331	23	243	:	:	PUNCT
admet-331	23	244	37	37	NUM
admet-331	23	245	nm	nm	NOUN
admet-331	23	246	[	[	X
admet-331	23	247	1	1	NUM
admet-331	23	248	]	]	PUNCT
admet-331	23	249	glaucoma	glaucoma	NOUN
admet-331	23	250	phase	phase	NOUN
admet-331	23	251	ii	ii	PROPN
admet-331	23	252	(	(	PUNCT
admet-331	23	253	discontinued	discontinue	VERB
admet-331	23	254	)	)	PUNCT
admet-331	23	255	ins117548	ins117548	NOUN
admet-331	23	256	n	n	PROPN
admet-331	23	257	/	/	SYM
admet-331	23	258	a	a	DET
admet-331	23	259	inspire	inspire	NOUN
admet-331	23	260	/merck	/merck	INTJ
admet-331	23	261	rock	rock	NOUN
admet-331	23	262	i	i	PRON
admet-331	23	263	:	:	PUNCT
admet-331	23	264	5	5	NUM
admet-331	23	265	nm	nm	NOUN
admet-331	23	266	[	[	X
admet-331	23	267	1	1	NUM
admet-331	23	268	]	]	X
admet-331	23	269	rock	rock	PROPN
admet-331	23	270	ii	ii	PROPN
admet-331	23	271	:	:	PUNCT
admet-331	23	272	14	14	NUM
admet-331	23	273	nm	nm	NOUN
admet-331	23	274	[	[	X
admet-331	23	275	1	1	NUM
admet-331	23	276	]	]	PUNCT
admet-331	23	277	glaucoma	glaucoma	NOUN
admet-331	23	278	phase	phase	NOUN
admet-331	23	279	i	i	PRON
admet-331	23	280	(	(	PUNCT
admet-331	23	281	discontinued	discontinued	ADJ
admet-331	23	282	)	)	PUNCT
admet-331	23	283	de104	de104	PROPN
admet-331	23	284	n	n	CCONJ
admet-331	23	285	/	/	SYM
admet-331	23	286	a	a	DET
admet-331	23	287	santen	santen	ADJ
admet-331	23	288	rock	rock	NOUN
admet-331	23	289	i	i	PROPN
admet-331	23	290	-	-	PUNCT
admet-331	23	291	ii	ii	PROPN
admet-331	23	292	:	:	PUNCT
admet-331	23	293	n	n	CCONJ
admet-331	23	294	/	/	SYM
admet-331	23	295	a	a	DET
admet-331	23	296	glaucoma	glaucoma	NOUN
admet-331	23	297	phase	phase	NOUN
admet-331	23	298	ii	ii	PROPN
admet-331	23	299	(	(	PUNCT
admet-331	23	300	discontinued	discontinue	VERB
admet-331	23	301	)	)	PUNCT
admet-331	23	302	kd025	kd025	PROPN
admet-331	23	303	*	*	X
admet-331	23	304	kadmon	kadmon	PROPN
admet-331	23	305	rock	rock	PROPN
admet-331	23	306	i	i	PROPN
admet-331	23	307	:	:	PUNCT
admet-331	23	308	>	>	PUNCT
admet-331	23	309	10	10	NUM
admet-331	23	310	µm	µm	PART
admet-331	23	311	[	[	X
admet-331	23	312	12	12	NUM
admet-331	23	313	]	]	X
admet-331	23	314	rock	rock	PROPN
admet-331	23	315	ii	ii	PROPN
admet-331	23	316	:	:	PUNCT
admet-331	23	317	59	59	NUM
admet-331	23	318	nm	nm	NOUN
admet-331	23	319	[	[	X
admet-331	23	320	12	12	NUM
admet-331	23	321	]	]	PUNCT
admet-331	23	322	psoriasis	psoriasis	NOUN
admet-331	23	323	phase	phase	NOUN
admet-331	23	324	ii	ii	PROPN
admet-331	23	325	(	(	PUNCT
admet-331	23	326	nct02106195	nct02106195	ADJ
admet-331	23	327	)	)	PUNCT
admet-331	23	328	idiopathic	idiopathic	ADJ
admet-331	23	329	pulmonary	pulmonary	ADJ
admet-331	23	330	fibrosis	fibrosis	NOUN
admet-331	23	331	phase	phase	NOUN
admet-331	23	332	ii	ii	PROPN
admet-331	23	333	(	(	PUNCT
admet-331	23	334	nct02688647	nct02688647	ADJ
admet-331	23	335	)	)	PUNCT
admet-331	23	336	graft	graft	NOUN
admet-331	23	337	versus	versus	ADP
admet-331	23	338	host	host	NOUN
admet-331	23	339	disease	disease	NOUN
admet-331	23	340	(	(	PUNCT
admet-331	23	341	gvhd	gvhd	NOUN
admet-331	23	342	)	)	PUNCT
admet-331	23	343	phase	phase	NOUN
admet-331	23	344	ii	ii	PROPN
admet-331	23	345	(	(	PUNCT
admet-331	23	346	nct02841995	nct02841995	NOUN
admet-331	23	347	)	)	PUNCT
admet-331	23	348	*	*	PUNCT
admet-331	23	349	these	these	DET
admet-331	23	350	drugs	drug	NOUN
admet-331	23	351	are	be	AUX
admet-331	23	352	still	still	ADV
admet-331	23	353	being	be	AUX
admet-331	23	354	used	use	VERB
admet-331	23	355	for	for	ADP
admet-331	23	356	in	in	ADP
admet-331	23	357	vitro	vitro	X
admet-331	23	358	or	or	CCONJ
admet-331	23	359	animal	animal	NOUN
admet-331	23	360	research	research	NOUN
admet-331	23	361	éva	éva	PROPN
admet-331	23	362	halász	halász	NOUN
admet-331	23	363	,	,	PUNCT
admet-331	23	364	ellen	ellen	PROPN
admet-331	23	365	townes	townes	PROPN
admet-331	23	366	-	-	PUNCT
admet-331	23	367	anderson	anderson	PROPN
admet-331	23	368	admet	admet	PROPN
admet-331	23	369	&	&	CCONJ
admet-331	23	370	dmpk	dmpk	PROPN
admet-331	23	371	4(4	4(4	NUM
admet-331	23	372	)	)	PUNCT
admet-331	23	373	(	(	PUNCT
admet-331	23	374	2016	2016	NUM
admet-331	23	375	)	)	PUNCT
admet-331	23	376	280	280	NUM
admet-331	23	377	-	-	SYM
admet-331	23	378	301	301	NUM
admet-331	23	379	282	282	NUM
admet-331	23	380	small	small	ADJ
admet-331	23	381	modifications	modification	NOUN
admet-331	23	382	in	in	ADP
admet-331	23	383	structure	structure	NOUN
admet-331	23	384	lead	lead	NOUN
admet-331	23	385	to	to	ADP
admet-331	23	386	remarkable	remarkable	ADJ
admet-331	23	387	changes	change	NOUN
admet-331	23	388	.	.	PUNCT
admet-331	24	1	for	for	ADP
admet-331	24	2	example	example	NOUN
admet-331	24	3	,	,	PUNCT
admet-331	24	4	the	the	DET
admet-331	24	5	fasudil	fasudil	NOUN
admet-331	24	6	derivative	derivative	ADJ
admet-331	24	7	ripasudil	ripasudil	NOUN
admet-331	24	8	at	at	ADP
admet-331	24	9	50	50	NUM
admet-331	24	10	%	%	NOUN
admet-331	24	11	of	of	ADP
admet-331	24	12	its	its	PRON
admet-331	24	13	effective	effective	ADJ
admet-331	24	14	concentration	concentration	NOUN
admet-331	24	15	against	against	ADP
admet-331	24	16	rock	rock	NOUN
admet-331	24	17	i	i	PRON
admet-331	24	18	in	in	ADP
admet-331	24	19	cell	cell	NOUN
admet-331	24	20	free	free	ADJ
admet-331	24	21	assays	assay	NOUN
admet-331	24	22	(	(	PUNCT
admet-331	24	23	ic50(ki)=0.051	ic50(ki)=0.051	ADJ
admet-331	24	24	µm	µm	NOUN
admet-331	24	25	)	)	PUNCT
admet-331	25	1	[	[	X
admet-331	25	2	6	6	NUM
admet-331	25	3	]	]	PUNCT
admet-331	25	4	has	have	VERB
admet-331	25	5	at	at	ADV
admet-331	25	6	least	least	ADJ
admet-331	25	7	a	a	DET
admet-331	25	8	2	2	NUM
admet-331	25	9	-	-	SYM
admet-331	25	10	6	6	NUM
admet-331	25	11	times	time	NOUN
admet-331	25	12	higher	high	ADJ
admet-331	25	13	binding	bind	VERB
admet-331	25	14	affinity	affinity	NOUN
admet-331	25	15	than	than	ADP
admet-331	25	16	that	that	PRON
admet-331	25	17	of	of	ADP
admet-331	25	18	other	other	ADJ
admet-331	25	19	rock	rock	NOUN
admet-331	25	20	inhibitors	inhibitor	NOUN
admet-331	25	21	such	such	ADJ
admet-331	25	22	as	as	ADP
admet-331	25	23	y27632	y27632	PROPN
admet-331	25	24	(	(	PUNCT
admet-331	25	25	ic	ic	NOUN
admet-331	25	26	50(ki	50(ki	NUM
admet-331	25	27	)	)	PUNCT
admet-331	26	1	=	=	NOUN
admet-331	26	2	0.14	0.14	NUM
admet-331	26	3	µm	µm	NOUN
admet-331	26	4	)	)	PUNCT
admet-331	26	5	or	or	CCONJ
admet-331	26	6	fasudil	fasudil	NOUN
admet-331	26	7	(	(	PUNCT
admet-331	26	8	ic	ic	NOUN
admet-331	26	9	50(ki	50(ki	NUM
admet-331	26	10	)	)	PUNCT
admet-331	26	11	=	=	NOUN
admet-331	26	12	0.33	0.33	NUM
admet-331	26	13	µm	µm	NOUN
admet-331	26	14	)	)	PUNCT
admet-331	27	1	[	[	X
admet-331	27	2	5	5	NUM
admet-331	27	3	]	]	PUNCT
admet-331	27	4	at	at	ADP
admet-331	27	5	the	the	DET
admet-331	27	6	same	same	ADJ
admet-331	27	7	effective	effective	ADJ
admet-331	27	8	concentration	concentration	NOUN
admet-331	27	9	.	.	PUNCT
admet-331	28	1	ama0076	ama0076	NOUN
admet-331	28	2	and	and	CCONJ
admet-331	28	3	y39983	y39983	PROPN
admet-331	28	4	are	be	AUX
admet-331	28	5	both	both	ADV
admet-331	28	6	structurally	structurally	ADV
admet-331	28	7	related	related	ADJ
admet-331	28	8	to	to	ADP
admet-331	28	9	y27632	y27632	PROPN
admet-331	29	1	[	[	X
admet-331	29	2	7	7	NUM
admet-331	29	3	]	]	PUNCT
admet-331	29	4	.	.	PUNCT
admet-331	30	1	in	in	ADP
admet-331	30	2	in	in	ADP
admet-331	30	3	vitro	vitro	X
admet-331	30	4	assays	assay	NOUN
admet-331	30	5	,	,	PUNCT
admet-331	30	6	ama0076	ama0076	NOUN
admet-331	30	7	(	(	PUNCT
admet-331	30	8	ic50=2.3+/-0.9	ic50=2.3+/-0.9	NOUN
admet-331	30	9	nm	nm	NOUN
admet-331	30	10	)	)	PUNCT
admet-331	30	11	and	and	CCONJ
admet-331	30	12	y39983	y39983	PROPN
admet-331	30	13	(	(	PUNCT
admet-331	30	14	ic50=4.3+/-2.1	ic50=4.3+/-2.1	PROPN
admet-331	30	15	nm	nm	AUX
admet-331	30	16	)	)	PUNCT
admet-331	30	17	showed	show	VERB
admet-331	30	18	similar	similar	ADJ
admet-331	30	19	on	on	ADP
admet-331	30	20	-	-	PUNCT
admet-331	30	21	target	target	NOUN
admet-331	30	22	potency	potency	NOUN
admet-331	30	23	for	for	ADP
admet-331	30	24	rock	rock	NOUN
admet-331	30	25	ii	ii	PROPN
admet-331	30	26	,	,	PUNCT
admet-331	30	27	but	but	CCONJ
admet-331	30	28	they	they	PRON
admet-331	30	29	were	be	AUX
admet-331	30	30	at	at	ADV
admet-331	30	31	least	least	ADJ
admet-331	30	32	ten	ten	NUM
admet-331	30	33	times	time	NOUN
admet-331	30	34	more	more	ADV
admet-331	30	35	potent	potent	ADJ
admet-331	30	36	than	than	ADP
admet-331	30	37	y27632	y27632	PROPN
admet-331	30	38	(	(	PUNCT
admet-331	30	39	ic50=54+/-23	ic50=54+/-23	NOUN
admet-331	30	40	nm	nm	NOUN
admet-331	30	41	)	)	PUNCT
admet-331	30	42	.	.	PUNCT
admet-331	31	1	in	in	ADP
admet-331	31	2	normotensive	normotensive	ADJ
admet-331	31	3	rabbits	rabbit	NOUN
admet-331	31	4	ama0076	ama0076	NOUN
admet-331	31	5	also	also	ADV
admet-331	31	6	was	be	AUX
admet-331	31	7	slightly	slightly	ADV
admet-331	31	8	more	more	ADV
admet-331	31	9	effective	effective	ADJ
admet-331	31	10	in	in	ADP
admet-331	31	11	reducing	reduce	VERB
admet-331	31	12	the	the	DET
admet-331	31	13	fluid	fluid	NOUN
admet-331	31	14	-	-	PUNCT
admet-331	31	15	based	base	VERB
admet-331	31	16	pressure	pressure	NOUN
admet-331	31	17	of	of	ADP
admet-331	31	18	the	the	DET
admet-331	31	19	eyeball	eyeball	NOUN
admet-331	31	20	,	,	PUNCT
admet-331	31	21	a	a	DET
admet-331	31	22	measure	measure	NOUN
admet-331	31	23	used	use	VERB
admet-331	31	24	to	to	PART
admet-331	31	25	diagnose	diagnose	VERB
admet-331	31	26	glaucoma	glaucoma	NOUN
admet-331	31	27	and	and	CCONJ
admet-331	31	28	called	call	VERB
admet-331	31	29	the	the	DET
admet-331	31	30	intraocular	intraocular	ADJ
admet-331	31	31	pressure	pressure	NOUN
admet-331	31	32	(	(	PUNCT
admet-331	31	33	iop	iop	PROPN
admet-331	31	34	)	)	PUNCT
admet-331	31	35	,	,	PUNCT
admet-331	31	36	than	than	ADP
admet-331	31	37	y39983	y39983	PROPN
admet-331	32	1	[	[	X
admet-331	32	2	8	8	NUM
admet-331	32	3	]	]	PUNCT
admet-331	32	4	.	.	PUNCT
admet-331	33	1	stability	stability	NOUN
admet-331	33	2	in	in	ADP
admet-331	33	3	solution	solution	NOUN
admet-331	33	4	can	can	AUX
admet-331	33	5	also	also	ADV
admet-331	33	6	be	be	AUX
admet-331	33	7	disparate	disparate	ADJ
admet-331	33	8	.	.	PUNCT
admet-331	34	1	both	both	PRON
admet-331	34	2	fasudil	fasudil	NOUN
admet-331	34	3	and	and	CCONJ
admet-331	34	4	y27632	y27632	PROPN
admet-331	34	5	were	be	AUX
admet-331	34	6	effective	effective	ADJ
admet-331	34	7	at	at	ADP
admet-331	34	8	reducing	reduce	VERB
admet-331	34	9	iop	iop	NOUN
admet-331	34	10	in	in	ADP
admet-331	34	11	animal	animal	NOUN
admet-331	34	12	models	model	NOUN
admet-331	34	13	[	[	X
admet-331	34	14	6	6	NUM
admet-331	34	15	]	]	PUNCT
admet-331	34	16	,	,	PUNCT
admet-331	34	17	however	however	ADV
admet-331	34	18	the	the	DET
admet-331	34	19	stability	stability	NOUN
admet-331	34	20	of	of	ADP
admet-331	34	21	the	the	DET
admet-331	34	22	solutions	solution	NOUN
admet-331	34	23	was	be	AUX
admet-331	34	24	poor	poor	ADJ
admet-331	34	25	[	[	X
admet-331	34	26	9,10	9,10	NUM
admet-331	34	27	]	]	X
admet-331	34	28	.	.	PUNCT
admet-331	35	1	the	the	DET
admet-331	35	2	y27632	y27632	PROPN
admet-331	35	3	-	-	PUNCT
admet-331	35	4	derivative	derivative	ADJ
admet-331	35	5	y39983	y39983	PROPN
admet-331	35	6	was	be	AUX
admet-331	35	7	stabile	stabile	ADJ
admet-331	35	8	in	in	ADP
admet-331	35	9	solution	solution	NOUN
admet-331	35	10	and	and	CCONJ
admet-331	35	11	shown	show	VERB
admet-331	35	12	to	to	PART
admet-331	35	13	have	have	VERB
admet-331	35	14	30	30	NUM
admet-331	35	15	times	time	NOUN
admet-331	35	16	more	more	ADJ
admet-331	35	17	rock	rock	NOUN
admet-331	35	18	inhibition	inhibition	NOUN
admet-331	35	19	and	and	CCONJ
admet-331	35	20	to	to	PART
admet-331	35	21	be	be	AUX
admet-331	35	22	10	10	NUM
admet-331	35	23	fold	fold	VERB
admet-331	35	24	more	more	ADV
admet-331	35	25	effective	effective	ADJ
admet-331	35	26	at	at	ADP
admet-331	35	27	lowering	lower	VERB
admet-331	35	28	iop	iop	NOUN
admet-331	35	29	than	than	ADP
admet-331	35	30	y27632	y27632	PROPN
admet-331	35	31	in	in	ADP
admet-331	35	32	animal	animal	NOUN
admet-331	35	33	models	model	NOUN
admet-331	35	34	[	[	X
admet-331	35	35	9	9	NUM
admet-331	35	36	]	]	PUNCT
admet-331	35	37	.	.	PUNCT
admet-331	36	1	nonetheless	nonetheless	ADV
admet-331	36	2	,	,	PUNCT
admet-331	36	3	clinical	clinical	ADJ
admet-331	36	4	trials	trial	NOUN
admet-331	36	5	with	with	ADP
admet-331	36	6	y39983	y39983	PROPN
admet-331	36	7	were	be	AUX
admet-331	36	8	discontinued	discontinue	VERB
admet-331	36	9	after	after	ADP
admet-331	36	10	phase	phase	NOUN
admet-331	36	11	ii	ii	NOUN
admet-331	36	12	,	,	PUNCT
admet-331	36	13	probably	probably	ADV
admet-331	36	14	because	because	SCONJ
admet-331	36	15	of	of	ADP
admet-331	36	16	treatment	treatment	NOUN
admet-331	36	17	-	-	PUNCT
admet-331	36	18	related	relate	VERB
admet-331	36	19	side	side	NOUN
admet-331	36	20	effects	effect	NOUN
admet-331	36	21	[	[	X
admet-331	36	22	11	11	NUM
admet-331	36	23	]	]	PUNCT
admet-331	36	24	.	.	PUNCT
admet-331	37	1	fasudil	fasudil	NOUN
admet-331	37	2	-	-	PUNCT
admet-331	37	3	derived	derive	VERB
admet-331	37	4	ripasudil	ripasudil	NOUN
admet-331	37	5	proved	prove	VERB
admet-331	37	6	to	to	PART
admet-331	37	7	be	be	AUX
admet-331	37	8	safe	safe	ADJ
admet-331	37	9	and	and	CCONJ
admet-331	37	10	stabile	stabile	ADJ
admet-331	37	11	for	for	ADP
admet-331	37	12	topical	topical	ADJ
admet-331	37	13	instillation	instillation	NOUN
admet-331	37	14	and	and	CCONJ
admet-331	37	15	,	,	PUNCT
admet-331	37	16	as	as	SCONJ
admet-331	37	17	noted	note	VERB
admet-331	37	18	,	,	PUNCT
admet-331	37	19	has	have	AUX
admet-331	37	20	been	be	AUX
admet-331	37	21	approved	approve	VERB
admet-331	37	22	for	for	ADP
admet-331	37	23	treatment	treatment	NOUN
admet-331	37	24	of	of	ADP
admet-331	37	25	glaucoma	glaucoma	NOUN
admet-331	38	1	[	[	X
admet-331	38	2	2	2	NUM
admet-331	38	3	]	]	PUNCT
admet-331	38	4	.	.	PUNCT
admet-331	39	1	one	one	NUM
admet-331	39	2	important	important	ADJ
admet-331	39	3	direction	direction	NOUN
admet-331	39	4	for	for	ADP
admet-331	39	5	future	future	ADJ
admet-331	39	6	rock	rock	NOUN
admet-331	39	7	inhibition	inhibition	NOUN
admet-331	39	8	development	development	NOUN
admet-331	39	9	is	be	AUX
admet-331	39	10	the	the	DET
admet-331	39	11	development	development	NOUN
admet-331	39	12	of	of	ADP
admet-331	39	13	rock	rock	NOUN
admet-331	39	14	i	i	PROPN
admet-331	39	15	and	and	CCONJ
admet-331	39	16	rock	rock	PROPN
admet-331	39	17	ii	ii	PROPN
admet-331	39	18	specific	specific	ADJ
admet-331	39	19	drugs	drug	NOUN
admet-331	39	20	.	.	PUNCT
admet-331	40	1	kd025	kd025	ADJ
admet-331	40	2	is	be	AUX
admet-331	40	3	an	an	DET
admet-331	40	4	orally	orally	ADV
admet-331	40	5	available	available	ADJ
admet-331	40	6	,	,	PUNCT
admet-331	40	7	potent	potent	ADJ
admet-331	40	8	and	and	CCONJ
admet-331	40	9	highly	highly	ADV
admet-331	40	10	selective	selective	ADJ
admet-331	40	11	small	small	ADJ
admet-331	40	12	molecule	molecule	NOUN
admet-331	40	13	rock	rock	NOUN
admet-331	40	14	ii	ii	PROPN
admet-331	40	15	inhibitor	inhibitor	NOUN
admet-331	40	16	(	(	PUNCT
admet-331	40	17	ic	ic	PROPN
admet-331	40	18	50=~60	50=~60	NUM
admet-331	40	19	nm	nm	ADJ
admet-331	40	20	/	/	SYM
admet-331	40	21	l	l	NOUN
admet-331	40	22	)	)	PUNCT
admet-331	41	1	[	[	X
admet-331	41	2	12	12	NUM
admet-331	41	3	]	]	PUNCT
admet-331	41	4	,	,	PUNCT
admet-331	41	5	developed	develop	VERB
admet-331	41	6	by	by	ADP
admet-331	41	7	kadmon	kadmon	PROPN
admet-331	41	8	company	company	PROPN
admet-331	41	9	and	and	CCONJ
admet-331	41	10	currently	currently	ADV
admet-331	41	11	in	in	ADP
admet-331	41	12	phase	phase	NOUN
admet-331	41	13	ii	ii	NOUN
admet-331	41	14	clinical	clinical	ADJ
admet-331	41	15	trials	trial	NOUN
admet-331	41	16	for	for	ADP
admet-331	41	17	chronic	chronic	ADJ
admet-331	41	18	pulmonary	pulmonary	ADJ
admet-331	41	19	fibrotic	fibrotic	ADJ
admet-331	41	20	and	and	CCONJ
admet-331	41	21	systemic	systemic	ADJ
admet-331	41	22	autoimmune	autoimmune	ADJ
admet-331	41	23	disease	disease	NOUN
admet-331	41	24	(	(	PUNCT
admet-331	41	25	clinicaltrials.gov	clinicaltrials.gov	NOUN
admet-331	41	26	:	:	PUNCT
admet-331	41	27	nct02106195	nct02106195	ADJ
admet-331	41	28	;	;	PUNCT
admet-331	41	29	nct02688647	nct02688647	ADJ
admet-331	41	30	)	)	PUNCT
admet-331	41	31	.	.	PUNCT
admet-331	42	1	bior	bior	ADJ
admet-331	42	2	tri	tri	ADJ
admet-331	42	3	-	-	ADJ
admet-331	42	4	functional	functional	ADJ
admet-331	42	5	small	small	ADJ
admet-331	42	6	molecule	molecule	NOUN
admet-331	42	7	inhibitors	inhibitor	NOUN
admet-331	42	8	are	be	AUX
admet-331	42	9	also	also	ADV
admet-331	42	10	being	be	AUX
admet-331	42	11	developed	develop	VERB
admet-331	42	12	.	.	PUNCT
admet-331	43	1	these	these	DET
admet-331	43	2	drugs	drug	NOUN
admet-331	43	3	usually	usually	ADV
admet-331	43	4	are	be	AUX
admet-331	43	5	comprised	comprise	VERB
admet-331	43	6	of	of	ADP
admet-331	43	7	a	a	DET
admet-331	43	8	rock	rock	NOUN
admet-331	43	9	inhibitor	inhibitor	NOUN
admet-331	43	10	and	and	CCONJ
admet-331	43	11	one	one	NUM
admet-331	43	12	or	or	CCONJ
admet-331	43	13	more	more	ADJ
admet-331	43	14	drugs	drug	NOUN
admet-331	43	15	with	with	ADP
admet-331	43	16	additional	additional	ADJ
admet-331	43	17	therapeutically	therapeutically	ADV
admet-331	43	18	relevant	relevant	ADJ
admet-331	43	19	targets	target	NOUN
admet-331	43	20	.	.	PUNCT
admet-331	44	1	for	for	ADP
admet-331	44	2	example	example	NOUN
admet-331	44	3	,	,	PUNCT
admet-331	44	4	rhopressa	rhopressa	NOUN
admet-331	44	5	,	,	PUNCT
admet-331	44	6	a	a	DET
admet-331	44	7	bi	bi	ADJ
admet-331	44	8	-	-	ADJ
admet-331	44	9	functional	functional	ADJ
admet-331	44	10	drug	drug	NOUN
admet-331	44	11	,	,	PUNCT
admet-331	44	12	is	be	AUX
admet-331	44	13	made	make	VERB
admet-331	44	14	up	up	ADP
admet-331	44	15	of	of	ADP
admet-331	44	16	a	a	DET
admet-331	44	17	rock	rock	NOUN
admet-331	44	18	inhibitor	inhibitor	NOUN
admet-331	44	19	and	and	CCONJ
admet-331	44	20	a	a	DET
admet-331	44	21	norepinephrine	norepinephrine	NOUN
admet-331	44	22	transporter	transporter	NOUN
admet-331	44	23	inhibitor	inhibitor	NOUN
admet-331	44	24	[	[	X
admet-331	44	25	13	13	NUM
admet-331	44	26	]	]	PUNCT
admet-331	44	27	,	,	PUNCT
admet-331	44	28	and	and	CCONJ
admet-331	44	29	roclatan	roclatan	ADJ
admet-331	44	30	,	,	PUNCT
admet-331	44	31	a	a	DET
admet-331	44	32	tri	tri	ADJ
admet-331	44	33	-	-	ADJ
admet-331	44	34	functional	functional	ADJ
admet-331	44	35	drug	drug	NOUN
admet-331	44	36	,	,	PUNCT
admet-331	44	37	is	be	AUX
admet-331	44	38	made	make	VERB
admet-331	44	39	up	up	ADP
admet-331	44	40	of	of	ADP
admet-331	44	41	a	a	DET
admet-331	44	42	fixed	fix	VERB
admet-331	44	43	combination	combination	NOUN
admet-331	44	44	of	of	ADP
admet-331	44	45	rhopressa	rhopressa	NOUN
admet-331	44	46	with	with	ADP
admet-331	44	47	latanoprost	latanoprost	ADJ
admet-331	45	1	[	[	X
admet-331	45	2	14	14	NUM
admet-331	45	3	]	]	PUNCT
admet-331	45	4	.	.	PUNCT
admet-331	46	1	both	both	PRON
admet-331	46	2	of	of	ADP
admet-331	46	3	them	they	PRON
admet-331	46	4	were	be	AUX
admet-331	46	5	developed	develop	VERB
admet-331	46	6	by	by	ADP
admet-331	46	7	aerie	aerie	PROPN
admet-331	46	8	pharmaceuticals	pharmaceutical	NOUN
admet-331	46	9	and	and	CCONJ
admet-331	46	10	are	be	AUX
admet-331	46	11	in	in	ADP
admet-331	46	12	phase	phase	NOUN
admet-331	46	13	iii	iii	NUM
admet-331	46	14	clinical	clinical	ADJ
admet-331	46	15	trials	trial	NOUN
admet-331	46	16	[	[	X
admet-331	46	17	15	15	NUM
admet-331	46	18	]	]	PUNCT
admet-331	46	19	.	.	PUNCT
admet-331	47	1	a	a	DET
admet-331	47	2	drug	drug	NOUN
admet-331	47	3	approach	approach	NOUN
admet-331	47	4	with	with	ADP
admet-331	47	5	less	less	ADJ
admet-331	47	6	side	side	NOUN
admet-331	47	7	effects	effect	NOUN
admet-331	47	8	has	have	AUX
admet-331	47	9	been	be	AUX
admet-331	47	10	developed	develop	VERB
admet-331	47	11	by	by	ADP
admet-331	47	12	the	the	DET
admet-331	47	13	amakem	amakem	PROPN
admet-331	47	14	company	company	NOUN
admet-331	47	15	for	for	ADP
admet-331	47	16	localized	localized	ADJ
admet-331	47	17	applications	application	NOUN
admet-331	47	18	of	of	ADP
admet-331	47	19	rock	rock	NOUN
admet-331	47	20	inhibitors	inhibitor	NOUN
admet-331	47	21	.	.	PUNCT
admet-331	48	1	in	in	ADP
admet-331	48	2	this	this	DET
admet-331	48	3	approach	approach	NOUN
admet-331	48	4	,	,	PUNCT
admet-331	48	5	the	the	DET
admet-331	48	6	drug	drug	NOUN
admet-331	48	7	is	be	AUX
admet-331	48	8	active	active	ADJ
admet-331	48	9	where	where	SCONJ
admet-331	48	10	it	it	PRON
admet-331	48	11	is	be	AUX
admet-331	48	12	applied	apply	VERB
admet-331	48	13	but	but	CCONJ
admet-331	48	14	once	once	SCONJ
admet-331	48	15	the	the	DET
admet-331	48	16	drug	drug	NOUN
admet-331	48	17	enters	enter	VERB
admet-331	48	18	the	the	DET
admet-331	48	19	systemic	systemic	ADJ
admet-331	48	20	circulation	circulation	NOUN
admet-331	48	21	,	,	PUNCT
admet-331	48	22	the	the	DET
admet-331	48	23	compounds	compound	NOUN
admet-331	48	24	are	be	AUX
admet-331	48	25	metabolized	metabolize	VERB
admet-331	48	26	into	into	ADP
admet-331	48	27	non	non	ADJ
admet-331	48	28	-	-	ADJ
admet-331	48	29	toxic	toxic	ADJ
admet-331	48	30	inactive	inactive	ADJ
admet-331	48	31	metabolites	metabolite	NOUN
admet-331	48	32	through	through	ADP
admet-331	48	33	the	the	DET
admet-331	48	34	activity	activity	NOUN
admet-331	48	35	of	of	ADP
admet-331	48	36	an	an	DET
admet-331	48	37	esterase	esterase	NOUN
admet-331	48	38	.	.	PUNCT
admet-331	49	1	these	these	DET
admet-331	49	2	drugs	drug	NOUN
admet-331	49	3	are	be	AUX
admet-331	49	4	known	know	VERB
admet-331	49	5	as	as	ADP
admet-331	49	6	soft	soft	ADJ
admet-331	49	7	drugs	drug	NOUN
admet-331	49	8	.	.	PUNCT
admet-331	50	1	adding	add	VERB
admet-331	50	2	(	(	PUNCT
admet-331	50	3	and	and	CCONJ
admet-331	50	4	modifying	modify	VERB
admet-331	50	5	)	)	PUNCT
admet-331	50	6	ester	ester	NOUN
admet-331	50	7	moieties	moiety	NOUN
admet-331	50	8	to	to	ADP
admet-331	50	9	an	an	DET
admet-331	50	10	otherwise	otherwise	ADV
admet-331	50	11	classical	classical	ADJ
admet-331	50	12	rock	rock	NOUN
admet-331	50	13	inhibitor	inhibitor	NOUN
admet-331	50	14	results	result	NOUN
admet-331	50	15	in	in	ADP
admet-331	50	16	variability	variability	NOUN
admet-331	50	17	in	in	ADP
admet-331	50	18	drug	drug	NOUN
admet-331	50	19	stability	stability	NOUN
admet-331	50	20	,	,	PUNCT
admet-331	50	21	with	with	ADP
admet-331	50	22	plasma	plasma	NOUN
admet-331	50	23	half	half	ADJ
admet-331	50	24	-	-	PUNCT
admet-331	50	25	life	life	NOUN
admet-331	50	26	times	time	NOUN
admet-331	50	27	from	from	ADP
admet-331	50	28	less	less	ADJ
admet-331	50	29	than	than	ADP
admet-331	50	30	5	5	NUM
admet-331	50	31	minutes	minute	NOUN
admet-331	50	32	to	to	ADP
admet-331	50	33	more	more	ADJ
admet-331	50	34	than	than	ADP
admet-331	50	35	120	120	NUM
admet-331	50	36	minutes	minute	NOUN
admet-331	50	37	[	[	X
admet-331	50	38	7	7	NUM
admet-331	50	39	]	]	PUNCT
admet-331	50	40	.	.	PUNCT
admet-331	51	1	ama0076	ama0076	PROPN
admet-331	51	2	lowered	lower	VERB
admet-331	51	3	intraocular	intraocular	ADJ
admet-331	51	4	pressure	pressure	NOUN
admet-331	51	5	in	in	ADP
admet-331	51	6	new	new	PROPN
admet-331	51	7	zealand	zealand	PROPN
admet-331	51	8	white	white	PROPN
admet-331	51	9	rabbits	rabbit	NOUN
admet-331	51	10	with	with	ADP
admet-331	51	11	minimal	minimal	ADJ
admet-331	51	12	hyperemia	hyperemia	NOUN
admet-331	51	13	,	,	PUNCT
admet-331	51	14	and	and	CCONJ
admet-331	51	15	was	be	AUX
admet-331	51	16	more	more	ADV
admet-331	51	17	efficient	efficient	ADJ
admet-331	51	18	than	than	ADP
admet-331	51	19	y39983	y39983	PROPN
admet-331	51	20	at	at	ADP
admet-331	51	21	the	the	DET
admet-331	51	22	same	same	ADJ
admet-331	51	23	concentration	concentration	NOUN
admet-331	51	24	[	[	X
admet-331	51	25	8	8	NUM
admet-331	51	26	]	]	PUNCT
admet-331	51	27	.	.	PUNCT
admet-331	52	1	this	this	DET
admet-331	52	2	soft	soft	ADJ
admet-331	52	3	drug	drug	NOUN
admet-331	52	4	was	be	AUX
admet-331	52	5	in	in	ADP
admet-331	52	6	phase	phase	NOUN
admet-331	52	7	ii	ii	NOUN
admet-331	52	8	clinical	clinical	ADJ
admet-331	52	9	trials	trial	NOUN
admet-331	52	10	in	in	ADP
admet-331	52	11	2014	2014	NUM
admet-331	52	12	,	,	PUNCT
admet-331	52	13	however	however	ADV
admet-331	52	14	results	result	NOUN
admet-331	52	15	from	from	ADP
admet-331	52	16	the	the	DET
admet-331	52	17	trials	trial	NOUN
admet-331	52	18	have	have	AUX
admet-331	52	19	not	not	PART
admet-331	52	20	yet	yet	ADV
admet-331	52	21	been	be	AUX
admet-331	52	22	disclosed	disclose	VERB
admet-331	52	23	.	.	PUNCT
admet-331	53	1	another	another	DET
admet-331	53	2	soft	soft	ADJ
admet-331	53	3	rock	rock	NOUN
admet-331	53	4	inhibitor	inhibitor	NOUN
admet-331	53	5	,	,	PUNCT
admet-331	53	6	ama0428	ama0428	PROPN
admet-331	53	7	,	,	PUNCT
admet-331	53	8	has	have	AUX
admet-331	53	9	been	be	AUX
admet-331	53	10	shown	show	VERB
admet-331	53	11	to	to	PART
admet-331	53	12	not	not	PART
admet-331	53	13	only	only	ADV
admet-331	53	14	reduce	reduce	VERB
admet-331	53	15	neoangiogenesis	neoangiogenesis	NOUN
admet-331	53	16	but	but	CCONJ
admet-331	53	17	also	also	ADV
admet-331	53	18	to	to	PART
admet-331	53	19	block	block	VERB
admet-331	53	20	inflammation	inflammation	NOUN
admet-331	53	21	and	and	CCONJ
admet-331	53	22	fibrosis	fibrosis	NOUN
admet-331	53	23	in	in	ADP
admet-331	53	24	an	an	DET
admet-331	53	25	animal	animal	NOUN
admet-331	53	26	model	model	NOUN
admet-331	53	27	of	of	ADP
admet-331	53	28	neovascular	neovascular	PROPN
admet-331	53	29	age	age	NOUN
admet-331	53	30	-	-	PUNCT
admet-331	53	31	related	relate	VERB
admet-331	53	32	macular	macular	ADJ
admet-331	53	33	degeneration	degeneration	NOUN
admet-331	53	34	(	(	PUNCT
admet-331	53	35	amd	amd	PROPN
admet-331	53	36	)	)	PUNCT
admet-331	54	1	[	[	X
admet-331	54	2	16	16	NUM
admet-331	54	3	]	]	PUNCT
admet-331	54	4	.	.	PUNCT
admet-331	55	1	rock	rock	NOUN
admet-331	55	2	and	and	CCONJ
admet-331	55	3	the	the	DET
admet-331	55	4	rho	rho	ADJ
admet-331	55	5	signaling	signal	VERB
admet-331	55	6	pathway	pathway	NOUN
admet-331	55	7	rocks	rock	NOUN
admet-331	55	8	(	(	PUNCT
admet-331	55	9	also	also	ADV
admet-331	55	10	called	call	VERB
admet-331	55	11	coiled	coil	VERB
admet-331	55	12	-	-	PUNCT
admet-331	55	13	coil	coil	NOUN
admet-331	55	14	containing	contain	VERB
admet-331	55	15	protein	protein	NOUN
admet-331	55	16	kinases	kinase	NOUN
admet-331	55	17	)	)	PUNCT
admet-331	55	18	are	be	AUX
admet-331	55	19	small	small	ADJ
admet-331	55	20	160	160	NUM
admet-331	55	21	kda	kda	NOUN
admet-331	55	22	serine	serine	NOUN
admet-331	55	23	/	/	SYM
admet-331	55	24	threonine	threonine	ADJ
admet-331	55	25	kinases	kinase	NOUN
admet-331	55	26	.	.	PUNCT
admet-331	56	1	they	they	PRON
admet-331	56	2	were	be	AUX
admet-331	56	3	first	first	ADV
admet-331	56	4	described	describe	VERB
admet-331	56	5	as	as	ADP
admet-331	56	6	rhoa	rhoa	PROPN
admet-331	56	7	-	-	PUNCT
admet-331	56	8	gtp	gtp	NOUN
admet-331	56	9	interacting	interact	VERB
admet-331	56	10	proteins	protein	NOUN
admet-331	56	11	[	[	X
admet-331	56	12	17	17	NUM
admet-331	56	13	]	]	PUNCT
admet-331	56	14	.	.	PUNCT
admet-331	57	1	two	two	NUM
admet-331	57	2	isoforms	isoform	NOUN
admet-331	57	3	of	of	ADP
admet-331	57	4	rock	rock	NOUN
admet-331	57	5	have	have	AUX
admet-331	57	6	been	be	AUX
admet-331	57	7	identified	identify	VERB
admet-331	57	8	:	:	PUNCT
admet-331	57	9	rock	rock	NOUN
admet-331	57	10	i	i	PROPN
admet-331	57	11	and	and	CCONJ
admet-331	57	12	rock	rock	PROPN
admet-331	57	13	ii	ii	PROPN
admet-331	57	14	.	.	PUNCT
admet-331	58	1	in	in	ADP
admet-331	58	2	humans	human	NOUN
admet-331	58	3	the	the	DET
admet-331	58	4	two	two	NUM
admet-331	58	5	isoforms	isoform	NOUN
admet-331	58	6	share	share	VERB
admet-331	58	7	more	more	ADJ
admet-331	58	8	than	than	ADP
admet-331	58	9	60	60	NUM
admet-331	58	10	%	%	NOUN
admet-331	58	11	identity	identity	NOUN
admet-331	58	12	in	in	ADP
admet-331	58	13	their	their	PRON
admet-331	58	14	amino	amino	NOUN
admet-331	58	15	admet	admet	NOUN
admet-331	58	16	&	&	CCONJ
admet-331	58	17	dmpk	dmpk	PROPN
admet-331	58	18	4(4	4(4	NUM
admet-331	58	19	)	)	PUNCT
admet-331	58	20	(	(	PUNCT
admet-331	58	21	2016	2016	NUM
admet-331	58	22	)	)	PUNCT
admet-331	58	23	280	280	NUM
admet-331	58	24	-	-	SYM
admet-331	58	25	301	301	NUM
admet-331	58	26	rock	rock	NOUN
admet-331	58	27	inhibitors	inhibitor	NOUN
admet-331	58	28	in	in	ADP
admet-331	58	29	ocular	ocular	ADJ
admet-331	58	30	disease	disease	NOUN
admet-331	58	31	doi	doi	NOUN
admet-331	58	32	:	:	PUNCT
admet-331	58	33	10.5599	10.5599	NUM
admet-331	58	34	/	/	SYM
admet-331	58	35	admet.4.4.331	admet.4.4.331	PROPN
admet-331	58	36	283	283	NUM
admet-331	58	37	acid	acid	NOUN
admet-331	58	38	sequence	sequence	NOUN
admet-331	58	39	and	and	CCONJ
admet-331	58	40	around	around	ADV
admet-331	58	41	90	90	NUM
admet-331	58	42	%	%	NOUN
admet-331	58	43	homology	homology	NOUN
admet-331	58	44	of	of	ADP
admet-331	58	45	their	their	PRON
admet-331	58	46	kinase	kinase	NOUN
admet-331	58	47	domain	domain	NOUN
admet-331	58	48	[	[	X
admet-331	58	49	18,19	18,19	NUM
admet-331	58	50	]	]	X
admet-331	58	51	.	.	PUNCT
admet-331	59	1	structurally	structurally	ADV
admet-331	59	2	rocks	rock	NOUN
admet-331	59	3	are	be	AUX
admet-331	59	4	composed	compose	VERB
admet-331	59	5	of	of	ADP
admet-331	59	6	the	the	DET
admet-331	59	7	following	follow	VERB
admet-331	59	8	major	major	ADJ
admet-331	59	9	parts	part	NOUN
admet-331	59	10	:	:	PUNCT
admet-331	59	11	a	a	DET
admet-331	59	12	kinase	kinase	NOUN
admet-331	59	13	domain	domain	NOUN
admet-331	59	14	at	at	ADP
admet-331	59	15	the	the	DET
admet-331	59	16	n	n	PROPN
admet-331	59	17	terminal	terminal	NOUN
admet-331	59	18	,	,	PUNCT
admet-331	59	19	which	which	PRON
admet-331	59	20	phosphorylates	phosphorylate	VERB
admet-331	59	21	the	the	DET
admet-331	59	22	protein	protein	NOUN
admet-331	59	23	targets	target	NOUN
admet-331	59	24	,	,	PUNCT
admet-331	59	25	a	a	DET
admet-331	59	26	rho	rho	ADJ
admet-331	59	27	-	-	ADJ
admet-331	59	28	binding	bind	VERB
admet-331	59	29	domain	domain	NOUN
admet-331	59	30	(	(	PUNCT
admet-331	59	31	rbd	rbd	NOUN
admet-331	59	32	)	)	PUNCT
admet-331	59	33	,	,	PUNCT
admet-331	59	34	where	where	SCONJ
admet-331	59	35	the	the	DET
admet-331	59	36	upstream	upstream	ADJ
admet-331	59	37	activator	activator	NOUN
admet-331	59	38	binds	bind	VERB
admet-331	59	39	,	,	PUNCT
admet-331	59	40	and	and	CCONJ
admet-331	59	41	the	the	DET
admet-331	59	42	c	c	NOUN
admet-331	59	43	-	-	PUNCT
admet-331	59	44	terminal	terminal	NOUN
admet-331	59	45	,	,	PUNCT
admet-331	59	46	which	which	PRON
admet-331	59	47	contains	contain	VERB
admet-331	59	48	a	a	DET
admet-331	59	49	pleckstrin	pleckstrin	NOUN
admet-331	59	50	homology	homology	NOUN
admet-331	59	51	(	(	PUNCT
admet-331	59	52	ph	ph	PROPN
admet-331	59	53	)	)	PUNCT
admet-331	59	54	and	and	CCONJ
admet-331	59	55	cysteine	cysteine	ADJ
admet-331	59	56	rich	rich	ADJ
admet-331	59	57	domain	domain	NOUN
admet-331	59	58	(	(	PUNCT
admet-331	59	59	crd	crd	NOUN
admet-331	59	60	)	)	PUNCT
admet-331	59	61	.	.	PUNCT
admet-331	60	1	rho	rho	ADJ
admet-331	60	2	a	a	DET
admet-331	60	3	,	,	PUNCT
admet-331	60	4	rho	rho	ADJ
admet-331	60	5	b	b	NOUN
admet-331	60	6	and	and	CCONJ
admet-331	60	7	rho	rho	PROPN
admet-331	60	8	c	c	PROPN
admet-331	60	9	are	be	AUX
admet-331	60	10	isoforms	isoform	NOUN
admet-331	60	11	,	,	PUNCT
admet-331	60	12	small	small	ADJ
admet-331	60	13	gtpases	gtpase	NOUN
admet-331	60	14	of	of	ADP
admet-331	60	15	the	the	DET
admet-331	60	16	rho	rho	ADJ
admet-331	60	17	family	family	NOUN
admet-331	60	18	,	,	PUNCT
admet-331	60	19	and	and	CCONJ
admet-331	60	20	are	be	AUX
admet-331	60	21	usually	usually	ADV
admet-331	60	22	collectively	collectively	ADV
admet-331	60	23	known	know	VERB
admet-331	60	24	as	as	ADP
admet-331	60	25	rho	rho	ADJ
admet-331	60	26	[	[	X
admet-331	60	27	17	17	NUM
admet-331	60	28	]	]	PUNCT
admet-331	60	29	.	.	PUNCT
admet-331	61	1	rocks	rock	NOUN
admet-331	61	2	can	can	AUX
admet-331	61	3	be	be	AUX
admet-331	61	4	activated	activate	VERB
admet-331	61	5	by	by	ADP
admet-331	61	6	the	the	DET
admet-331	61	7	gtp	gtp	NOUN
admet-331	61	8	-	-	PUNCT
admet-331	61	9	bound	bind	VERB
admet-331	61	10	form	form	NOUN
admet-331	61	11	of	of	ADP
admet-331	61	12	rho	rho	NOUN
admet-331	61	13	.	.	PUNCT
admet-331	62	1	binding	bind	VERB
admet-331	62	2	of	of	ADP
admet-331	62	3	rho	rho	ADJ
admet-331	62	4	-	-	PUNCT
admet-331	62	5	gtp	gtp	NOUN
admet-331	62	6	opens	open	VERB
admet-331	62	7	the	the	DET
admet-331	62	8	loop	loop	NOUN
admet-331	62	9	formation	formation	NOUN
admet-331	62	10	of	of	ADP
admet-331	62	11	the	the	DET
admet-331	62	12	enzyme	enzyme	NOUN
admet-331	62	13	,	,	PUNCT
admet-331	62	14	and	and	CCONJ
admet-331	62	15	the	the	DET
admet-331	62	16	activated	activate	VERB
admet-331	62	17	form	form	NOUN
admet-331	62	18	then	then	ADV
admet-331	62	19	phosphorylates	phosphorylate	VERB
admet-331	62	20	downstream	downstream	ADJ
admet-331	62	21	targets	target	NOUN
admet-331	62	22	[	[	X
admet-331	62	23	17	17	NUM
admet-331	62	24	]	]	PUNCT
admet-331	62	25	(	(	PUNCT
admet-331	62	26	figure	figure	NOUN
admet-331	62	27	1	1	NUM
admet-331	62	28	)	)	PUNCT
admet-331	62	29	.	.	PUNCT
admet-331	63	1	among	among	ADP
admet-331	63	2	other	other	ADJ
admet-331	63	3	substrates	substrate	NOUN
admet-331	63	4	,	,	PUNCT
admet-331	63	5	rock	rock	NOUN
admet-331	63	6	directly	directly	ADV
admet-331	63	7	phosphorylates	phosphorylate	VERB
admet-331	63	8	myosin	myosin	PROPN
admet-331	63	9	light	light	PROPN
admet-331	63	10	chain	chain	PROPN
admet-331	63	11	(	(	PUNCT
admet-331	63	12	mlc	mlc	PROPN
admet-331	63	13	)	)	PUNCT
admet-331	63	14	and	and	CCONJ
admet-331	63	15	the	the	DET
admet-331	63	16	myosin	myosin	NOUN
admet-331	63	17	binding	bind	VERB
admet-331	63	18	subunit	subunit	NOUN
admet-331	63	19	of	of	ADP
admet-331	63	20	myosin	myosin	PROPN
admet-331	63	21	light	light	PROPN
admet-331	63	22	chain	chain	NOUN
admet-331	63	23	phosphatase	phosphatase	NOUN
admet-331	63	24	,	,	PUNCT
admet-331	63	25	thereby	thereby	ADV
admet-331	63	26	enhancing	enhance	VERB
admet-331	63	27	actin	actin	NOUN
admet-331	63	28	-	-	PUNCT
admet-331	63	29	myosin	myosin	NOUN
admet-331	63	30	-	-	PUNCT
admet-331	63	31	mediated	mediate	VERB
admet-331	63	32	contractility	contractility	NOUN
admet-331	63	33	and	and	CCONJ
admet-331	63	34	promoting	promote	VERB
admet-331	63	35	formation	formation	NOUN
admet-331	63	36	of	of	ADP
admet-331	63	37	stress	stress	ADJ
admet-331	63	38	fibers	fiber	NOUN
admet-331	63	39	and	and	CCONJ
admet-331	63	40	focal	focal	ADJ
admet-331	63	41	adhesions	adhesion	NOUN
admet-331	63	42	[	[	X
admet-331	63	43	20	20	NUM
admet-331	63	44	-	-	SYM
admet-331	63	45	22	22	NUM
admet-331	63	46	]	]	PUNCT
admet-331	63	47	.	.	PUNCT
admet-331	64	1	lim	lim	PROPN
admet-331	64	2	kinases	kinases	PROPN
admet-331	64	3	are	be	AUX
admet-331	64	4	also	also	ADV
admet-331	64	5	downstream	downstream	ADJ
admet-331	64	6	targets	target	NOUN
admet-331	64	7	of	of	ADP
admet-331	64	8	rock	rock	NOUN
admet-331	64	9	,	,	PUNCT
admet-331	64	10	and	and	CCONJ
admet-331	64	11	these	these	DET
admet-331	64	12	kinases	kinase	NOUN
admet-331	64	13	have	have	VERB
admet-331	64	14	a	a	DET
admet-331	64	15	pivotal	pivotal	ADJ
admet-331	64	16	role	role	NOUN
admet-331	64	17	in	in	ADP
admet-331	64	18	cofilin	cofilin	NOUN
admet-331	64	19	-	-	PUNCT
admet-331	64	20	mediated	mediate	VERB
admet-331	64	21	actin	actin	NOUN
admet-331	64	22	filament	filament	NOUN
admet-331	64	23	disassembly	disassembly	NOUN
admet-331	64	24	.	.	PUNCT
admet-331	65	1	cofilin	cofilin	PROPN
admet-331	65	2	binds	bind	VERB
admet-331	65	3	to	to	ADP
admet-331	65	4	actin	actin	VERB
admet-331	65	5	and	and	CCONJ
admet-331	65	6	enhances	enhance	VERB
admet-331	65	7	actin	actin	NOUN
admet-331	65	8	depolymerization	depolymerization	NOUN
admet-331	65	9	,	,	PUNCT
admet-331	65	10	whereas	whereas	SCONJ
admet-331	65	11	activated	activate	VERB
admet-331	65	12	lim	lim	PROPN
admet-331	65	13	kinases	kinases	PROPN
admet-331	65	14	phosphorylate	phosphorylate	VERB
admet-331	65	15	the	the	DET
admet-331	65	16	cofilin	cofilin	NOUN
admet-331	65	17	and	and	CCONJ
admet-331	65	18	inhibit	inhibit	VERB
admet-331	65	19	its	its	PRON
admet-331	65	20	filament	filament	NOUN
admet-331	65	21	binding	bind	VERB
admet-331	65	22	activity	activity	NOUN
admet-331	65	23	[	[	X
admet-331	65	24	23	23	NUM
admet-331	65	25	]	]	PUNCT
admet-331	65	26	.	.	PUNCT
admet-331	66	1	rocks	rock	NOUN
admet-331	66	2	also	also	ADV
admet-331	66	3	phosphorylate	phosphorylate	VERB
admet-331	66	4	other	other	ADJ
admet-331	66	5	actin	actin	NOUN
admet-331	66	6	binding	bind	VERB
admet-331	66	7	proteins	protein	NOUN
admet-331	66	8	,	,	PUNCT
admet-331	66	9	for	for	ADP
admet-331	66	10	instance	instance	NOUN
admet-331	66	11	adducin	adducin	PROPN
admet-331	66	12	,	,	PUNCT
admet-331	66	13	which	which	PRON
admet-331	66	14	interacts	interact	VERB
admet-331	66	15	with	with	ADP
admet-331	66	16	spectrin	spectrin	NOUN
admet-331	66	17	-	-	PUNCT
admet-331	66	18	actinnetworks	actinnetwork	NOUN
admet-331	66	19	and	and	CCONJ
admet-331	66	20	erm	erm	PROPN
admet-331	66	21	(	(	PUNCT
admet-331	66	22	ezrin	ezrin	NOUN
admet-331	66	23	-	-	PUNCT
admet-331	66	24	radixin	radixin	NOUN
admet-331	66	25	-	-	PUNCT
admet-331	66	26	moesin	moesin	NOUN
admet-331	66	27	)	)	PUNCT
admet-331	66	28	proteins	protein	NOUN
admet-331	66	29	which	which	PRON
admet-331	66	30	are	be	AUX
admet-331	66	31	cross	cross	NOUN
admet-331	66	32	linkers	linker	NOUN
admet-331	66	33	between	between	ADP
admet-331	66	34	actin	actin	NOUN
admet-331	66	35	filaments	filament	NOUN
admet-331	66	36	and	and	CCONJ
admet-331	66	37	membrane	membrane	NOUN
admet-331	66	38	proteins	protein	NOUN
admet-331	66	39	[	[	X
admet-331	66	40	17,24	17,24	NUM
admet-331	66	41	]	]	PUNCT
admet-331	66	42	.	.	PUNCT
admet-331	67	1	taken	take	VERB
admet-331	67	2	together	together	ADV
admet-331	67	3	,	,	PUNCT
admet-331	67	4	rho	rho	ADJ
admet-331	67	5	pathway	pathway	NOUN
admet-331	67	6	activation	activation	NOUN
admet-331	67	7	leads	lead	VERB
admet-331	67	8	to	to	ADP
admet-331	67	9	a	a	DET
admet-331	67	10	concerted	concerted	ADJ
admet-331	67	11	series	series	NOUN
admet-331	67	12	of	of	ADP
admet-331	67	13	events	event	NOUN
admet-331	67	14	resulting	result	VERB
admet-331	67	15	in	in	ADP
admet-331	67	16	increased	increase	VERB
admet-331	67	17	actin	actin	NOUN
admet-331	67	18	-	-	PUNCT
admet-331	67	19	myosin	myosin	NOUN
admet-331	67	20	contractility	contractility	NOUN
admet-331	67	21	and	and	CCONJ
admet-331	67	22	cytoskeletal	cytoskeletal	ADJ
admet-331	67	23	change	change	NOUN
admet-331	67	24	.	.	PUNCT
admet-331	68	1	figure	figure	NOUN
admet-331	68	2	1	1	NUM
admet-331	68	3	.	.	PUNCT
admet-331	69	1	regulation	regulation	NOUN
admet-331	69	2	of	of	ADP
admet-331	69	3	rho	rho	ADJ
admet-331	69	4	kinase	kinase	NOUN
admet-331	69	5	(	(	PUNCT
admet-331	69	6	rock	rock	NOUN
admet-331	69	7	)	)	PUNCT
admet-331	69	8	and	and	CCONJ
admet-331	69	9	downstream	downstream	ADJ
admet-331	69	10	effectors	effector	NOUN
admet-331	69	11	.	.	PUNCT
admet-331	70	1	(	(	PUNCT
admet-331	70	2	rbd	rbd	NOUN
admet-331	70	3	:	:	PUNCT
admet-331	70	4	rho	rho	ADJ
admet-331	70	5	-	-	ADJ
admet-331	70	6	binding	bind	VERB
admet-331	70	7	domain	domain	NOUN
admet-331	70	8	,	,	PUNCT
admet-331	70	9	ph	ph	ADJ
admet-331	70	10	:	:	PUNCT
admet-331	70	11	pleckstrin	pleckstrin	ADJ
admet-331	70	12	homology	homology	NOUN
admet-331	70	13	domain	domain	NOUN
admet-331	70	14	,	,	PUNCT
admet-331	70	15	crb	crb	PROPN
admet-331	70	16	:	:	PUNCT
admet-331	70	17	cysteine	cysteine	NOUN
admet-331	70	18	-	-	PUNCT
admet-331	70	19	rich	rich	ADJ
admet-331	70	20	region	region	NOUN
admet-331	70	21	domain	domain	NOUN
admet-331	70	22	,	,	PUNCT
admet-331	70	23	gef	gef	NOUN
admet-331	70	24	:	:	PUNCT
admet-331	70	25	guaninenucleotide	guaninenucleotide	ADJ
admet-331	70	26	exchange	exchange	NOUN
admet-331	70	27	factor	factor	NOUN
admet-331	70	28	,	,	PUNCT
admet-331	70	29	gap	gap	NOUN
admet-331	70	30	:	:	PUNCT
admet-331	70	31	gtpase	gtpase	NOUN
admet-331	70	32	activating	activate	VERB
admet-331	70	33	proteins	protein	NOUN
admet-331	70	34	,	,	PUNCT
admet-331	70	35	gdp	gdp	NOUN
admet-331	70	36	:	:	PUNCT
admet-331	70	37	guanosine	guanosine	PROPN
admet-331	70	38	diphosphate	diphosphate	PROPN
admet-331	70	39	,	,	PUNCT
admet-331	70	40	gtp	gtp	PROPN
admet-331	70	41	:	:	PUNCT
admet-331	70	42	guanosine	guanosine	NOUN
admet-331	70	43	triphosphate	triphosphate	NOUN
admet-331	70	44	,	,	PUNCT
admet-331	70	45	mlcp	mlcp	NOUN
admet-331	70	46	:	:	PUNCT
admet-331	70	47	myosin	myosin	PROPN
admet-331	70	48	light	light	PROPN
admet-331	70	49	chain	chain	NOUN
admet-331	70	50	phosphatase	phosphatase	NOUN
admet-331	70	51	,	,	PUNCT
admet-331	70	52	mlc	mlc	PROPN
admet-331	70	53	:	:	PUNCT
admet-331	70	54	myosin	myosin	PROPN
admet-331	70	55	light	light	PROPN
admet-331	70	56	chain	chain	NOUN
admet-331	70	57	,	,	PUNCT
admet-331	70	58	limk	limk	PROPN
admet-331	70	59	:	:	PUNCT
admet-331	70	60	lim	lim	PROPN
admet-331	70	61	kinases	kinases	PROPN
admet-331	70	62	,	,	PUNCT
admet-331	70	63	marck	marck	PROPN
admet-331	70	64	:	:	PUNCT
admet-331	70	65	myristoylated	myristoylate	VERB
admet-331	70	66	alanine	alanine	NOUN
admet-331	70	67	-	-	PUNCT
admet-331	70	68	rich	rich	ADJ
admet-331	70	69	c	c	PROPN
admet-331	70	70	kinase	kinase	NOUN
admet-331	70	71	substrate	substrate	NOUN
admet-331	70	72	,	,	PUNCT
admet-331	70	73	nf	nf	NOUN
admet-331	70	74	-	-	PUNCT
admet-331	70	75	l	l	NOUN
admet-331	70	76	:	:	PUNCT
admet-331	70	77	neurofilament	neurofilament	ADJ
admet-331	70	78	l	l	PROPN
admet-331	70	79	protein	protein	NOUN
admet-331	70	80	,	,	PUNCT
admet-331	70	81	crmp2	crmp2	PROPN
admet-331	70	82	:	:	PUNCT
admet-331	70	83	collapsin	collapsin	PROPN
admet-331	70	84	response	response	PROPN
admet-331	70	85	mediator	mediator	PROPN
admet-331	70	86	protein-2	protein-2	PROPN
admet-331	70	87	,	,	PUNCT
admet-331	70	88	nhe-1	nhe-1	NOUN
admet-331	70	89	:	:	PUNCT
admet-331	70	90	sodium	sodium	NOUN
admet-331	70	91	/	/	SYM
admet-331	70	92	hydrogen	hydrogen	PROPN
admet-331	70	93	exchanger-1	exchanger-1	NOUN
admet-331	70	94	,	,	PUNCT
admet-331	70	95	erm	erm	PROPN
admet-331	70	96	:	:	PUNCT
admet-331	70	97	ezrin	ezrin	NOUN
admet-331	70	98	-	-	PUNCT
admet-331	70	99	radixin	radixin	NOUN
admet-331	70	100	-	-	PUNCT
admet-331	70	101	moesin	moesin	NOUN
admet-331	70	102	)	)	PUNCT
admet-331	70	103	genetic	genetic	ADJ
admet-331	70	104	deletion	deletion	NOUN
admet-331	70	105	of	of	ADP
admet-331	70	106	rock	rock	NOUN
admet-331	70	107	i	i	PROPN
admet-331	70	108	and	and	CCONJ
admet-331	70	109	ii	ii	PROPN
admet-331	70	110	in	in	ADP
admet-331	70	111	mice	mouse	NOUN
admet-331	70	112	helped	helped	AUX
admet-331	70	113	explore	explore	VERB
admet-331	70	114	specific	specific	ADJ
admet-331	70	115	functions	function	NOUN
admet-331	70	116	of	of	ADP
admet-331	70	117	rock	rock	NOUN
admet-331	70	118	i	i	PROPN
admet-331	70	119	and	and	CCONJ
admet-331	70	120	rock	rock	PROPN
admet-331	70	121	ii	ii	PROPN
admet-331	70	122	(	(	PUNCT
admet-331	70	123	during	during	ADP
admet-331	70	124	development	development	NOUN
admet-331	70	125	)	)	PUNCT
admet-331	70	126	.	.	PUNCT
admet-331	71	1	homozygous	homozygous	ADJ
admet-331	71	2	rock	rock	NOUN
admet-331	71	3	i	i	PRON
admet-331	71	4	-/-mice	-/-mice	PROPN
admet-331	71	5	were	be	AUX
admet-331	71	6	born	bear	VERB
admet-331	71	7	in	in	ADP
admet-331	71	8	the	the	DET
admet-331	71	9	expected	expect	VERB
admet-331	71	10	mendelian	mendelian	ADJ
admet-331	71	11	ratio	ratio	NOUN
admet-331	71	12	,	,	PUNCT
admet-331	71	13	however	however	ADV
admet-331	71	14	they	they	PRON
admet-331	71	15	had	have	VERB
admet-331	71	16	a	a	DET
admet-331	71	17	developmental	developmental	ADJ
admet-331	71	18	defect	defect	NOUN
admet-331	71	19	in	in	ADP
admet-331	71	20	eyelid	eyelid	NOUN
admet-331	71	21	and	and	CCONJ
admet-331	71	22	ventral	ventral	ADJ
admet-331	71	23	body	body	NOUN
admet-331	71	24	closure	closure	NOUN
admet-331	71	25	,	,	PUNCT
admet-331	71	26	resulting	result	VERB
admet-331	71	27	in	in	ADP
admet-331	71	28	different	different	ADJ
admet-331	71	29	degrees	degree	NOUN
admet-331	71	30	of	of	ADP
admet-331	71	31	eye	eye	NOUN
admet-331	71	32	opening	opening	NOUN
admet-331	71	33	at	at	ADP
admet-331	71	34	birth	birth	NOUN
admet-331	71	35	(	(	PUNCT
admet-331	71	36	eob	eob	PROPN
admet-331	71	37	)	)	PUNCT
admet-331	71	38	and	and	CCONJ
admet-331	71	39	omphalocele	omphalocele	NOUN
admet-331	72	1	[	[	X
admet-331	72	2	25	25	NUM
admet-331	72	3	]	]	PUNCT
admet-331	72	4	.	.	PUNCT
admet-331	73	1	in	in	ADP
admet-331	73	2	contrast	contrast	NOUN
admet-331	73	3	,	,	PUNCT
admet-331	73	4	for	for	ADP
admet-331	73	5	rock	rock	PROPN
admet-331	73	6	ii	ii	PROPN
admet-331	73	7	-/mice	-/mice	PROPN
admet-331	73	8	,	,	PUNCT
admet-331	73	9	approximately	approximately	ADV
admet-331	73	10	90	90	NUM
admet-331	73	11	%	%	NOUN
admet-331	73	12	of	of	ADP
admet-331	73	13	the	the	DET
admet-331	73	14	embryos	embryo	NOUN
admet-331	73	15	died	die	VERB
admet-331	73	16	in	in	ADP
admet-331	73	17	utero	utero	PROPN
admet-331	73	18	.	.	PUNCT
admet-331	74	1	the	the	DET
admet-331	74	2	newborns	newborn	NOUN
admet-331	74	3	that	that	PRON
admet-331	74	4	did	do	AUX
admet-331	74	5	survive	survive	VERB
admet-331	74	6	were	be	AUX
admet-331	74	7	runts	runt	NOUN
admet-331	74	8	,	,	PUNCT
admet-331	74	9	albeit	albeit	SCONJ
admet-331	74	10	subsequently	subsequently	ADV
admet-331	74	11	fertile	fertile	ADJ
admet-331	74	12	without	without	ADP
admet-331	74	13	particular	particular	ADJ
admet-331	74	14	anatomical	anatomical	ADJ
admet-331	74	15	abnormality	abnormality	NOUN
admet-331	74	16	[	[	X
admet-331	74	17	26	26	NUM
admet-331	74	18	]	]	PUNCT
admet-331	74	19	.	.	PUNCT
admet-331	75	1	double	double	ADJ
admet-331	75	2	rock	rock	NOUN
admet-331	75	3	i	i	PROPN
admet-331	75	4	+	+	PROPN
admet-331	75	5	/and	/and	PROPN
admet-331	75	6	rock	rock	PROPN
admet-331	75	7	ii	ii	PROPN
admet-331	76	1	+	+	NOUN
admet-331	76	2	/heterozygous	/heterozygous	ADJ
admet-331	76	3	mice	mouse	NOUN
admet-331	76	4	were	be	AUX
admet-331	76	5	also	also	ADV
admet-331	76	6	born	bear	VERB
admet-331	76	7	with	with	ADP
admet-331	76	8	open	open	ADJ
admet-331	76	9	eyelids	eyelid	NOUN
admet-331	76	10	and	and	CCONJ
admet-331	76	11	incomplete	incomplete	ADJ
admet-331	76	12	ventral	ventral	ADJ
admet-331	76	13	body	body	NOUN
admet-331	76	14	closure	closure	NOUN
admet-331	76	15	[	[	X
admet-331	76	16	27	27	NUM
admet-331	76	17	]	]	PUNCT
admet-331	76	18	.	.	PUNCT
admet-331	77	1	histological	histological	ADJ
admet-331	77	2	examination	examination	NOUN
admet-331	77	3	revealed	reveal	VERB
admet-331	77	4	impaired	impaired	ADJ
admet-331	77	5	formation	formation	NOUN
admet-331	77	6	of	of	ADP
admet-331	77	7	actomyosin	actomyosin	NOUN
admet-331	77	8	cables	cable	NOUN
admet-331	77	9	,	,	PUNCT
admet-331	77	10	demonstrating	demonstrate	VERB
admet-331	77	11	that	that	SCONJ
admet-331	77	12	both	both	DET
admet-331	77	13	kinases	kinase	NOUN
admet-331	77	14	promote	promote	VERB
admet-331	77	15	actin	actin	NOUN
admet-331	77	16	bundling	bundle	VERB
admet-331	77	17	in	in	ADP
admet-331	77	18	vivo	vivo	NOUN
admet-331	77	19	.	.	PUNCT
admet-331	78	1	however	however	ADV
admet-331	78	2	,	,	PUNCT
admet-331	78	3	the	the	DET
admet-331	78	4	results	result	NOUN
admet-331	78	5	suggest	suggest	VERB
admet-331	78	6	that	that	SCONJ
admet-331	78	7	the	the	DET
admet-331	78	8	function	function	NOUN
admet-331	78	9	of	of	ADP
admet-331	78	10	two	two	NUM
admet-331	78	11	enzymes	enzyme	NOUN
admet-331	78	12	are	be	AUX
admet-331	78	13	not	not	PART
admet-331	78	14	100	100	NUM
admet-331	78	15	%	%	NOUN
admet-331	78	16	identical	identical	ADJ
admet-331	78	17	;	;	PUNCT
admet-331	78	18	in	in	ADP
admet-331	78	19	these	these	DET
admet-331	78	20	systems	system	NOUN
admet-331	78	21	,	,	PUNCT
admet-331	78	22	the	the	DET
admet-331	78	23	isoforms	isoform	NOUN
admet-331	78	24	éva	éva	PROPN
admet-331	78	25	halász	halász	NOUN
admet-331	78	26	,	,	PUNCT
admet-331	78	27	ellen	ellen	PROPN
admet-331	78	28	townes	townes	PROPN
admet-331	78	29	-	-	PUNCT
admet-331	78	30	anderson	anderson	PROPN
admet-331	78	31	admet	admet	PROPN
admet-331	78	32	&	&	CCONJ
admet-331	78	33	dmpk	dmpk	PROPN
admet-331	78	34	4(4	4(4	NUM
admet-331	78	35	)	)	PUNCT
admet-331	78	36	(	(	PUNCT
admet-331	78	37	2016	2016	NUM
admet-331	78	38	)	)	PUNCT
admet-331	78	39	280	280	NUM
admet-331	78	40	-	-	SYM
admet-331	78	41	301	301	NUM
admet-331	78	42	284	284	NUM
admet-331	78	43	do	do	AUX
admet-331	78	44	not	not	PART
admet-331	78	45	compensate	compensate	VERB
admet-331	78	46	for	for	ADP
admet-331	78	47	the	the	DET
admet-331	78	48	loss	loss	NOUN
admet-331	78	49	of	of	ADP
admet-331	78	50	each	each	DET
admet-331	78	51	other	other	ADJ
admet-331	78	52	.	.	PUNCT
admet-331	79	1	both	both	DET
admet-331	79	2	rock	rock	NOUN
admet-331	79	3	isomers	isomer	NOUN
admet-331	79	4	are	be	AUX
admet-331	79	5	present	present	ADJ
admet-331	79	6	in	in	ADP
admet-331	79	7	ocular	ocular	ADJ
admet-331	79	8	tissues	tissue	NOUN
admet-331	80	1	[	[	X
admet-331	80	2	28	28	NUM
admet-331	80	3	]	]	PUNCT
admet-331	80	4	and	and	CCONJ
admet-331	80	5	aberrant	aberrant	ADJ
admet-331	80	6	regulation	regulation	NOUN
admet-331	80	7	of	of	ADP
admet-331	80	8	rock	rock	NOUN
admet-331	80	9	levels	level	NOUN
admet-331	80	10	plays	play	VERB
admet-331	80	11	a	a	DET
admet-331	80	12	role	role	NOUN
admet-331	80	13	in	in	ADP
admet-331	80	14	the	the	DET
admet-331	80	15	pathogenesis	pathogenesis	NOUN
admet-331	80	16	of	of	ADP
admet-331	80	17	glaucoma	glaucoma	NOUN
admet-331	80	18	,	,	PUNCT
admet-331	80	19	diabetic	diabetic	ADJ
admet-331	80	20	retinopathy	retinopathy	NOUN
admet-331	80	21	,	,	PUNCT
admet-331	80	22	and	and	CCONJ
admet-331	80	23	amd	amd	ADJ
admet-331	80	24	,	,	PUNCT
admet-331	80	25	to	to	PART
admet-331	80	26	mention	mention	VERB
admet-331	80	27	the	the	DET
admet-331	80	28	most	most	ADV
admet-331	80	29	frequently	frequently	ADV
admet-331	80	30	investigated	investigate	VERB
admet-331	80	31	areas	area	NOUN
admet-331	80	32	.	.	PUNCT
admet-331	81	1	corneal	corneal	ADJ
admet-331	81	2	wound	wound	ADJ
admet-331	81	3	healing	heal	VERB
admet-331	81	4	corneal	corneal	ADJ
admet-331	81	5	endothelial	endothelial	ADJ
admet-331	81	6	cells	cell	NOUN
admet-331	81	7	are	be	AUX
admet-331	81	8	the	the	DET
admet-331	81	9	innermost	innermost	ADJ
admet-331	81	10	layer	layer	NOUN
admet-331	81	11	of	of	ADP
admet-331	81	12	the	the	DET
admet-331	81	13	cornea	cornea	NOUN
admet-331	81	14	and	and	CCONJ
admet-331	81	15	have	have	VERB
admet-331	81	16	a	a	DET
admet-331	81	17	crucial	crucial	ADJ
admet-331	81	18	role	role	NOUN
admet-331	81	19	in	in	ADP
admet-331	81	20	maintaining	maintain	VERB
admet-331	81	21	cornea	cornea	NOUN
admet-331	81	22	transparency	transparency	NOUN
admet-331	81	23	.	.	PUNCT
admet-331	82	1	in	in	ADP
admet-331	82	2	late	late	ADJ
admet-331	82	3	adulthood	adulthood	NOUN
admet-331	82	4	,	,	PUNCT
admet-331	82	5	the	the	DET
admet-331	82	6	cell	cell	NOUN
admet-331	82	7	density	density	NOUN
admet-331	82	8	of	of	ADP
admet-331	82	9	the	the	DET
admet-331	82	10	healthy	healthy	ADJ
admet-331	82	11	cornea	cornea	NOUN
admet-331	82	12	endothelium	endothelium	NOUN
admet-331	82	13	is	be	AUX
admet-331	82	14	approximately	approximately	ADV
admet-331	82	15	2500	2500	NUM
admet-331	82	16	cells	cell	NOUN
admet-331	82	17	/	/	SYM
admet-331	82	18	mm2	mm2	NOUN
admet-331	82	19	,	,	PUNCT
admet-331	82	20	however	however	ADV
admet-331	82	21	if	if	SCONJ
admet-331	82	22	for	for	ADP
admet-331	82	23	some	some	DET
admet-331	82	24	reason	reason	NOUN
admet-331	82	25	density	density	NOUN
admet-331	82	26	falls	fall	VERB
admet-331	82	27	under	under	ADP
admet-331	82	28	the	the	DET
admet-331	82	29	critical	critical	ADJ
admet-331	82	30	level	level	NOUN
admet-331	82	31	of	of	ADP
admet-331	82	32	500	500	NUM
admet-331	82	33	cells	cell	NOUN
admet-331	82	34	/	/	SYM
admet-331	82	35	mm2	mm2	NOUN
admet-331	82	36	compensatory	compensatory	ADJ
admet-331	82	37	changes	change	NOUN
admet-331	82	38	begin	begin	VERB
admet-331	82	39	and	and	CCONJ
admet-331	82	40	the	the	DET
admet-331	82	41	cornea	cornea	NOUN
admet-331	82	42	exhibits	exhibit	VERB
admet-331	82	43	edema	edema	NOUN
admet-331	82	44	and	and	CCONJ
admet-331	82	45	haziness	haziness	NOUN
admet-331	82	46	,	,	PUNCT
admet-331	82	47	notably	notably	ADV
admet-331	82	48	decreasing	decrease	VERB
admet-331	82	49	visual	visual	ADJ
admet-331	82	50	acuity	acuity	NOUN
admet-331	82	51	.	.	PUNCT
admet-331	83	1	typical	typical	ADJ
admet-331	83	2	reasons	reason	NOUN
admet-331	83	3	for	for	ADP
admet-331	83	4	endothelial	endothelial	ADJ
admet-331	83	5	cell	cell	NOUN
admet-331	83	6	loss	loss	NOUN
admet-331	83	7	can	can	AUX
admet-331	83	8	be	be	AUX
admet-331	83	9	trauma	trauma	NOUN
admet-331	83	10	caused	cause	VERB
admet-331	83	11	by	by	ADP
admet-331	83	12	cataract	cataract	NOUN
admet-331	83	13	surgery	surgery	NOUN
admet-331	83	14	,	,	PUNCT
admet-331	83	15	pseudophakic	pseudophakic	NOUN
admet-331	83	16	bullous	bullous	ADJ
admet-331	83	17	keratopathy	keratopathy	ADJ
admet-331	83	18	and	and	CCONJ
admet-331	83	19	fuchs	fuchs	VERB
admet-331	83	20	endothelial	endothelial	ADJ
admet-331	83	21	dystrophy	dystrophy	NOUN
admet-331	83	22	.	.	PUNCT
admet-331	84	1	since	since	SCONJ
admet-331	84	2	human	human	ADJ
admet-331	84	3	endothelial	endothelial	NOUN
admet-331	84	4	cells	cell	NOUN
admet-331	84	5	have	have	VERB
admet-331	84	6	poor	poor	ADJ
admet-331	84	7	in	in	ADP
admet-331	84	8	vivo	vivo	ADJ
admet-331	84	9	proliferative	proliferative	ADJ
admet-331	84	10	potency	potency	NOUN
admet-331	84	11	,	,	PUNCT
admet-331	84	12	these	these	DET
admet-331	84	13	conditions	condition	NOUN
admet-331	84	14	lead	lead	VERB
admet-331	84	15	to	to	ADP
admet-331	84	16	compensatory	compensatory	ADJ
admet-331	84	17	enlargement	enlargement	NOUN
admet-331	84	18	of	of	ADP
admet-331	84	19	the	the	DET
admet-331	84	20	remaining	remain	VERB
admet-331	84	21	endothelial	endothelial	ADJ
admet-331	84	22	cells	cell	NOUN
admet-331	84	23	and	and	CCONJ
admet-331	84	24	corneal	corneal	ADJ
admet-331	84	25	endothelial	endothelial	ADJ
admet-331	84	26	dysfunction	dysfunction	NOUN
admet-331	84	27	.	.	PUNCT
admet-331	85	1	long	long	ADJ
admet-331	85	2	term	term	NOUN
admet-331	85	3	,	,	PUNCT
admet-331	85	4	chronic	chronic	ADJ
admet-331	85	5	inflammation	inflammation	NOUN
admet-331	85	6	and	and	CCONJ
admet-331	85	7	cytokine	cytokine	ADJ
admet-331	85	8	imbalance	imbalance	NOUN
admet-331	85	9	can	can	AUX
admet-331	85	10	also	also	ADV
admet-331	85	11	cause	cause	VERB
admet-331	85	12	corneal	corneal	ADJ
admet-331	85	13	neovascularization	neovascularization	NOUN
admet-331	85	14	,	,	PUNCT
admet-331	85	15	which	which	PRON
admet-331	85	16	affects	affect	VERB
admet-331	85	17	different	different	ADJ
admet-331	85	18	layers	layer	NOUN
admet-331	85	19	of	of	ADP
admet-331	85	20	the	the	DET
admet-331	85	21	cornea	cornea	NOUN
admet-331	85	22	.	.	PUNCT
admet-331	86	1	at	at	ADP
admet-331	86	2	present	present	ADJ
admet-331	86	3	definitive	definitive	ADJ
admet-331	86	4	clinical	clinical	ADJ
admet-331	86	5	therapy	therapy	NOUN
admet-331	86	6	for	for	ADP
admet-331	86	7	effective	effective	ADJ
admet-331	86	8	treatment	treatment	NOUN
admet-331	86	9	of	of	ADP
admet-331	86	10	corneal	corneal	ADJ
admet-331	86	11	endothelial	endothelial	ADJ
admet-331	86	12	dysfunction	dysfunction	NOUN
admet-331	86	13	has	have	AUX
admet-331	86	14	not	not	PART
admet-331	86	15	been	be	AUX
admet-331	86	16	developed	develop	VERB
admet-331	86	17	.	.	PUNCT
admet-331	87	1	in	in	ADP
admet-331	87	2	advanced	advanced	ADJ
admet-331	87	3	phases	phase	NOUN
admet-331	87	4	,	,	PUNCT
admet-331	87	5	corneal	corneal	ADJ
admet-331	87	6	transplantation	transplantation	NOUN
admet-331	87	7	can	can	AUX
admet-331	87	8	be	be	AUX
admet-331	87	9	performed	perform	VERB
admet-331	87	10	,	,	PUNCT
admet-331	87	11	however	however	ADV
admet-331	87	12	several	several	ADJ
admet-331	87	13	problems	problem	NOUN
admet-331	87	14	can	can	AUX
admet-331	87	15	arise	arise	VERB
admet-331	87	16	associated	associate	VERB
admet-331	87	17	with	with	ADP
admet-331	87	18	the	the	DET
admet-331	87	19	operation	operation	NOUN
admet-331	87	20	including	include	VERB
admet-331	87	21	primary	primary	ADJ
admet-331	87	22	graft	graft	NOUN
admet-331	87	23	failure	failure	NOUN
admet-331	87	24	,	,	PUNCT
admet-331	87	25	graft	graft	NOUN
admet-331	87	26	rejection	rejection	NOUN
admet-331	87	27	or	or	CCONJ
admet-331	87	28	inflammation	inflammation	NOUN
admet-331	87	29	.	.	PUNCT
admet-331	88	1	however	however	ADV
admet-331	88	2	,	,	PUNCT
admet-331	88	3	in	in	ADP
admet-331	88	4	the	the	DET
admet-331	88	5	past	past	ADJ
admet-331	88	6	few	few	ADJ
admet-331	88	7	years	year	NOUN
admet-331	88	8	rock	rock	NOUN
admet-331	88	9	inhibitors	inhibitor	NOUN
admet-331	88	10	have	have	AUX
admet-331	88	11	been	be	AUX
admet-331	88	12	investigated	investigate	VERB
admet-331	88	13	to	to	PART
admet-331	88	14	elucidate	elucidate	VERB
admet-331	88	15	their	their	PRON
admet-331	88	16	role	role	NOUN
admet-331	88	17	and	and	CCONJ
admet-331	88	18	potential	potential	ADJ
admet-331	88	19	applicability	applicability	NOUN
admet-331	88	20	as	as	ADP
admet-331	88	21	treatment	treatment	NOUN
admet-331	88	22	of	of	ADP
admet-331	88	23	corneal	corneal	ADJ
admet-331	88	24	endothelial	endothelial	ADJ
admet-331	88	25	disorders	disorder	NOUN
admet-331	88	26	.	.	PUNCT
admet-331	89	1	intriguing	intriguing	ADJ
admet-331	89	2	recent	recent	ADJ
admet-331	89	3	findings	finding	NOUN
admet-331	89	4	suggest	suggest	VERB
admet-331	89	5	that	that	SCONJ
admet-331	89	6	rock	rock	NOUN
admet-331	89	7	inhibitors	inhibitor	NOUN
admet-331	89	8	have	have	VERB
admet-331	89	9	a	a	DET
admet-331	89	10	beneficial	beneficial	ADJ
admet-331	89	11	effect	effect	NOUN
admet-331	89	12	in	in	ADP
admet-331	89	13	corneal	corneal	ADJ
admet-331	89	14	wound	wound	ADJ
admet-331	89	15	healing	healing	NOUN
admet-331	89	16	.	.	PUNCT
admet-331	90	1	in	in	ADP
admet-331	90	2	2009	2009	NUM
admet-331	90	3	,	,	PUNCT
admet-331	90	4	okumara	okumara	PROPN
admet-331	90	5	et	et	PROPN
admet-331	90	6	al	al	PROPN
admet-331	90	7	.	.	PUNCT
admet-331	91	1	[	[	X
admet-331	91	2	29	29	NUM
admet-331	91	3	]	]	PUNCT
admet-331	91	4	showed	show	VERB
admet-331	91	5	that	that	SCONJ
admet-331	91	6	different	different	ADJ
admet-331	91	7	concentrations	concentration	NOUN
admet-331	91	8	of	of	ADP
admet-331	91	9	y27632	y27632	PROPN
admet-331	91	10	(	(	PUNCT
admet-331	91	11	1	1	NUM
admet-331	91	12	,	,	PUNCT
admet-331	91	13	10	10	NUM
admet-331	91	14	,	,	PUNCT
admet-331	91	15	33	33	NUM
admet-331	91	16	,	,	PUNCT
admet-331	91	17	100	100	NUM
admet-331	91	18	µm	µm	NOUN
admet-331	91	19	)	)	PUNCT
admet-331	91	20	enhanced	enhance	VERB
admet-331	91	21	the	the	DET
admet-331	91	22	survival	survival	NOUN
admet-331	91	23	of	of	ADP
admet-331	91	24	monkey	monkey	NOUN
admet-331	91	25	corneal	corneal	ADJ
admet-331	91	26	endothelial	endothelial	ADJ
admet-331	91	27	cells	cell	NOUN
admet-331	91	28	,	,	PUNCT
admet-331	91	29	however	however	ADV
admet-331	91	30	,	,	PUNCT
admet-331	91	31	only	only	ADV
admet-331	91	32	the	the	DET
admet-331	91	33	10	10	NUM
admet-331	91	34	µm	µm	NOUN
admet-331	91	35	concentration	concentration	NOUN
admet-331	91	36	resulted	result	VERB
admet-331	91	37	in	in	ADP
admet-331	91	38	a	a	DET
admet-331	91	39	significant	significant	ADJ
admet-331	91	40	increase	increase	NOUN
admet-331	91	41	in	in	ADP
admet-331	91	42	cell	cell	NOUN
admet-331	91	43	survival	survival	NOUN
admet-331	91	44	.	.	PUNCT
admet-331	92	1	these	these	DET
admet-331	92	2	in	in	ADP
admet-331	92	3	vitro	vitro	X
admet-331	92	4	studies	study	NOUN
admet-331	92	5	indicated	indicate	VERB
admet-331	92	6	that	that	SCONJ
admet-331	92	7	the	the	DET
admet-331	92	8	optimal	optimal	ADJ
admet-331	92	9	concentration	concentration	NOUN
admet-331	92	10	of	of	ADP
admet-331	92	11	y27632	y27632	PROPN
admet-331	92	12	also	also	ADV
admet-331	92	13	promoted	promote	VERB
admet-331	92	14	cell	cell	NOUN
admet-331	92	15	adhesion	adhesion	NOUN
admet-331	92	16	and	and	CCONJ
admet-331	92	17	increased	increase	VERB
admet-331	92	18	proliferative	proliferative	ADJ
admet-331	92	19	capacity	capacity	NOUN
admet-331	92	20	[	[	X
admet-331	92	21	29	29	NUM
admet-331	92	22	]	]	PUNCT
admet-331	92	23	.	.	PUNCT
admet-331	93	1	based	base	VERB
admet-331	93	2	on	on	ADP
admet-331	93	3	these	these	DET
admet-331	93	4	findings	finding	NOUN
admet-331	93	5	,	,	PUNCT
admet-331	93	6	in	in	ADP
admet-331	93	7	vivo	vivo	ADJ
admet-331	93	8	studies	study	NOUN
admet-331	93	9	using	use	VERB
admet-331	93	10	topically	topically	ADV
admet-331	93	11	administered	administer	VERB
admet-331	93	12	y27632	y27632	PROPN
admet-331	93	13	were	be	AUX
admet-331	93	14	performed	perform	VERB
admet-331	93	15	.	.	PUNCT
admet-331	94	1	in	in	ADP
admet-331	94	2	a	a	DET
admet-331	94	3	primate	primate	NOUN
admet-331	94	4	endothelial	endothelial	ADJ
admet-331	94	5	injury	injury	NOUN
admet-331	94	6	model	model	NOUN
admet-331	94	7	,	,	PUNCT
admet-331	94	8	artificially	artificially	ADV
admet-331	94	9	injured	injure	VERB
admet-331	94	10	eyes	eye	NOUN
admet-331	94	11	were	be	AUX
admet-331	94	12	treated	treat	VERB
admet-331	94	13	with	with	ADP
admet-331	94	14	10	10	NUM
admet-331	94	15	mm	mm	NOUN
admet-331	94	16	y27632	y27632	NOUN
admet-331	94	17	using	use	VERB
admet-331	94	18	eye	eye	NOUN
admet-331	94	19	drops	drop	NOUN
admet-331	94	20	,	,	PUNCT
admet-331	94	21	six	six	NUM
admet-331	94	22	times	time	NOUN
admet-331	94	23	a	a	DET
admet-331	94	24	day	day	NOUN
admet-331	94	25	.	.	PUNCT
admet-331	95	1	after	after	ADP
admet-331	95	2	two	two	NUM
admet-331	95	3	days	day	NOUN
admet-331	95	4	the	the	DET
admet-331	95	5	difference	difference	NOUN
admet-331	95	6	between	between	ADP
admet-331	95	7	the	the	DET
admet-331	95	8	treated	treat	VERB
admet-331	95	9	and	and	CCONJ
admet-331	95	10	the	the	DET
admet-331	95	11	non	non	ADJ
admet-331	95	12	-	-	ADJ
admet-331	95	13	treated	treat	VERB
admet-331	95	14	eye	eye	NOUN
admet-331	95	15	in	in	ADP
admet-331	95	16	the	the	DET
admet-331	95	17	size	size	NOUN
admet-331	95	18	of	of	ADP
admet-331	95	19	the	the	DET
admet-331	95	20	wound	wound	NOUN
admet-331	95	21	was	be	AUX
admet-331	95	22	remarkable	remarkable	ADJ
admet-331	95	23	.	.	PUNCT
admet-331	96	1	furthermore	furthermore	ADV
admet-331	96	2	,	,	PUNCT
admet-331	96	3	after	after	ADP
admet-331	96	4	one	one	NUM
admet-331	96	5	week	week	NOUN
admet-331	96	6	non	non	ADJ
admet-331	96	7	-	-	ADJ
admet-331	96	8	contact	contact	ADJ
admet-331	96	9	specular	specular	ADJ
admet-331	96	10	microscopy	microscopy	NOUN
admet-331	96	11	showed	show	VERB
admet-331	96	12	normal	normal	ADJ
admet-331	96	13	cell	cell	NOUN
admet-331	96	14	morphology	morphology	NOUN
admet-331	96	15	and	and	CCONJ
admet-331	96	16	cell	cell	NOUN
admet-331	96	17	density	density	NOUN
admet-331	96	18	(	(	PUNCT
admet-331	96	19	of	of	ADP
admet-331	96	20	3000	3000	NUM
admet-331	96	21	cell	cell	NOUN
admet-331	96	22	/	/	SYM
admet-331	96	23	mm2	mm2	NOUN
admet-331	96	24	)	)	PUNCT
admet-331	96	25	in	in	ADP
admet-331	96	26	the	the	DET
admet-331	96	27	treated	treat	VERB
admet-331	96	28	group	group	NOUN
admet-331	96	29	,	,	PUNCT
admet-331	96	30	in	in	ADP
admet-331	96	31	contrast	contrast	NOUN
admet-331	96	32	with	with	ADP
admet-331	96	33	the	the	DET
admet-331	96	34	control	control	NOUN
admet-331	96	35	group	group	NOUN
admet-331	96	36	,	,	PUNCT
admet-331	96	37	where	where	SCONJ
admet-331	96	38	the	the	DET
admet-331	96	39	examined	examine	VERB
admet-331	96	40	area	area	NOUN
admet-331	96	41	exhibited	exhibit	VERB
admet-331	96	42	enlarged	enlarge	VERB
admet-331	96	43	corneal	corneal	ADJ
admet-331	96	44	endothelial	endothelial	ADJ
admet-331	96	45	cells	cell	NOUN
admet-331	96	46	(	(	PUNCT
admet-331	96	47	cec	cec	PROPN
admet-331	96	48	)	)	PUNCT
admet-331	96	49	and	and	CCONJ
admet-331	96	50	a	a	DET
admet-331	96	51	cell	cell	NOUN
admet-331	96	52	density	density	NOUN
admet-331	96	53	of	of	ADP
admet-331	96	54	only	only	ADV
admet-331	96	55	1500	1500	NUM
admet-331	96	56	cells	cell	NOUN
admet-331	96	57	/	/	SYM
admet-331	96	58	mm2	mm2	NOUN
admet-331	97	1	[	[	X
admet-331	97	2	30	30	NUM
admet-331	97	3	]	]	PUNCT
admet-331	97	4	.	.	PUNCT
admet-331	98	1	descemet	descemet	PROPN
admet-331	98	2	’s	’s	PART
admet-331	98	3	membrane	membrane	NOUN
admet-331	98	4	is	be	AUX
admet-331	98	5	the	the	DET
admet-331	98	6	basement	basement	NOUN
admet-331	98	7	membrane	membrane	NOUN
admet-331	98	8	of	of	ADP
admet-331	98	9	the	the	DET
admet-331	98	10	corneal	corneal	ADJ
admet-331	98	11	endothelium	endothelium	NOUN
admet-331	98	12	.	.	PUNCT
admet-331	99	1	it	it	PRON
admet-331	99	2	can	can	AUX
admet-331	99	3	detach	detach	VERB
admet-331	99	4	spontaneously	spontaneously	ADV
admet-331	99	5	,	,	PUNCT
admet-331	99	6	or	or	CCONJ
admet-331	99	7	be	be	AUX
admet-331	99	8	removed	remove	VERB
admet-331	99	9	during	during	ADP
admet-331	99	10	cataract	cataract	NOUN
admet-331	99	11	surgery	surgery	NOUN
admet-331	99	12	,	,	PUNCT
admet-331	99	13	or	or	CCONJ
admet-331	99	14	other	other	ADJ
admet-331	99	15	injuries	injury	NOUN
admet-331	99	16	.	.	PUNCT
admet-331	100	1	the	the	DET
admet-331	100	2	importance	importance	NOUN
admet-331	100	3	of	of	ADP
admet-331	100	4	an	an	DET
admet-331	100	5	intact	intact	ADJ
admet-331	100	6	descemet	descemet	NOUN
admet-331	100	7	’s	’s	PART
admet-331	100	8	membrane	membrane	NOUN
admet-331	100	9	in	in	ADP
admet-331	100	10	corneal	corneal	ADJ
admet-331	100	11	endothelial	endothelial	ADJ
admet-331	100	12	recovery	recovery	NOUN
admet-331	100	13	has	have	AUX
admet-331	100	14	been	be	AUX
admet-331	100	15	investigated	investigate	VERB
admet-331	100	16	in	in	ADP
admet-331	100	17	in	in	ADP
admet-331	100	18	vitro	vitro	X
admet-331	100	19	studies	study	NOUN
admet-331	100	20	[	[	X
admet-331	100	21	31,32	31,32	NUM
admet-331	100	22	]	]	PUNCT
admet-331	100	23	.	.	PUNCT
admet-331	101	1	in	in	ADP
admet-331	101	2	a	a	DET
admet-331	101	3	rabbit	rabbit	NOUN
admet-331	101	4	organ	organ	NOUN
admet-331	101	5	culture	culture	NOUN
admet-331	101	6	model	model	NOUN
admet-331	101	7	(	(	PUNCT
admet-331	101	8	treated	treat	VERB
admet-331	101	9	with	with	ADP
admet-331	101	10	10	10	NUM
admet-331	101	11	µm	µm	NUM
admet-331	101	12	y27632	y27632	PROPN
admet-331	101	13	for	for	ADP
admet-331	101	14	48	48	NUM
admet-331	101	15	hours	hour	NOUN
admet-331	101	16	)	)	PUNCT
admet-331	101	17	there	there	PRON
admet-331	101	18	was	be	VERB
admet-331	101	19	no	no	DET
admet-331	101	20	difference	difference	NOUN
admet-331	101	21	between	between	ADP
admet-331	101	22	the	the	DET
admet-331	101	23	presence	presence	NOUN
admet-331	101	24	and	and	CCONJ
admet-331	101	25	absence	absence	NOUN
admet-331	101	26	of	of	ADP
admet-331	101	27	descemet	descemet	NOUN
admet-331	101	28	’s	’s	PART
admet-331	101	29	membrane	membrane	NOUN
admet-331	101	30	,	,	PUNCT
admet-331	101	31	and	and	CCONJ
admet-331	101	32	the	the	DET
admet-331	101	33	rock	rock	NOUN
admet-331	101	34	inhibitor	inhibitor	NOUN
admet-331	101	35	increased	increase	VERB
admet-331	101	36	cec	cec	PROPN
admet-331	101	37	proliferation	proliferation	NOUN
admet-331	101	38	to	to	ADP
admet-331	101	39	approximately	approximately	ADV
admet-331	101	40	the	the	DET
admet-331	101	41	same	same	ADJ
admet-331	101	42	level	level	NOUN
admet-331	101	43	in	in	ADP
admet-331	101	44	both	both	DET
admet-331	101	45	samples	sample	NOUN
admet-331	101	46	[	[	X
admet-331	101	47	31	31	NUM
admet-331	101	48	]	]	PUNCT
admet-331	101	49	.	.	PUNCT
admet-331	102	1	in	in	ADP
admet-331	102	2	contrast	contrast	NOUN
admet-331	102	3	,	,	PUNCT
admet-331	102	4	in	in	ADP
admet-331	102	5	human	human	PROPN
admet-331	102	6	cec	cec	PROPN
admet-331	102	7	culture	culture	NOUN
admet-331	102	8	(	(	PUNCT
admet-331	102	9	treated	treat	VERB
admet-331	102	10	with	with	ADP
admet-331	102	11	10	10	NUM
admet-331	102	12	µm	µm	NUM
admet-331	102	13	y27632	y27632	PROPN
admet-331	102	14	for	for	ADP
admet-331	102	15	14	14	NUM
admet-331	102	16	days	day	NOUN
admet-331	102	17	)	)	PUNCT
admet-331	102	18	,	,	PUNCT
admet-331	102	19	results	result	NOUN
admet-331	102	20	suggest	suggest	VERB
admet-331	102	21	that	that	SCONJ
admet-331	102	22	the	the	DET
admet-331	102	23	presence	presence	NOUN
admet-331	102	24	of	of	ADP
admet-331	102	25	an	an	DET
admet-331	102	26	intact	intact	ADJ
admet-331	102	27	descemet	descemet	NOUN
admet-331	102	28	’s	’s	PART
admet-331	102	29	membrane	membrane	NOUN
admet-331	102	30	does	do	AUX
admet-331	102	31	affect	affect	VERB
admet-331	102	32	corneal	corneal	ADJ
admet-331	102	33	endothelial	endothelial	ADJ
admet-331	102	34	wound	wound	NOUN
admet-331	102	35	healing	healing	NOUN
admet-331	102	36	[	[	X
admet-331	102	37	32	32	NUM
admet-331	102	38	]	]	PUNCT
admet-331	102	39	.	.	PUNCT
admet-331	103	1	soh	soh	INTJ
admet-331	103	2	et	et	PROPN
admet-331	103	3	al	al	PROPN
admet-331	103	4	.	.	PUNCT
admet-331	104	1	[	[	X
admet-331	104	2	32	32	NUM
admet-331	104	3	]	]	PUNCT
admet-331	104	4	observed	observe	VERB
admet-331	104	5	that	that	SCONJ
admet-331	104	6	the	the	DET
admet-331	104	7	maximum	maximum	ADJ
admet-331	104	8	endothelial	endothelial	ADJ
admet-331	104	9	recovery	recovery	NOUN
admet-331	104	10	in	in	ADP
admet-331	104	11	culture	culture	NOUN
admet-331	104	12	without	without	ADP
admet-331	104	13	descemet	descemet	NOUN
admet-331	104	14	’s	’s	PART
admet-331	104	15	membrane	membrane	NOUN
admet-331	104	16	was	be	AUX
admet-331	104	17	around	around	ADV
admet-331	104	18	20	20	NUM
admet-331	104	19	%	%	NOUN
admet-331	104	20	,	,	PUNCT
admet-331	104	21	whereas	whereas	SCONJ
admet-331	104	22	with	with	ADP
admet-331	104	23	intact	intact	ADJ
admet-331	104	24	descemet	descemet	NOUN
admet-331	104	25	’s	’s	PART
admet-331	104	26	membrane	membrane	NOUN
admet-331	104	27	recovery	recovery	NOUN
admet-331	104	28	was	be	AUX
admet-331	104	29	approximately	approximately	ADV
admet-331	104	30	80	80	NUM
admet-331	104	31	%	%	NOUN
admet-331	104	32	due	due	ADP
admet-331	104	33	to	to	ADP
admet-331	104	34	increased	increase	VERB
admet-331	104	35	endothelial	endothelial	ADJ
admet-331	104	36	migration	migration	NOUN
admet-331	104	37	.	.	PUNCT
admet-331	105	1	these	these	DET
admet-331	105	2	differing	differ	VERB
admet-331	105	3	results	result	NOUN
admet-331	105	4	may	may	AUX
admet-331	105	5	be	be	AUX
admet-331	105	6	due	due	ADJ
admet-331	105	7	to	to	ADP
admet-331	105	8	species	species	NOUN
admet-331	105	9	differences	difference	NOUN
admet-331	105	10	or	or	CCONJ
admet-331	105	11	differences	difference	NOUN
admet-331	105	12	in	in	ADP
admet-331	105	13	the	the	DET
admet-331	105	14	experimental	experimental	ADJ
admet-331	105	15	models	model	NOUN
admet-331	105	16	.	.	PUNCT
admet-331	106	1	for	for	ADP
admet-331	106	2	instance	instance	NOUN
admet-331	106	3	,	,	PUNCT
admet-331	106	4	in	in	ADP
admet-331	106	5	the	the	DET
admet-331	106	6	case	case	NOUN
admet-331	106	7	of	of	ADP
admet-331	106	8	the	the	DET
admet-331	106	9	rabbit	rabbit	NOUN
admet-331	106	10	organ	organ	NOUN
admet-331	106	11	culture	culture	NOUN
admet-331	106	12	the	the	DET
admet-331	106	13	epithelium	epithelium	NOUN
admet-331	106	14	was	be	AUX
admet-331	106	15	also	also	ADV
admet-331	106	16	removed	remove	VERB
admet-331	106	17	,	,	PUNCT
admet-331	106	18	thus	thus	ADV
admet-331	106	19	enhancing	enhance	VERB
admet-331	106	20	the	the	DET
admet-331	106	21	access	access	NOUN
admet-331	106	22	of	of	ADP
admet-331	106	23	the	the	DET
admet-331	106	24	drug	drug	NOUN
admet-331	106	25	to	to	ADP
admet-331	106	26	the	the	DET
admet-331	106	27	corneal	corneal	ADJ
admet-331	106	28	endothelium	endothelium	NOUN
admet-331	106	29	.	.	PUNCT
admet-331	107	1	another	another	DET
admet-331	107	2	approach	approach	NOUN
admet-331	107	3	to	to	ADP
admet-331	107	4	the	the	DET
admet-331	107	5	treatment	treatment	NOUN
admet-331	107	6	of	of	ADP
admet-331	107	7	corneal	corneal	ADJ
admet-331	107	8	endothelial	endothelial	ADJ
admet-331	107	9	disorders	disorder	NOUN
admet-331	107	10	is	be	AUX
admet-331	107	11	injection	injection	NOUN
admet-331	107	12	of	of	ADP
admet-331	107	13	cultured	cultured	ADJ
admet-331	107	14	allogeneic	allogeneic	ADJ
admet-331	107	15	admet	admet	NOUN
admet-331	107	16	&	&	CCONJ
admet-331	107	17	dmpk	dmpk	PROPN
admet-331	107	18	4(4	4(4	NUM
admet-331	107	19	)	)	PUNCT
admet-331	107	20	(	(	PUNCT
admet-331	107	21	2016	2016	NUM
admet-331	107	22	)	)	PUNCT
admet-331	107	23	280	280	NUM
admet-331	107	24	-	-	SYM
admet-331	107	25	301	301	NUM
admet-331	107	26	rock	rock	NOUN
admet-331	107	27	inhibitors	inhibitor	NOUN
admet-331	107	28	in	in	ADP
admet-331	107	29	ocular	ocular	ADJ
admet-331	107	30	disease	disease	NOUN
admet-331	107	31	doi	doi	NOUN
admet-331	107	32	:	:	PUNCT
admet-331	107	33	10.5599	10.5599	NUM
admet-331	107	34	/	/	SYM
admet-331	107	35	admet.4.4.331	admet.4.4.331	PROPN
admet-331	107	36	285	285	NUM
admet-331	107	37	corneal	corneal	ADJ
admet-331	107	38	endothelial	endothelial	ADJ
admet-331	107	39	cells	cell	NOUN
admet-331	107	40	(	(	PUNCT
admet-331	107	41	cecs	cecs	PROPN
admet-331	107	42	)	)	PUNCT
admet-331	107	43	into	into	ADP
admet-331	107	44	the	the	DET
admet-331	107	45	anterior	anterior	ADJ
admet-331	107	46	chamber	chamber	PROPN
admet-331	107	47	.	.	PUNCT
admet-331	108	1	intracameral	intracameral	ADJ
admet-331	108	2	injection	injection	NOUN
admet-331	108	3	of	of	ADP
admet-331	108	4	cecs	cec	NOUN
admet-331	108	5	followed	follow	VERB
admet-331	108	6	by	by	ADP
admet-331	108	7	facedown	facedown	NOUN
admet-331	108	8	positioning	positioning	NOUN
admet-331	108	9	for	for	ADP
admet-331	108	10	3	3	NUM
admet-331	108	11	hours	hour	NOUN
admet-331	108	12	was	be	AUX
admet-331	108	13	performed	perform	VERB
admet-331	108	14	with	with	ADP
admet-331	108	15	or	or	CCONJ
admet-331	108	16	without	without	ADP
admet-331	108	17	supplementation	supplementation	NOUN
admet-331	108	18	of	of	ADP
admet-331	108	19	a	a	DET
admet-331	108	20	rock	rock	NOUN
admet-331	108	21	inhibitor	inhibitor	NOUN
admet-331	108	22	(	(	PUNCT
admet-331	108	23	y27632	y27632	PROPN
admet-331	108	24	)	)	PUNCT
admet-331	108	25	in	in	ADP
admet-331	108	26	rabbit	rabbit	NOUN
admet-331	108	27	and	and	CCONJ
admet-331	108	28	monkey	monkey	NOUN
admet-331	108	29	corneas	cornea	NOUN
admet-331	108	30	with	with	ADP
admet-331	108	31	the	the	DET
admet-331	108	32	endothelium	endothelium	NOUN
admet-331	108	33	removed	remove	VERB
admet-331	108	34	but	but	CCONJ
admet-331	108	35	an	an	DET
admet-331	108	36	intact	intact	ADJ
admet-331	108	37	descemet	descemet	NOUN
admet-331	108	38	’s	’s	PART
admet-331	108	39	membrane	membrane	NOUN
admet-331	108	40	.	.	PUNCT
admet-331	109	1	in	in	ADP
admet-331	109	2	the	the	DET
admet-331	109	3	rabbit	rabbit	NOUN
admet-331	109	4	,	,	PUNCT
admet-331	109	5	intracameral	intracameral	ADJ
admet-331	109	6	injection	injection	NOUN
admet-331	109	7	of	of	ADP
admet-331	109	8	cecs	cec	NOUN
admet-331	109	9	with	with	ADP
admet-331	109	10	100	100	NUM
admet-331	109	11	µm	µm	ADP
admet-331	109	12	y27632	y27632	PROPN
admet-331	109	13	(	(	PUNCT
admet-331	109	14	for	for	ADP
admet-331	109	15	2	2	NUM
admet-331	109	16	weeks	week	NOUN
admet-331	109	17	)	)	PUNCT
admet-331	109	18	helped	help	VERB
admet-331	109	19	in	in	ADP
admet-331	109	20	the	the	DET
admet-331	109	21	recovery	recovery	NOUN
admet-331	109	22	of	of	ADP
admet-331	109	23	corneal	corneal	ADJ
admet-331	109	24	transparency	transparency	NOUN
admet-331	109	25	and	and	CCONJ
admet-331	109	26	decreased	decrease	VERB
admet-331	109	27	edema	edema	NOUN
admet-331	109	28	.	.	PUNCT
admet-331	110	1	the	the	DET
admet-331	110	2	central	central	ADJ
admet-331	110	3	corneal	corneal	ADJ
admet-331	110	4	thickness	thickness	NOUN
admet-331	110	5	in	in	ADP
admet-331	110	6	the	the	DET
admet-331	110	7	y27632	y27632	PROPN
admet-331	110	8	supplemented	supplement	VERB
admet-331	110	9	group	group	NOUN
admet-331	110	10	was	be	AUX
admet-331	110	11	<	<	X
admet-331	110	12	800	800	NUM
admet-331	110	13	µm	µm	NUM
admet-331	110	14	,	,	PUNCT
admet-331	110	15	whereas	whereas	SCONJ
admet-331	110	16	without	without	ADP
admet-331	110	17	drug	drug	NOUN
admet-331	110	18	it	it	PRON
admet-331	110	19	was	be	AUX
admet-331	110	20	>	>	X
admet-331	110	21	1200	1200	NUM
admet-331	110	22	µm	µm	ADP
admet-331	110	23	during	during	ADP
admet-331	110	24	the	the	DET
admet-331	110	25	2	2	NUM
admet-331	110	26	-	-	PUNCT
admet-331	110	27	week	week	NOUN
admet-331	110	28	period	period	NOUN
admet-331	110	29	.	.	PUNCT
admet-331	111	1	in	in	ADP
admet-331	111	2	the	the	DET
admet-331	111	3	monkey	monkey	NOUN
admet-331	111	4	model	model	NOUN
admet-331	111	5	3	3	NUM
admet-331	111	6	months	month	NOUN
admet-331	111	7	after	after	ADP
admet-331	111	8	allogeneic	allogeneic	ADJ
admet-331	111	9	transplantation	transplantation	NOUN
admet-331	111	10	of	of	ADP
admet-331	111	11	cecs	cec	NOUN
admet-331	111	12	,	,	PUNCT
admet-331	111	13	the	the	DET
admet-331	111	14	cell	cell	NOUN
admet-331	111	15	density	density	NOUN
admet-331	111	16	in	in	ADP
admet-331	111	17	the	the	DET
admet-331	111	18	drug	drug	NOUN
admet-331	111	19	supported	support	VERB
admet-331	111	20	group	group	NOUN
admet-331	111	21	was	be	AUX
admet-331	111	22	3	3	NUM
admet-331	111	23	times	time	NOUN
admet-331	111	24	higher	high	ADJ
admet-331	111	25	compared	compare	VERB
admet-331	111	26	to	to	ADP
admet-331	111	27	the	the	DET
admet-331	111	28	“	"	PUNCT
admet-331	111	29	pure	pure	ADJ
admet-331	111	30	”	"	PUNCT
admet-331	111	31	cec	cec	PROPN
admet-331	111	32	-	-	PUNCT
admet-331	111	33	injected	inject	VERB
admet-331	111	34	group	group	NOUN
admet-331	111	35	.	.	PUNCT
admet-331	112	1	in	in	ADP
admet-331	112	2	both	both	DET
admet-331	112	3	animal	animal	NOUN
admet-331	112	4	models	model	NOUN
admet-331	112	5	,	,	PUNCT
admet-331	112	6	reconstructed	reconstruct	VERB
admet-331	112	7	endothelium	endothelium	NOUN
admet-331	112	8	with	with	ADP
admet-331	112	9	y27632	y27632	PROPN
admet-331	112	10	treatment	treatment	NOUN
admet-331	112	11	exhibited	exhibit	VERB
admet-331	112	12	monolayer	monolayer	NOUN
admet-331	112	13	hexagonal	hexagonal	ADJ
admet-331	112	14	cell	cell	NOUN
admet-331	112	15	shapes	shape	NOUN
admet-331	112	16	with	with	ADP
admet-331	112	17	normal	normal	ADJ
admet-331	112	18	expression	expression	NOUN
admet-331	112	19	of	of	ADP
admet-331	112	20	functionallyrelated	functionallyrelate	VERB
admet-331	112	21	endothelial	endothelial	ADJ
admet-331	112	22	markers	marker	NOUN
admet-331	112	23	.	.	PUNCT
admet-331	113	1	in	in	ADP
admet-331	113	2	contrast	contrast	NOUN
admet-331	113	3	,	,	PUNCT
admet-331	113	4	in	in	ADP
admet-331	113	5	the	the	DET
admet-331	113	6	absence	absence	NOUN
admet-331	113	7	of	of	ADP
admet-331	113	8	rock	rock	NOUN
admet-331	113	9	inhibitor	inhibitor	NOUN
admet-331	113	10	,	,	PUNCT
admet-331	113	11	cells	cell	NOUN
admet-331	113	12	showed	show	VERB
admet-331	113	13	a	a	DET
admet-331	113	14	stratified	stratified	ADJ
admet-331	113	15	fibroblastic	fibroblastic	ADJ
admet-331	113	16	phenotype	phenotype	NOUN
admet-331	113	17	,	,	PUNCT
admet-331	113	18	and	and	CCONJ
admet-331	113	19	reduced	reduced	ADJ
admet-331	113	20	levels	level	NOUN
admet-331	113	21	of	of	ADP
admet-331	113	22	endothelial	endothelial	ADJ
admet-331	113	23	functional	functional	ADJ
admet-331	113	24	markers	marker	NOUN
admet-331	113	25	[	[	X
admet-331	113	26	33	33	NUM
admet-331	113	27	]	]	PUNCT
admet-331	113	28	.	.	PUNCT
admet-331	114	1	in	in	ADP
admet-331	114	2	a	a	DET
admet-331	114	3	feline	feline	ADJ
admet-331	114	4	model	model	NOUN
admet-331	114	5	of	of	ADP
admet-331	114	6	endothelial	endothelial	ADJ
admet-331	114	7	dysfunction	dysfunction	NOUN
admet-331	114	8	,	,	PUNCT
admet-331	114	9	bostan	bostan	PROPN
admet-331	114	10	et	et	PROPN
admet-331	114	11	al	al	PROPN
admet-331	114	12	.	.	PROPN
admet-331	114	13	examined	examine	VERB
admet-331	114	14	the	the	DET
admet-331	114	15	contribution	contribution	NOUN
admet-331	114	16	of	of	ADP
admet-331	114	17	injected	inject	VERB
admet-331	114	18	cecs	cec	NOUN
admet-331	114	19	to	to	ADP
admet-331	114	20	the	the	DET
admet-331	114	21	new	new	ADJ
admet-331	114	22	endothelium	endothelium	NOUN
admet-331	114	23	and	and	CCONJ
admet-331	114	24	whether	whether	SCONJ
admet-331	114	25	repair	repair	NOUN
admet-331	114	26	with	with	ADP
admet-331	114	27	rock	rock	NOUN
admet-331	114	28	inhibition	inhibition	NOUN
admet-331	114	29	worked	work	VERB
admet-331	114	30	through	through	ADP
admet-331	114	31	increased	increase	VERB
admet-331	114	32	adherence	adherence	NOUN
admet-331	114	33	of	of	ADP
admet-331	114	34	the	the	DET
admet-331	114	35	injected	inject	VERB
admet-331	114	36	cells	cell	NOUN
admet-331	114	37	,	,	PUNCT
admet-331	114	38	stimulation	stimulation	NOUN
admet-331	114	39	of	of	ADP
admet-331	114	40	cec	cec	PROPN
admet-331	114	41	migration	migration	NOUN
admet-331	114	42	to	to	ADP
admet-331	114	43	the	the	DET
admet-331	114	44	injured	injure	VERB
admet-331	114	45	area	area	NOUN
admet-331	114	46	,	,	PUNCT
admet-331	114	47	or	or	CCONJ
admet-331	114	48	both	both	PRON
admet-331	114	49	.	.	PUNCT
admet-331	115	1	surprisingly	surprisingly	ADV
admet-331	115	2	,	,	PUNCT
admet-331	115	3	the	the	DET
admet-331	115	4	best	good	ADJ
admet-331	115	5	endothelial	endothelial	ADJ
admet-331	115	6	recovery	recovery	NOUN
admet-331	115	7	occurred	occur	VERB
admet-331	115	8	in	in	ADP
admet-331	115	9	a	a	DET
admet-331	115	10	scenario	scenario	NOUN
admet-331	115	11	where	where	SCONJ
admet-331	115	12	y27632	y27632	PROPN
admet-331	115	13	was	be	AUX
admet-331	115	14	injected	inject	VERB
admet-331	115	15	without	without	ADP
admet-331	115	16	cecs	cec	NOUN
admet-331	115	17	and	and	CCONJ
admet-331	115	18	with	with	ADP
admet-331	115	19	limited	limited	ADJ
admet-331	115	20	endothelial	endothelial	ADJ
admet-331	115	21	scraping	scraping	NOUN
admet-331	115	22	allowing	allow	VERB
admet-331	115	23	the	the	DET
admet-331	115	24	host	host	NOUN
admet-331	115	25	to	to	PART
admet-331	115	26	provide	provide	VERB
admet-331	115	27	sufficient	sufficient	ADJ
admet-331	115	28	peripheral	peripheral	ADJ
admet-331	115	29	endothelial	endothelial	ADJ
admet-331	115	30	cells	cell	NOUN
admet-331	115	31	to	to	PART
admet-331	115	32	migrate	migrate	VERB
admet-331	115	33	towards	towards	ADP
admet-331	115	34	and	and	CCONJ
admet-331	115	35	cover	cover	VERB
admet-331	115	36	the	the	DET
admet-331	115	37	wound	wound	NOUN
admet-331	115	38	[	[	X
admet-331	115	39	34	34	NUM
admet-331	115	40	]	]	PUNCT
admet-331	115	41	.	.	PUNCT
admet-331	116	1	y27632	y27632	PROPN
admet-331	116	2	has	have	AUX
admet-331	116	3	not	not	PART
admet-331	116	4	yet	yet	ADV
admet-331	116	5	been	be	AUX
admet-331	116	6	approved	approve	VERB
admet-331	116	7	for	for	ADP
admet-331	116	8	human	human	ADJ
admet-331	116	9	application	application	NOUN
admet-331	116	10	.	.	PUNCT
admet-331	117	1	a	a	DET
admet-331	117	2	phase	phase	NOUN
admet-331	117	3	1	1	NUM
admet-331	117	4	clinical	clinical	ADJ
admet-331	117	5	trial	trial	NOUN
admet-331	117	6	was	be	AUX
admet-331	117	7	performed	perform	VERB
admet-331	117	8	in	in	ADP
admet-331	117	9	japan	japan	PROPN
admet-331	117	10	involving	involve	VERB
admet-331	117	11	10	10	NUM
admet-331	117	12	healthy	healthy	ADJ
admet-331	117	13	volunteers	volunteer	NOUN
admet-331	117	14	.	.	PUNCT
admet-331	118	1	this	this	DET
admet-331	118	2	study	study	NOUN
admet-331	118	3	confirmed	confirm	VERB
admet-331	118	4	that	that	SCONJ
admet-331	118	5	y27632	y27632	PROPN
admet-331	118	6	,	,	PUNCT
admet-331	118	7	applied	apply	VERB
admet-331	118	8	as	as	SCONJ
admet-331	118	9	10	10	NUM
admet-331	118	10	mm	mm	PROPN
admet-331	118	11	eye	eye	NOUN
admet-331	118	12	drops	drop	VERB
admet-331	118	13	6	6	NUM
admet-331	118	14	times	time	NOUN
admet-331	118	15	daily	daily	ADV
admet-331	118	16	for	for	ADP
admet-331	118	17	7	7	NUM
admet-331	118	18	days	day	NOUN
admet-331	118	19	,	,	PUNCT
admet-331	118	20	did	do	AUX
admet-331	118	21	not	not	PART
admet-331	118	22	cause	cause	VERB
admet-331	118	23	any	any	DET
admet-331	118	24	systemic	systemic	ADJ
admet-331	118	25	or	or	CCONJ
admet-331	118	26	local	local	ADJ
admet-331	118	27	side	side	NOUN
admet-331	118	28	effects	effect	NOUN
admet-331	118	29	[	[	X
admet-331	118	30	30	30	NUM
admet-331	118	31	]	]	PUNCT
admet-331	118	32	.	.	PUNCT
admet-331	119	1	eight	eight	NUM
admet-331	119	2	patients	patient	NOUN
admet-331	119	3	who	who	PRON
admet-331	119	4	suffered	suffer	VERB
admet-331	119	5	from	from	ADP
admet-331	119	6	corneal	corneal	ADJ
admet-331	119	7	deficiency	deficiency	NOUN
admet-331	119	8	were	be	AUX
admet-331	119	9	subsequently	subsequently	ADV
admet-331	119	10	enrolled	enrol	VERB
admet-331	119	11	to	to	PART
admet-331	119	12	test	test	VERB
admet-331	119	13	the	the	DET
admet-331	119	14	feasibility	feasibility	NOUN
admet-331	119	15	of	of	ADP
admet-331	119	16	the	the	DET
admet-331	119	17	drug	drug	NOUN
admet-331	119	18	in	in	ADP
admet-331	119	19	pathological	pathological	ADJ
admet-331	119	20	conditions	condition	NOUN
admet-331	119	21	.	.	PUNCT
admet-331	120	1	after	after	ADP
admet-331	120	2	6	6	NUM
admet-331	120	3	months	month	NOUN
admet-331	120	4	,	,	PUNCT
admet-331	120	5	y27632	y27632	NOUN
admet-331	120	6	-	-	PUNCT
admet-331	120	7	treated	treat	VERB
admet-331	120	8	participants	participant	NOUN
admet-331	120	9	with	with	ADP
admet-331	120	10	central	central	ADJ
admet-331	120	11	corneal	corneal	ADJ
admet-331	120	12	edema	edema	NOUN
admet-331	120	13	showed	show	VERB
admet-331	120	14	slight	slight	ADJ
admet-331	120	15	reductions	reduction	NOUN
admet-331	120	16	in	in	ADP
admet-331	120	17	the	the	DET
admet-331	120	18	central	central	ADJ
admet-331	120	19	corneal	corneal	ADJ
admet-331	120	20	thickness	thickness	NOUN
admet-331	120	21	;	;	PUNCT
admet-331	120	22	however	however	ADV
admet-331	120	23	,	,	PUNCT
admet-331	120	24	for	for	ADP
admet-331	120	25	those	those	DET
admet-331	120	26	patients	patient	NOUN
admet-331	120	27	with	with	ADP
admet-331	120	28	diffuse	diffuse	PROPN
admet-331	120	29	edema	edema	NOUN
admet-331	120	30	there	there	PRON
admet-331	120	31	was	be	VERB
admet-331	120	32	no	no	DET
admet-331	120	33	difference	difference	NOUN
admet-331	120	34	between	between	ADP
admet-331	120	35	the	the	DET
admet-331	120	36	preand	preand	NOUN
admet-331	120	37	post	post	ADJ
admet-331	120	38	-	-	ADJ
admet-331	120	39	treatment	treatment	ADJ
admet-331	120	40	thickness	thickness	NOUN
admet-331	120	41	.	.	PUNCT
admet-331	121	1	among	among	ADP
admet-331	121	2	the	the	DET
admet-331	121	3	8	8	NUM
admet-331	121	4	patients	patient	NOUN
admet-331	121	5	,	,	PUNCT
admet-331	121	6	there	there	PRON
admet-331	121	7	were	be	VERB
admet-331	121	8	a	a	DET
admet-331	121	9	few	few	ADJ
admet-331	121	10	cases	case	NOUN
admet-331	121	11	where	where	SCONJ
admet-331	121	12	the	the	DET
admet-331	121	13	best	well	ADV
admet-331	121	14	corrected	correct	VERB
admet-331	121	15	visual	visual	ADJ
admet-331	121	16	acuity	acuity	NOUN
admet-331	121	17	also	also	ADV
admet-331	121	18	improved	improve	VERB
admet-331	121	19	,	,	PUNCT
admet-331	121	20	but	but	CCONJ
admet-331	121	21	for	for	ADP
admet-331	121	22	most	most	ADJ
admet-331	121	23	,	,	PUNCT
admet-331	121	24	vision	vision	NOUN
admet-331	121	25	remained	remain	VERB
admet-331	121	26	the	the	DET
admet-331	121	27	same	same	ADJ
admet-331	121	28	[	[	X
admet-331	121	29	30	30	NUM
admet-331	121	30	]	]	PUNCT
admet-331	121	31	.	.	PUNCT
admet-331	122	1	a	a	DET
admet-331	122	2	case	case	NOUN
admet-331	122	3	report	report	NOUN
admet-331	122	4	of	of	ADP
admet-331	122	5	lateonset	lateonset	NOUN
admet-331	122	6	fuchs	fuchs	PROPN
admet-331	122	7	corneal	corneal	ADJ
admet-331	122	8	dystrophy	dystrophy	NOUN
admet-331	122	9	of	of	ADP
admet-331	122	10	a	a	DET
admet-331	122	11	52	52	NUM
admet-331	122	12	-	-	PUNCT
admet-331	122	13	year	year	NOUN
admet-331	122	14	-	-	PUNCT
admet-331	122	15	old	old	ADJ
admet-331	122	16	patient	patient	NOUN
admet-331	122	17	who	who	PRON
admet-331	122	18	received	receive	VERB
admet-331	122	19	10	10	NUM
admet-331	122	20	mm	mm	NUM
admet-331	122	21	y27632	y27632	INTJ
admet-331	122	22	topically	topically	ADV
admet-331	122	23	six	six	NUM
admet-331	122	24	times	time	NOUN
admet-331	122	25	daily	daily	ADV
admet-331	122	26	for	for	ADP
admet-331	122	27	one	one	NUM
admet-331	122	28	week	week	NOUN
admet-331	122	29	showed	show	VERB
admet-331	122	30	recovered	recover	VERB
admet-331	122	31	corneal	corneal	ADJ
admet-331	122	32	clarity	clarity	NOUN
admet-331	122	33	and	and	CCONJ
admet-331	122	34	improved	improve	VERB
admet-331	122	35	visual	visual	ADJ
admet-331	122	36	acuity	acuity	NOUN
admet-331	122	37	after	after	ADP
admet-331	122	38	two	two	NUM
admet-331	122	39	weeks	week	NOUN
admet-331	122	40	.	.	PUNCT
admet-331	123	1	these	these	DET
admet-331	123	2	positive	positive	ADJ
admet-331	123	3	changes	change	NOUN
admet-331	123	4	were	be	AUX
admet-331	123	5	maintained	maintain	VERB
admet-331	123	6	up	up	ADP
admet-331	123	7	to	to	ADP
admet-331	123	8	the	the	DET
admet-331	123	9	final	final	ADJ
admet-331	123	10	examination	examination	NOUN
admet-331	123	11	,	,	PUNCT
admet-331	123	12	two	two	NUM
admet-331	123	13	years	year	NOUN
admet-331	123	14	later	later	ADV
admet-331	123	15	in	in	ADP
admet-331	123	16	this	this	DET
admet-331	123	17	case	case	NOUN
admet-331	123	18	[	[	X
admet-331	123	19	35	35	NUM
admet-331	123	20	]	]	PUNCT
admet-331	123	21	.	.	PUNCT
admet-331	124	1	last	last	ADJ
admet-331	124	2	,	,	PUNCT
admet-331	124	3	but	but	CCONJ
admet-331	124	4	not	not	PART
admet-331	124	5	least	least	ADJ
admet-331	124	6	,	,	PUNCT
admet-331	124	7	in	in	ADP
admet-331	124	8	2015	2015	NUM
admet-331	124	9	,	,	PUNCT
admet-331	124	10	okumara	okumara	ADV
admet-331	124	11	et	et	PROPN
admet-331	124	12	al	al	PROPN
admet-331	124	13	.	.	PUNCT
admet-331	125	1	[	[	X
admet-331	125	2	31	31	NUM
admet-331	125	3	]	]	PUNCT
admet-331	125	4	reported	report	VERB
admet-331	125	5	on	on	ADP
admet-331	125	6	3	3	NUM
admet-331	125	7	patients	patient	NOUN
admet-331	125	8	who	who	PRON
admet-331	125	9	had	have	VERB
admet-331	125	10	severe	severe	ADJ
admet-331	125	11	corneal	corneal	ADJ
admet-331	125	12	endothelial	endothelial	ADJ
admet-331	125	13	damage	damage	NOUN
admet-331	125	14	due	due	ADP
admet-331	125	15	to	to	ADP
admet-331	125	16	cataract	cataract	VERB
admet-331	125	17	surgery	surgery	NOUN
admet-331	125	18	and	and	CCONJ
admet-331	125	19	received	receive	VERB
admet-331	125	20	y27632	y27632	PROPN
admet-331	125	21	eye	eye	NOUN
admet-331	125	22	drops	drop	NOUN
admet-331	125	23	.	.	PUNCT
admet-331	126	1	two	two	NUM
admet-331	126	2	of	of	ADP
admet-331	126	3	them	they	PRON
admet-331	126	4	received	receive	VERB
admet-331	126	5	1	1	NUM
admet-331	126	6	mm	mm	NOUN
admet-331	126	7	y27632	y27632	PROPN
admet-331	126	8	eye	eye	NOUN
admet-331	126	9	drops	drop	NOUN
admet-331	126	10	administered	administer	VERB
admet-331	126	11	6	6	NUM
admet-331	126	12	times	time	NOUN
admet-331	126	13	daily	daily	ADV
admet-331	126	14	in	in	ADP
admet-331	126	15	the	the	DET
admet-331	126	16	first	first	ADJ
admet-331	126	17	4	4	NUM
admet-331	126	18	months	month	NOUN
admet-331	126	19	,	,	PUNCT
admet-331	126	20	and	and	CCONJ
admet-331	126	21	4	4	NUM
admet-331	126	22	times	time	NOUN
admet-331	126	23	daily	daily	ADV
admet-331	126	24	during	during	ADP
admet-331	126	25	the	the	DET
admet-331	126	26	following	follow	VERB
admet-331	126	27	2	2	NUM
admet-331	126	28	months	month	NOUN
admet-331	126	29	;	;	PUNCT
admet-331	126	30	the	the	DET
admet-331	126	31	third	third	ADJ
admet-331	126	32	patient	patient	NOUN
admet-331	126	33	used	use	VERB
admet-331	126	34	the	the	DET
admet-331	126	35	drug	drug	NOUN
admet-331	126	36	four	four	NUM
admet-331	126	37	times	time	NOUN
admet-331	126	38	daily	daily	ADJ
admet-331	126	39	only	only	ADV
admet-331	126	40	for	for	ADP
admet-331	126	41	3	3	NUM
admet-331	126	42	months	month	NOUN
admet-331	126	43	.	.	PUNCT
admet-331	127	1	the	the	DET
admet-331	127	2	first	first	ADJ
admet-331	127	3	two	two	NUM
admet-331	127	4	patients	patient	NOUN
admet-331	127	5	had	have	VERB
admet-331	127	6	spontaneous	spontaneous	ADJ
admet-331	127	7	detachment	detachment	NOUN
admet-331	127	8	of	of	ADP
admet-331	127	9	descemet	descemet	NOUN
admet-331	127	10	’s	’s	PART
admet-331	127	11	membrane	membrane	NOUN
admet-331	127	12	during	during	ADP
admet-331	127	13	surgery	surgery	NOUN
admet-331	127	14	,	,	PUNCT
admet-331	127	15	which	which	PRON
admet-331	127	16	could	could	AUX
admet-331	127	17	have	have	AUX
admet-331	127	18	further	far	ADV
admet-331	127	19	impaired	impair	VERB
admet-331	127	20	the	the	DET
admet-331	127	21	healing	healing	NOUN
admet-331	127	22	of	of	ADP
admet-331	127	23	the	the	DET
admet-331	127	24	wound	wound	NOUN
admet-331	127	25	.	.	PUNCT
admet-331	128	1	however	however	ADV
admet-331	128	2	,	,	PUNCT
admet-331	128	3	in	in	ADP
admet-331	128	4	contrast	contrast	NOUN
admet-331	128	5	with	with	ADP
admet-331	128	6	the	the	DET
admet-331	128	7	in	in	X
admet-331	128	8	vitro	vitro	X
admet-331	128	9	findings	finding	NOUN
admet-331	128	10	[	[	X
admet-331	128	11	32	32	NUM
admet-331	128	12	]	]	PUNCT
admet-331	128	13	,	,	PUNCT
admet-331	128	14	in	in	ADP
admet-331	128	15	these	these	DET
admet-331	128	16	cases	case	NOUN
admet-331	128	17	the	the	DET
admet-331	128	18	corneal	corneal	ADJ
admet-331	128	19	endothelium	endothelium	NOUN
admet-331	128	20	was	be	AUX
admet-331	128	21	reconstructed	reconstruct	VERB
admet-331	128	22	on	on	ADP
admet-331	128	23	bare	bare	ADJ
admet-331	128	24	corneal	corneal	ADJ
admet-331	128	25	stroma	stroma	NOUN
admet-331	128	26	and	and	CCONJ
admet-331	128	27	the	the	DET
admet-331	128	28	corneal	corneal	ADJ
admet-331	128	29	clarity	clarity	NOUN
admet-331	128	30	recovered	recover	VERB
admet-331	128	31	.	.	PUNCT
admet-331	129	1	when	when	SCONJ
admet-331	129	2	the	the	DET
admet-331	129	3	first	first	ADJ
admet-331	129	4	patient	patient	NOUN
admet-331	129	5	was	be	AUX
admet-331	129	6	referred	refer	VERB
admet-331	129	7	to	to	ADP
admet-331	129	8	the	the	DET
admet-331	129	9	cornea	cornea	PROPN
admet-331	129	10	clinic	clinic	NOUN
admet-331	129	11	she	she	PRON
admet-331	129	12	was	be	AUX
admet-331	129	13	only	only	ADV
admet-331	129	14	able	able	ADJ
admet-331	129	15	to	to	PART
admet-331	129	16	count	count	VERB
admet-331	129	17	fingers	finger	NOUN
admet-331	129	18	with	with	ADP
admet-331	129	19	her	her	PRON
admet-331	129	20	right	right	ADJ
admet-331	129	21	eye	eye	NOUN
admet-331	129	22	.	.	PUNCT
admet-331	130	1	by	by	ADP
admet-331	130	2	three	three	NUM
admet-331	130	3	months	month	NOUN
admet-331	130	4	,	,	PUNCT
admet-331	130	5	her	her	PRON
admet-331	130	6	vision	vision	NOUN
admet-331	130	7	was	be	AUX
admet-331	130	8	20/20	20/20	NUM
admet-331	130	9	.	.	PUNCT
admet-331	131	1	the	the	DET
admet-331	131	2	third	third	ADJ
admet-331	131	3	patient	patient	NOUN
admet-331	131	4	had	have	VERB
admet-331	131	5	an	an	DET
admet-331	131	6	intact	intact	ADJ
admet-331	131	7	descemet	descemet	NOUN
admet-331	131	8	membrane	membrane	NOUN
admet-331	131	9	but	but	CCONJ
admet-331	131	10	the	the	DET
admet-331	131	11	corneal	corneal	ADJ
admet-331	131	12	endothelial	endothelial	ADJ
admet-331	131	13	cell	cell	NOUN
admet-331	131	14	density	density	NOUN
admet-331	131	15	was	be	AUX
admet-331	131	16	critically	critically	ADV
admet-331	131	17	low	low	ADJ
admet-331	131	18	(	(	PUNCT
admet-331	131	19	508	508	NUM
admet-331	131	20	cells	cell	NOUN
admet-331	131	21	/	/	SYM
admet-331	131	22	mm2	mm2	NOUN
admet-331	131	23	)	)	PUNCT
admet-331	131	24	.	.	PUNCT
admet-331	132	1	contrary	contrary	ADJ
admet-331	132	2	to	to	ADP
admet-331	132	3	expectations	expectation	NOUN
admet-331	132	4	,	,	PUNCT
admet-331	132	5	by	by	ADP
admet-331	132	6	the	the	DET
admet-331	132	7	third	third	ADJ
admet-331	132	8	month	month	NOUN
admet-331	132	9	,	,	PUNCT
admet-331	132	10	the	the	DET
admet-331	132	11	cornea	cornea	NOUN
admet-331	132	12	became	become	VERB
admet-331	132	13	clear	clear	ADJ
admet-331	132	14	and	and	CCONJ
admet-331	132	15	the	the	DET
admet-331	132	16	visual	visual	ADJ
admet-331	132	17	acuity	acuity	NOUN
admet-331	132	18	increased	increase	VERB
admet-331	132	19	from	from	ADP
admet-331	132	20	the	the	DET
admet-331	132	21	initial	initial	ADJ
admet-331	132	22	20/63	20/63	NUM
admet-331	132	23	to	to	ADP
admet-331	132	24	20/25	20/25	NUM
admet-331	133	1	[	[	PUNCT
admet-331	133	2	31	31	NUM
admet-331	133	3	]	]	PUNCT
admet-331	133	4	.	.	PUNCT
admet-331	134	1	although	although	SCONJ
admet-331	134	2	these	these	DET
admet-331	134	3	human	human	ADJ
admet-331	134	4	studies	study	NOUN
admet-331	134	5	have	have	VERB
admet-331	134	6	a	a	DET
admet-331	134	7	number	number	NOUN
admet-331	134	8	of	of	ADP
admet-331	134	9	limitations	limitation	NOUN
admet-331	134	10	,	,	PUNCT
admet-331	134	11	for	for	ADP
admet-331	134	12	example	example	NOUN
admet-331	134	13	patients	patient	NOUN
admet-331	134	14	without	without	ADP
admet-331	134	15	treatment	treatment	NOUN
admet-331	134	16	were	be	AUX
admet-331	134	17	not	not	PART
admet-331	134	18	followed	follow	VERB
admet-331	134	19	and	and	CCONJ
admet-331	134	20	the	the	DET
admet-331	134	21	results	result	NOUN
admet-331	134	22	are	be	AUX
admet-331	134	23	very	very	ADV
admet-331	134	24	preliminary	preliminary	ADJ
admet-331	134	25	,	,	PUNCT
admet-331	134	26	taken	take	VERB
admet-331	134	27	together	together	ADV
admet-331	134	28	they	they	PRON
admet-331	134	29	suggest	suggest	VERB
admet-331	134	30	that	that	SCONJ
admet-331	134	31	rock	rock	NOUN
admet-331	134	32	inhibitors	inhibitor	NOUN
admet-331	134	33	may	may	AUX
admet-331	134	34	be	be	AUX
admet-331	134	35	effective	effective	ADJ
admet-331	134	36	in	in	ADP
admet-331	134	37	reducing	reduce	VERB
admet-331	134	38	corneal	corneal	ADJ
admet-331	134	39	edema	edema	NOUN
admet-331	134	40	,	,	PUNCT
admet-331	134	41	and/or	and/or	CCONJ
admet-331	134	42	improve	improve	VERB
admet-331	134	43	wound	wound	ADJ
admet-331	134	44	healing	healing	NOUN
admet-331	134	45	.	.	PUNCT
admet-331	135	1	another	another	DET
admet-331	135	2	rock	rock	NOUN
admet-331	135	3	inhibitor	inhibitor	NOUN
admet-331	135	4	,	,	PUNCT
admet-331	135	5	y39983	y39983	PROPN
admet-331	135	6	,	,	PUNCT
admet-331	135	7	has	have	AUX
admet-331	135	8	been	be	AUX
admet-331	135	9	applied	apply	VERB
admet-331	135	10	to	to	ADP
admet-331	135	11	in	in	ADP
admet-331	135	12	vitro	vitro	X
admet-331	135	13	and	and	CCONJ
admet-331	135	14	in	in	ADP
admet-331	135	15	vivo	vivo	ADJ
admet-331	135	16	corneal	corneal	ADJ
admet-331	135	17	endothelial	endothelial	ADJ
admet-331	135	18	wound	wound	NOUN
admet-331	135	19	healing	healing	NOUN
admet-331	135	20	models	model	NOUN
admet-331	135	21	and	and	CCONJ
admet-331	135	22	seems	seem	VERB
admet-331	135	23	to	to	PART
admet-331	135	24	be	be	AUX
admet-331	135	25	more	more	ADV
admet-331	135	26	effective	effective	ADJ
admet-331	135	27	for	for	ADP
admet-331	135	28	corneal	corneal	ADJ
admet-331	135	29	endothelial	endothelial	ADJ
admet-331	135	30	cell	cell	NOUN
admet-331	135	31	proliferation	proliferation	NOUN
admet-331	135	32	than	than	ADP
admet-331	135	33	y27632	y27632	PROPN
admet-331	135	34	.	.	PROPN
admet-331	135	35	éva	éva	PROPN
admet-331	135	36	halász	halász	PROPN
admet-331	135	37	,	,	PUNCT
admet-331	135	38	ellen	ellen	PROPN
admet-331	135	39	townes	townes	PROPN
admet-331	135	40	-	-	PUNCT
admet-331	135	41	anderson	anderson	PROPN
admet-331	135	42	admet	admet	PROPN
admet-331	135	43	&	&	CCONJ
admet-331	135	44	dmpk	dmpk	PROPN
admet-331	135	45	4(4	4(4	NUM
admet-331	135	46	)	)	PUNCT
admet-331	135	47	(	(	PUNCT
admet-331	135	48	2016	2016	NUM
admet-331	135	49	)	)	PUNCT
admet-331	135	50	280	280	NUM
admet-331	135	51	-	-	SYM
admet-331	135	52	301	301	NUM
admet-331	135	53	286	286	NUM
admet-331	135	54	according	accord	VERB
admet-331	135	55	to	to	ADP
admet-331	135	56	results	result	NOUN
admet-331	135	57	in	in	ADP
admet-331	135	58	human	human	ADJ
admet-331	135	59	endothelial	endothelial	NOUN
admet-331	135	60	cell	cell	NOUN
admet-331	135	61	culture	culture	NOUN
admet-331	135	62	,	,	PUNCT
admet-331	135	63	y39983	y39983	PROPN
admet-331	135	64	increased	increase	VERB
admet-331	135	65	the	the	DET
admet-331	135	66	percentage	percentage	NOUN
admet-331	135	67	of	of	ADP
admet-331	135	68	proliferating	proliferate	VERB
admet-331	135	69	cells	cell	NOUN
admet-331	135	70	in	in	ADP
admet-331	135	71	a	a	DET
admet-331	135	72	dose	dose	ADJ
admet-331	135	73	dependent	dependent	ADJ
admet-331	135	74	manner	manner	NOUN
admet-331	135	75	;	;	PUNCT
admet-331	135	76	application	application	NOUN
admet-331	135	77	of	of	ADP
admet-331	135	78	3	3	NUM
admet-331	135	79	µm	µm	PART
admet-331	135	80	y39983	y39983	PROPN
admet-331	135	81	achieved	achieve	VERB
admet-331	135	82	a	a	DET
admet-331	135	83	significant	significant	ADJ
admet-331	135	84	increase	increase	NOUN
admet-331	135	85	compared	compare	VERB
admet-331	135	86	to	to	ADP
admet-331	135	87	the	the	DET
admet-331	135	88	control	control	NOUN
admet-331	135	89	group	group	NOUN
admet-331	135	90	.	.	PUNCT
admet-331	136	1	in	in	ADP
admet-331	136	2	addition	addition	NOUN
admet-331	136	3	,	,	PUNCT
admet-331	136	4	in	in	ADP
admet-331	136	5	monkey	monkey	NOUN
admet-331	136	6	corneal	corneal	ADJ
admet-331	136	7	endothelial	endothelial	ADJ
admet-331	136	8	cell	cell	NOUN
admet-331	136	9	culture	culture	NOUN
admet-331	136	10	administration	administration	NOUN
admet-331	136	11	of	of	ADP
admet-331	136	12	only	only	ADV
admet-331	136	13	0.3	0.3	NUM
admet-331	136	14	or	or	CCONJ
admet-331	136	15	3	3	NUM
admet-331	136	16	µm	µm	ADP
admet-331	136	17	y39983	y39983	PROPN
admet-331	136	18	resulted	result	VERB
admet-331	136	19	in	in	ADP
admet-331	136	20	the	the	DET
admet-331	136	21	same	same	ADJ
admet-331	136	22	level	level	NOUN
admet-331	136	23	of	of	ADP
admet-331	136	24	cec	cec	NOUN
admet-331	136	25	proliferation	proliferation	NOUN
admet-331	136	26	that	that	PRON
admet-331	136	27	was	be	AUX
admet-331	136	28	achieved	achieve	VERB
admet-331	136	29	with	with	ADP
admet-331	136	30	10	10	NUM
admet-331	136	31	µm	µm	SYM
admet-331	136	32	y27632	y27632	PROPN
admet-331	136	33	.	.	PROPN
admet-331	136	34	topical	topical	ADJ
admet-331	136	35	administration	administration	NOUN
admet-331	136	36	of	of	ADP
admet-331	136	37	0.095	0.095	NUM
admet-331	136	38	mm	mm	PROPN
admet-331	136	39	y39983	y39983	PROPN
admet-331	136	40	six	six	NUM
admet-331	136	41	times	time	NOUN
admet-331	136	42	daily	daily	ADV
admet-331	136	43	for	for	ADP
admet-331	136	44	two	two	NUM
admet-331	136	45	days	day	NOUN
admet-331	136	46	in	in	ADP
admet-331	136	47	a	a	DET
admet-331	136	48	rabbit	rabbit	NOUN
admet-331	136	49	model	model	NOUN
admet-331	136	50	significantly	significantly	ADV
admet-331	136	51	decreased	decrease	VERB
admet-331	136	52	the	the	DET
admet-331	136	53	size	size	NOUN
admet-331	136	54	of	of	ADP
admet-331	136	55	the	the	DET
admet-331	136	56	corneal	corneal	ADJ
admet-331	136	57	endothelial	endothelial	ADJ
admet-331	136	58	wound	wound	NOUN
admet-331	136	59	and	and	CCONJ
admet-331	136	60	increased	increase	VERB
admet-331	136	61	corneal	corneal	ADJ
admet-331	136	62	endothelial	endothelial	ADJ
admet-331	136	63	cell	cell	NOUN
admet-331	136	64	proliferation	proliferation	NOUN
admet-331	136	65	compared	compare	VERB
admet-331	136	66	to	to	ADP
admet-331	136	67	the	the	DET
admet-331	136	68	non	non	ADJ
admet-331	136	69	-	-	ADJ
admet-331	136	70	treated	treat	VERB
admet-331	136	71	control	control	NOUN
admet-331	136	72	group	group	NOUN
admet-331	137	1	[	[	X
admet-331	137	2	36	36	NUM
admet-331	137	3	]	]	PUNCT
admet-331	137	4	.	.	PUNCT
admet-331	138	1	given	give	VERB
admet-331	138	2	the	the	DET
admet-331	138	3	recently	recently	ADV
admet-331	138	4	reported	report	VERB
admet-331	138	5	promising	promise	VERB
admet-331	138	6	outcomes	outcome	NOUN
admet-331	138	7	with	with	ADP
admet-331	138	8	rock	rock	NOUN
admet-331	138	9	inhibitors	inhibitor	NOUN
admet-331	138	10	in	in	ADP
admet-331	138	11	glaucoma	glaucoma	NOUN
admet-331	138	12	(	(	PUNCT
admet-331	138	13	see	see	VERB
admet-331	138	14	the	the	DET
admet-331	138	15	next	next	ADJ
admet-331	138	16	section	section	NOUN
admet-331	138	17	)	)	PUNCT
admet-331	138	18	,	,	PUNCT
admet-331	138	19	okumara	okumara	NOUN
admet-331	138	20	et	et	PROPN
admet-331	138	21	al	al	PROPN
admet-331	138	22	.	.	PUNCT
admet-331	139	1	[	[	X
admet-331	139	2	37	37	NUM
admet-331	139	3	]	]	PUNCT
admet-331	139	4	examined	examine	VERB
admet-331	139	5	the	the	DET
admet-331	139	6	applicability	applicability	NOUN
admet-331	139	7	of	of	ADP
admet-331	139	8	ripasudil	ripasudil	NOUN
admet-331	139	9	eye	eye	NOUN
admet-331	139	10	drops	drop	NOUN
admet-331	139	11	as	as	ADP
admet-331	139	12	a	a	DET
admet-331	139	13	potential	potential	ADJ
admet-331	139	14	therapeutic	therapeutic	ADJ
admet-331	139	15	agent	agent	NOUN
admet-331	139	16	in	in	ADP
admet-331	139	17	corneal	corneal	ADJ
admet-331	139	18	endothelial	endothelial	ADJ
admet-331	139	19	injuries	injury	NOUN
admet-331	139	20	.	.	PUNCT
admet-331	140	1	in	in	ADP
admet-331	140	2	human	human	PROPN
admet-331	140	3	cec	cec	PROPN
admet-331	140	4	cultures	culture	NOUN
admet-331	140	5	all	all	DET
admet-331	140	6	concentrations	concentration	NOUN
admet-331	140	7	of	of	ADP
admet-331	140	8	ripasudil	ripasudil	NOUN
admet-331	140	9	(	(	PUNCT
admet-331	140	10	0.3	0.3	NUM
admet-331	140	11	,	,	PUNCT
admet-331	140	12	1	1	NUM
admet-331	140	13	,	,	PUNCT
admet-331	140	14	3	3	NUM
admet-331	140	15	,	,	PUNCT
admet-331	140	16	10	10	NUM
admet-331	140	17	,	,	PUNCT
admet-331	140	18	30	30	NUM
admet-331	140	19	µm	µm	NOUN
admet-331	140	20	)	)	PUNCT
admet-331	140	21	enhanced	enhance	VERB
admet-331	140	22	the	the	DET
admet-331	140	23	proliferative	proliferative	ADJ
admet-331	140	24	potential	potential	NOUN
admet-331	140	25	of	of	ADP
admet-331	140	26	the	the	DET
admet-331	140	27	corneal	corneal	ADJ
admet-331	140	28	endothelium	endothelium	NOUN
admet-331	140	29	at	at	ADP
admet-331	140	30	least	least	ADJ
admet-331	140	31	the	the	DET
admet-331	140	32	same	same	ADJ
admet-331	140	33	or	or	CCONJ
admet-331	140	34	more	more	ADV
admet-331	140	35	effectively	effectively	ADV
admet-331	140	36	than	than	ADP
admet-331	140	37	10	10	NUM
admet-331	140	38	µm	µm	NUM
admet-331	140	39	y27632	y27632	PROPN
admet-331	140	40	or	or	CCONJ
admet-331	140	41	10	10	NUM
admet-331	140	42	µm	µm	NOUN
admet-331	140	43	fasudil	fasudil	NOUN
admet-331	140	44	.	.	PUNCT
admet-331	141	1	in	in	ADP
admet-331	141	2	an	an	DET
admet-331	141	3	in	in	ADP
admet-331	141	4	vivo	vivo	NOUN
admet-331	141	5	model	model	NOUN
admet-331	141	6	of	of	ADP
admet-331	141	7	corneal	corneal	ADJ
admet-331	141	8	wounding	wounding	NOUN
admet-331	141	9	,	,	PUNCT
admet-331	141	10	rabbits	rabbit	NOUN
admet-331	141	11	received	receive	VERB
admet-331	141	12	0.4	0.4	NUM
admet-331	141	13	%	%	NOUN
admet-331	141	14	ripasudil	ripasudil	NOUN
admet-331	141	15	eye	eye	NOUN
admet-331	141	16	drops	drop	VERB
admet-331	141	17	three	three	NUM
admet-331	141	18	times	time	NOUN
admet-331	141	19	daily	daily	ADV
admet-331	141	20	for	for	ADP
admet-331	141	21	two	two	NUM
admet-331	141	22	weeks	week	NOUN
admet-331	141	23	;	;	PUNCT
admet-331	141	24	five	five	NUM
admet-331	141	25	of	of	ADP
admet-331	141	26	six	six	NUM
admet-331	141	27	ripasudil	ripasudil	ADV
admet-331	141	28	-	-	PUNCT
admet-331	141	29	treated	treat	VERB
admet-331	141	30	corneas	cornea	NOUN
admet-331	141	31	became	become	VERB
admet-331	141	32	transparent	transparent	ADJ
admet-331	141	33	again	again	ADV
admet-331	141	34	and	and	CCONJ
admet-331	141	35	the	the	DET
admet-331	141	36	central	central	ADJ
admet-331	141	37	corneal	corneal	ADJ
admet-331	141	38	thickness	thickness	NOUN
admet-331	141	39	decreased	decrease	VERB
admet-331	141	40	to	to	ADP
admet-331	141	41	a	a	DET
admet-331	141	42	normal	normal	ADJ
admet-331	141	43	value	value	NOUN
admet-331	141	44	,	,	PUNCT
admet-331	141	45	whereas	whereas	SCONJ
admet-331	141	46	the	the	DET
admet-331	141	47	control	control	NOUN
admet-331	141	48	corneas	cornea	NOUN
admet-331	141	49	did	do	AUX
admet-331	141	50	not	not	PART
admet-331	141	51	change	change	VERB
admet-331	141	52	.	.	PUNCT
admet-331	142	1	moreover	moreover	ADV
admet-331	142	2	,	,	PUNCT
admet-331	142	3	the	the	DET
admet-331	142	4	corneal	corneal	ADJ
admet-331	142	5	endothelial	endothelial	ADJ
admet-331	142	6	cell	cell	NOUN
admet-331	142	7	-	-	PUNCT
admet-331	142	8	density	density	NOUN
admet-331	142	9	and	and	CCONJ
admet-331	142	10	the	the	DET
admet-331	142	11	expression	expression	NOUN
admet-331	142	12	of	of	ADP
admet-331	142	13	pump	pump	ADJ
admet-331	142	14	function	function	NOUN
admet-331	142	15	-	-	PUNCT
admet-331	142	16	related	relate	VERB
admet-331	142	17	markers	marker	NOUN
admet-331	142	18	were	be	AUX
admet-331	142	19	higher	high	ADJ
admet-331	142	20	in	in	ADP
admet-331	142	21	the	the	DET
admet-331	142	22	ripasudil	ripasudil	ADV
admet-331	142	23	-	-	PUNCT
admet-331	142	24	treated	treat	VERB
admet-331	142	25	animals	animal	NOUN
admet-331	142	26	compared	compare	VERB
admet-331	142	27	to	to	ADP
admet-331	142	28	the	the	DET
admet-331	142	29	vehicle	vehicle	NOUN
admet-331	142	30	-	-	PUNCT
admet-331	142	31	treated	treat	VERB
admet-331	142	32	group	group	NOUN
admet-331	142	33	.	.	PUNCT
admet-331	143	1	according	accord	VERB
admet-331	143	2	to	to	ADP
admet-331	143	3	their	their	PRON
admet-331	143	4	findings	finding	NOUN
admet-331	143	5	,	,	PUNCT
admet-331	143	6	proliferating	proliferate	VERB
admet-331	143	7	cells	cell	NOUN
admet-331	143	8	were	be	AUX
admet-331	143	9	not	not	PART
admet-331	143	10	observed	observe	VERB
admet-331	143	11	after	after	SCONJ
admet-331	143	12	the	the	DET
admet-331	143	13	injured	injure	VERB
admet-331	143	14	area	area	NOUN
admet-331	143	15	was	be	AUX
admet-331	143	16	fully	fully	ADV
admet-331	143	17	covered	cover	VERB
admet-331	143	18	by	by	ADP
admet-331	143	19	cecs	cec	NOUN
admet-331	143	20	,	,	PUNCT
admet-331	143	21	which	which	PRON
admet-331	143	22	indicates	indicate	VERB
admet-331	143	23	that	that	SCONJ
admet-331	143	24	rock	rock	NOUN
admet-331	143	25	inhibitors	inhibitor	NOUN
admet-331	143	26	do	do	AUX
admet-331	143	27	not	not	PART
admet-331	143	28	induce	induce	VERB
admet-331	143	29	cell	cell	NOUN
admet-331	143	30	proliferation	proliferation	NOUN
admet-331	143	31	after	after	SCONJ
admet-331	143	32	the	the	DET
admet-331	143	33	endothelium	endothelium	NOUN
admet-331	143	34	is	be	AUX
admet-331	143	35	successfully	successfully	ADV
admet-331	143	36	reconstructed	reconstruct	VERB
admet-331	143	37	[	[	PUNCT
admet-331	143	38	37	37	NUM
admet-331	143	39	]	]	PUNCT
admet-331	143	40	.	.	PUNCT
admet-331	144	1	in	in	ADP
admet-331	144	2	light	light	NOUN
admet-331	144	3	of	of	ADP
admet-331	144	4	the	the	DET
admet-331	144	5	fact	fact	NOUN
admet-331	144	6	that	that	SCONJ
admet-331	144	7	the	the	DET
admet-331	144	8	cornea	cornea	NOUN
admet-331	144	9	is	be	AUX
admet-331	144	10	normally	normally	ADV
admet-331	144	11	avascular	avascular	ADJ
admet-331	144	12	,	,	PUNCT
admet-331	144	13	it	it	PRON
admet-331	144	14	can	can	AUX
admet-331	144	15	be	be	AUX
admet-331	144	16	a	a	DET
admet-331	144	17	useful	useful	ADJ
admet-331	144	18	organ	organ	NOUN
admet-331	144	19	in	in	ADP
admet-331	144	20	the	the	DET
admet-331	144	21	evaluation	evaluation	NOUN
admet-331	144	22	of	of	ADP
admet-331	144	23	angiogenesis	angiogenesis	NOUN
admet-331	144	24	.	.	PUNCT
admet-331	145	1	in	in	ADP
admet-331	145	2	an	an	DET
admet-331	145	3	in	in	ADP
admet-331	145	4	vivo	vivo	NOUN
admet-331	145	5	mouse	mouse	NOUN
admet-331	145	6	model	model	NOUN
admet-331	145	7	,	,	PUNCT
admet-331	145	8	it	it	PRON
admet-331	145	9	has	have	AUX
admet-331	145	10	been	be	AUX
admet-331	145	11	reported	report	VERB
admet-331	145	12	that	that	SCONJ
admet-331	145	13	fasudil	fasudil	NOUN
admet-331	145	14	can	can	AUX
admet-331	145	15	inhibit	inhibit	VERB
admet-331	145	16	vegf	vegf	NOUN
admet-331	145	17	-	-	PUNCT
admet-331	145	18	induced	induce	VERB
admet-331	145	19	corneal	corneal	ADJ
admet-331	145	20	neovascularization	neovascularization	NOUN
admet-331	145	21	without	without	ADP
admet-331	145	22	adverse	adverse	ADJ
admet-331	145	23	effects	effect	NOUN
admet-331	145	24	such	such	ADJ
admet-331	145	25	as	as	ADP
admet-331	145	26	corneal	corneal	ADJ
admet-331	145	27	edema	edema	NOUN
admet-331	145	28	or	or	CCONJ
admet-331	145	29	inflammation	inflammation	NOUN
admet-331	145	30	.	.	PUNCT
admet-331	146	1	however	however	ADV
admet-331	146	2	,	,	PUNCT
admet-331	146	3	in	in	ADP
admet-331	146	4	this	this	DET
admet-331	146	5	experimental	experimental	ADJ
admet-331	146	6	model	model	NOUN
admet-331	146	7	the	the	DET
admet-331	146	8	concentration	concentration	NOUN
admet-331	146	9	of	of	ADP
admet-331	146	10	the	the	DET
admet-331	146	11	effective	effective	ADJ
admet-331	146	12	dose	dose	NOUN
admet-331	146	13	in	in	ADP
admet-331	146	14	the	the	DET
admet-331	146	15	cornea	cornea	NOUN
admet-331	146	16	could	could	AUX
admet-331	146	17	not	not	PART
admet-331	146	18	be	be	AUX
admet-331	146	19	measured	measure	VERB
admet-331	146	20	precisely	precisely	ADV
admet-331	146	21	,	,	PUNCT
admet-331	146	22	because	because	SCONJ
admet-331	146	23	they	they	PRON
admet-331	146	24	administered	administer	VERB
admet-331	146	25	the	the	DET
admet-331	146	26	drug	drug	NOUN
admet-331	146	27	in	in	ADP
admet-331	146	28	the	the	DET
admet-331	146	29	form	form	NOUN
admet-331	146	30	of	of	ADP
admet-331	146	31	hydron	hydron	NOUN
admet-331	146	32	pellets	pellet	NOUN
admet-331	146	33	[	[	X
admet-331	146	34	38	38	NUM
admet-331	146	35	]	]	PUNCT
admet-331	146	36	.	.	PUNCT
admet-331	147	1	in	in	ADP
admet-331	147	2	live	live	ADJ
admet-331	147	3	rabbits	rabbit	NOUN
admet-331	147	4	,	,	PUNCT
admet-331	147	5	alkali	alkali	ADJ
admet-331	147	6	-	-	PUNCT
admet-331	147	7	burn	burn	NOUN
admet-331	147	8	-	-	PUNCT
admet-331	147	9	induced	induce	VERB
admet-331	147	10	corneal	corneal	ADJ
admet-331	147	11	fibrosis	fibrosis	NOUN
admet-331	147	12	and	and	CCONJ
admet-331	147	13	neovascularization	neovascularization	NOUN
admet-331	147	14	were	be	AUX
admet-331	147	15	also	also	ADV
admet-331	147	16	significantly	significantly	ADV
admet-331	147	17	reduced	reduce	VERB
admet-331	147	18	by	by	ADP
admet-331	147	19	fasudil	fasudil	NOUN
admet-331	147	20	(	(	PUNCT
admet-331	147	21	50	50	NUM
admet-331	147	22	µl	µl	NOUN
admet-331	147	23	,	,	PUNCT
admet-331	147	24	3	3	NUM
admet-331	147	25	nm	nm	NOUN
admet-331	147	26	)	)	PUNCT
admet-331	147	27	applied	apply	VERB
admet-331	147	28	topically	topically	ADV
admet-331	147	29	twice	twice	ADV
admet-331	147	30	daily	daily	ADV
admet-331	147	31	for	for	ADP
admet-331	147	32	three	three	NUM
admet-331	147	33	days	day	NOUN
admet-331	147	34	(	(	PUNCT
admet-331	147	35	corneas	cornea	NOUN
admet-331	147	36	were	be	AUX
admet-331	147	37	harvested	harvest	VERB
admet-331	147	38	after	after	ADP
admet-331	147	39	two	two	NUM
admet-331	147	40	weeks	week	NOUN
admet-331	147	41	)	)	PUNCT
admet-331	147	42	compared	compare	VERB
admet-331	147	43	to	to	ADP
admet-331	147	44	the	the	DET
admet-331	147	45	basic	basic	ADJ
admet-331	147	46	salinetreated	salinetreate	VERB
admet-331	147	47	control	control	NOUN
admet-331	147	48	group	group	NOUN
admet-331	147	49	.	.	PUNCT
admet-331	148	1	the	the	DET
admet-331	148	2	histological	histological	ADJ
admet-331	148	3	examination	examination	NOUN
admet-331	148	4	confirmed	confirm	VERB
admet-331	148	5	the	the	DET
admet-331	148	6	initial	initial	ADJ
admet-331	148	7	biomicroscopical	biomicroscopical	ADJ
admet-331	148	8	findings	finding	NOUN
admet-331	148	9	:	:	PUNCT
admet-331	148	10	the	the	DET
admet-331	148	11	fasudil	fasudil	NOUN
admet-331	148	12	-	-	PUNCT
admet-331	148	13	treated	treat	VERB
admet-331	148	14	corneas	cornea	NOUN
admet-331	148	15	exhibited	exhibit	VERB
admet-331	148	16	significantly	significantly	ADV
admet-331	148	17	less	less	ADV
admet-331	148	18	staining	stain	VERB
admet-331	148	19	for	for	ADP
admet-331	148	20	fibrotic	fibrotic	ADJ
admet-331	148	21	markers	marker	NOUN
admet-331	148	22	(	(	PUNCT
admet-331	148	23	smooth	smooth	ADJ
admet-331	148	24	muscle	muscle	NOUN
admet-331	148	25	actin	actin	NOUN
admet-331	148	26	,	,	PUNCT
admet-331	148	27	fibronectin	fibronectin	NOUN
admet-331	148	28	,	,	PUNCT
admet-331	148	29	f	f	NOUN
admet-331	148	30	-	-	PUNCT
admet-331	148	31	actin	actin	NOUN
admet-331	148	32	)	)	PUNCT
admet-331	148	33	than	than	ADP
admet-331	148	34	the	the	DET
admet-331	148	35	control	control	NOUN
admet-331	148	36	group	group	NOUN
admet-331	149	1	[	[	X
admet-331	149	2	39	39	NUM
admet-331	149	3	]	]	PUNCT
admet-331	149	4	.	.	PUNCT
admet-331	150	1	zeng	zeng	PROPN
admet-331	150	2	et	et	PROPN
admet-331	150	3	al	al	PROPN
admet-331	150	4	.	.	PUNCT
admet-331	151	1	[	[	X
admet-331	151	2	40	40	NUM
admet-331	151	3	]	]	PUNCT
admet-331	151	4	also	also	ADV
admet-331	151	5	demonstrated	demonstrate	VERB
admet-331	151	6	that	that	SCONJ
admet-331	151	7	rock	rock	NOUN
admet-331	151	8	inhibitors	inhibitor	NOUN
admet-331	151	9	(	(	PUNCT
admet-331	151	10	fasudil	fasudil	NOUN
admet-331	151	11	)	)	PUNCT
admet-331	151	12	can	can	AUX
admet-331	151	13	promote	promote	VERB
admet-331	151	14	the	the	DET
admet-331	151	15	healing	healing	NOUN
admet-331	151	16	of	of	ADP
admet-331	151	17	corneal	corneal	ADJ
admet-331	151	18	epithelial	epithelial	ADJ
admet-331	151	19	defects	defect	NOUN
admet-331	151	20	and	and	CCONJ
admet-331	151	21	inhibit	inhibit	VERB
admet-331	151	22	the	the	DET
admet-331	151	23	formation	formation	NOUN
admet-331	151	24	of	of	ADP
admet-331	151	25	neovascularization	neovascularization	NOUN
admet-331	151	26	.	.	PUNCT
admet-331	152	1	in	in	ADP
admet-331	152	2	their	their	PRON
admet-331	152	3	alkali	alkali	ADJ
admet-331	152	4	burn	burn	NOUN
admet-331	152	5	mouse	mouse	NOUN
admet-331	152	6	cornea	cornea	PROPN
admet-331	152	7	model	model	NOUN
admet-331	152	8	they	they	PRON
admet-331	152	9	used	use	VERB
admet-331	152	10	different	different	ADJ
admet-331	152	11	concentrations	concentration	NOUN
admet-331	152	12	of	of	ADP
admet-331	152	13	fasudil	fasudil	NOUN
admet-331	152	14	(	(	PUNCT
admet-331	152	15	30	30	NUM
admet-331	152	16	,	,	PUNCT
admet-331	152	17	100	100	NUM
admet-331	152	18	,	,	PUNCT
admet-331	152	19	300	300	NUM
admet-331	152	20	,	,	PUNCT
admet-331	152	21	1000	1000	NUM
admet-331	152	22	µm	µm	ADP
admet-331	152	23	eye	eye	NOUN
admet-331	152	24	drops	drop	NOUN
admet-331	152	25	,	,	PUNCT
admet-331	152	26	applied	apply	VERB
admet-331	152	27	4	4	NUM
admet-331	152	28	times	time	NOUN
admet-331	152	29	daily	daily	ADV
admet-331	152	30	,	,	PUNCT
admet-331	152	31	for	for	ADP
admet-331	152	32	14	14	NUM
admet-331	152	33	days	day	NOUN
admet-331	152	34	)	)	PUNCT
admet-331	152	35	.	.	PUNCT
admet-331	153	1	although	although	SCONJ
admet-331	153	2	only	only	ADV
admet-331	153	3	the	the	DET
admet-331	153	4	100	100	NUM
admet-331	153	5	µm	µm	NUM
admet-331	153	6	dose	dose	NOUN
admet-331	153	7	inhibited	inhibit	VERB
admet-331	153	8	the	the	DET
admet-331	153	9	corneal	corneal	ADJ
admet-331	153	10	neovascularization	neovascularization	NOUN
admet-331	153	11	significantly	significantly	ADV
admet-331	153	12	at	at	ADP
admet-331	153	13	all	all	DET
admet-331	153	14	time	time	NOUN
admet-331	153	15	points	point	NOUN
admet-331	153	16	examined	examine	VERB
admet-331	153	17	compared	compare	VERB
admet-331	153	18	to	to	ADP
admet-331	153	19	the	the	DET
admet-331	153	20	control	control	NOUN
admet-331	153	21	group	group	NOUN
admet-331	153	22	,	,	PUNCT
admet-331	153	23	corneal	corneal	ADJ
admet-331	153	24	re	re	NOUN
admet-331	153	25	-	-	NOUN
admet-331	153	26	epithelization	epithelization	NOUN
admet-331	153	27	was	be	AUX
admet-331	153	28	significantly	significantly	ADV
admet-331	153	29	accelerated	accelerate	VERB
admet-331	153	30	by	by	ADP
admet-331	153	31	100	100	NUM
admet-331	153	32	,	,	PUNCT
admet-331	153	33	300	300	NUM
admet-331	153	34	,	,	PUNCT
admet-331	153	35	and	and	CCONJ
admet-331	153	36	1000	1000	NUM
admet-331	153	37	µm	µm	NOUN
admet-331	153	38	of	of	ADP
admet-331	153	39	fasudil	fasudil	NOUN
admet-331	153	40	.	.	PUNCT
admet-331	154	1	according	accord	VERB
admet-331	154	2	to	to	ADP
admet-331	154	3	current	current	ADJ
admet-331	154	4	understanding	understanding	NOUN
admet-331	154	5	,	,	PUNCT
admet-331	154	6	inflammation	inflammation	NOUN
admet-331	154	7	and	and	CCONJ
admet-331	154	8	reactive	reactive	ADJ
admet-331	154	9	oxygen	oxygen	NOUN
admet-331	154	10	species	specie	NOUN
admet-331	154	11	(	(	PUNCT
admet-331	154	12	ros	ros	PROPN
admet-331	154	13	)	)	PUNCT
admet-331	154	14	contribute	contribute	VERB
admet-331	154	15	,	,	PUNCT
admet-331	154	16	at	at	ADP
admet-331	154	17	least	least	ADJ
admet-331	154	18	in	in	ADP
admet-331	154	19	part	part	NOUN
admet-331	154	20	,	,	PUNCT
admet-331	154	21	to	to	ADP
admet-331	154	22	neo	neo	NOUN
admet-331	154	23	-	-	NOUN
admet-331	154	24	angiogenesis	angiogenesis	NOUN
admet-331	154	25	.	.	PUNCT
admet-331	155	1	in	in	ADP
admet-331	155	2	an	an	DET
admet-331	155	3	in	in	ADP
admet-331	155	4	vivo	vivo	ADJ
admet-331	155	5	corneal	corneal	ADJ
admet-331	155	6	neovascularization	neovascularization	NOUN
admet-331	155	7	murine	murine	ADJ
admet-331	155	8	model	model	NOUN
admet-331	155	9	,	,	PUNCT
admet-331	155	10	100	100	NUM
admet-331	155	11	µm	µm	ADP
admet-331	155	12	topical	topical	ADJ
admet-331	155	13	fasudil	fasudil	NOUN
admet-331	155	14	appeared	appear	VERB
admet-331	155	15	to	to	PART
admet-331	155	16	serve	serve	VERB
admet-331	155	17	as	as	ADP
admet-331	155	18	a	a	DET
admet-331	155	19	potential	potential	ADJ
admet-331	155	20	antioxidant	antioxidant	NOUN
admet-331	155	21	because	because	SCONJ
admet-331	155	22	there	there	PRON
admet-331	155	23	was	be	VERB
admet-331	155	24	decreased	decrease	VERB
admet-331	155	25	ros	ros	NOUN
admet-331	155	26	activity	activity	NOUN
admet-331	155	27	,	,	PUNCT
admet-331	155	28	as	as	ADV
admet-331	155	29	well	well	ADV
admet-331	155	30	as	as	ADP
admet-331	155	31	reduced	reduce	VERB
admet-331	155	32	expression	expression	NOUN
admet-331	155	33	of	of	ADP
admet-331	155	34	angiogenesis	angiogenesis	NOUN
admet-331	155	35	related	relate	VERB
admet-331	155	36	genes	gene	NOUN
admet-331	155	37	(	(	PUNCT
admet-331	155	38	vegf	vegf	PROPN
admet-331	155	39	,	,	PUNCT
admet-331	155	40	tnf	tnf	PROPN
admet-331	155	41	-	-	PUNCT
admet-331	155	42	alfa	alfa	PROPN
admet-331	155	43	,	,	PUNCT
admet-331	155	44	mmp-8	mmp-8	ADV
admet-331	155	45	,	,	PUNCT
admet-331	155	46	mmp-9	mmp-9	NUM
admet-331	155	47	)	)	PUNCT
admet-331	155	48	and	and	CCONJ
admet-331	155	49	increased	increase	VERB
admet-331	155	50	levels	level	NOUN
admet-331	155	51	of	of	ADP
admet-331	155	52	protective	protective	ADJ
admet-331	155	53	heme	heme	NOUN
admet-331	155	54	oxygenase	oxygenase	NOUN
admet-331	155	55	1	1	NUM
admet-331	155	56	(	(	PUNCT
admet-331	155	57	ho-1	ho-1	ADJ
admet-331	155	58	)	)	PUNCT
admet-331	155	59	.	.	PUNCT
admet-331	156	1	in	in	ADP
admet-331	156	2	addition	addition	NOUN
admet-331	156	3	,	,	PUNCT
admet-331	156	4	the	the	DET
admet-331	156	5	number	number	NOUN
admet-331	156	6	of	of	ADP
admet-331	156	7	inflammatory	inflammatory	ADJ
admet-331	156	8	cells	cell	NOUN
admet-331	156	9	in	in	ADP
admet-331	156	10	the	the	DET
admet-331	156	11	cornea	cornea	NOUN
admet-331	156	12	was	be	AUX
admet-331	156	13	reduced	reduce	VERB
admet-331	156	14	[	[	X
admet-331	156	15	40	40	NUM
admet-331	156	16	]	]	PUNCT
admet-331	156	17	.	.	PUNCT
admet-331	157	1	thus	thus	ADV
admet-331	157	2	,	,	PUNCT
admet-331	157	3	rock	rock	NOUN
admet-331	157	4	inhibition	inhibition	NOUN
admet-331	157	5	has	have	AUX
admet-331	157	6	been	be	AUX
admet-331	157	7	shown	show	VERB
admet-331	157	8	to	to	PART
admet-331	157	9	have	have	VERB
admet-331	157	10	effects	effect	NOUN
admet-331	157	11	on	on	ADP
admet-331	157	12	corneal	corneal	ADJ
admet-331	157	13	endothelial	endothelial	ADJ
admet-331	157	14	migration	migration	NOUN
admet-331	157	15	and	and	CCONJ
admet-331	157	16	proliferation	proliferation	NOUN
admet-331	157	17	and	and	CCONJ
admet-331	157	18	on	on	ADP
admet-331	157	19	corneal	corneal	ADJ
admet-331	157	20	neovascularization	neovascularization	NOUN
admet-331	157	21	.	.	PUNCT
admet-331	158	1	admet	admet	PROPN
admet-331	158	2	&	&	CCONJ
admet-331	158	3	dmpk	dmpk	PROPN
admet-331	158	4	4(4	4(4	NUM
admet-331	158	5	)	)	PUNCT
admet-331	158	6	(	(	PUNCT
admet-331	158	7	2016	2016	NUM
admet-331	158	8	)	)	PUNCT
admet-331	158	9	280	280	NUM
admet-331	158	10	-	-	SYM
admet-331	158	11	301	301	NUM
admet-331	158	12	rock	rock	NOUN
admet-331	158	13	inhibitors	inhibitor	NOUN
admet-331	158	14	in	in	ADP
admet-331	158	15	ocular	ocular	ADJ
admet-331	158	16	disease	disease	NOUN
admet-331	158	17	doi	doi	NOUN
admet-331	158	18	:	:	PUNCT
admet-331	158	19	10.5599	10.5599	NUM
admet-331	158	20	/	/	SYM
admet-331	158	21	admet.4.4.331	admet.4.4.331	PROPN
admet-331	158	22	287	287	NUM
admet-331	158	23	glaucoma	glaucoma	NOUN
admet-331	158	24	glaucoma	glaucoma	NOUN
admet-331	158	25	is	be	AUX
admet-331	158	26	a	a	DET
admet-331	158	27	progressive	progressive	ADJ
admet-331	158	28	optic	optic	ADJ
admet-331	158	29	neuropathy	neuropathy	ADJ
admet-331	158	30	characterized	characterize	VERB
admet-331	158	31	by	by	ADP
admet-331	158	32	ganglion	ganglion	NOUN
admet-331	158	33	cell	cell	NOUN
admet-331	158	34	death	death	NOUN
admet-331	158	35	which	which	PRON
admet-331	158	36	leads	lead	VERB
admet-331	158	37	to	to	ADP
admet-331	158	38	concomitant	concomitant	ADJ
admet-331	158	39	thinning	thinning	NOUN
admet-331	158	40	of	of	ADP
admet-331	158	41	the	the	DET
admet-331	158	42	retinal	retinal	ADJ
admet-331	158	43	nerve	nerve	NOUN
admet-331	158	44	fiber	fiber	NOUN
admet-331	158	45	layer	layer	NOUN
admet-331	158	46	and	and	CCONJ
admet-331	158	47	visual	visual	ADJ
admet-331	158	48	field	field	NOUN
admet-331	158	49	loss	loss	NOUN
admet-331	158	50	.	.	PUNCT
admet-331	159	1	in	in	ADP
admet-331	159	2	spite	spite	NOUN
admet-331	159	3	of	of	ADP
admet-331	159	4	the	the	DET
admet-331	159	5	fact	fact	NOUN
admet-331	159	6	that	that	SCONJ
admet-331	159	7	glaucoma	glaucoma	NOUN
admet-331	159	8	is	be	AUX
admet-331	159	9	the	the	DET
admet-331	159	10	leading	lead	VERB
admet-331	159	11	cause	cause	NOUN
admet-331	159	12	of	of	ADP
admet-331	159	13	irreversible	irreversible	ADJ
admet-331	159	14	blindness	blindness	NOUN
admet-331	159	15	worldwide	worldwide	ADV
admet-331	159	16	,	,	PUNCT
admet-331	159	17	the	the	DET
admet-331	159	18	etiology	etiology	NOUN
admet-331	159	19	of	of	ADP
admet-331	159	20	the	the	DET
admet-331	159	21	disease	disease	NOUN
admet-331	159	22	is	be	AUX
admet-331	159	23	still	still	ADV
admet-331	159	24	not	not	PART
admet-331	159	25	fully	fully	ADV
admet-331	159	26	understood	understand	VERB
admet-331	159	27	.	.	PUNCT
admet-331	160	1	present	present	ADJ
admet-331	160	2	clinical	clinical	ADJ
admet-331	160	3	therapeutic	therapeutic	ADJ
admet-331	160	4	strategies	strategy	NOUN
admet-331	160	5	focus	focus	VERB
admet-331	160	6	on	on	ADP
admet-331	160	7	lowering	lower	VERB
admet-331	160	8	intraocular	intraocular	ADJ
admet-331	160	9	pressure	pressure	NOUN
admet-331	160	10	(	(	PUNCT
admet-331	160	11	iop	iop	NOUN
admet-331	160	12	)	)	PUNCT
admet-331	160	13	via	via	ADP
admet-331	160	14	pharmacologic	pharmacologic	ADJ
admet-331	160	15	agents	agent	NOUN
admet-331	160	16	or	or	CCONJ
admet-331	160	17	surgical	surgical	ADJ
admet-331	160	18	procedures	procedure	NOUN
admet-331	160	19	.	.	PUNCT
admet-331	161	1	rock	rock	NOUN
admet-331	161	2	inhibitors	inhibitor	NOUN
admet-331	161	3	may	may	AUX
admet-331	161	4	have	have	VERB
admet-331	161	5	potential	potential	NOUN
admet-331	161	6	in	in	ADP
admet-331	161	7	glaucoma	glaucoma	NOUN
admet-331	161	8	therapy	therapy	NOUN
admet-331	161	9	in	in	ADP
admet-331	161	10	at	at	ADV
admet-331	161	11	least	least	ADV
admet-331	161	12	three	three	NUM
admet-331	161	13	ways	way	NOUN
admet-331	161	14	:	:	PUNCT
admet-331	161	15	lowering	lower	VERB
admet-331	161	16	the	the	DET
admet-331	161	17	intraocular	intraocular	ADJ
admet-331	161	18	pressure	pressure	NOUN
admet-331	161	19	,	,	PUNCT
admet-331	161	20	reducing	reduce	VERB
admet-331	161	21	the	the	DET
admet-331	161	22	scarring	scarring	NOUN
admet-331	161	23	after	after	ADP
admet-331	161	24	filtration	filtration	NOUN
admet-331	161	25	surgery	surgery	NOUN
admet-331	161	26	,	,	PUNCT
admet-331	161	27	and	and	CCONJ
admet-331	161	28	neuroprotection	neuroprotection	NOUN
admet-331	161	29	(	(	PUNCT
admet-331	161	30	neuroprotection	neuroprotection	NOUN
admet-331	161	31	is	be	AUX
admet-331	161	32	discussed	discuss	VERB
admet-331	161	33	in	in	ADP
admet-331	161	34	the	the	DET
admet-331	161	35	retina	retina	NOUN
admet-331	161	36	section	section	NOUN
admet-331	161	37	)	)	PUNCT
admet-331	161	38	.	.	PUNCT
admet-331	162	1	proposed	propose	VERB
admet-331	162	2	iop	iop	NOUN
admet-331	162	3	lowering	lower	VERB
admet-331	162	4	mechanism	mechanism	NOUN
admet-331	162	5	:	:	PUNCT
admet-331	162	6	the	the	DET
admet-331	162	7	cause	cause	NOUN
admet-331	162	8	of	of	ADP
admet-331	162	9	elevated	elevated	ADJ
admet-331	162	10	iop	iop	NOUN
admet-331	162	11	levels	level	NOUN
admet-331	162	12	originates	originate	NOUN
admet-331	162	13	from	from	ADP
admet-331	162	14	the	the	DET
admet-331	162	15	imbalance	imbalance	NOUN
admet-331	162	16	between	between	ADP
admet-331	162	17	production	production	NOUN
admet-331	162	18	of	of	ADP
admet-331	162	19	aqueous	aqueous	ADJ
admet-331	162	20	humor	humor	NOUN
admet-331	162	21	and	and	CCONJ
admet-331	162	22	drainage	drainage	NOUN
admet-331	162	23	of	of	ADP
admet-331	162	24	aqueous	aqueous	ADJ
admet-331	162	25	humor	humor	NOUN
admet-331	162	26	.	.	PUNCT
admet-331	163	1	the	the	DET
admet-331	163	2	aqueous	aqueous	ADJ
admet-331	163	3	humor	humor	NOUN
admet-331	163	4	is	be	AUX
admet-331	163	5	traditionally	traditionally	ADV
admet-331	163	6	considered	consider	VERB
admet-331	163	7	to	to	PART
admet-331	163	8	drain	drain	VERB
admet-331	163	9	out	out	ADP
admet-331	163	10	of	of	ADP
admet-331	163	11	the	the	DET
admet-331	163	12	eye	eye	NOUN
admet-331	163	13	through	through	ADP
admet-331	163	14	either	either	CCONJ
admet-331	163	15	the	the	DET
admet-331	163	16	conventional	conventional	ADJ
admet-331	163	17	pathway	pathway	NOUN
admet-331	163	18	via	via	ADP
admet-331	163	19	the	the	DET
admet-331	163	20	trabecular	trabecular	ADJ
admet-331	163	21	meshwork	meshwork	NOUN
admet-331	163	22	(	(	PUNCT
admet-331	163	23	tm	tm	NOUN
admet-331	163	24	)	)	PUNCT
admet-331	163	25	or	or	CCONJ
admet-331	163	26	the	the	DET
admet-331	163	27	unconventional	unconventional	ADJ
admet-331	163	28	pathway	pathway	NOUN
admet-331	163	29	via	via	ADP
admet-331	163	30	the	the	DET
admet-331	163	31	uveoscleral	uveoscleral	ADJ
admet-331	163	32	route	route	NOUN
admet-331	163	33	.	.	PUNCT
admet-331	164	1	normally	normally	ADV
admet-331	164	2	,	,	PUNCT
admet-331	164	3	the	the	DET
admet-331	164	4	tm	tm	PROPN
admet-331	164	5	is	be	AUX
admet-331	164	6	a	a	DET
admet-331	164	7	spongy	spongy	ADJ
admet-331	164	8	connective	connective	ADJ
admet-331	164	9	tissue	tissue	NOUN
admet-331	164	10	containing	contain	VERB
admet-331	164	11	collagen	collagen	NOUN
admet-331	164	12	and	and	CCONJ
admet-331	164	13	elastin	elastin	NOUN
admet-331	164	14	fibers	fiber	NOUN
admet-331	164	15	surrounded	surround	VERB
admet-331	164	16	by	by	ADP
admet-331	164	17	trabecular	trabecular	ADJ
admet-331	164	18	cells	cell	NOUN
admet-331	164	19	,	,	PUNCT
admet-331	164	20	which	which	PRON
admet-331	164	21	display	display	VERB
admet-331	164	22	smooth	smooth	ADJ
admet-331	164	23	-	-	PUNCT
admet-331	164	24	muscle	muscle	NOUN
admet-331	164	25	like	like	ADP
admet-331	164	26	properties	property	NOUN
admet-331	164	27	such	such	ADJ
admet-331	164	28	as	as	ADP
admet-331	164	29	actin	actin	NOUN
admet-331	164	30	-	-	PUNCT
admet-331	164	31	myosin	myosin	NOUN
admet-331	164	32	contractility	contractility	NOUN
admet-331	164	33	.	.	PUNCT
admet-331	165	1	contraction	contraction	NOUN
admet-331	165	2	of	of	ADP
admet-331	165	3	tm	tm	PROPN
admet-331	165	4	cells	cell	NOUN
admet-331	165	5	or	or	CCONJ
admet-331	165	6	ciliary	ciliary	ADJ
admet-331	165	7	muscle	muscle	NOUN
admet-331	165	8	results	result	NOUN
admet-331	165	9	in	in	ADP
admet-331	165	10	reduced	reduced	ADJ
admet-331	165	11	aqueous	aqueous	ADJ
admet-331	165	12	humor	humor	NOUN
admet-331	165	13	outflow	outflow	NOUN
admet-331	165	14	and	and	CCONJ
admet-331	165	15	increases	increase	VERB
admet-331	165	16	the	the	DET
admet-331	165	17	iop	iop	PROPN
admet-331	165	18	.	.	PROPN
admet-331	166	1	activated	activate	VERB
admet-331	166	2	rock	rock	NOUN
admet-331	166	3	takes	take	VERB
admet-331	166	4	part	part	NOUN
admet-331	166	5	in	in	ADP
admet-331	166	6	regulation	regulation	NOUN
admet-331	166	7	of	of	ADP
admet-331	166	8	ciliary	ciliary	ADJ
admet-331	166	9	muscle	muscle	NOUN
admet-331	166	10	and	and	CCONJ
admet-331	166	11	trabecular	trabecular	ADJ
admet-331	166	12	meshwork	meshwork	ADJ
admet-331	166	13	cell	cell	NOUN
admet-331	166	14	contraction	contraction	NOUN
admet-331	166	15	through	through	ADP
admet-331	166	16	phosphorylation	phosphorylation	NOUN
admet-331	166	17	of	of	ADP
admet-331	166	18	the	the	DET
admet-331	166	19	myosin	myosin	NOUN
admet-331	166	20	binding	bind	VERB
admet-331	166	21	subunit	subunit	NOUN
admet-331	166	22	of	of	ADP
admet-331	166	23	myosin	myosin	PROPN
admet-331	166	24	light	light	PROPN
admet-331	166	25	chain	chain	NOUN
admet-331	166	26	phosphatase	phosphatase	NOUN
admet-331	166	27	[	[	X
admet-331	166	28	28	28	NUM
admet-331	166	29	]	]	PUNCT
admet-331	166	30	and	and	CCONJ
admet-331	166	31	direct	direct	ADJ
admet-331	166	32	phosphorylation	phosphorylation	NOUN
admet-331	166	33	of	of	ADP
admet-331	166	34	myosin	myosin	PROPN
admet-331	166	35	light	light	PROPN
admet-331	166	36	chain	chain	NOUN
admet-331	166	37	[	[	X
admet-331	166	38	41	41	NUM
admet-331	166	39	]	]	PUNCT
admet-331	166	40	.	.	PUNCT
admet-331	167	1	as	as	SCONJ
admet-331	167	2	previously	previously	ADV
admet-331	167	3	described	describe	VERB
admet-331	167	4	,	,	PUNCT
admet-331	167	5	lim	lim	PROPN
admet-331	167	6	kinases	kinase	NOUN
admet-331	167	7	are	be	AUX
admet-331	167	8	downstream	downstream	ADJ
admet-331	167	9	targets	target	NOUN
admet-331	167	10	of	of	ADP
admet-331	167	11	rock	rock	NOUN
admet-331	167	12	,	,	PUNCT
admet-331	167	13	and	and	CCONJ
admet-331	167	14	their	their	PRON
admet-331	167	15	activation	activation	NOUN
admet-331	167	16	leads	lead	VERB
admet-331	167	17	to	to	ADP
admet-331	167	18	stabilization	stabilization	NOUN
admet-331	167	19	of	of	ADP
admet-331	167	20	actin	actin	NOUN
admet-331	167	21	polymerization	polymerization	NOUN
admet-331	167	22	by	by	ADP
admet-331	167	23	phosphorylated	phosphorylate	VERB
admet-331	167	24	cofilin	cofilin	NOUN
admet-331	167	25	.	.	PUNCT
admet-331	168	1	limk	limk	NOUN
admet-331	168	2	inhibition	inhibition	NOUN
admet-331	168	3	(	(	PUNCT
admet-331	168	4	either	either	CCONJ
admet-331	168	5	directly	directly	ADV
admet-331	168	6	or	or	CCONJ
admet-331	168	7	through	through	ADP
admet-331	168	8	a	a	DET
admet-331	168	9	rock	rock	NOUN
admet-331	168	10	inhibitor	inhibitor	NOUN
admet-331	168	11	)	)	PUNCT
admet-331	168	12	is	be	AUX
admet-331	168	13	considered	consider	VERB
admet-331	168	14	to	to	PART
admet-331	168	15	induce	induce	VERB
admet-331	168	16	trabecular	trabecular	ADJ
admet-331	168	17	meshwork	meshwork	ADJ
admet-331	168	18	relaxation	relaxation	NOUN
admet-331	168	19	via	via	ADP
admet-331	168	20	depolymerization	depolymerization	NOUN
admet-331	168	21	of	of	ADP
admet-331	168	22	actin	actin	NOUN
admet-331	168	23	filaments	filament	NOUN
admet-331	168	24	[	[	X
admet-331	168	25	42	42	NUM
admet-331	168	26	]	]	PUNCT
admet-331	168	27	.	.	PUNCT
admet-331	169	1	aqueous	aqueous	ADJ
admet-331	169	2	humor	humor	NOUN
admet-331	169	3	in	in	ADP
admet-331	169	4	patients	patient	NOUN
admet-331	169	5	with	with	ADP
admet-331	169	6	primary	primary	ADJ
admet-331	169	7	open	open	ADJ
admet-331	169	8	angle	angle	NOUN
admet-331	169	9	glaucoma	glaucoma	NOUN
admet-331	169	10	contains	contain	VERB
admet-331	169	11	elevated	elevated	ADJ
admet-331	169	12	levels	level	NOUN
admet-331	169	13	of	of	ADP
admet-331	169	14	endothelin	endothelin	PROPN
admet-331	169	15	1	1	NUM
admet-331	169	16	(	(	PUNCT
admet-331	169	17	et-1	et-1	X
admet-331	169	18	)	)	PUNCT
admet-331	170	1	[	[	X
admet-331	170	2	43	43	NUM
admet-331	170	3	]	]	PUNCT
admet-331	170	4	and	and	CCONJ
admet-331	170	5	tissue	tissue	NOUN
admet-331	170	6	growth	growth	NOUN
admet-331	170	7	factor	factor	NOUN
admet-331	170	8	-	-	PUNCT
admet-331	170	9	β	β	X
admet-331	170	10	(	(	PUNCT
admet-331	170	11	tgf	tgf	PROPN
admet-331	170	12	-	-	PUNCT
admet-331	170	13	β	β	NOUN
admet-331	170	14	)	)	PUNCT
admet-331	171	1	[	[	X
admet-331	171	2	44	44	NUM
admet-331	171	3	]	]	PUNCT
admet-331	171	4	which	which	PRON
admet-331	171	5	are	be	AUX
admet-331	171	6	upstream	upstream	ADJ
admet-331	171	7	activators	activator	NOUN
admet-331	171	8	of	of	ADP
admet-331	171	9	the	the	DET
admet-331	171	10	rho	rho	ADJ
admet-331	171	11	-	-	ADJ
admet-331	171	12	rock	rock	NOUN
admet-331	171	13	pathway	pathway	NOUN
admet-331	172	1	[	[	X
admet-331	172	2	3,45	3,45	NUM
admet-331	172	3	]	]	X
admet-331	172	4	.	.	PUNCT
admet-331	173	1	rock	rock	NOUN
admet-331	173	2	inhibitors	inhibitor	NOUN
admet-331	173	3	have	have	AUX
admet-331	173	4	been	be	AUX
admet-331	173	5	shown	show	VERB
admet-331	173	6	to	to	PART
admet-331	173	7	act	act	VERB
admet-331	173	8	directly	directly	ADV
admet-331	173	9	on	on	ADP
admet-331	173	10	primate	primate	NOUN
admet-331	173	11	tm	tm	NOUN
admet-331	173	12	and	and	CCONJ
admet-331	173	13	schlemm	schlemm	NOUN
admet-331	173	14	’s	’s	PART
admet-331	173	15	canal	canal	NOUN
admet-331	173	16	(	(	PUNCT
admet-331	173	17	sc	sc	PROPN
admet-331	173	18	)	)	PUNCT
admet-331	173	19	,	,	PUNCT
admet-331	173	20	lowering	lower	VERB
admet-331	173	21	the	the	DET
admet-331	173	22	iop	iop	NOUN
admet-331	173	23	by	by	ADP
admet-331	173	24	increasing	increase	VERB
admet-331	173	25	the	the	DET
admet-331	173	26	outflow	outflow	NOUN
admet-331	173	27	of	of	ADP
admet-331	173	28	the	the	DET
admet-331	173	29	aqueous	aqueous	ADJ
admet-331	173	30	humor	humor	NOUN
admet-331	173	31	through	through	ADP
admet-331	173	32	the	the	DET
admet-331	173	33	conventional	conventional	ADJ
admet-331	173	34	pathway	pathway	NOUN
admet-331	173	35	.	.	PUNCT
admet-331	174	1	in	in	ADP
admet-331	174	2	normotensive	normotensive	ADJ
admet-331	174	3	monkeys	monkey	NOUN
admet-331	174	4	,	,	PUNCT
admet-331	174	5	ar13324	ar13324	PROPN
admet-331	174	6	increased	increase	VERB
admet-331	174	7	the	the	DET
admet-331	174	8	outflow	outflow	NOUN
admet-331	174	9	facility	facility	NOUN
admet-331	174	10	by	by	ADP
admet-331	174	11	53	53	NUM
admet-331	174	12	%	%	NOUN
admet-331	174	13	and	and	CCONJ
admet-331	174	14	reduced	reduce	VERB
admet-331	174	15	the	the	DET
admet-331	174	16	iop	iop	NOUN
admet-331	174	17	by	by	ADP
admet-331	174	18	more	more	ADJ
admet-331	174	19	than	than	ADP
admet-331	174	20	20	20	NUM
admet-331	174	21	%	%	NOUN
admet-331	174	22	compared	compare	VERB
admet-331	174	23	to	to	ADP
admet-331	174	24	the	the	DET
admet-331	174	25	contralateral	contralateral	ADJ
admet-331	174	26	vehicle	vehicle	NOUN
admet-331	174	27	-	-	PUNCT
admet-331	174	28	treated	treat	VERB
admet-331	174	29	eye	eye	NOUN
admet-331	175	1	[	[	X
admet-331	175	2	46	46	NUM
admet-331	175	3	]	]	PUNCT
admet-331	175	4	.	.	PUNCT
admet-331	176	1	primate	primate	VERB
admet-331	176	2	trabecular	trabecular	ADJ
admet-331	176	3	meshwork	meshwork	ADJ
admet-331	176	4	cells	cell	NOUN
admet-331	176	5	treated	treat	VERB
admet-331	176	6	with	with	ADP
admet-331	176	7	different	different	ADJ
admet-331	176	8	rock	rock	NOUN
admet-331	176	9	inhibitors	inhibitor	NOUN
admet-331	176	10	(	(	PUNCT
admet-331	176	11	y27632	y27632	PROPN
admet-331	176	12	,	,	PUNCT
admet-331	176	13	fasudil	fasudil	NOUN
admet-331	176	14	,	,	PUNCT
admet-331	176	15	ripasudil	ripasudil	PROPN
admet-331	176	16	)	)	PUNCT
admet-331	176	17	exhibited	exhibit	VERB
admet-331	176	18	rounding	round	VERB
admet-331	176	19	and	and	CCONJ
admet-331	176	20	a	a	DET
admet-331	176	21	decreased	decrease	VERB
admet-331	176	22	number	number	NOUN
admet-331	176	23	of	of	ADP
admet-331	176	24	actin	actin	NOUN
admet-331	176	25	bundles	bundle	NOUN
admet-331	176	26	.	.	PUNCT
admet-331	177	1	these	these	DET
admet-331	177	2	changes	change	NOUN
admet-331	177	3	returned	return	VERB
admet-331	177	4	two	two	NUM
admet-331	177	5	hours	hour	NOUN
admet-331	177	6	after	after	ADP
admet-331	177	7	drug	drug	NOUN
admet-331	177	8	removal	removal	NOUN
admet-331	177	9	.	.	PUNCT
admet-331	178	1	all	all	DET
admet-331	178	2	three	three	NUM
admet-331	178	3	of	of	ADP
admet-331	178	4	these	these	DET
admet-331	178	5	rock	rock	NOUN
admet-331	178	6	inhibitors	inhibitor	NOUN
admet-331	178	7	enhanced	enhance	VERB
admet-331	178	8	schlemm	schlemm	NOUN
admet-331	178	9	’s	’s	PART
admet-331	178	10	canal	canal	NOUN
admet-331	178	11	endothelial	endothelial	ADJ
admet-331	178	12	cell	cell	NOUN
admet-331	178	13	permeability	permeability	NOUN
admet-331	178	14	probably	probably	ADV
admet-331	178	15	via	via	ADP
admet-331	178	16	tight	tight	ADJ
admet-331	178	17	junction	junction	NOUN
admet-331	178	18	disruption	disruption	NOUN
admet-331	178	19	[	[	X
admet-331	178	20	6	6	NUM
admet-331	178	21	]	]	PUNCT
admet-331	178	22	.	.	PUNCT
admet-331	179	1	in	in	ADP
admet-331	179	2	human	human	ADJ
admet-331	179	3	tm	tm	PROPN
admet-331	179	4	and	and	CCONJ
admet-331	179	5	sc	sc	PROPN
admet-331	179	6	cell	cell	NOUN
admet-331	179	7	culture	culture	NOUN
admet-331	179	8	,	,	PUNCT
admet-331	179	9	y27632	y27632	PROPN
admet-331	179	10	caused	cause	VERB
admet-331	179	11	reversible	reversible	ADJ
admet-331	179	12	changes	change	NOUN
admet-331	179	13	in	in	ADP
admet-331	179	14	cell	cell	NOUN
admet-331	179	15	shape	shape	NOUN
admet-331	179	16	,	,	PUNCT
admet-331	179	17	decreased	decrease	VERB
admet-331	179	18	the	the	DET
admet-331	179	19	presence	presence	NOUN
admet-331	179	20	of	of	ADP
admet-331	179	21	actin	actin	NOUN
admet-331	179	22	stress	stress	NOUN
admet-331	179	23	fibers	fiber	NOUN
admet-331	179	24	and	and	CCONJ
admet-331	179	25	focal	focal	ADJ
admet-331	179	26	adhesions	adhesion	NOUN
admet-331	179	27	,	,	PUNCT
admet-331	179	28	and	and	CCONJ
admet-331	179	29	significantly	significantly	ADV
admet-331	179	30	increased	increase	VERB
admet-331	179	31	the	the	DET
admet-331	179	32	schlemm	schlemm	NOUN
admet-331	179	33	’s	’s	PART
admet-331	179	34	canal	canal	NOUN
admet-331	179	35	monolayer	monolayer	NOUN
admet-331	179	36	permeability	permeability	NOUN
admet-331	179	37	(	(	PUNCT
admet-331	179	38	figure	figure	NOUN
admet-331	179	39	2	2	NUM
admet-331	179	40	)	)	PUNCT
admet-331	179	41	.	.	PUNCT
admet-331	180	1	the	the	DET
admet-331	180	2	iop	iop	NOUN
admet-331	180	3	lowering	lower	VERB
admet-331	180	4	effect	effect	NOUN
admet-331	180	5	of	of	ADP
admet-331	180	6	different	different	ADJ
admet-331	180	7	rock	rock	NOUN
admet-331	180	8	inhibitors	inhibitor	NOUN
admet-331	180	9	has	have	AUX
admet-331	180	10	been	be	AUX
admet-331	180	11	examined	examine	VERB
admet-331	180	12	in	in	ADP
admet-331	180	13	many	many	ADJ
admet-331	180	14	other	other	ADJ
admet-331	180	15	in	in	ADP
admet-331	180	16	vivo	vivo	NOUN
admet-331	180	17	and	and	CCONJ
admet-331	180	18	in	in	ADP
admet-331	180	19	vitro	vitro	X
admet-331	180	20	animal	animal	NOUN
admet-331	180	21	models	model	NOUN
admet-331	180	22	.	.	PUNCT
admet-331	181	1	in	in	ADP
admet-331	181	2	rabbits	rabbit	NOUN
admet-331	181	3	,	,	PUNCT
admet-331	181	4	a	a	DET
admet-331	181	5	single	single	ADJ
admet-331	181	6	instillation	instillation	NOUN
admet-331	181	7	of	of	ADP
admet-331	181	8	0.4	0.4	NUM
admet-331	181	9	%	%	NOUN
admet-331	181	10	ripasudil	ripasudil	NOUN
admet-331	181	11	doubled	double	VERB
admet-331	181	12	the	the	DET
admet-331	181	13	conventional	conventional	ADJ
admet-331	181	14	outflow	outflow	NOUN
admet-331	181	15	facility	facility	NOUN
admet-331	181	16	,	,	PUNCT
admet-331	181	17	although	although	SCONJ
admet-331	181	18	there	there	PRON
admet-331	181	19	was	be	VERB
admet-331	181	20	no	no	DET
admet-331	181	21	effect	effect	NOUN
admet-331	181	22	on	on	ADP
admet-331	181	23	the	the	DET
admet-331	181	24	uveoscleral	uveoscleral	ADJ
admet-331	181	25	route	route	NOUN
admet-331	181	26	[	[	X
admet-331	181	27	47	47	NUM
admet-331	181	28	]	]	PUNCT
admet-331	181	29	.	.	PUNCT
admet-331	182	1	enucleated	enucleate	VERB
admet-331	182	2	porcine	porcine	NOUN
admet-331	182	3	eyes	eye	NOUN
admet-331	182	4	perfused	perfuse	VERB
admet-331	182	5	with	with	ADP
admet-331	182	6	y27632	y27632	PROPN
admet-331	182	7	(	(	PUNCT
admet-331	182	8	10	10	NUM
admet-331	182	9	,	,	PUNCT
admet-331	182	10	50	50	NUM
admet-331	182	11	,	,	PUNCT
admet-331	182	12	100	100	NUM
admet-331	182	13	µm	µm	NOUN
admet-331	182	14	)	)	PUNCT
admet-331	182	15	showed	show	VERB
admet-331	182	16	in	in	ADP
admet-331	182	17	a	a	DET
admet-331	182	18	significant	significant	ADJ
admet-331	182	19	increase	increase	NOUN
admet-331	182	20	in	in	ADP
admet-331	182	21	aqueous	aqueous	ADJ
admet-331	182	22	humor	humor	NOUN
admet-331	182	23	outflow	outflow	NOUN
admet-331	182	24	facility	facility	NOUN
admet-331	182	25	,	,	PUNCT
admet-331	182	26	and	and	CCONJ
admet-331	182	27	structurally	structurally	ADV
admet-331	182	28	the	the	DET
admet-331	182	29	entire	entire	ADJ
admet-331	182	30	tm	tm	NOUN
admet-331	182	31	appeared	appear	VERB
admet-331	182	32	to	to	PART
admet-331	182	33	be	be	AUX
admet-331	182	34	distended	distend	VERB
admet-331	182	35	and	and	CCONJ
admet-331	182	36	exhibited	exhibit	VERB
admet-331	182	37	widening	widening	NOUN
admet-331	182	38	of	of	ADP
admet-331	182	39	extracellular	extracellular	ADJ
admet-331	182	40	spaces	space	NOUN
admet-331	182	41	[	[	X
admet-331	182	42	41	41	NUM
admet-331	182	43	]	]	PUNCT
admet-331	182	44	.	.	PUNCT
admet-331	183	1	using	use	VERB
admet-331	183	2	optical	optical	ADJ
admet-331	183	3	coherence	coherence	NOUN
admet-331	183	4	tomography	tomography	NOUN
admet-331	183	5	in	in	ADP
admet-331	183	6	the	the	DET
admet-331	183	7	living	living	NOUN
admet-331	183	8	mouse	mouse	NOUN
admet-331	183	9	,	,	PUNCT
admet-331	183	10	the	the	DET
admet-331	183	11	real	real	ADJ
admet-331	183	12	-	-	PUNCT
admet-331	183	13	time	time	NOUN
admet-331	183	14	drug	drug	NOUN
admet-331	183	15	effects	effect	NOUN
admet-331	183	16	on	on	ADP
admet-331	183	17	tm	tm	PROPN
admet-331	183	18	and	and	CCONJ
admet-331	183	19	schlemm	schlemm	NOUN
admet-331	183	20	’s	’s	PART
admet-331	183	21	canal	canal	NOUN
admet-331	183	22	were	be	AUX
admet-331	183	23	observed	observe	VERB
admet-331	183	24	.	.	PUNCT
admet-331	184	1	li	li	PROPN
admet-331	184	2	at	at	ADP
admet-331	184	3	al	al	PROPN
admet-331	184	4	.	.	PUNCT
admet-331	185	1	[	[	X
admet-331	185	2	48	48	NUM
admet-331	185	3	]	]	PUNCT
admet-331	185	4	reported	report	VERB
admet-331	185	5	that	that	SCONJ
admet-331	185	6	topically	topically	ADV
admet-331	185	7	applied	apply	VERB
admet-331	185	8	rock	rock	NOUN
admet-331	185	9	inhibitor	inhibitor	NOUN
admet-331	185	10	(	(	PUNCT
admet-331	185	11	ar13324	ar13324	PROPN
admet-331	185	12	)	)	PUNCT
admet-331	185	13	expanded	expand	VERB
admet-331	185	14	the	the	DET
admet-331	185	15	tm	tm	NOUN
admet-331	185	16	and	and	CCONJ
admet-331	185	17	increased	increase	VERB
admet-331	185	18	the	the	DET
admet-331	185	19	cross	cross	ADJ
admet-331	185	20	-	-	ADJ
admet-331	185	21	sectional	sectional	ADJ
admet-331	185	22	area	area	NOUN
admet-331	185	23	of	of	ADP
admet-331	185	24	the	the	DET
admet-331	185	25	schlemm	schlemm	NOUN
admet-331	185	26	’s	’s	PART
admet-331	185	27	canal	canal	NOUN
admet-331	185	28	and	and	CCONJ
admet-331	185	29	thereby	thereby	ADV
admet-331	185	30	lowered	lower	VERB
admet-331	185	31	the	the	DET
admet-331	185	32	iop	iop	NOUN
admet-331	185	33	through	through	ADP
admet-331	185	34	increased	increase	VERB
admet-331	185	35	perfusion	perfusion	NOUN
admet-331	185	36	through	through	ADP
admet-331	185	37	the	the	DET
admet-331	185	38	conventional	conventional	ADJ
admet-331	185	39	outflow	outflow	ADJ
admet-331	185	40	tissues	tissue	NOUN
admet-331	185	41	.	.	PUNCT
admet-331	186	1	éva	éva	PROPN
admet-331	186	2	halász	halász	PROPN
admet-331	186	3	,	,	PUNCT
admet-331	186	4	ellen	ellen	PROPN
admet-331	186	5	townes	townes	PROPN
admet-331	186	6	-	-	PUNCT
admet-331	186	7	anderson	anderson	PROPN
admet-331	186	8	admet	admet	PROPN
admet-331	186	9	&	&	CCONJ
admet-331	186	10	dmpk	dmpk	PROPN
admet-331	186	11	4(4	4(4	NUM
admet-331	186	12	)	)	PUNCT
admet-331	186	13	(	(	PUNCT
admet-331	186	14	2016	2016	NUM
admet-331	186	15	)	)	PUNCT
admet-331	186	16	280	280	NUM
admet-331	186	17	-	-	SYM
admet-331	186	18	301	301	NUM
admet-331	186	19	288	288	NUM
admet-331	186	20	figure	figure	NOUN
admet-331	186	21	2	2	NUM
admet-331	186	22	.	.	PUNCT
admet-331	186	23	proposed	propose	VERB
admet-331	186	24	mechanism	mechanism	NOUN
admet-331	186	25	of	of	ADP
admet-331	186	26	rock	rock	NOUN
admet-331	186	27	inhibition	inhibition	NOUN
admet-331	186	28	in	in	ADP
admet-331	186	29	lowering	lower	VERB
admet-331	186	30	intraocular	intraocular	ADJ
admet-331	186	31	pressure	pressure	NOUN
admet-331	186	32	.	.	PUNCT
admet-331	187	1	(	(	PUNCT
admet-331	187	2	mlcp	mlcp	NOUN
admet-331	187	3	:	:	PUNCT
admet-331	187	4	myosin	myosin	PROPN
admet-331	187	5	light	light	PROPN
admet-331	187	6	chain	chain	NOUN
admet-331	187	7	phosphatase	phosphatase	NOUN
admet-331	187	8	,	,	PUNCT
admet-331	187	9	mlc	mlc	PROPN
admet-331	187	10	:	:	PUNCT
admet-331	187	11	myosin	myosin	PROPN
admet-331	187	12	light	light	PROPN
admet-331	187	13	chain	chain	NOUN
admet-331	187	14	,	,	PUNCT
admet-331	187	15	mlck	mlck	NOUN
admet-331	187	16	:	:	PUNCT
admet-331	187	17	myosin	myosin	PROPN
admet-331	187	18	light	light	PROPN
admet-331	187	19	chain	chain	PROPN
admet-331	187	20	kinase	kinase	PROPN
admet-331	187	21	,	,	PUNCT
admet-331	187	22	limk	limk	PROPN
admet-331	187	23	:	:	PUNCT
admet-331	187	24	lim	lim	PROPN
admet-331	187	25	kinases	kinases	PROPN
admet-331	187	26	)	)	PUNCT
admet-331	187	27	filtration	filtration	NOUN
admet-331	187	28	surgery	surgery	NOUN
admet-331	187	29	:	:	PUNCT
admet-331	187	30	accumulating	accumulate	VERB
admet-331	187	31	data	data	NOUN
admet-331	187	32	suggests	suggest	VERB
admet-331	187	33	that	that	SCONJ
admet-331	187	34	rock	rock	NOUN
admet-331	187	35	inhibitors	inhibitor	NOUN
admet-331	187	36	enhance	enhance	VERB
admet-331	187	37	the	the	DET
admet-331	187	38	success	success	NOUN
admet-331	187	39	rate	rate	NOUN
admet-331	187	40	of	of	ADP
admet-331	187	41	glaucoma	glaucoma	NOUN
admet-331	187	42	filtration	filtration	NOUN
admet-331	187	43	surgery	surgery	NOUN
admet-331	187	44	through	through	ADP
admet-331	187	45	inhibition	inhibition	NOUN
admet-331	187	46	of	of	ADP
admet-331	187	47	tgf	tgf	PROPN
admet-331	187	48	-	-	PUNCT
admet-331	187	49	β	β	NOUN
admet-331	187	50	-	-	ADJ
admet-331	187	51	induced	induced	ADJ
admet-331	187	52	scarring	scarring	NOUN
admet-331	187	53	.	.	PUNCT
admet-331	188	1	a	a	DET
admet-331	188	2	frequent	frequent	ADJ
admet-331	188	3	reason	reason	NOUN
admet-331	188	4	for	for	ADP
admet-331	188	5	failed	fail	VERB
admet-331	188	6	filtration	filtration	NOUN
admet-331	188	7	surgery	surgery	NOUN
admet-331	188	8	is	be	AUX
admet-331	188	9	excessive	excessive	ADJ
admet-331	188	10	postoperative	postoperative	ADJ
admet-331	188	11	scarring	scarring	NOUN
admet-331	188	12	,	,	PUNCT
admet-331	188	13	which	which	PRON
admet-331	188	14	closes	close	VERB
admet-331	188	15	off	off	ADP
admet-331	188	16	the	the	DET
admet-331	188	17	bypass	bypass	NOUN
admet-331	188	18	for	for	ADP
admet-331	188	19	aqueous	aqueous	ADJ
admet-331	188	20	humor	humor	NOUN
admet-331	188	21	.	.	PUNCT
admet-331	189	1	as	as	SCONJ
admet-331	189	2	previously	previously	ADV
admet-331	189	3	mentioned	mention	VERB
admet-331	189	4	,	,	PUNCT
admet-331	189	5	tgf	tgf	PROPN
admet-331	189	6	-	-	PUNCT
admet-331	189	7	β	β	PROPN
admet-331	189	8	is	be	AUX
admet-331	189	9	elevated	elevate	VERB
admet-331	189	10	in	in	ADP
admet-331	189	11	glaucoma	glaucoma	NOUN
admet-331	189	12	.	.	PUNCT
admet-331	190	1	the	the	DET
admet-331	190	2	cytokine	cytokine	NOUN
admet-331	190	3	has	have	VERB
admet-331	190	4	a	a	DET
admet-331	190	5	crucial	crucial	ADJ
admet-331	190	6	role	role	NOUN
admet-331	190	7	in	in	ADP
admet-331	190	8	fibroblastmyofibroblast	fibroblastmyofibroblast	ADJ
admet-331	190	9	differentiation	differentiation	NOUN
admet-331	190	10	[	[	X
admet-331	190	11	49	49	NUM
admet-331	190	12	]	]	PUNCT
admet-331	190	13	,	,	PUNCT
admet-331	190	14	which	which	PRON
admet-331	190	15	leads	lead	VERB
admet-331	190	16	to	to	ADP
admet-331	190	17	fibrosis	fibrosis	NOUN
admet-331	190	18	after	after	ADP
admet-331	190	19	surgery	surgery	NOUN
admet-331	190	20	.	.	PUNCT
admet-331	191	1	on	on	ADP
admet-331	191	2	the	the	DET
admet-331	191	3	basis	basis	NOUN
admet-331	191	4	of	of	ADP
admet-331	191	5	in	in	ADP
admet-331	191	6	vitro	vitro	X
admet-331	191	7	studies	study	NOUN
admet-331	191	8	with	with	ADP
admet-331	191	9	human	human	ADJ
admet-331	191	10	fibroblasts	fibroblast	NOUN
admet-331	191	11	from	from	ADP
admet-331	191	12	the	the	DET
admet-331	191	13	tenon	tenon	NOUN
admet-331	191	14	capsule	capsule	NOUN
admet-331	191	15	of	of	ADP
admet-331	191	16	the	the	DET
admet-331	191	17	eye	eye	NOUN
admet-331	191	18	,	,	PUNCT
admet-331	191	19	y27632	y27632	PROPN
admet-331	191	20	has	have	AUX
admet-331	191	21	been	be	AUX
admet-331	191	22	proposed	propose	VERB
admet-331	191	23	to	to	PART
admet-331	191	24	interfere	interfere	VERB
admet-331	191	25	with	with	ADP
admet-331	191	26	postoperative	postoperative	ADJ
admet-331	191	27	bleb	bleb	ADJ
admet-331	191	28	formation	formation	NOUN
admet-331	191	29	through	through	ADP
admet-331	191	30	inhibition	inhibition	NOUN
admet-331	191	31	of	of	ADP
admet-331	191	32	cell	cell	NOUN
admet-331	191	33	contraction	contraction	NOUN
admet-331	191	34	and	and	CCONJ
admet-331	191	35	fibroblast	fibroblast	ADJ
admet-331	191	36	activation	activation	NOUN
admet-331	191	37	(	(	PUNCT
admet-331	191	38	transdifferentiation	transdifferentiation	NOUN
admet-331	191	39	to	to	ADP
admet-331	191	40	myofibroblasts	myofibroblast	NOUN
admet-331	191	41	)	)	PUNCT
admet-331	192	1	[	[	X
admet-331	192	2	50	50	NUM
admet-331	192	3	]	]	PUNCT
admet-331	192	4	.	.	PUNCT
admet-331	193	1	recent	recent	ADJ
admet-331	193	2	in	in	ADP
admet-331	193	3	vitro	vitro	X
admet-331	193	4	results	result	NOUN
admet-331	193	5	indicate	indicate	VERB
admet-331	193	6	that	that	DET
admet-331	193	7	ripasudil	ripasudil	NOUN
admet-331	193	8	also	also	ADV
admet-331	193	9	significantly	significantly	ADV
admet-331	193	10	diminishes	diminish	VERB
admet-331	193	11	the	the	DET
admet-331	193	12	tgf	tgf	PROPN
admet-331	193	13	-	-	PUNCT
admet-331	193	14	β2	β2	NOUN
admet-331	193	15	-	-	PUNCT
admet-331	193	16	induced	induce	VERB
admet-331	193	17	human	human	ADJ
admet-331	193	18	conjunctival	conjunctival	NOUN
admet-331	193	19	fibroblast	fibroblast	ADJ
admet-331	193	20	activation	activation	NOUN
admet-331	193	21	,	,	PUNCT
admet-331	193	22	extracellular	extracellular	ADJ
admet-331	193	23	matrix	matrix	NOUN
admet-331	193	24	expression	expression	NOUN
admet-331	193	25	,	,	PUNCT
admet-331	193	26	and	and	CCONJ
admet-331	193	27	collagen	collagen	NOUN
admet-331	193	28	gel	gel	NOUN
admet-331	193	29	contraction	contraction	NOUN
admet-331	194	1	[	[	X
admet-331	194	2	51	51	NUM
admet-331	194	3	]	]	PUNCT
admet-331	194	4	.	.	PUNCT
admet-331	195	1	honjo	honjo	VERB
admet-331	195	2	et	et	PROPN
admet-331	195	3	al	al	PROPN
admet-331	195	4	.	.	PUNCT
admet-331	196	1	[	[	X
admet-331	196	2	50	50	NUM
admet-331	196	3	]	]	PUNCT
admet-331	196	4	performed	perform	VERB
admet-331	196	5	a	a	DET
admet-331	196	6	sclerostomy	sclerostomy	NOUN
admet-331	196	7	in	in	ADP
admet-331	196	8	rabbits	rabbit	NOUN
admet-331	196	9	and	and	CCONJ
admet-331	196	10	demonstrated	demonstrate	VERB
admet-331	196	11	that	that	SCONJ
admet-331	196	12	10	10	NUM
admet-331	196	13	mm	mm	NUM
admet-331	196	14	y27632	y27632	PROPN
admet-331	196	15	applied	apply	VERB
admet-331	196	16	topically	topically	ADV
admet-331	196	17	for	for	ADP
admet-331	196	18	seven	seven	NUM
admet-331	196	19	days	day	NOUN
admet-331	196	20	improved	improve	VERB
admet-331	196	21	the	the	DET
admet-331	196	22	surgical	surgical	ADJ
admet-331	196	23	outcome	outcome	NOUN
admet-331	196	24	by	by	ADP
admet-331	196	25	inhibiting	inhibit	VERB
admet-331	196	26	fibrosis	fibrosis	NOUN
admet-331	196	27	and	and	CCONJ
admet-331	196	28	decreasing	decrease	VERB
admet-331	196	29	collagen	collagen	NOUN
admet-331	196	30	deposition	deposition	NOUN
admet-331	196	31	in	in	ADP
admet-331	196	32	the	the	DET
admet-331	196	33	surgical	surgical	ADJ
admet-331	196	34	area	area	NOUN
admet-331	196	35	compared	compare	VERB
admet-331	196	36	to	to	ADP
admet-331	196	37	vehicle	vehicle	NOUN
admet-331	196	38	-	-	PUNCT
admet-331	196	39	treated	treat	VERB
admet-331	196	40	eyes	eye	NOUN
admet-331	196	41	.	.	PUNCT
admet-331	197	1	recent	recent	ADJ
admet-331	197	2	status	status	NOUN
admet-331	197	3	of	of	ADP
admet-331	197	4	rock	rock	NOUN
admet-331	197	5	inhibitors	inhibitor	NOUN
admet-331	197	6	in	in	ADP
admet-331	197	7	clinical	clinical	ADJ
admet-331	197	8	application	application	NOUN
admet-331	197	9	given	give	VERB
admet-331	197	10	the	the	DET
admet-331	197	11	fact	fact	NOUN
admet-331	197	12	that	that	SCONJ
admet-331	197	13	ripasudil	ripasudil	NOUN
admet-331	197	14	is	be	AUX
admet-331	197	15	marketed	market	VERB
admet-331	197	16	in	in	ADP
admet-331	197	17	japan	japan	PROPN
admet-331	197	18	as	as	ADP
admet-331	197	19	a	a	DET
admet-331	197	20	possible	possible	ADJ
admet-331	197	21	second	second	ADJ
admet-331	197	22	-	-	PUNCT
admet-331	197	23	line	line	NOUN
admet-331	197	24	treatment	treatment	NOUN
admet-331	197	25	for	for	ADP
admet-331	197	26	glaucoma	glaucoma	NOUN
admet-331	197	27	and	and	CCONJ
admet-331	197	28	ocular	ocular	ADJ
admet-331	197	29	hypertension	hypertension	NOUN
admet-331	197	30	[	[	X
admet-331	197	31	2	2	NUM
admet-331	197	32	]	]	PUNCT
admet-331	197	33	,	,	PUNCT
admet-331	197	34	the	the	DET
admet-331	197	35	recent	recent	ADJ
admet-331	197	36	clinical	clinical	ADJ
admet-331	197	37	trials	trial	NOUN
admet-331	197	38	for	for	ADP
admet-331	197	39	rock	rock	NOUN
admet-331	197	40	-	-	PUNCT
admet-331	197	41	inhibitor	inhibitor	NOUN
admet-331	197	42	based	base	VERB
admet-331	197	43	anti	anti	ADJ
admet-331	197	44	-	-	ADJ
admet-331	197	45	glaucoma	glaucoma	ADJ
admet-331	197	46	drugs	drug	NOUN
admet-331	197	47	may	may	AUX
admet-331	197	48	be	be	AUX
admet-331	197	49	promising	promise	VERB
admet-331	197	50	.	.	PUNCT
admet-331	198	1	in	in	ADP
admet-331	198	2	completed	complete	VERB
admet-331	198	3	clinical	clinical	ADJ
admet-331	198	4	trials	trial	NOUN
admet-331	198	5	,	,	PUNCT
admet-331	198	6	twice	twice	ADV
admet-331	198	7	daily	daily	ADJ
admet-331	198	8	application	application	NOUN
admet-331	198	9	of	of	ADP
admet-331	198	10	0.4	0.4	NUM
admet-331	198	11	%	%	NOUN
admet-331	198	12	ripasudil	ripasudil	NOUN
admet-331	198	13	proved	prove	VERB
admet-331	198	14	to	to	PART
admet-331	198	15	be	be	AUX
admet-331	198	16	safe	safe	ADJ
admet-331	198	17	and	and	CCONJ
admet-331	198	18	effective	effective	ADJ
admet-331	198	19	from	from	ADP
admet-331	198	20	the	the	DET
admet-331	198	21	viewpoint	viewpoint	NOUN
admet-331	198	22	of	of	ADP
admet-331	198	23	lowering	lower	VERB
admet-331	198	24	the	the	DET
admet-331	198	25	iop	iop	NOUN
admet-331	198	26	[	[	X
admet-331	198	27	52–54	52–54	NUM
admet-331	198	28	]	]	PUNCT
admet-331	198	29	.	.	PUNCT
admet-331	199	1	furthermore	furthermore	ADV
admet-331	199	2	,	,	PUNCT
admet-331	199	3	an	an	DET
admet-331	199	4	8	8	NUM
admet-331	199	5	week	week	NOUN
admet-331	199	6	study	study	NOUN
admet-331	199	7	(	(	PUNCT
admet-331	199	8	with	with	ADP
admet-331	199	9	four	four	NUM
admet-331	199	10	hundred	hundred	NUM
admet-331	199	11	and	and	CCONJ
admet-331	199	12	thirteen	thirteen	NUM
admet-331	199	13	patients	patient	NOUN
admet-331	199	14	)	)	PUNCT
admet-331	199	15	pointed	point	VERB
admet-331	199	16	out	out	ADP
admet-331	199	17	that	that	SCONJ
admet-331	199	18	ripasudil	ripasudil	NOUN
admet-331	199	19	has	have	VERB
admet-331	199	20	additional	additional	ADJ
admet-331	199	21	pressure	pressure	NOUN
admet-331	199	22	-	-	PUNCT
admet-331	199	23	lowering	lower	VERB
admet-331	199	24	effects	effect	NOUN
admet-331	199	25	when	when	SCONJ
admet-331	199	26	combined	combine	VERB
admet-331	199	27	with	with	ADP
admet-331	199	28	betablockers	betablocker	NOUN
admet-331	199	29	or	or	CCONJ
admet-331	199	30	prostaglandin	prostaglandin	NOUN
admet-331	199	31	analogues	analogue	NOUN
admet-331	199	32	[	[	X
admet-331	199	33	55	55	NUM
admet-331	199	34	]	]	PUNCT
admet-331	199	35	.	.	PUNCT
admet-331	200	1	although	although	SCONJ
admet-331	200	2	ripasudil	ripasudil	VERB
admet-331	200	3	with	with	ADP
admet-331	200	4	beta	beta	NOUN
admet-331	200	5	-	-	PUNCT
admet-331	200	6	blockers	blocker	NOUN
admet-331	200	7	and	and	CCONJ
admet-331	200	8	prostaglandin	prostaglandin	NOUN
admet-331	200	9	analogues	analogue	NOUN
admet-331	200	10	has	have	VERB
admet-331	200	11	an	an	DET
admet-331	200	12	additive	additive	ADJ
admet-331	200	13	effect	effect	NOUN
admet-331	200	14	,	,	PUNCT
admet-331	200	15	pilocarpine	pilocarpine	NOUN
admet-331	200	16	(	(	PUNCT
admet-331	200	17	another	another	DET
admet-331	200	18	anti	anti	ADJ
admet-331	200	19	-	-	ADJ
admet-331	200	20	glaucoma	glaucoma	ADJ
admet-331	200	21	eyedrop	eyedrop	NOUN
admet-331	200	22	)	)	PUNCT
admet-331	200	23	seems	seem	VERB
admet-331	200	24	to	to	PART
admet-331	200	25	diminish	diminish	VERB
admet-331	200	26	the	the	DET
admet-331	200	27	ripasudil	ripasudil	NOUN
admet-331	200	28	iop	iop	NOUN
admet-331	200	29	lowering	lower	VERB
admet-331	200	30	effect	effect	NOUN
admet-331	200	31	in	in	ADP
admet-331	200	32	mice	mice	NOUN
admet-331	200	33	eyes	eye	NOUN
admet-331	200	34	in	in	ADP
admet-331	200	35	the	the	DET
admet-331	200	36	case	case	NOUN
admet-331	200	37	of	of	ADP
admet-331	200	38	concomitant	concomitant	ADJ
admet-331	200	39	administration	administration	NOUN
admet-331	200	40	of	of	ADP
admet-331	200	41	ripasudil	ripasudil	NOUN
admet-331	200	42	and	and	CCONJ
admet-331	200	43	pilocarpine	pilocarpine	VERB
admet-331	200	44	[	[	X
admet-331	200	45	56	56	NUM
admet-331	200	46	]	]	PUNCT
admet-331	200	47	.	.	PUNCT
admet-331	201	1	a	a	DET
admet-331	201	2	common	common	ADJ
admet-331	201	3	adverse	adverse	ADJ
admet-331	201	4	effect	effect	NOUN
admet-331	201	5	of	of	ADP
admet-331	201	6	rock	rock	NOUN
admet-331	201	7	inhibitor	inhibitor	NOUN
admet-331	201	8	treatment	treatment	NOUN
admet-331	201	9	is	be	AUX
admet-331	201	10	mild	mild	ADJ
admet-331	201	11	or	or	CCONJ
admet-331	201	12	moderate	moderate	ADJ
admet-331	201	13	hyperemia	hyperemia	NOUN
admet-331	201	14	,	,	PUNCT
admet-331	201	15	which	which	PRON
admet-331	201	16	resolves	resolve	VERB
admet-331	201	17	spontaneously	spontaneously	ADV
admet-331	201	18	in	in	ADP
admet-331	201	19	hours	hour	NOUN
admet-331	201	20	.	.	PUNCT
admet-331	202	1	hyperemia	hyperemia	PROPN
admet-331	202	2	is	be	AUX
admet-331	202	3	attributed	attribute	VERB
admet-331	202	4	to	to	ADP
admet-331	202	5	the	the	DET
admet-331	202	6	vasodilatatory	vasodilatatory	ADJ
admet-331	202	7	effect	effect	NOUN
admet-331	202	8	of	of	ADP
admet-331	202	9	rock	rock	NOUN
admet-331	202	10	inhibitors	inhibitor	NOUN
admet-331	202	11	on	on	ADP
admet-331	202	12	conjunctival	conjunctival	ADJ
admet-331	202	13	blood	blood	NOUN
admet-331	202	14	vessels	vessel	NOUN
admet-331	202	15	.	.	PUNCT
admet-331	203	1	in	in	ADP
admet-331	203	2	addition	addition	NOUN
admet-331	203	3	to	to	ADP
admet-331	203	4	the	the	DET
admet-331	203	5	relatively	relatively	ADV
admet-331	203	6	harmless	harmless	ADJ
admet-331	203	7	hyperemia	hyperemia	NOUN
admet-331	203	8	,	,	PUNCT
admet-331	203	9	a	a	DET
admet-331	203	10	one	one	NUM
admet-331	203	11	-	-	PUNCT
admet-331	203	12	year	year	NOUN
admet-331	203	13	study	study	NOUN
admet-331	203	14	[	[	X
admet-331	203	15	57	57	NUM
admet-331	203	16	]	]	PUNCT
admet-331	203	17	revealed	reveal	VERB
admet-331	203	18	that	that	SCONJ
admet-331	203	19	after	after	ADP
admet-331	203	20	8	8	NUM
admet-331	203	21	weeks	week	NOUN
admet-331	203	22	of	of	ADP
admet-331	203	23	ripasudil	ripasudil	NOUN
admet-331	203	24	instillation	instillation	NOUN
admet-331	203	25	there	there	PRON
admet-331	203	26	is	be	VERB
admet-331	203	27	an	an	DET
admet-331	203	28	occurrence	occurrence	NOUN
admet-331	203	29	of	of	ADP
admet-331	203	30	allergic	allergic	ADJ
admet-331	203	31	blepharitis	blepharitis	NOUN
admet-331	203	32	(	(	PUNCT
admet-331	203	33	20	20	NUM
admet-331	203	34	%	%	NOUN
admet-331	203	35	)	)	PUNCT
admet-331	203	36	and	and	CCONJ
admet-331	203	37	conjunctivitis	conjunctivitis	NOUN
admet-331	203	38	(	(	PUNCT
admet-331	203	39	17	17	NUM
admet-331	203	40	%	%	NOUN
admet-331	203	41	)	)	PUNCT
admet-331	203	42	;	;	PUNCT
admet-331	203	43	some	some	DET
admet-331	203	44	patients	patient	NOUN
admet-331	203	45	left	leave	VERB
admet-331	203	46	the	the	DET
admet-331	203	47	study	study	NOUN
admet-331	203	48	due	due	ADP
admet-331	203	49	to	to	ADP
admet-331	203	50	these	these	DET
admet-331	203	51	adverse	adverse	ADJ
admet-331	203	52	events	event	NOUN
admet-331	203	53	.	.	PUNCT
admet-331	204	1	moreover	moreover	ADV
admet-331	204	2	,	,	PUNCT
admet-331	204	3	lens	lens	NOUN
admet-331	204	4	opacity	opacity	NOUN
admet-331	204	5	was	be	AUX
admet-331	204	6	observed	observe	VERB
admet-331	204	7	in	in	ADP
admet-331	204	8	mammals	mammal	NOUN
admet-331	204	9	treated	treat	VERB
admet-331	204	10	with	with	ADP
admet-331	204	11	high	high	ADJ
admet-331	204	12	concentrations	concentration	NOUN
admet-331	204	13	of	of	ADP
admet-331	204	14	ripasudil	ripasudil	NOUN
admet-331	204	15	in	in	ADP
admet-331	204	16	preclinical	preclinical	ADJ
admet-331	204	17	studies	study	NOUN
admet-331	204	18	.	.	PUNCT
admet-331	205	1	cataract	cataract	PROPN
admet-331	205	2	admet	admet	PROPN
admet-331	205	3	&	&	CCONJ
admet-331	205	4	dmpk	dmpk	PROPN
admet-331	205	5	4(4	4(4	NUM
admet-331	205	6	)	)	PUNCT
admet-331	205	7	(	(	PUNCT
admet-331	205	8	2016	2016	NUM
admet-331	205	9	)	)	PUNCT
admet-331	205	10	280	280	NUM
admet-331	205	11	-	-	SYM
admet-331	205	12	301	301	NUM
admet-331	205	13	rock	rock	NOUN
admet-331	205	14	inhibitors	inhibitor	NOUN
admet-331	205	15	in	in	ADP
admet-331	205	16	ocular	ocular	ADJ
admet-331	205	17	disease	disease	NOUN
admet-331	205	18	doi	doi	NOUN
admet-331	205	19	:	:	PUNCT
admet-331	205	20	10.5599	10.5599	NUM
admet-331	205	21	/	/	SYM
admet-331	205	22	admet.4.4.331	admet.4.4.331	PROPN
admet-331	205	23	289	289	NUM
admet-331	205	24	progression	progression	NOUN
admet-331	205	25	in	in	ADP
admet-331	205	26	humans	human	NOUN
admet-331	205	27	was	be	AUX
admet-331	205	28	not	not	PART
admet-331	205	29	noted	note	VERB
admet-331	205	30	as	as	ADP
admet-331	205	31	drug	drug	NOUN
admet-331	205	32	-	-	PUNCT
admet-331	205	33	related	relate	VERB
admet-331	205	34	;	;	PUNCT
admet-331	205	35	clinicians	clinician	NOUN
admet-331	205	36	diagnosed	diagnose	VERB
admet-331	205	37	lens	lens	NOUN
admet-331	205	38	opacity	opacity	NOUN
admet-331	205	39	change	change	NOUN
admet-331	205	40	as	as	ADP
admet-331	205	41	a	a	DET
admet-331	205	42	natural	natural	ADJ
admet-331	205	43	progression	progression	NOUN
admet-331	205	44	of	of	ADP
admet-331	205	45	age	age	NOUN
admet-331	205	46	-	-	PUNCT
admet-331	205	47	related	relate	VERB
admet-331	205	48	senile	senile	ADJ
admet-331	205	49	cataract	cataract	NOUN
admet-331	205	50	[	[	X
admet-331	205	51	57	57	NUM
admet-331	205	52	]	]	PUNCT
admet-331	205	53	.	.	PUNCT
admet-331	206	1	the	the	DET
admet-331	206	2	same	same	ADJ
admet-331	206	3	one	one	NUM
admet-331	206	4	-	-	PUNCT
admet-331	206	5	year	year	NOUN
admet-331	206	6	study	study	NOUN
admet-331	206	7	did	do	AUX
admet-331	206	8	not	not	PART
admet-331	206	9	report	report	VERB
admet-331	206	10	any	any	DET
admet-331	206	11	adverse	adverse	ADJ
admet-331	206	12	corneal	corneal	ADJ
admet-331	206	13	effects	effect	NOUN
admet-331	206	14	.	.	PUNCT
admet-331	207	1	nakagawa	nakagawa	PROPN
admet-331	207	2	et	et	PROPN
admet-331	207	3	al	al	PROPN
admet-331	207	4	.	.	PUNCT
admet-331	208	1	[	[	X
admet-331	208	2	58	58	NUM
admet-331	208	3	]	]	PUNCT
admet-331	208	4	however	however	ADV
admet-331	208	5	,	,	PUNCT
admet-331	208	6	observed	observe	VERB
admet-331	208	7	reversible	reversible	ADJ
admet-331	208	8	pseudo	pseudo	NOUN
admet-331	208	9	-	-	NOUN
admet-331	208	10	guttae	guttae	NOUN
admet-331	208	11	-	-	PUNCT
admet-331	208	12	like	like	ADJ
admet-331	208	13	corneal	corneal	ADJ
admet-331	208	14	endothelial	endothelial	ADJ
admet-331	208	15	changes	change	NOUN
admet-331	208	16	during	during	ADP
admet-331	208	17	one	one	NUM
admet-331	208	18	week	week	NOUN
admet-331	208	19	twice	twice	ADP
admet-331	208	20	daily	daily	ADJ
admet-331	208	21	topical	topical	ADJ
admet-331	208	22	instillation	instillation	NOUN
admet-331	208	23	of	of	ADP
admet-331	208	24	0.4	0.4	NUM
admet-331	208	25	%	%	NOUN
admet-331	208	26	ripasudil	ripasudil	NOUN
admet-331	208	27	in	in	ADP
admet-331	208	28	healthy	healthy	ADJ
admet-331	208	29	humans	human	NOUN
admet-331	208	30	.	.	PUNCT
admet-331	209	1	one	one	NUM
admet-331	209	2	and	and	CCONJ
admet-331	209	3	a	a	DET
admet-331	209	4	half	half	NOUN
admet-331	209	5	hours	hour	NOUN
admet-331	209	6	after	after	ADP
admet-331	209	7	ripasudil	ripasudil	PROPN
admet-331	209	8	administration	administration	PROPN
admet-331	209	9	,	,	PUNCT
admet-331	209	10	non	non	ADJ
admet-331	209	11	-	-	ADJ
admet-331	209	12	contact	contact	ADJ
admet-331	209	13	specular	specular	ADJ
admet-331	209	14	microscopy	microscopy	NOUN
admet-331	209	15	showed	show	VERB
admet-331	209	16	drug	drug	NOUN
admet-331	209	17	-	-	PUNCT
admet-331	209	18	related	relate	VERB
admet-331	209	19	morphological	morphological	ADJ
admet-331	209	20	changes	change	NOUN
admet-331	209	21	in	in	ADP
admet-331	209	22	corneal	corneal	ADJ
admet-331	209	23	endothelium	endothelium	NOUN
admet-331	209	24	,	,	PUNCT
admet-331	209	25	which	which	PRON
admet-331	209	26	disappeared	disappear	VERB
admet-331	209	27	within	within	ADP
admet-331	209	28	6	6	NUM
admet-331	209	29	hours	hour	NOUN
admet-331	209	30	.	.	PUNCT
admet-331	210	1	these	these	DET
admet-331	210	2	findings	finding	NOUN
admet-331	210	3	were	be	AUX
admet-331	210	4	in	in	ADP
admet-331	210	5	line	line	NOUN
admet-331	210	6	with	with	ADP
admet-331	210	7	an	an	DET
admet-331	210	8	animal	animal	NOUN
admet-331	210	9	model	model	NOUN
admet-331	210	10	[	[	X
admet-331	210	11	59	59	NUM
admet-331	210	12	]	]	X
admet-331	210	13	:	:	PUNCT
admet-331	210	14	rabbits	rabbit	NOUN
admet-331	210	15	exhibited	exhibit	VERB
admet-331	210	16	indistinct	indistinct	ADJ
admet-331	210	17	corneal	corneal	ADJ
admet-331	210	18	endothelial	endothelial	ADJ
admet-331	210	19	cell	cell	NOUN
admet-331	210	20	borders	border	NOUN
admet-331	210	21	one	one	NUM
admet-331	210	22	hour	hour	NOUN
admet-331	210	23	after	after	ADP
admet-331	210	24	instillation	instillation	NOUN
admet-331	210	25	of	of	ADP
admet-331	210	26	a	a	DET
admet-331	210	27	rock	rock	NOUN
admet-331	210	28	inhibitor	inhibitor	NOUN
admet-331	210	29	,	,	PUNCT
admet-331	210	30	similar	similar	ADJ
admet-331	210	31	to	to	ADP
admet-331	210	32	human	human	ADJ
admet-331	210	33	subjects	subject	NOUN
admet-331	210	34	.	.	PUNCT
admet-331	211	1	these	these	DET
admet-331	211	2	abnormalities	abnormality	NOUN
admet-331	211	3	resolved	resolve	VERB
admet-331	211	4	to	to	ADP
admet-331	211	5	normal	normal	ADJ
admet-331	211	6	within	within	ADP
admet-331	211	7	hours	hour	NOUN
admet-331	211	8	.	.	PUNCT
admet-331	212	1	using	use	VERB
admet-331	212	2	scanning	scanning	NOUN
admet-331	212	3	and	and	CCONJ
admet-331	212	4	transmission	transmission	NOUN
admet-331	212	5	electron	electron	NOUN
admet-331	212	6	microscopy	microscopy	NOUN
admet-331	212	7	,	,	PUNCT
admet-331	212	8	protrusions	protrusion	NOUN
admet-331	212	9	along	along	ADP
admet-331	212	10	the	the	DET
admet-331	212	11	intercellular	intercellular	ADJ
admet-331	212	12	cell	cell	NOUN
admet-331	212	13	borders	border	NOUN
admet-331	212	14	were	be	AUX
admet-331	212	15	observed	observe	VERB
admet-331	212	16	,	,	PUNCT
admet-331	212	17	probably	probably	ADV
admet-331	212	18	caused	cause	VERB
admet-331	212	19	by	by	ADP
admet-331	212	20	the	the	DET
admet-331	212	21	decreased	decrease	VERB
admet-331	212	22	actin	actin	NOUN
admet-331	212	23	-	-	PUNCT
admet-331	212	24	myosin	myosin	NOUN
admet-331	212	25	contractility	contractility	NOUN
admet-331	212	26	of	of	ADP
admet-331	212	27	corneal	corneal	ADJ
admet-331	212	28	endothelial	endothelial	ADJ
admet-331	212	29	cells	cell	NOUN
admet-331	212	30	from	from	ADP
admet-331	212	31	rock	rock	NOUN
admet-331	212	32	inhibition	inhibition	NOUN
admet-331	212	33	.	.	PUNCT
admet-331	213	1	physicians	physician	NOUN
admet-331	213	2	should	should	AUX
admet-331	213	3	be	be	AUX
admet-331	213	4	aware	aware	ADJ
admet-331	213	5	that	that	SCONJ
admet-331	213	6	ripasudil	ripasudil	NOUN
admet-331	213	7	can	can	AUX
admet-331	213	8	cause	cause	VERB
admet-331	213	9	transient	transient	ADJ
admet-331	213	10	guttae	guttae	NOUN
admet-331	213	11	-	-	PUNCT
admet-331	213	12	like	like	ADJ
admet-331	213	13	formation	formation	NOUN
admet-331	213	14	in	in	ADP
admet-331	213	15	the	the	DET
admet-331	213	16	cornea	cornea	NOUN
admet-331	213	17	,	,	PUNCT
admet-331	213	18	in	in	ADP
admet-331	213	19	order	order	NOUN
admet-331	213	20	to	to	PART
admet-331	213	21	avoid	avoid	VERB
admet-331	213	22	misdiagnosing	misdiagnose	VERB
admet-331	213	23	patients	patient	NOUN
admet-331	213	24	as	as	ADP
admet-331	213	25	having	have	VERB
admet-331	213	26	chronic	chronic	ADJ
admet-331	213	27	corneal	corneal	ADJ
admet-331	213	28	endothelial	endothelial	ADJ
admet-331	213	29	disease	disease	NOUN
admet-331	213	30	such	such	ADJ
admet-331	213	31	as	as	ADP
admet-331	213	32	fuchs	fuchs	ADJ
admet-331	213	33	-	-	PUNCT
admet-331	213	34	endothelial	endothelial	ADJ
admet-331	213	35	dystrophy	dystrophy	NOUN
admet-331	213	36	.	.	PUNCT
admet-331	214	1	taken	take	VERB
admet-331	214	2	together	together	ADV
admet-331	214	3	,	,	PUNCT
admet-331	214	4	it	it	PRON
admet-331	214	5	appears	appear	VERB
admet-331	214	6	that	that	SCONJ
admet-331	214	7	further	further	ADJ
admet-331	214	8	studies	study	NOUN
admet-331	214	9	are	be	AUX
admet-331	214	10	needed	need	VERB
admet-331	214	11	to	to	PART
admet-331	214	12	explore	explore	VERB
admet-331	214	13	the	the	DET
admet-331	214	14	possible	possible	ADJ
admet-331	214	15	long	long	ADJ
admet-331	214	16	-	-	PUNCT
admet-331	214	17	term	term	NOUN
admet-331	214	18	side	side	NOUN
admet-331	214	19	effects	effect	NOUN
admet-331	214	20	of	of	ADP
admet-331	214	21	ripasudil	ripasudil	NOUN
admet-331	214	22	treatment	treatment	NOUN
admet-331	214	23	.	.	PUNCT
admet-331	215	1	among	among	ADP
admet-331	215	2	the	the	DET
admet-331	215	3	ongoing	ongoing	ADJ
admet-331	215	4	clinical	clinical	ADJ
admet-331	215	5	trials	trial	NOUN
admet-331	215	6	with	with	ADP
admet-331	215	7	other	other	ADJ
admet-331	215	8	rock	rock	NOUN
admet-331	215	9	inhibitors	inhibitor	NOUN
admet-331	215	10	the	the	DET
admet-331	215	11	most	most	ADV
admet-331	215	12	promising	promising	ADJ
admet-331	215	13	is	be	AUX
admet-331	215	14	ar13324	ar13324	NOUN
admet-331	215	15	(	(	PUNCT
admet-331	215	16	also	also	ADV
admet-331	215	17	known	know	VERB
admet-331	215	18	as	as	ADP
admet-331	215	19	netarsudil	netarsudil	NOUN
admet-331	215	20	or	or	CCONJ
admet-331	215	21	rhopressa	rhopressa	NOUN
admet-331	215	22	)	)	PUNCT
admet-331	215	23	,	,	PUNCT
admet-331	215	24	developed	develop	VERB
admet-331	215	25	by	by	ADP
admet-331	215	26	aerie	aerie	PROPN
admet-331	215	27	pharmaceuticals	pharmaceutical	NOUN
admet-331	215	28	[	[	X
admet-331	215	29	13	13	NUM
admet-331	215	30	]	]	PUNCT
admet-331	215	31	.	.	PUNCT
admet-331	216	1	ar13324	ar13324	PROPN
admet-331	216	2	is	be	AUX
admet-331	216	3	a	a	DET
admet-331	216	4	so	so	ADV
admet-331	216	5	called	call	VERB
admet-331	216	6	dual	dual	ADJ
admet-331	216	7	-	-	PUNCT
admet-331	216	8	acting	act	VERB
admet-331	216	9	drug	drug	NOUN
admet-331	216	10	;	;	PUNCT
admet-331	216	11	the	the	DET
admet-331	216	12	rock	rock	NOUN
admet-331	216	13	inhibitor	inhibitor	NOUN
admet-331	216	14	part	part	NOUN
admet-331	216	15	diminishes	diminish	VERB
admet-331	216	16	the	the	DET
admet-331	216	17	iop	iop	NOUN
admet-331	216	18	by	by	ADP
admet-331	216	19	increasing	increase	VERB
admet-331	216	20	the	the	DET
admet-331	216	21	outflow	outflow	NOUN
admet-331	216	22	through	through	ADP
admet-331	216	23	the	the	DET
admet-331	216	24	trabecular	trabecular	ADJ
admet-331	216	25	meshwork	meshwork	NOUN
admet-331	216	26	and	and	CCONJ
admet-331	216	27	the	the	DET
admet-331	216	28	norepinephrine	norepinephrine	NOUN
admet-331	216	29	transporter	transporter	NOUN
admet-331	216	30	(	(	PUNCT
admet-331	216	31	net	net	ADJ
admet-331	216	32	)	)	PUNCT
admet-331	216	33	inhibitor	inhibitor	NOUN
admet-331	216	34	decreases	decrease	VERB
admet-331	216	35	the	the	DET
admet-331	216	36	production	production	NOUN
admet-331	216	37	of	of	ADP
admet-331	216	38	the	the	DET
admet-331	216	39	aqueous	aqueous	ADJ
admet-331	216	40	humor	humor	NOUN
admet-331	216	41	.	.	PUNCT
admet-331	217	1	from	from	ADP
admet-331	217	2	animal	animal	NOUN
admet-331	217	3	models	model	NOUN
admet-331	217	4	,	,	PUNCT
admet-331	217	5	the	the	DET
admet-331	217	6	iop	iop	NOUN
admet-331	217	7	-	-	PUNCT
admet-331	217	8	lowering	lower	VERB
admet-331	217	9	effect	effect	NOUN
admet-331	217	10	of	of	ADP
admet-331	217	11	once	once	ADV
admet-331	217	12	daily	daily	ADJ
admet-331	217	13	0.04	0.04	NUM
admet-331	217	14	%	%	NOUN
admet-331	217	15	ar13324	ar13324	NOUN
admet-331	217	16	was	be	AUX
admet-331	217	17	certified	certify	VERB
admet-331	217	18	as	as	ADP
admet-331	217	19	effective	effective	ADJ
admet-331	217	20	[	[	X
admet-331	217	21	60,46	60,46	NOUN
admet-331	217	22	]	]	PUNCT
admet-331	217	23	.	.	PUNCT
admet-331	218	1	however	however	ADV
admet-331	218	2	,	,	PUNCT
admet-331	218	3	during	during	ADP
admet-331	218	4	the	the	DET
admet-331	218	5	first	first	ADJ
admet-331	218	6	human	human	ADJ
admet-331	218	7	study	study	NOUN
admet-331	218	8	,	,	PUNCT
admet-331	218	9	a	a	DET
admet-331	218	10	0.02	0.02	NUM
admet-331	218	11	%	%	NOUN
admet-331	218	12	concentration	concentration	NOUN
admet-331	218	13	of	of	ADP
admet-331	218	14	ar13324	ar13324	PROPN
admet-331	218	15	seemed	seem	VERB
admet-331	218	16	to	to	PART
admet-331	218	17	be	be	AUX
admet-331	218	18	the	the	DET
admet-331	218	19	most	most	ADV
admet-331	218	20	potent	potent	ADJ
admet-331	218	21	and	and	CCONJ
admet-331	218	22	produced	produce	VERB
admet-331	218	23	the	the	DET
admet-331	218	24	best	good	ADJ
admet-331	218	25	dose	dose	NOUN
admet-331	218	26	-	-	PUNCT
admet-331	218	27	response	response	NOUN
admet-331	218	28	curve	curve	NOUN
admet-331	218	29	from	from	ADP
admet-331	218	30	the	the	DET
admet-331	218	31	viewpoint	viewpoint	NOUN
admet-331	218	32	of	of	ADP
admet-331	218	33	iop	iop	NOUN
admet-331	218	34	reduction	reduction	NOUN
admet-331	218	35	[	[	X
admet-331	218	36	61	61	NUM
admet-331	218	37	]	]	PUNCT
admet-331	218	38	.	.	PUNCT
admet-331	219	1	eighteen	eighteen	NUM
admet-331	219	2	healthy	healthy	ADJ
admet-331	219	3	volunteers	volunteer	NOUN
admet-331	219	4	were	be	AUX
admet-331	219	5	involved	involve	VERB
admet-331	219	6	in	in	ADP
admet-331	219	7	a	a	DET
admet-331	219	8	phase	phase	NOUN
admet-331	219	9	i	i	PRON
admet-331	219	10	clinical	clinical	ADJ
admet-331	219	11	study	study	NOUN
admet-331	219	12	to	to	PART
admet-331	219	13	evaluate	evaluate	VERB
admet-331	219	14	the	the	DET
admet-331	219	15	ocular	ocular	ADJ
admet-331	219	16	and	and	CCONJ
admet-331	219	17	systemic	systemic	ADJ
admet-331	219	18	safety	safety	NOUN
admet-331	219	19	of	of	ADP
admet-331	219	20	the	the	DET
admet-331	219	21	drug	drug	NOUN
admet-331	219	22	.	.	PUNCT
admet-331	220	1	a	a	DET
admet-331	220	2	once	once	ADV
admet-331	220	3	daily	daily	ADJ
admet-331	220	4	0.02	0.02	NUM
admet-331	220	5	%	%	NOUN
admet-331	220	6	ar13324	ar13324	NOUN
admet-331	220	7	application	application	NOUN
admet-331	220	8	in	in	ADP
admet-331	220	9	the	the	DET
admet-331	220	10	morning	morning	NOUN
admet-331	220	11	for	for	ADP
admet-331	220	12	eight	eight	NUM
admet-331	220	13	days	day	NOUN
admet-331	220	14	was	be	AUX
admet-331	220	15	without	without	ADP
admet-331	220	16	any	any	DET
admet-331	220	17	systemic	systemic	ADJ
admet-331	220	18	side	side	NOUN
admet-331	220	19	effect	effect	NOUN
admet-331	220	20	.	.	PUNCT
admet-331	221	1	moreover	moreover	ADV
admet-331	221	2	,	,	PUNCT
admet-331	221	3	the	the	DET
admet-331	221	4	pressure	pressure	NOUN
admet-331	221	5	-	-	PUNCT
admet-331	221	6	lowering	lower	VERB
admet-331	221	7	effect	effect	NOUN
admet-331	221	8	was	be	AUX
admet-331	221	9	maintained	maintain	VERB
admet-331	221	10	for	for	ADP
admet-331	221	11	more	more	ADJ
admet-331	221	12	than	than	ADP
admet-331	221	13	24	24	NUM
admet-331	221	14	hours	hour	NOUN
admet-331	221	15	after	after	ADP
admet-331	221	16	the	the	DET
admet-331	221	17	end	end	NOUN
admet-331	221	18	of	of	ADP
admet-331	221	19	the	the	DET
admet-331	221	20	treatment	treatment	NOUN
admet-331	221	21	,	,	PUNCT
admet-331	221	22	which	which	PRON
admet-331	221	23	is	be	AUX
admet-331	221	24	unique	unique	ADJ
admet-331	221	25	.	.	PUNCT
admet-331	222	1	surprisingly	surprisingly	ADV
admet-331	222	2	the	the	DET
admet-331	222	3	drug	drug	NOUN
admet-331	222	4	was	be	AUX
admet-331	222	5	notably	notably	ADV
admet-331	222	6	less	less	ADV
admet-331	222	7	effective	effective	ADJ
admet-331	222	8	on	on	ADP
admet-331	222	9	day	day	NOUN
admet-331	222	10	one	one	NUM
admet-331	222	11	compared	compare	VERB
admet-331	222	12	to	to	ADP
admet-331	222	13	day	day	NOUN
admet-331	222	14	eight	eight	NUM
admet-331	222	15	[	[	NOUN
admet-331	222	16	62	62	NUM
admet-331	222	17	]	]	PUNCT
admet-331	222	18	.	.	PUNCT
admet-331	223	1	two	two	NUM
admet-331	223	2	hundred	hundred	NUM
admet-331	223	3	and	and	CCONJ
admet-331	223	4	thirteen	thirteen	NUM
admet-331	223	5	patients	patient	NOUN
admet-331	223	6	with	with	ADP
admet-331	223	7	primary	primary	ADJ
admet-331	223	8	open	open	ADJ
admet-331	223	9	-	-	PUNCT
admet-331	223	10	angle	angle	NOUN
admet-331	223	11	glaucoma	glaucoma	NOUN
admet-331	223	12	and	and	CCONJ
admet-331	223	13	ocular	ocular	ADJ
admet-331	223	14	hypertension	hypertension	NOUN
admet-331	223	15	completed	complete	VERB
admet-331	223	16	a	a	DET
admet-331	223	17	28	28	NUM
admet-331	223	18	-	-	PUNCT
admet-331	223	19	day	day	NOUN
admet-331	223	20	trial	trial	NOUN
admet-331	223	21	with	with	ADP
admet-331	223	22	ar13324	ar13324	PROPN
admet-331	223	23	.	.	PUNCT
admet-331	224	1	once	once	ADV
admet-331	224	2	daily	daily	ADJ
admet-331	224	3	0.02	0.02	NUM
admet-331	224	4	%	%	NOUN
admet-331	224	5	ar13324	ar13324	NOUN
admet-331	224	6	was	be	AUX
admet-331	224	7	a	a	DET
admet-331	224	8	little	little	ADV
admet-331	224	9	less	less	ADV
admet-331	224	10	effective	effective	ADJ
admet-331	224	11	than	than	ADP
admet-331	224	12	latanoprost	latanoprost	ADJ
admet-331	224	13	(	(	PUNCT
admet-331	224	14	0.005	0.005	NUM
admet-331	224	15	%	%	NOUN
admet-331	224	16	)	)	PUNCT
admet-331	224	17	in	in	ADP
admet-331	224	18	pressure	pressure	NOUN
admet-331	224	19	-	-	PUNCT
admet-331	224	20	lowering	lower	VERB
admet-331	224	21	efficacy	efficacy	NOUN
admet-331	224	22	[	[	X
admet-331	224	23	63	63	NUM
admet-331	224	24	]	]	PUNCT
admet-331	224	25	.	.	PUNCT
admet-331	225	1	ar13324	ar13324	PROPN
admet-331	225	2	(	(	PUNCT
admet-331	225	3	0.02	0.02	NUM
admet-331	225	4	%	%	NOUN
admet-331	225	5	)	)	PUNCT
admet-331	225	6	once	once	ADV
admet-331	225	7	and	and	CCONJ
admet-331	225	8	twice	twice	ADV
admet-331	225	9	daily	daily	ADJ
admet-331	225	10	was	be	AUX
admet-331	225	11	also	also	ADV
admet-331	225	12	compared	compare	VERB
admet-331	225	13	to	to	ADP
admet-331	225	14	timolol	timolol	NOUN
admet-331	225	15	instilled	instill	VERB
admet-331	225	16	twice	twice	ADV
admet-331	225	17	daily	daily	ADV
admet-331	225	18	in	in	ADP
admet-331	225	19	3	3	NUM
admet-331	225	20	month	month	NOUN
admet-331	225	21	-	-	PUNCT
admet-331	225	22	long	long	ADJ
admet-331	225	23	trials	trial	NOUN
admet-331	225	24	(	(	PUNCT
admet-331	225	25	called	call	VERB
admet-331	225	26	rocket	rocket	NOUN
admet-331	225	27	i	i	PROPN
admet-331	225	28	and	and	CCONJ
admet-331	225	29	rocket	rocket	PROPN
admet-331	225	30	ii	ii	PROPN
admet-331	225	31	)	)	PUNCT
admet-331	225	32	.	.	PUNCT
admet-331	226	1	rocket	rocket	NOUN
admet-331	226	2	ii	ii	PROPN
admet-331	226	3	achieved	achieve	VERB
admet-331	226	4	the	the	DET
admet-331	226	5	primary	primary	ADJ
admet-331	226	6	endpoint	endpoint	NOUN
admet-331	226	7	and	and	CCONJ
admet-331	226	8	was	be	AUX
admet-331	226	9	non	non	ADJ
admet-331	226	10	-	-	ADJ
admet-331	226	11	inferior	inferior	ADJ
admet-331	226	12	to	to	ADP
admet-331	226	13	timolol	timolol	NOUN
admet-331	226	14	application	application	NOUN
admet-331	226	15	.	.	PUNCT
admet-331	227	1	two	two	NUM
admet-331	227	2	additional	additional	ADJ
admet-331	227	3	trials	trial	NOUN
admet-331	227	4	are	be	AUX
admet-331	227	5	in	in	ADP
admet-331	227	6	process	process	NOUN
admet-331	227	7	:	:	PUNCT
admet-331	227	8	rocket	rocket	NOUN
admet-331	227	9	iii	iii	NOUN
admet-331	227	10	is	be	AUX
admet-331	227	11	a	a	DET
admet-331	227	12	one	one	NUM
admet-331	227	13	-	-	PUNCT
admet-331	227	14	year	year	NOUN
admet-331	227	15	safety	safety	NOUN
admet-331	227	16	study	study	NOUN
admet-331	227	17	in	in	ADP
admet-331	227	18	canada	canada	PROPN
admet-331	227	19	and	and	CCONJ
admet-331	227	20	rocket	rocket	NOUN
admet-331	227	21	iv	iv	NOUN
admet-331	227	22	is	be	AUX
admet-331	227	23	a	a	DET
admet-331	227	24	three	three	NUM
admet-331	227	25	month	month	NOUN
admet-331	227	26	non	non	ADJ
admet-331	227	27	-	-	ADJ
admet-331	227	28	inferiority	inferiority	ADJ
admet-331	227	29	study	study	NOUN
admet-331	227	30	comparing	compare	VERB
admet-331	227	31	once	once	ADV
admet-331	227	32	daily	daily	ADJ
admet-331	227	33	ar13324	ar13324	NOUN
admet-331	227	34	to	to	ADP
admet-331	227	35	twice	twice	ADV
admet-331	227	36	-	-	PUNCT
admet-331	227	37	daily	daily	ADJ
admet-331	227	38	timolol	timolol	NOUN
admet-331	227	39	with	with	ADP
admet-331	227	40	a	a	DET
admet-331	227	41	six	six	NUM
admet-331	227	42	month	month	NOUN
admet-331	227	43	follow	follow	NOUN
admet-331	227	44	-	-	PUNCT
admet-331	227	45	up	up	NOUN
admet-331	227	46	safety	safety	NOUN
admet-331	227	47	evaluation	evaluation	NOUN
admet-331	227	48	[	[	X
admet-331	227	49	15	15	NUM
admet-331	227	50	]	]	PUNCT
admet-331	227	51	.	.	PUNCT
admet-331	228	1	aerie	aerie	PROPN
admet-331	228	2	phamaceuticals	phamaceutical	NOUN
admet-331	228	3	has	have	AUX
admet-331	228	4	also	also	ADV
admet-331	228	5	developed	develop	VERB
admet-331	228	6	a	a	DET
admet-331	228	7	triple	triple	ADJ
admet-331	228	8	-	-	PUNCT
admet-331	228	9	action	action	NOUN
admet-331	228	10	anti	anti	ADJ
admet-331	228	11	-	-	ADJ
admet-331	228	12	glaucoma	glaucoma	ADJ
admet-331	228	13	eye	eye	NOUN
admet-331	228	14	drop	drop	NOUN
admet-331	228	15	named	name	VERB
admet-331	228	16	pg324	pg324	PROPN
admet-331	228	17	(	(	PUNCT
admet-331	228	18	synonym	synonym	NOUN
admet-331	228	19	roclatan	roclatan	PROPN
admet-331	228	20	)	)	PUNCT
admet-331	228	21	,	,	PUNCT
admet-331	228	22	which	which	PRON
admet-331	228	23	is	be	AUX
admet-331	228	24	a	a	DET
admet-331	228	25	fixed	fix	VERB
admet-331	228	26	-	-	PUNCT
admet-331	228	27	dose	dose	NOUN
admet-331	228	28	combination	combination	NOUN
admet-331	228	29	of	of	ADP
admet-331	228	30	ar13324	ar13324	NOUN
admet-331	228	31	(	(	PUNCT
admet-331	228	32	0.02	0.02	NUM
admet-331	228	33	%	%	NOUN
admet-331	228	34	)	)	PUNCT
admet-331	228	35	with	with	ADP
admet-331	228	36	latanoprost	latanoprost	ADJ
admet-331	228	37	(	(	PUNCT
admet-331	228	38	0.005	0.005	NUM
admet-331	228	39	%	%	NOUN
admet-331	228	40	)	)	PUNCT
admet-331	228	41	.	.	PUNCT
admet-331	229	1	two	two	NUM
admet-331	229	2	hundred	hundred	NUM
admet-331	229	3	and	and	CCONJ
admet-331	229	4	ninety	ninety	NUM
admet-331	229	5	-	-	PUNCT
admet-331	229	6	two	two	NUM
admet-331	229	7	patients	patient	NOUN
admet-331	229	8	completed	complete	VERB
admet-331	229	9	a	a	DET
admet-331	229	10	28	28	NUM
admet-331	229	11	-	-	PUNCT
admet-331	229	12	day	day	NOUN
admet-331	229	13	trial	trial	NOUN
admet-331	229	14	,	,	PUNCT
admet-331	229	15	where	where	SCONJ
admet-331	229	16	0.01	0.01	NUM
admet-331	229	17	%	%	NOUN
admet-331	229	18	and	and	CCONJ
admet-331	229	19	0.02	0.02	NUM
admet-331	229	20	%	%	NOUN
admet-331	229	21	roclatan	roclatan	NOUN
admet-331	229	22	proved	prove	VERB
admet-331	229	23	to	to	PART
admet-331	229	24	be	be	AUX
admet-331	229	25	a	a	DET
admet-331	229	26	clinically	clinically	ADV
admet-331	229	27	and	and	CCONJ
admet-331	229	28	statistically	statistically	ADV
admet-331	229	29	more	more	ADV
admet-331	229	30	efficacious	efficacious	ADJ
admet-331	229	31	and	and	CCONJ
admet-331	229	32	safe	safe	ADJ
admet-331	229	33	hypotensive	hypotensive	ADJ
admet-331	229	34	agent	agent	NOUN
admet-331	229	35	relative	relative	ADJ
admet-331	229	36	to	to	ADP
admet-331	229	37	its	its	PRON
admet-331	229	38	single	single	ADJ
admet-331	229	39	components	component	NOUN
admet-331	229	40	[	[	X
admet-331	229	41	14	14	NUM
admet-331	229	42	]	]	PUNCT
admet-331	229	43	.	.	PUNCT
admet-331	230	1	there	there	PRON
admet-331	230	2	are	be	VERB
admet-331	230	3	several	several	ADJ
admet-331	230	4	phase	phase	NOUN
admet-331	230	5	iii	iii	NUM
admet-331	230	6	clinical	clinical	ADJ
admet-331	230	7	trials	trial	NOUN
admet-331	230	8	with	with	ADP
admet-331	230	9	roclatan	roclatan	PROPN
admet-331	230	10	expected	expect	VERB
admet-331	230	11	to	to	PART
admet-331	230	12	begin	begin	VERB
admet-331	230	13	or	or	CCONJ
admet-331	230	14	already	already	ADV
admet-331	230	15	enrolling	enrol	VERB
admet-331	230	16	patients	patient	NOUN
admet-331	230	17	.	.	PUNCT
admet-331	231	1	mercury	mercury	NOUN
admet-331	232	1	i	i	PRON
admet-331	232	2	is	be	AUX
admet-331	232	3	a	a	DET
admet-331	232	4	one	one	NUM
admet-331	232	5	-	-	PUNCT
admet-331	232	6	year	year	NOUN
admet-331	232	7	safety	safety	NOUN
admet-331	232	8	trial	trial	NOUN
admet-331	232	9	and	and	CCONJ
admet-331	232	10	mercury	mercury	PROPN
admet-331	232	11	ii	ii	PROPN
admet-331	232	12	is	be	AUX
admet-331	232	13	a	a	DET
admet-331	232	14	three	three	NUM
admet-331	232	15	months	month	NOUN
admet-331	232	16	efficacy	efficacy	NOUN
admet-331	232	17	study	study	NOUN
admet-331	232	18	,	,	PUNCT
admet-331	232	19	both	both	PRON
admet-331	232	20	of	of	ADP
admet-331	232	21	them	they	PRON
admet-331	232	22	comparing	compare	VERB
admet-331	232	23	roclatan	roclatan	NOUN
admet-331	232	24	to	to	ADP
admet-331	232	25	ar13324	ar13324	NOUN
admet-331	232	26	and	and	CCONJ
admet-331	232	27	latanoprost	latanoprost	VERB
admet-331	232	28	in	in	ADP
admet-331	232	29	the	the	DET
admet-331	232	30	united	united	PROPN
admet-331	232	31	states	states	PROPN
admet-331	232	32	.	.	PUNCT
admet-331	233	1	mercury	mercury	NOUN
admet-331	233	2	iii	iii	PROPN
admet-331	233	3	will	will	AUX
admet-331	233	4	evaluate	evaluate	VERB
admet-331	233	5	six	six	NUM
admet-331	233	6	months	month	NOUN
admet-331	233	7	safety	safety	NOUN
admet-331	233	8	and	and	CCONJ
admet-331	233	9	efficacy	efficacy	NOUN
admet-331	233	10	of	of	ADP
admet-331	233	11	the	the	DET
admet-331	233	12	new	new	ADJ
admet-331	233	13	drug	drug	NOUN
admet-331	233	14	relative	relative	ADJ
admet-331	233	15	to	to	ADP
admet-331	233	16	another	another	DET
admet-331	233	17	clinically	clinically	ADV
admet-331	233	18	used	use	VERB
admet-331	233	19	fixed	fix	VERB
admet-331	233	20	-	-	PUNCT
admet-331	233	21	dose	dose	NOUN
admet-331	233	22	combination	combination	NOUN
admet-331	233	23	hypotensive	hypotensive	ADJ
admet-331	233	24	eye	eye	NOUN
admet-331	233	25	-	-	PUNCT
admet-331	233	26	drop	drop	NOUN
admet-331	233	27	in	in	ADP
admet-331	233	28	europe	europe	PROPN
admet-331	234	1	[	[	X
admet-331	234	2	15	15	NUM
admet-331	234	3	]	]	PUNCT
admet-331	234	4	.	.	PUNCT
admet-331	235	1	ama0076	ama0076	PROPN
admet-331	235	2	,	,	PUNCT
admet-331	235	3	designed	design	VERB
admet-331	235	4	by	by	ADP
admet-331	235	5	amakem	amakem	PROPN
admet-331	235	6	,	,	PUNCT
admet-331	235	7	is	be	AUX
admet-331	235	8	called	call	VERB
admet-331	235	9	a	a	DET
admet-331	235	10	soft	soft	ADJ
admet-331	235	11	rock	rock	NOUN
admet-331	235	12	inhibitor	inhibitor	NOUN
admet-331	235	13	(	(	PUNCT
admet-331	235	14	see	see	VERB
admet-331	235	15	definition	definition	NOUN
admet-331	235	16	in	in	ADP
admet-331	235	17	introduction	introduction	NOUN
admet-331	235	18	)	)	PUNCT
admet-331	235	19	,	,	PUNCT
admet-331	235	20	because	because	SCONJ
admet-331	235	21	its	its	PRON
admet-331	235	22	effects	effect	NOUN
admet-331	235	23	are	be	AUX
admet-331	235	24	localized	localize	VERB
admet-331	235	25	thereby	thereby	ADV
admet-331	235	26	resulting	result	VERB
admet-331	235	27	in	in	ADP
admet-331	235	28	fewer	few	ADJ
admet-331	235	29	side	side	NOUN
admet-331	235	30	effects	effect	NOUN
admet-331	235	31	.	.	PUNCT
admet-331	236	1	the	the	DET
admet-331	236	2	compound	compound	NOUN
admet-331	236	3	contains	contain	VERB
admet-331	236	4	a	a	DET
admet-331	236	5	carboxylic	carboxylic	ADJ
admet-331	236	6	ester	ester	NOUN
admet-331	236	7	éva	éva	PROPN
admet-331	236	8	halász	halász	NOUN
admet-331	236	9	,	,	PUNCT
admet-331	236	10	ellen	ellen	PROPN
admet-331	236	11	townes	townes	PROPN
admet-331	236	12	-	-	PUNCT
admet-331	236	13	anderson	anderson	PROPN
admet-331	236	14	admet	admet	PROPN
admet-331	236	15	&	&	CCONJ
admet-331	236	16	dmpk	dmpk	PROPN
admet-331	236	17	4(4	4(4	NUM
admet-331	236	18	)	)	PUNCT
admet-331	236	19	(	(	PUNCT
admet-331	236	20	2016	2016	NUM
admet-331	236	21	)	)	PUNCT
admet-331	236	22	280	280	NUM
admet-331	236	23	-	-	SYM
admet-331	236	24	301	301	NUM
admet-331	236	25	290	290	NUM
admet-331	236	26	group	group	NOUN
admet-331	236	27	and	and	CCONJ
admet-331	236	28	exhibits	exhibit	VERB
admet-331	236	29	high	high	ADJ
admet-331	236	30	rock	rock	NOUN
admet-331	236	31	efficacy	efficacy	NOUN
admet-331	236	32	(	(	PUNCT
admet-331	236	33	rock	rock	PROPN
admet-331	236	34	ii	ii	PROPN
admet-331	236	35	ic50=2.5	ic50=2.5	PROPN
admet-331	236	36	nm	nm	NOUN
admet-331	236	37	)	)	PUNCT
admet-331	237	1	[	[	X
admet-331	237	2	7	7	NUM
admet-331	237	3	]	]	PUNCT
admet-331	237	4	.	.	PUNCT
admet-331	238	1	topically	topically	ADV
admet-331	238	2	instilled	instill	VERB
admet-331	238	3	drug	drug	NOUN
admet-331	238	4	,	,	PUNCT
admet-331	238	5	once	once	SCONJ
admet-331	238	6	it	it	PRON
admet-331	238	7	gets	get	VERB
admet-331	238	8	through	through	ADP
admet-331	238	9	the	the	DET
admet-331	238	10	cornea	cornea	NOUN
admet-331	238	11	into	into	ADP
admet-331	238	12	the	the	DET
admet-331	238	13	aqueous	aqueous	ADJ
admet-331	238	14	humor	humor	NOUN
admet-331	238	15	,	,	PUNCT
admet-331	238	16	remains	remain	VERB
admet-331	238	17	stable	stable	ADJ
admet-331	238	18	.	.	PUNCT
admet-331	239	1	however	however	ADV
admet-331	239	2	,	,	PUNCT
admet-331	239	3	drug	drug	NOUN
admet-331	239	4	on	on	ADP
admet-331	239	5	the	the	DET
admet-331	239	6	surface	surface	NOUN
admet-331	239	7	of	of	ADP
admet-331	239	8	the	the	DET
admet-331	239	9	eye	eye	NOUN
admet-331	239	10	(	(	PUNCT
admet-331	239	11	in	in	ADP
admet-331	239	12	conjunctiva	conjunctiva	NOUN
admet-331	239	13	and	and	CCONJ
admet-331	239	14	other	other	ADJ
admet-331	239	15	tissues	tissue	NOUN
admet-331	239	16	)	)	PUNCT
admet-331	239	17	undergoes	undergo	VERB
admet-331	239	18	rapid	rapid	ADJ
admet-331	239	19	metabolic	metabolic	NOUN
admet-331	239	20	inactivation	inactivation	NOUN
admet-331	239	21	by	by	ADP
admet-331	239	22	esterase	esterase	NOUN
admet-331	239	23	.	.	PUNCT
admet-331	240	1	a	a	DET
admet-331	240	2	notable	notable	ADJ
admet-331	240	3	advantage	advantage	NOUN
admet-331	240	4	of	of	ADP
admet-331	240	5	this	this	DET
admet-331	240	6	rock	rock	NOUN
admet-331	240	7	inhibitor	inhibitor	NOUN
admet-331	240	8	is	be	AUX
admet-331	240	9	that	that	SCONJ
admet-331	240	10	the	the	DET
admet-331	240	11	degree	degree	NOUN
admet-331	240	12	of	of	ADP
admet-331	240	13	hyperemia	hyperemia	NOUN
admet-331	240	14	is	be	AUX
admet-331	240	15	significantly	significantly	ADV
admet-331	240	16	less	less	ADJ
admet-331	240	17	than	than	ADP
admet-331	240	18	any	any	PRON
admet-331	240	19	of	of	ADP
admet-331	240	20	the	the	DET
admet-331	240	21	other	other	ADJ
admet-331	240	22	candidates	candidate	NOUN
admet-331	240	23	,	,	PUNCT
admet-331	240	24	thus	thus	ADV
admet-331	240	25	improving	improve	VERB
admet-331	240	26	the	the	DET
admet-331	240	27	tolerability	tolerability	NOUN
admet-331	240	28	profile	profile	NOUN
admet-331	240	29	.	.	PUNCT
admet-331	241	1	in	in	ADP
admet-331	241	2	in	in	ADP
admet-331	241	3	vitro	vitro	X
admet-331	241	4	human	human	ADJ
admet-331	241	5	trabecular	trabecular	ADJ
admet-331	241	6	meshwork	meshwork	ADJ
admet-331	241	7	cultures	culture	NOUN
admet-331	241	8	,	,	PUNCT
admet-331	241	9	ama0076	ama0076	ADJ
admet-331	241	10	exposure	exposure	NOUN
admet-331	241	11	temporarily	temporarily	ADV
admet-331	241	12	altered	alter	VERB
admet-331	241	13	cell	cell	NOUN
admet-331	241	14	shape	shape	NOUN
admet-331	241	15	through	through	ADP
admet-331	241	16	significant	significant	ADJ
admet-331	241	17	reduction	reduction	NOUN
admet-331	241	18	in	in	ADP
admet-331	241	19	actin	actin	NOUN
admet-331	241	20	stress	stress	NOUN
admet-331	241	21	fibers	fiber	NOUN
admet-331	241	22	and	and	CCONJ
admet-331	241	23	focal	focal	ADJ
admet-331	241	24	adhesions	adhesion	NOUN
admet-331	241	25	.	.	PUNCT
admet-331	242	1	in	in	ADP
admet-331	242	2	new	new	PROPN
admet-331	242	3	zealand	zealand	PROPN
admet-331	242	4	white	white	PROPN
admet-331	242	5	rabbits	rabbit	NOUN
admet-331	242	6	,	,	PUNCT
admet-331	242	7	0.1	0.1	NUM
admet-331	242	8	,	,	PUNCT
admet-331	242	9	0.3	0.3	NUM
admet-331	242	10	and	and	CCONJ
admet-331	242	11	0.5	0.5	NUM
admet-331	242	12	%	%	NOUN
admet-331	242	13	eye	eye	NOUN
admet-331	242	14	-	-	PUNCT
admet-331	242	15	drop	drop	NOUN
admet-331	242	16	concentrations	concentration	NOUN
admet-331	242	17	all	all	PRON
admet-331	242	18	proved	prove	VERB
admet-331	242	19	to	to	PART
admet-331	242	20	be	be	AUX
admet-331	242	21	more	more	ADV
admet-331	242	22	efficient	efficient	ADJ
admet-331	242	23	in	in	ADP
admet-331	242	24	lowering	lower	VERB
admet-331	242	25	intraocular	intraocular	ADJ
admet-331	242	26	pressure	pressure	NOUN
admet-331	242	27	than	than	ADP
admet-331	242	28	the	the	DET
admet-331	242	29	same	same	ADJ
admet-331	242	30	concentrations	concentration	NOUN
admet-331	242	31	of	of	ADP
admet-331	242	32	y39983	y39983	PROPN
admet-331	242	33	[	[	X
admet-331	242	34	8	8	NUM
admet-331	242	35	]	]	PUNCT
admet-331	242	36	.	.	PUNCT
admet-331	243	1	human	human	ADJ
admet-331	243	2	trials	trial	NOUN
admet-331	243	3	were	be	AUX
admet-331	243	4	completed	complete	VERB
admet-331	243	5	recently	recently	ADV
admet-331	243	6	(	(	PUNCT
admet-331	243	7	clinicaltrials.gov	clinicaltrials.gov	NOUN
admet-331	243	8	identifier	identifier	NOUN
admet-331	243	9	:	:	PUNCT
admet-331	243	10	nct02003547	nct02003547	NOUN
admet-331	243	11	,	,	PUNCT
admet-331	243	12	nct01693315	nct01693315	ADV
admet-331	243	13	,	,	PUNCT
admet-331	243	14	nct02136940	nct02136940	NOUN
admet-331	243	15	)	)	PUNCT
admet-331	243	16	.	.	PUNCT
admet-331	244	1	in	in	ADP
admet-331	244	2	the	the	DET
admet-331	244	3	first	first	ADJ
admet-331	244	4	human	human	ADJ
admet-331	244	5	trials	trial	NOUN
admet-331	244	6	,	,	PUNCT
admet-331	244	7	ama0076	ama0076	NOUN
admet-331	244	8	proved	prove	VERB
admet-331	244	9	to	to	PART
admet-331	244	10	be	be	AUX
admet-331	244	11	safe	safe	ADJ
admet-331	244	12	and	and	CCONJ
admet-331	244	13	efficient	efficient	ADJ
admet-331	244	14	in	in	ADP
admet-331	244	15	iop	iop	NOUN
admet-331	244	16	reduction	reduction	NOUN
admet-331	244	17	with	with	ADP
admet-331	244	18	no	no	DET
admet-331	244	19	significant	significant	ADJ
admet-331	244	20	conjunctival	conjunctival	NOUN
admet-331	244	21	hyperemia	hyperemia	NOUN
admet-331	244	22	associated	associate	VERB
admet-331	244	23	with	with	ADP
admet-331	244	24	the	the	DET
admet-331	244	25	treatment	treatment	NOUN
admet-331	244	26	;	;	PUNCT
admet-331	244	27	results	result	NOUN
admet-331	244	28	from	from	ADP
admet-331	244	29	the	the	DET
admet-331	244	30	last	last	ADJ
admet-331	244	31	,	,	PUNCT
admet-331	244	32	four	four	NUM
admet-331	244	33	week	week	NOUN
admet-331	244	34	-	-	PUNCT
admet-331	244	35	long	long	ADJ
admet-331	244	36	phase	phase	NOUN
admet-331	244	37	iia	iia	VERB
admet-331	244	38	clinical	clinical	ADJ
admet-331	244	39	study	study	NOUN
admet-331	244	40	have	have	AUX
admet-331	244	41	not	not	PART
admet-331	244	42	yet	yet	ADV
admet-331	244	43	been	be	AUX
admet-331	244	44	published	publish	VERB
admet-331	244	45	.	.	PUNCT
admet-331	245	1	despite	despite	SCONJ
admet-331	245	2	the	the	DET
admet-331	245	3	early	early	ADJ
admet-331	245	4	favorable	favorable	ADJ
admet-331	245	5	outcomes	outcome	NOUN
admet-331	245	6	of	of	ADP
admet-331	245	7	animal	animal	NOUN
admet-331	245	8	or	or	CCONJ
admet-331	245	9	human	human	ADJ
admet-331	245	10	studies	study	NOUN
admet-331	245	11	,	,	PUNCT
admet-331	245	12	development	development	NOUN
admet-331	245	13	of	of	ADP
admet-331	245	14	many	many	ADJ
admet-331	245	15	rock	rock	NOUN
admet-331	245	16	inhibitors	inhibitor	NOUN
admet-331	245	17	for	for	ADP
admet-331	245	18	clinical	clinical	ADJ
admet-331	245	19	use	use	NOUN
admet-331	245	20	in	in	ADP
admet-331	245	21	glaucoma	glaucoma	NOUN
admet-331	245	22	have	have	AUX
admet-331	245	23	failed	fail	VERB
admet-331	245	24	or	or	CCONJ
admet-331	245	25	been	be	AUX
admet-331	245	26	suspended	suspend	VERB
admet-331	245	27	.	.	PUNCT
admet-331	246	1	for	for	ADP
admet-331	246	2	instance	instance	NOUN
admet-331	246	3	,	,	PUNCT
admet-331	246	4	ar12286	ar12286	PROPN
admet-331	246	5	(	(	PUNCT
admet-331	246	6	developed	develop	VERB
admet-331	246	7	by	by	ADP
admet-331	246	8	aerie	aerie	PROPN
admet-331	246	9	pharmaceuticals	pharmaceutical	NOUN
admet-331	246	10	)	)	PUNCT
admet-331	246	11	completed	complete	VERB
admet-331	246	12	a	a	DET
admet-331	246	13	phase	phase	NOUN
admet-331	246	14	iia	iia	VERB
admet-331	246	15	human	human	ADJ
admet-331	246	16	study	study	NOUN
admet-331	246	17	,	,	PUNCT
admet-331	246	18	and	and	CCONJ
admet-331	246	19	produced	produce	VERB
admet-331	246	20	significant	significant	ADJ
admet-331	246	21	dose	dose	NOUN
admet-331	246	22	-	-	PUNCT
admet-331	246	23	dependent	dependent	ADJ
admet-331	246	24	iop	iop	NOUN
admet-331	246	25	reduction	reduction	NOUN
admet-331	246	26	[	[	X
admet-331	246	27	64	64	NUM
admet-331	246	28	]	]	PUNCT
admet-331	246	29	,	,	PUNCT
admet-331	246	30	however	however	ADV
admet-331	246	31	no	no	DET
admet-331	246	32	further	far	ADV
admet-331	246	33	human	human	ADJ
admet-331	246	34	trials	trial	NOUN
admet-331	246	35	have	have	AUX
admet-331	246	36	been	be	AUX
admet-331	246	37	initiated	initiate	VERB
admet-331	246	38	.	.	PUNCT
admet-331	247	1	y39983	y39983	PROPN
admet-331	247	2	(	(	PUNCT
admet-331	247	3	also	also	ADV
admet-331	247	4	called	call	VERB
admet-331	247	5	rki-983	rki-983	ADJ
admet-331	247	6	,	,	PUNCT
admet-331	247	7	snj-1656	snj-1656	NOUN
admet-331	247	8	)	)	PUNCT
admet-331	247	9	proved	prove	VERB
admet-331	247	10	to	to	PART
admet-331	247	11	be	be	AUX
admet-331	247	12	safe	safe	ADJ
admet-331	247	13	and	and	CCONJ
admet-331	247	14	an	an	DET
admet-331	247	15	efficient	efficient	ADJ
admet-331	247	16	hypotensive	hypotensive	ADJ
admet-331	247	17	agent	agent	NOUN
admet-331	247	18	in	in	ADP
admet-331	247	19	rabbits	rabbit	NOUN
admet-331	247	20	[	[	X
admet-331	247	21	8	8	NUM
admet-331	247	22	]	]	PUNCT
admet-331	247	23	,	,	PUNCT
admet-331	247	24	in	in	ADP
admet-331	247	25	monkeys	monkey	NOUN
admet-331	247	26	[	[	X
admet-331	247	27	9	9	NUM
admet-331	247	28	]	]	PUNCT
admet-331	247	29	and	and	CCONJ
admet-331	247	30	in	in	ADP
admet-331	247	31	humans	human	NOUN
admet-331	247	32	[	[	X
admet-331	247	33	65	65	NUM
admet-331	247	34	]	]	PUNCT
admet-331	247	35	.	.	PUNCT
admet-331	248	1	however	however	ADV
admet-331	248	2	,	,	PUNCT
admet-331	248	3	a	a	DET
admet-331	248	4	seven	seven	NUM
admet-331	248	5	day	day	NOUN
admet-331	248	6	-	-	PUNCT
admet-331	248	7	long	long	ADJ
admet-331	248	8	phase	phase	NOUN
admet-331	248	9	ii	ii	NOUN
admet-331	248	10	clinical	clinical	ADJ
admet-331	248	11	trial	trial	NOUN
admet-331	248	12	with	with	ADP
admet-331	248	13	66	66	NUM
admet-331	248	14	patients	patient	NOUN
admet-331	248	15	revealed	reveal	VERB
admet-331	248	16	unexpected	unexpected	ADJ
admet-331	248	17	side	side	NOUN
admet-331	248	18	effects	effect	NOUN
admet-331	248	19	related	relate	VERB
admet-331	248	20	to	to	ADP
admet-331	248	21	the	the	DET
admet-331	248	22	drug	drug	NOUN
admet-331	248	23	instillation	instillation	NOUN
admet-331	248	24	such	such	ADJ
admet-331	248	25	as	as	ADP
admet-331	248	26	punctate	punctate	NOUN
admet-331	248	27	keratitis	keratitis	NOUN
admet-331	248	28	,	,	PUNCT
admet-331	248	29	headache	headache	NOUN
admet-331	248	30	,	,	PUNCT
admet-331	248	31	and	and	CCONJ
admet-331	248	32	hepatic	hepatic	ADJ
admet-331	248	33	dysfunction	dysfunction	NOUN
admet-331	249	1	[	[	X
admet-331	249	2	11	11	NUM
admet-331	249	3	]	]	PUNCT
admet-331	249	4	.	.	PUNCT
admet-331	250	1	ins117548	ins117548	NOUN
admet-331	250	2	(	(	PUNCT
admet-331	250	3	developed	develop	VERB
admet-331	250	4	by	by	ADP
admet-331	250	5	inspire	inspire	NOUN
admet-331	250	6	pharmaceuticals	pharmaceutical	NOUN
admet-331	250	7	)	)	PUNCT
admet-331	250	8	was	be	AUX
admet-331	250	9	abandoned	abandon	VERB
admet-331	250	10	after	after	ADP
admet-331	250	11	completion	completion	NOUN
admet-331	250	12	of	of	ADP
admet-331	250	13	a	a	DET
admet-331	250	14	phase	phase	NOUN
admet-331	250	15	i	i	PRON
admet-331	250	16	clinical	clinical	ADJ
admet-331	250	17	trial	trial	NOUN
admet-331	250	18	(	(	PUNCT
admet-331	250	19	clinicaltrials.gov	clinicaltrials.gov	NOUN
admet-331	250	20	identifier	identifier	NOUN
admet-331	250	21	:	:	PUNCT
admet-331	250	22	nct00767793	nct00767793	ADJ
admet-331	250	23	)	)	PUNCT
admet-331	250	24	,	,	PUNCT
admet-331	250	25	probably	probably	ADV
admet-331	250	26	because	because	SCONJ
admet-331	250	27	the	the	DET
admet-331	250	28	twice	twice	ADJ
admet-331	250	29	daily	daily	PROPN
admet-331	250	30	administration	administration	NOUN
admet-331	250	31	was	be	AUX
admet-331	250	32	reported	report	VERB
admet-331	250	33	to	to	PART
admet-331	250	34	cause	cause	VERB
admet-331	250	35	ocular	ocular	ADJ
admet-331	250	36	burning	burning	NOUN
admet-331	250	37	and	and	CCONJ
admet-331	250	38	stinging	sting	VERB
admet-331	250	39	in	in	ADP
admet-331	250	40	a	a	DET
admet-331	250	41	dose	dose	NOUN
admet-331	250	42	-	-	PUNCT
admet-331	250	43	dependent	dependent	ADJ
admet-331	250	44	manner	manner	NOUN
admet-331	251	1	[	[	X
admet-331	251	2	66	66	NUM
admet-331	251	3	]	]	PUNCT
admet-331	251	4	.	.	PUNCT
admet-331	252	1	a	a	DET
admet-331	252	2	phase	phase	NOUN
admet-331	252	3	iia	iia	VERB
admet-331	252	4	clinical	clinical	ADJ
admet-331	252	5	trial	trial	NOUN
admet-331	252	6	was	be	AUX
admet-331	252	7	completed	complete	VERB
admet-331	252	8	with	with	ADP
admet-331	252	9	ats907	ats907	PROPN
admet-331	252	10	(	(	PUNCT
admet-331	252	11	clinicaltrials.gov	clinicaltrials.gov	X
admet-331	252	12	identifier	identifier	NOUN
admet-331	252	13	:	:	PUNCT
admet-331	252	14	nct01668524	nct01668524	ADJ
admet-331	252	15	)	)	PUNCT
admet-331	252	16	,	,	PUNCT
admet-331	252	17	and	and	CCONJ
admet-331	252	18	the	the	DET
admet-331	252	19	next	next	ADJ
admet-331	252	20	trial	trial	NOUN
admet-331	252	21	begun	begin	VERB
admet-331	252	22	(	(	PUNCT
admet-331	252	23	clinicaltrials.gov	clinicaltrials.gov	NOUN
admet-331	252	24	identifier	identifier	NOUN
admet-331	252	25	:	:	PUNCT
admet-331	252	26	nct01520116	nct01520116	ADJ
admet-331	252	27	)	)	PUNCT
admet-331	252	28	.	.	PUNCT
admet-331	253	1	however	however	ADV
admet-331	253	2	,	,	PUNCT
admet-331	253	3	the	the	DET
admet-331	253	4	company	company	NOUN
admet-331	253	5	closed	close	VERB
admet-331	253	6	in	in	ADP
admet-331	253	7	february	february	PROPN
admet-331	253	8	2013	2013	NUM
admet-331	253	9	,	,	PUNCT
admet-331	253	10	and	and	CCONJ
admet-331	253	11	no	no	DET
admet-331	253	12	results	result	NOUN
admet-331	253	13	from	from	ADP
admet-331	253	14	this	this	DET
admet-331	253	15	trial	trial	NOUN
admet-331	253	16	have	have	AUX
admet-331	253	17	been	be	AUX
admet-331	253	18	disclosed	disclose	VERB
admet-331	253	19	.	.	PUNCT
admet-331	254	1	nonetheless	nonetheless	ADV
admet-331	254	2	,	,	PUNCT
admet-331	254	3	the	the	DET
admet-331	254	4	number	number	NOUN
admet-331	254	5	of	of	ADP
admet-331	254	6	rock	rock	NOUN
admet-331	254	7	inhibitors	inhibitor	NOUN
admet-331	254	8	being	be	AUX
admet-331	254	9	tested	test	VERB
admet-331	254	10	for	for	ADP
admet-331	254	11	patient	patient	ADJ
admet-331	254	12	use	use	NOUN
admet-331	254	13	provides	provide	VERB
admet-331	254	14	hope	hope	NOUN
admet-331	254	15	that	that	SCONJ
admet-331	254	16	a	a	DET
admet-331	254	17	new	new	ADJ
admet-331	254	18	therapeutic	therapeutic	ADJ
admet-331	254	19	drug	drug	NOUN
admet-331	254	20	will	will	AUX
admet-331	254	21	be	be	AUX
admet-331	254	22	achieved	achieve	VERB
admet-331	254	23	soon	soon	ADV
admet-331	254	24	.	.	PUNCT
admet-331	255	1	retina	retina	VERB
admet-331	255	2	diabetic	diabetic	ADJ
admet-331	255	3	retinopathy	retinopathy	NOUN
admet-331	255	4	in	in	ADP
admet-331	255	5	the	the	DET
admet-331	255	6	past	past	ADJ
admet-331	255	7	few	few	ADJ
admet-331	255	8	years	year	NOUN
admet-331	255	9	,	,	PUNCT
admet-331	255	10	rhoa	rhoa	PROPN
admet-331	255	11	and	and	CCONJ
admet-331	255	12	rock	rock	NOUN
admet-331	255	13	has	have	AUX
admet-331	255	14	been	be	AUX
admet-331	255	15	implicated	implicate	VERB
admet-331	255	16	in	in	ADP
admet-331	255	17	the	the	DET
admet-331	255	18	pathogenesis	pathogenesis	NOUN
admet-331	255	19	of	of	ADP
admet-331	255	20	diabetic	diabetic	ADJ
admet-331	255	21	retinopathy	retinopathy	NOUN
admet-331	255	22	.	.	PUNCT
admet-331	256	1	the	the	DET
admet-331	256	2	basic	basic	ADJ
admet-331	256	3	problem	problem	NOUN
admet-331	256	4	is	be	AUX
admet-331	256	5	the	the	DET
admet-331	256	6	long	long	ADJ
admet-331	256	7	-	-	PUNCT
admet-331	256	8	term	term	NOUN
admet-331	256	9	glucose	glucose	NOUN
admet-331	256	10	homeostasis	homeostasis	NOUN
admet-331	256	11	imbalance	imbalance	NOUN
admet-331	256	12	,	,	PUNCT
admet-331	256	13	which	which	PRON
admet-331	256	14	leads	lead	VERB
admet-331	256	15	to	to	ADP
admet-331	256	16	an	an	DET
admet-331	256	17	accumulation	accumulation	NOUN
admet-331	256	18	of	of	ADP
admet-331	256	19	advanced	advanced	ADJ
admet-331	256	20	glycation	glycation	NOUN
admet-331	256	21	end	end	NOUN
admet-331	256	22	products	product	NOUN
admet-331	256	23	in	in	ADP
admet-331	256	24	the	the	DET
admet-331	256	25	vessels	vessel	NOUN
admet-331	256	26	.	.	PUNCT
admet-331	257	1	this	this	DET
admet-331	257	2	accumulation	accumulation	NOUN
admet-331	257	3	leads	lead	VERB
admet-331	257	4	to	to	ADP
admet-331	257	5	structural	structural	ADJ
admet-331	257	6	changes	change	NOUN
admet-331	257	7	including	include	VERB
admet-331	257	8	vascular	vascular	ADJ
admet-331	257	9	rigidity	rigidity	NOUN
admet-331	257	10	and	and	CCONJ
admet-331	257	11	hyperpermeability	hyperpermeability	NOUN
admet-331	257	12	.	.	PUNCT
admet-331	258	1	the	the	DET
admet-331	258	2	damaged	damage	VERB
admet-331	258	3	vessels	vessel	NOUN
admet-331	258	4	are	be	AUX
admet-331	258	5	not	not	PART
admet-331	258	6	able	able	ADJ
admet-331	258	7	to	to	PART
admet-331	258	8	provide	provide	VERB
admet-331	258	9	sufficient	sufficient	ADJ
admet-331	258	10	blood	blood	NOUN
admet-331	258	11	supply	supply	NOUN
admet-331	258	12	,	,	PUNCT
admet-331	258	13	potentially	potentially	ADV
admet-331	258	14	causing	cause	VERB
admet-331	258	15	hypoxia	hypoxia	NOUN
admet-331	258	16	.	.	PUNCT
admet-331	259	1	under	under	ADP
admet-331	259	2	these	these	DET
admet-331	259	3	circumstances	circumstance	NOUN
admet-331	259	4	new	new	ADJ
admet-331	259	5	vessel	vessel	NOUN
admet-331	259	6	growth	growth	NOUN
admet-331	259	7	is	be	AUX
admet-331	259	8	promoted	promote	VERB
admet-331	259	9	,	,	PUNCT
admet-331	259	10	however	however	ADV
admet-331	259	11	the	the	DET
admet-331	259	12	structure	structure	NOUN
admet-331	259	13	of	of	ADP
admet-331	259	14	the	the	DET
admet-331	259	15	new	new	ADJ
admet-331	259	16	vessels	vessel	NOUN
admet-331	259	17	is	be	AUX
admet-331	259	18	different	different	ADJ
admet-331	259	19	than	than	ADP
admet-331	259	20	the	the	DET
admet-331	259	21	normal	normal	ADJ
admet-331	259	22	,	,	PUNCT
admet-331	259	23	physiological	physiological	ADJ
admet-331	259	24	vasculature	vasculature	NOUN
admet-331	259	25	.	.	PUNCT
admet-331	260	1	in	in	ADP
admet-331	260	2	vitro	vitro	X
admet-331	260	3	studies	study	NOUN
admet-331	260	4	on	on	ADP
admet-331	260	5	rhesus	rhesus	NOUN
admet-331	260	6	macaque	macaque	ADJ
admet-331	260	7	retinal	retinal	ADJ
admet-331	260	8	endothelial	endothelial	NOUN
admet-331	260	9	cells	cell	NOUN
admet-331	260	10	showed	show	VERB
admet-331	260	11	that	that	SCONJ
admet-331	260	12	high	high	ADJ
admet-331	260	13	glucose	glucose	NOUN
admet-331	260	14	levels	level	NOUN
admet-331	260	15	induced	induce	VERB
admet-331	260	16	increased	increase	VERB
admet-331	260	17	rhoa	rhoa	NOUN
admet-331	260	18	activity	activity	NOUN
admet-331	260	19	and	and	CCONJ
admet-331	260	20	endothelial	endothelial	NOUN
admet-331	260	21	permeability	permeability	NOUN
admet-331	260	22	,	,	PUNCT
admet-331	260	23	through	through	ADP
admet-331	260	24	altered	altered	ADJ
admet-331	260	25	expression	expression	NOUN
admet-331	260	26	of	of	ADP
admet-331	260	27	tight	tight	ADJ
admet-331	260	28	junction	junction	NOUN
admet-331	260	29	proteins	protein	NOUN
admet-331	260	30	;	;	PUNCT
admet-331	260	31	both	both	DET
admet-331	260	32	fasudil	fasudil	NOUN
admet-331	260	33	and	and	CCONJ
admet-331	260	34	y27632	y27632	PROPN
admet-331	260	35	reversed	reverse	VERB
admet-331	260	36	the	the	DET
admet-331	260	37	high	high	ADJ
admet-331	260	38	glucose	glucose	NOUN
admet-331	260	39	-	-	PUNCT
admet-331	260	40	related	relate	VERB
admet-331	260	41	changes	change	NOUN
admet-331	260	42	[	[	X
admet-331	260	43	67	67	NUM
admet-331	260	44	]	]	PUNCT
admet-331	260	45	.	.	PUNCT
admet-331	261	1	higher	high	ADJ
admet-331	261	2	rock	rock	NOUN
admet-331	261	3	expression	expression	NOUN
admet-331	261	4	accompanied	accompany	VERB
admet-331	261	5	by	by	ADP
admet-331	261	6	increased	increase	VERB
admet-331	261	7	stiffness	stiffness	NOUN
admet-331	261	8	occurred	occur	VERB
admet-331	261	9	in	in	ADP
admet-331	261	10	diabetic	diabetic	ADJ
admet-331	261	11	mouse	mouse	NOUN
admet-331	261	12	retinal	retinal	ADJ
admet-331	261	13	capillaries	capillary	NOUN
admet-331	261	14	and	and	CCONJ
admet-331	261	15	also	also	ADV
admet-331	261	16	in	in	ADP
admet-331	261	17	high	high	ADJ
admet-331	261	18	glucosetreated	glucosetreate	VERB
admet-331	261	19	retinal	retinal	ADJ
admet-331	261	20	endothelial	endothelial	ADJ
admet-331	261	21	cell	cell	NOUN
admet-331	261	22	cultures	culture	NOUN
admet-331	261	23	[	[	X
admet-331	261	24	68	68	NUM
admet-331	261	25	]	]	PUNCT
admet-331	261	26	.	.	PUNCT
admet-331	262	1	the	the	DET
admet-331	262	2	stiffer	stiffer	ADJ
admet-331	262	3	high	high	ADJ
admet-331	262	4	glucose	glucose	NOUN
admet-331	262	5	-	-	PUNCT
admet-331	262	6	treated	treat	VERB
admet-331	262	7	retinal	retinal	ADJ
admet-331	262	8	endothelial	endothelial	ADJ
admet-331	262	9	cells	cell	NOUN
admet-331	262	10	also	also	ADV
admet-331	262	11	exhibited	exhibit	VERB
admet-331	262	12	lower	low	ADJ
admet-331	262	13	expression	expression	NOUN
admet-331	262	14	and	and	CCONJ
admet-331	262	15	activity	activity	NOUN
admet-331	262	16	of	of	ADP
admet-331	262	17	the	the	DET
admet-331	262	18	mechanosensitive	mechanosensitive	ADJ
admet-331	262	19	ion	ion	NOUN
admet-331	262	20	channel	channel	NOUN
admet-331	262	21	trpv4	trpv4	NOUN
admet-331	262	22	(	(	PUNCT
admet-331	262	23	transient	transient	ADJ
admet-331	262	24	receptor	receptor	NOUN
admet-331	262	25	potential	potential	ADJ
admet-331	262	26	vanilloid	vanilloid	NOUN
admet-331	262	27	)	)	PUNCT
admet-331	262	28	.	.	PUNCT
admet-331	263	1	rock	rock	NOUN
admet-331	263	2	inhibition	inhibition	NOUN
admet-331	263	3	resulted	result	VERB
admet-331	263	4	in	in	ADP
admet-331	263	5	significant	significant	ADJ
admet-331	263	6	recovery	recovery	NOUN
admet-331	263	7	of	of	ADP
admet-331	263	8	trpv4	trpv4	NOUN
admet-331	263	9	expression	expression	NOUN
admet-331	263	10	and	and	CCONJ
admet-331	263	11	activity	activity	NOUN
admet-331	263	12	,	,	PUNCT
admet-331	263	13	as	as	ADP
admet-331	263	14	admet	admet	PROPN
admet-331	263	15	&	&	CCONJ
admet-331	263	16	dmpk	dmpk	PROPN
admet-331	263	17	4(4	4(4	NUM
admet-331	263	18	)	)	PUNCT
admet-331	263	19	(	(	PUNCT
admet-331	263	20	2016	2016	NUM
admet-331	263	21	)	)	PUNCT
admet-331	263	22	280	280	NUM
admet-331	263	23	-	-	SYM
admet-331	263	24	301	301	NUM
admet-331	263	25	rock	rock	NOUN
admet-331	263	26	inhibitors	inhibitor	NOUN
admet-331	263	27	in	in	ADP
admet-331	263	28	ocular	ocular	ADJ
admet-331	263	29	disease	disease	NOUN
admet-331	263	30	doi	doi	NOUN
admet-331	263	31	:	:	PUNCT
admet-331	263	32	10.5599	10.5599	NUM
admet-331	263	33	/	/	SYM
admet-331	263	34	admet.4.4.331	admet.4.4.331	PROPN
admet-331	263	35	291	291	NUM
admet-331	263	36	well	well	ADV
admet-331	263	37	as	as	ADP
admet-331	263	38	enhanced	enhance	VERB
admet-331	263	39	endothelial	endothelial	NOUN
admet-331	263	40	no	no	DET
admet-331	263	41	production	production	NOUN
admet-331	263	42	and	and	CCONJ
admet-331	263	43	decreased	decrease	VERB
admet-331	263	44	monocyte	monocyte	NOUN
admet-331	263	45	adhesion	adhesion	NOUN
admet-331	263	46	to	to	ADP
admet-331	263	47	the	the	DET
admet-331	263	48	endothelium	endothelium	NOUN
admet-331	263	49	[	[	X
admet-331	263	50	68	68	NUM
admet-331	263	51	]	]	PUNCT
admet-331	263	52	.	.	PUNCT
admet-331	264	1	in	in	ADP
admet-331	264	2	diabetes	diabetes	NOUN
admet-331	264	3	,	,	PUNCT
admet-331	264	4	endothelial	endothelial	ADJ
admet-331	264	5	nitric	nitric	ADJ
admet-331	264	6	oxide	oxide	NOUN
admet-331	264	7	synthase	synthase	NOUN
admet-331	264	8	activity	activity	NOUN
admet-331	264	9	is	be	AUX
admet-331	264	10	reduced	reduce	VERB
admet-331	264	11	.	.	PUNCT
admet-331	265	1	fasudil	fasudil	NOUN
admet-331	265	2	can	can	AUX
admet-331	265	3	significantly	significantly	ADV
admet-331	265	4	reverse	reverse	VERB
admet-331	265	5	this	this	DET
admet-331	265	6	change	change	NOUN
admet-331	265	7	through	through	ADP
admet-331	265	8	increased	increase	VERB
admet-331	265	9	enos	eno	NOUN
admet-331	265	10	phosphorylation	phosphorylation	NOUN
admet-331	265	11	and	and	CCONJ
admet-331	265	12	thereby	thereby	ADV
admet-331	265	13	contributes	contribute	VERB
admet-331	265	14	to	to	ADP
admet-331	265	15	vasodilatation	vasodilatation	NOUN
admet-331	265	16	and	and	CCONJ
admet-331	265	17	vasculoprotection	vasculoprotection	NOUN
admet-331	266	1	[	[	X
admet-331	266	2	69,70	69,70	NOUN
admet-331	266	3	]	]	PUNCT
admet-331	266	4	.	.	PUNCT
admet-331	267	1	changes	change	NOUN
admet-331	267	2	in	in	ADP
admet-331	267	3	leukocyte	leukocyte	ADJ
admet-331	267	4	adhesion	adhesion	NOUN
admet-331	267	5	to	to	ADP
admet-331	267	6	endothelium	endothelium	NOUN
admet-331	267	7	are	be	AUX
admet-331	267	8	a	a	DET
admet-331	267	9	feature	feature	NOUN
admet-331	267	10	of	of	ADP
admet-331	267	11	the	the	DET
admet-331	267	12	early	early	ADJ
admet-331	267	13	stages	stage	NOUN
admet-331	267	14	of	of	ADP
admet-331	267	15	the	the	DET
admet-331	267	16	disease	disease	NOUN
admet-331	267	17	.	.	PUNCT
admet-331	268	1	bhaskaran	bhaskaran	NOUN
admet-331	268	2	et	et	PROPN
admet-331	268	3	al	al	PROPN
admet-331	268	4	.	.	PUNCT
admet-331	269	1	[	[	X
admet-331	269	2	71	71	NUM
admet-331	269	3	]	]	PUNCT
admet-331	269	4	suggest	suggest	VERB
admet-331	269	5	that	that	SCONJ
admet-331	269	6	high	high	ADJ
admet-331	269	7	glucose	glucose	NOUN
admet-331	269	8	-	-	PUNCT
admet-331	269	9	induced	induce	VERB
admet-331	269	10	endothelial	endothelial	ADJ
admet-331	269	11	monocyte	monocyte	NOUN
admet-331	269	12	adhesion	adhesion	NOUN
admet-331	269	13	contributes	contribute	VERB
admet-331	269	14	,	,	PUNCT
admet-331	269	15	at	at	ADP
admet-331	269	16	least	least	ADJ
admet-331	269	17	in	in	ADP
admet-331	269	18	part	part	NOUN
admet-331	269	19	,	,	PUNCT
admet-331	269	20	to	to	ADP
admet-331	269	21	increased	increase	VERB
admet-331	269	22	stiffness	stiffness	NOUN
admet-331	269	23	of	of	ADP
admet-331	269	24	retinal	retinal	ADJ
admet-331	269	25	endothelial	endothelial	ADJ
admet-331	269	26	cells	cell	NOUN
admet-331	269	27	and	and	CCONJ
admet-331	269	28	subendothelial	subendothelial	ADJ
admet-331	269	29	matrix	matrix	NOUN
admet-331	269	30	.	.	PUNCT
admet-331	270	1	human	human	ADJ
admet-331	270	2	retinal	retinal	ADJ
admet-331	270	3	endothelial	endothelial	NOUN
admet-331	270	4	cells	cell	NOUN
admet-331	270	5	co	co	VERB
admet-331	270	6	-	-	VERB
admet-331	270	7	cultured	cultured	ADJ
admet-331	270	8	with	with	ADP
admet-331	270	9	activated	activate	VERB
admet-331	270	10	monocytes	monocyte	NOUN
admet-331	270	11	for	for	ADP
admet-331	270	12	24	24	NUM
admet-331	270	13	and	and	CCONJ
admet-331	270	14	72	72	NUM
admet-331	270	15	hours	hour	NOUN
admet-331	270	16	significantly	significantly	ADV
admet-331	270	17	increased	increase	VERB
admet-331	270	18	rock	rock	NOUN
admet-331	270	19	expression	expression	NOUN
admet-331	270	20	and	and	CCONJ
admet-331	270	21	activity	activity	NOUN
admet-331	270	22	along	along	ADV
admet-331	270	23	with	with	ADP
admet-331	270	24	impaired	impaired	ADJ
admet-331	270	25	trpv4	trpv4	NOUN
admet-331	270	26	activity	activity	NOUN
admet-331	270	27	and	and	CCONJ
admet-331	270	28	expression	expression	NOUN
admet-331	270	29	[	[	X
admet-331	270	30	71	71	NUM
admet-331	270	31	]	]	PUNCT
admet-331	270	32	.	.	PUNCT
admet-331	271	1	in	in	ADP
admet-331	271	2	vitro	vitro	X
admet-331	271	3	and	and	CCONJ
admet-331	271	4	intravitreal	intravitreal	ADJ
admet-331	271	5	administration	administration	NOUN
admet-331	271	6	of	of	ADP
admet-331	271	7	fasudil	fasudil	NOUN
admet-331	271	8	in	in	ADP
admet-331	271	9	a	a	DET
admet-331	271	10	diabetic	diabetic	ADJ
admet-331	271	11	animal	animal	NOUN
admet-331	271	12	model	model	NOUN
admet-331	271	13	mitigated	mitigate	VERB
admet-331	271	14	the	the	DET
admet-331	271	15	leukocyte	leukocyte	NOUN
admet-331	271	16	-	-	PUNCT
admet-331	271	17	induced	induce	VERB
admet-331	271	18	microvascular	microvascular	ADJ
admet-331	271	19	damage	damage	NOUN
admet-331	271	20	through	through	ADP
admet-331	271	21	decreasing	decrease	VERB
admet-331	271	22	both	both	PRON
admet-331	271	23	icam-1	icam-1	NUM
admet-331	271	24	(	(	PUNCT
admet-331	271	25	intercellular	intercellular	ADJ
admet-331	271	26	adhesion	adhesion	NOUN
admet-331	271	27	molecule-1	molecule-1	NOUN
admet-331	271	28	)	)	PUNCT
admet-331	271	29	expression	expression	NOUN
admet-331	271	30	on	on	ADP
admet-331	271	31	the	the	DET
admet-331	271	32	endothelium	endothelium	NOUN
admet-331	271	33	and	and	CCONJ
admet-331	271	34	cd	cd	PROPN
admet-331	271	35	18a/	18a/	PROPN
admet-331	271	36	11b	11b	NOUN
admet-331	271	37	presentation	presentation	NOUN
admet-331	271	38	on	on	ADP
admet-331	271	39	the	the	DET
admet-331	271	40	neutrophil	neutrophil	ADJ
admet-331	271	41	granulocytes	granulocyte	NOUN
admet-331	271	42	[	[	X
admet-331	271	43	69,70	69,70	NOUN
admet-331	271	44	]	]	PUNCT
admet-331	271	45	.	.	PUNCT
admet-331	272	1	thus	thus	ADV
admet-331	272	2	rock	rock	NOUN
admet-331	272	3	inhibition	inhibition	NOUN
admet-331	272	4	reverses	reverse	VERB
admet-331	272	5	many	many	ADJ
admet-331	272	6	of	of	ADP
admet-331	272	7	the	the	DET
admet-331	272	8	changes	change	NOUN
admet-331	272	9	seen	see	VERB
admet-331	272	10	in	in	ADP
admet-331	272	11	the	the	DET
admet-331	272	12	retinal	retinal	ADJ
admet-331	272	13	vessels	vessel	NOUN
admet-331	272	14	in	in	ADP
admet-331	272	15	diabetes	diabetes	NOUN
admet-331	272	16	.	.	PUNCT
admet-331	273	1	monickaraj	monickaraj	NOUN
admet-331	273	2	et	et	PROPN
admet-331	273	3	al	al	PROPN
admet-331	273	4	.	.	PUNCT
admet-331	274	1	[	[	X
admet-331	274	2	72	72	NUM
admet-331	274	3	]	]	PUNCT
admet-331	274	4	reported	report	VERB
admet-331	274	5	that	that	SCONJ
admet-331	274	6	patients	patient	NOUN
admet-331	274	7	suffering	suffer	VERB
admet-331	274	8	from	from	ADP
admet-331	274	9	manifest	manifest	ADJ
admet-331	274	10	diabetic	diabetic	ADJ
admet-331	274	11	macular	macular	ADJ
admet-331	274	12	edema	edema	NOUN
admet-331	274	13	,	,	PUNCT
admet-331	274	14	a	a	DET
admet-331	274	15	consequence	consequence	NOUN
admet-331	274	16	of	of	ADP
admet-331	274	17	diabetic	diabetic	ADJ
admet-331	274	18	retinopathy	retinopathy	NOUN
admet-331	274	19	,	,	PUNCT
admet-331	274	20	had	have	VERB
admet-331	274	21	elevated	elevate	VERB
admet-331	274	22	cathepsin	cathepsin	NOUN
admet-331	274	23	d	d	PROPN
admet-331	274	24	levels	level	NOUN
admet-331	274	25	in	in	ADP
admet-331	274	26	their	their	PRON
admet-331	274	27	serum	serum	NOUN
admet-331	274	28	.	.	PUNCT
admet-331	275	1	the	the	DET
admet-331	275	2	protease	protease	NOUN
admet-331	275	3	caused	cause	VERB
admet-331	275	4	mechanical	mechanical	ADJ
admet-331	275	5	disruption	disruption	NOUN
admet-331	275	6	of	of	ADP
admet-331	275	7	the	the	DET
admet-331	275	8	endothelial	endothelial	ADJ
admet-331	275	9	barrier	barrier	NOUN
admet-331	275	10	through	through	ADP
admet-331	275	11	increased	increase	VERB
admet-331	275	12	rhoa	rhoa	PROPN
admet-331	275	13	-	-	PUNCT
admet-331	275	14	rock	rock	NOUN
admet-331	275	15	-	-	PUNCT
admet-331	275	16	dependent	dependent	ADJ
admet-331	275	17	contractility	contractility	NOUN
admet-331	275	18	in	in	ADP
admet-331	275	19	human	human	ADJ
admet-331	275	20	retinal	retinal	ADJ
admet-331	275	21	endothelial	endothelial	ADJ
admet-331	275	22	cells	cell	NOUN
admet-331	275	23	.	.	PUNCT
admet-331	276	1	application	application	NOUN
admet-331	276	2	of	of	ADP
admet-331	276	3	a	a	DET
admet-331	276	4	rock	rock	NOUN
admet-331	276	5	inhibitor	inhibitor	NOUN
admet-331	276	6	(	(	PUNCT
admet-331	276	7	y27632	y27632	PROPN
admet-331	276	8	)	)	PUNCT
admet-331	276	9	diminished	diminish	VERB
admet-331	276	10	the	the	DET
admet-331	276	11	effect	effect	NOUN
admet-331	276	12	of	of	ADP
admet-331	276	13	monocyte	monocyte	NOUN
admet-331	276	14	-	-	PUNCT
admet-331	276	15	derived	derive	VERB
admet-331	276	16	cathepsin	cathepsin	NOUN
admet-331	276	17	d	d	NOUN
admet-331	276	18	on	on	ADP
admet-331	276	19	endothelial	endothelial	ADJ
admet-331	276	20	cell	cell	NOUN
admet-331	276	21	permeability	permeability	NOUN
admet-331	276	22	.	.	PUNCT
admet-331	277	1	rothschild	rothschild	PROPN
admet-331	277	2	et	et	PROPN
admet-331	277	3	al	al	PROPN
admet-331	277	4	.	.	PUNCT
admet-331	278	1	[	[	X
admet-331	278	2	73	73	NUM
admet-331	278	3	]	]	PUNCT
admet-331	278	4	hypothesized	hypothesize	VERB
admet-331	278	5	that	that	SCONJ
admet-331	278	6	rho	rho	ADJ
admet-331	278	7	-	-	PUNCT
admet-331	278	8	pathway	pathway	NOUN
admet-331	278	9	activation	activation	NOUN
admet-331	278	10	is	be	AUX
admet-331	278	11	involved	involve	VERB
admet-331	278	12	in	in	ADP
admet-331	278	13	the	the	DET
admet-331	278	14	pathogenesis	pathogenesis	NOUN
admet-331	278	15	of	of	ADP
admet-331	278	16	diabetic	diabetic	ADJ
admet-331	278	17	macular	macular	ADJ
admet-331	278	18	edema	edema	NOUN
admet-331	278	19	through	through	ADP
admet-331	278	20	breakdown	breakdown	NOUN
admet-331	278	21	of	of	ADP
admet-331	278	22	the	the	DET
admet-331	278	23	retinal	retinal	ADJ
admet-331	278	24	pigment	pigment	NOUN
admet-331	278	25	epithelial	epithelial	NOUN
admet-331	278	26	(	(	PUNCT
admet-331	278	27	rpe	rpe	PROPN
admet-331	278	28	)	)	PUNCT
admet-331	278	29	cell	cell	NOUN
admet-331	278	30	barrier	barrier	NOUN
admet-331	278	31	.	.	PUNCT
admet-331	279	1	in	in	ADP
admet-331	279	2	their	their	PRON
admet-331	279	3	diabetic	diabetic	ADJ
admet-331	279	4	rat	rat	NOUN
admet-331	279	5	model	model	NOUN
admet-331	279	6	,	,	PUNCT
admet-331	279	7	rho	rho	ADJ
admet-331	279	8	pathway	pathway	NOUN
admet-331	279	9	activation	activation	NOUN
admet-331	279	10	caused	cause	VERB
admet-331	279	11	cytoskeletal	cytoskeletal	ADJ
admet-331	279	12	remodeling	remodeling	NOUN
admet-331	279	13	(	(	PUNCT
admet-331	279	14	apical	apical	ADJ
admet-331	279	15	constriction	constriction	NOUN
admet-331	279	16	and	and	CCONJ
admet-331	279	17	stress	stress	NOUN
admet-331	279	18	fiber	fiber	NOUN
admet-331	279	19	formation	formation	NOUN
admet-331	279	20	)	)	PUNCT
admet-331	279	21	in	in	ADP
admet-331	279	22	rpe	rpe	PROPN
admet-331	279	23	cells	cell	NOUN
admet-331	279	24	,	,	PUNCT
admet-331	279	25	leading	lead	VERB
admet-331	279	26	to	to	ADP
admet-331	279	27	intercellular	intercellular	ADJ
admet-331	279	28	junction	junction	NOUN
admet-331	279	29	opening	opening	NOUN
admet-331	279	30	.	.	PUNCT
admet-331	280	1	intravitreally	intravitreally	ADV
admet-331	280	2	applied	apply	VERB
admet-331	280	3	fasudil	fasudil	NOUN
admet-331	280	4	reversed	reverse	VERB
admet-331	280	5	the	the	DET
admet-331	280	6	morphologic	morphologic	ADJ
admet-331	280	7	abnormalities	abnormality	NOUN
admet-331	280	8	and	and	CCONJ
admet-331	280	9	improved	improve	VERB
admet-331	280	10	the	the	DET
admet-331	280	11	barrier	barrier	NOUN
admet-331	280	12	integrity	integrity	NOUN
admet-331	280	13	.	.	PUNCT
admet-331	281	1	in	in	ADP
admet-331	281	2	later	later	ADJ
admet-331	281	3	phases	phase	NOUN
admet-331	281	4	,	,	PUNCT
admet-331	281	5	neovascularization	neovascularization	NOUN
admet-331	281	6	and	and	CCONJ
admet-331	281	7	proliferative	proliferative	ADJ
admet-331	281	8	vitreoretinopathy	vitreoretinopathy	ADJ
admet-331	281	9	(	(	PUNCT
admet-331	281	10	pvr	pvr	NOUN
admet-331	281	11	)	)	PUNCT
admet-331	281	12	are	be	AUX
admet-331	281	13	hallmarks	hallmark	NOUN
admet-331	281	14	of	of	ADP
admet-331	281	15	the	the	DET
admet-331	281	16	progression	progression	NOUN
admet-331	281	17	of	of	ADP
admet-331	281	18	the	the	DET
admet-331	281	19	disease	disease	NOUN
admet-331	281	20	.	.	PUNCT
admet-331	282	1	cicatricial	cicatricial	ADJ
admet-331	282	2	contraction	contraction	NOUN
admet-331	282	3	of	of	ADP
admet-331	282	4	the	the	DET
admet-331	282	5	fibrous	fibrous	ADJ
admet-331	282	6	membrane	membrane	NOUN
admet-331	282	7	can	can	AUX
admet-331	282	8	lead	lead	VERB
admet-331	282	9	to	to	ADP
admet-331	282	10	tractional	tractional	ADJ
admet-331	282	11	retinal	retinal	ADJ
admet-331	282	12	detachment	detachment	NOUN
admet-331	282	13	with	with	ADP
admet-331	282	14	severe	severe	ADJ
admet-331	282	15	vision	vision	NOUN
admet-331	282	16	loss	loss	NOUN
admet-331	282	17	.	.	PUNCT
admet-331	283	1	patients	patient	NOUN
admet-331	283	2	suffering	suffer	VERB
admet-331	283	3	from	from	ADP
admet-331	283	4	proliferative	proliferative	ADJ
admet-331	283	5	retinal	retinal	ADJ
admet-331	283	6	disease	disease	NOUN
admet-331	283	7	have	have	VERB
admet-331	283	8	a	a	DET
admet-331	283	9	significantly	significantly	ADV
admet-331	283	10	higher	high	ADJ
admet-331	283	11	vitreal	vitreal	ADJ
admet-331	283	12	concentration	concentration	NOUN
admet-331	283	13	of	of	ADP
admet-331	283	14	tgf	tgf	PROPN
admet-331	283	15	-	-	PUNCT
admet-331	283	16	β2	β2	PROPN
admet-331	283	17	,	,	PUNCT
admet-331	283	18	than	than	ADP
admet-331	283	19	patients	patient	NOUN
admet-331	283	20	with	with	ADP
admet-331	283	21	non	non	ADJ
admet-331	283	22	-	-	ADJ
admet-331	283	23	proliferative	proliferative	ADJ
admet-331	283	24	diseases	disease	NOUN
admet-331	283	25	[	[	X
admet-331	283	26	74,75	74,75	NOUN
admet-331	283	27	]	]	PUNCT
admet-331	283	28	.	.	PUNCT
admet-331	284	1	activated	activate	VERB
admet-331	284	2	tgfβ2	tgfβ2	NOUN
admet-331	284	3	has	have	AUX
admet-331	284	4	been	be	AUX
admet-331	284	5	implicated	implicate	VERB
admet-331	284	6	in	in	ADP
admet-331	284	7	contraction	contraction	NOUN
admet-331	284	8	of	of	ADP
admet-331	284	9	the	the	DET
admet-331	284	10	fibrous	fibrous	ADJ
admet-331	284	11	membrane	membrane	NOUN
admet-331	284	12	through	through	ADP
admet-331	284	13	mlc	mlc	PROPN
admet-331	284	14	phosphorylation	phosphorylation	NOUN
admet-331	284	15	mediated	mediate	VERB
admet-331	284	16	by	by	ADP
admet-331	284	17	rock	rock	NOUN
admet-331	284	18	.	.	PUNCT
admet-331	285	1	in	in	ADP
admet-331	285	2	an	an	DET
admet-331	285	3	experimental	experimental	ADJ
admet-331	285	4	pvr	pvr	NOUN
admet-331	285	5	rabbit	rabbit	NOUN
admet-331	285	6	model	model	NOUN
admet-331	285	7	,	,	PUNCT
admet-331	285	8	intravitreal	intravitreal	ADJ
admet-331	285	9	injection	injection	NOUN
admet-331	285	10	of	of	ADP
admet-331	285	11	fasudil	fasudil	NOUN
admet-331	285	12	(	(	PUNCT
admet-331	285	13	30	30	NUM
admet-331	285	14	µm	µm	NOUN
admet-331	285	15	)	)	PUNCT
admet-331	285	16	effectively	effectively	ADV
admet-331	285	17	suppressed	suppress	VERB
admet-331	285	18	this	this	DET
admet-331	285	19	destructive	destructive	ADJ
admet-331	285	20	progression	progression	NOUN
admet-331	285	21	,	,	PUNCT
admet-331	285	22	even	even	ADV
admet-331	285	23	after	after	SCONJ
admet-331	285	24	the	the	DET
admet-331	285	25	proliferative	proliferative	ADJ
admet-331	285	26	membranes	membrane	NOUN
admet-331	285	27	formed	form	VERB
admet-331	285	28	or	or	CCONJ
admet-331	285	29	connected	connect	VERB
admet-331	285	30	to	to	ADP
admet-331	285	31	the	the	DET
admet-331	285	32	retina	retina	NOUN
admet-331	285	33	[	[	X
admet-331	285	34	76	76	NUM
admet-331	285	35	]	]	PUNCT
admet-331	285	36	.	.	PUNCT
admet-331	286	1	furthermore	furthermore	ADV
admet-331	286	2	,	,	PUNCT
admet-331	286	3	in	in	ADP
admet-331	286	4	another	another	DET
admet-331	286	5	pvr	pvr	NOUN
admet-331	286	6	rabbit	rabbit	NOUN
admet-331	286	7	model	model	NOUN
admet-331	286	8	,	,	PUNCT
admet-331	286	9	multiple	multiple	ADJ
admet-331	286	10	intravitreal	intravitreal	ADJ
admet-331	286	11	injections	injection	NOUN
admet-331	286	12	of	of	ADP
admet-331	286	13	y27632	y27632	PROPN
admet-331	286	14	(	(	PUNCT
admet-331	286	15	targeted	target	VERB
admet-331	286	16	intraocular	intraocular	ADJ
admet-331	286	17	concentration	concentration	NOUN
admet-331	286	18	was	be	AUX
admet-331	286	19	50	50	NUM
admet-331	286	20	µm	µm	NOUN
admet-331	286	21	)	)	PUNCT
admet-331	286	22	decreased	decrease	VERB
admet-331	286	23	the	the	DET
admet-331	286	24	development	development	NOUN
admet-331	286	25	of	of	ADP
admet-331	286	26	tractional	tractional	ADJ
admet-331	286	27	retinal	retinal	ADJ
admet-331	286	28	detachment	detachment	NOUN
admet-331	286	29	(	(	PUNCT
admet-331	286	30	figure	figure	NOUN
admet-331	286	31	3	3	NUM
admet-331	286	32	)	)	PUNCT
admet-331	287	1	[	[	X
admet-331	287	2	77	77	NUM
admet-331	287	3	]	]	PUNCT
admet-331	287	4	.	.	PUNCT
admet-331	288	1	because	because	SCONJ
admet-331	288	2	vascular	vascular	ADJ
admet-331	288	3	endothelial	endothelial	ADJ
admet-331	288	4	growth	growth	NOUN
admet-331	288	5	factor	factor	NOUN
admet-331	288	6	(	(	PUNCT
admet-331	288	7	vegf	vegf	PROPN
admet-331	288	8	)	)	PUNCT
admet-331	288	9	has	have	AUX
admet-331	288	10	been	be	AUX
admet-331	288	11	shown	show	VERB
admet-331	288	12	to	to	PART
admet-331	288	13	play	play	VERB
admet-331	288	14	a	a	DET
admet-331	288	15	pivotal	pivotal	ADJ
admet-331	288	16	role	role	NOUN
admet-331	288	17	in	in	ADP
admet-331	288	18	macular	macular	ADJ
admet-331	288	19	edema	edema	NOUN
admet-331	288	20	and	and	CCONJ
admet-331	288	21	retinal	retinal	ADJ
admet-331	288	22	neovascularization	neovascularization	NOUN
admet-331	288	23	,	,	PUNCT
admet-331	288	24	anti	anti	ADJ
admet-331	288	25	-	-	ADJ
admet-331	288	26	vegf	vegf	ADJ
admet-331	288	27	therapy	therapy	NOUN
admet-331	288	28	has	have	AUX
admet-331	288	29	been	be	AUX
admet-331	288	30	widely	widely	ADV
admet-331	288	31	used	use	VERB
admet-331	288	32	for	for	ADP
admet-331	288	33	the	the	DET
admet-331	288	34	treatment	treatment	NOUN
admet-331	288	35	of	of	ADP
admet-331	288	36	agerelated	agerelate	VERB
admet-331	288	37	macular	macular	ADJ
admet-331	288	38	degeneration	degeneration	NOUN
admet-331	288	39	and	and	CCONJ
admet-331	288	40	diabetic	diabetic	ADJ
admet-331	288	41	retinopathy	retinopathy	NOUN
admet-331	288	42	in	in	ADP
admet-331	288	43	clinical	clinical	ADJ
admet-331	288	44	studies	study	NOUN
admet-331	288	45	.	.	PUNCT
admet-331	289	1	however	however	ADV
admet-331	289	2	,	,	PUNCT
admet-331	289	3	in	in	ADP
admet-331	289	4	many	many	ADJ
admet-331	289	5	cases	case	NOUN
admet-331	289	6	,	,	PUNCT
admet-331	289	7	satisfying	satisfy	VERB
admet-331	289	8	visual	visual	ADJ
admet-331	289	9	or	or	CCONJ
admet-331	289	10	anatomical	anatomical	ADJ
admet-331	289	11	improvements	improvement	NOUN
admet-331	289	12	are	be	AUX
admet-331	289	13	not	not	PART
admet-331	289	14	achieved	achieve	VERB
admet-331	289	15	.	.	PUNCT
admet-331	290	1	moreover	moreover	ADV
admet-331	290	2	,	,	PUNCT
admet-331	290	3	the	the	DET
admet-331	290	4	treatment	treatment	NOUN
admet-331	290	5	has	have	VERB
admet-331	290	6	many	many	ADJ
admet-331	290	7	possible	possible	ADJ
admet-331	290	8	adverse	adverse	ADJ
admet-331	290	9	local	local	ADJ
admet-331	290	10	and	and	CCONJ
admet-331	290	11	systemic	systemic	ADJ
admet-331	290	12	effects	effect	NOUN
admet-331	290	13	,	,	PUNCT
admet-331	290	14	such	such	ADJ
admet-331	290	15	as	as	ADP
admet-331	290	16	iop	iop	PROPN
admet-331	290	17	elevation	elevation	NOUN
admet-331	290	18	,	,	PUNCT
admet-331	290	19	inflammation	inflammation	NOUN
admet-331	290	20	,	,	PUNCT
admet-331	290	21	hypertension	hypertension	NOUN
admet-331	290	22	,	,	PUNCT
admet-331	290	23	myocardial	myocardial	ADJ
admet-331	290	24	infarcts	infarct	NOUN
admet-331	290	25	or	or	CCONJ
admet-331	290	26	cerebrovascular	cerebrovascular	ADJ
admet-331	290	27	accidents	accident	NOUN
admet-331	290	28	.	.	PUNCT
admet-331	291	1	in	in	ADP
admet-331	291	2	2008	2008	NUM
admet-331	291	3	was	be	AUX
admet-331	291	4	the	the	DET
admet-331	291	5	first	first	ADJ
admet-331	291	6	report	report	NOUN
admet-331	291	7	,	,	PUNCT
admet-331	291	8	from	from	ADP
admet-331	291	9	in	in	ADP
admet-331	291	10	vivo	vivo	NOUN
admet-331	291	11	mouse	mouse	NOUN
admet-331	291	12	cornea	cornea	NOUN
admet-331	291	13	,	,	PUNCT
admet-331	291	14	that	that	DET
admet-331	291	15	fasudil	fasudil	NOUN
admet-331	291	16	had	have	VERB
admet-331	291	17	inhibitory	inhibitory	ADJ
admet-331	291	18	potential	potential	NOUN
admet-331	291	19	in	in	ADP
admet-331	291	20	ocular	ocular	ADJ
admet-331	291	21	angiogenesis	angiogenesis	NOUN
admet-331	291	22	[	[	X
admet-331	291	23	38	38	NUM
admet-331	291	24	]	]	PUNCT
admet-331	291	25	.	.	PUNCT
admet-331	292	1	additional	additional	ADJ
admet-331	292	2	evidence	evidence	NOUN
admet-331	292	3	from	from	ADP
admet-331	292	4	human	human	ADJ
admet-331	292	5	foreskin	foreskin	NOUN
admet-331	293	1	[	[	X
admet-331	293	2	78	78	NUM
admet-331	293	3	]	]	PUNCT
admet-331	293	4	and	and	CCONJ
admet-331	293	5	retinal	retinal	ADJ
admet-331	293	6	microvascular	microvascular	NOUN
admet-331	293	7	endothelial	endothelial	ADJ
admet-331	293	8	cell	cell	NOUN
admet-331	293	9	cultures	culture	NOUN
admet-331	293	10	[	[	X
admet-331	293	11	10	10	NUM
admet-331	293	12	]	]	PUNCT
admet-331	293	13	has	have	AUX
admet-331	293	14	demonstrated	demonstrate	VERB
admet-331	293	15	that	that	SCONJ
admet-331	293	16	rhoa	rhoa	PROPN
admet-331	293	17	or	or	CCONJ
admet-331	293	18	rho	rho	ADJ
admet-331	293	19	kinases	kinase	NOUN
admet-331	293	20	are	be	AUX
admet-331	293	21	involved	involve	VERB
admet-331	293	22	in	in	ADP
admet-331	293	23	vegf	vegf	NOUN
admet-331	293	24	-	-	PUNCT
admet-331	293	25	induced	induce	VERB
admet-331	293	26	cytoskeletal	cytoskeletal	ADJ
admet-331	293	27	changes	change	NOUN
admet-331	293	28	and	and	CCONJ
admet-331	293	29	cell	cell	NOUN
admet-331	293	30	migration	migration	NOUN
admet-331	293	31	.	.	PUNCT
admet-331	294	1	increased	increase	VERB
admet-331	294	2	rhoa	rhoa	NOUN
admet-331	294	3	activity	activity	NOUN
admet-331	294	4	was	be	AUX
admet-331	294	5	accompanied	accompany	VERB
admet-331	294	6	by	by	ADP
admet-331	294	7	elevated	elevated	ADJ
admet-331	294	8	phosphorylation	phosphorylation	NOUN
admet-331	294	9	and	and	CCONJ
admet-331	294	10	activity	activity	NOUN
admet-331	294	11	of	of	ADP
admet-331	294	12	the	the	DET
admet-331	294	13	vegf	vegf	NOUN
admet-331	294	14	receptor-2	receptor-2	PROPN
admet-331	294	15	,	,	PUNCT
admet-331	294	16	which	which	PRON
admet-331	294	17	might	might	AUX
admet-331	294	18	be	be	AUX
admet-331	294	19	the	the	DET
admet-331	294	20	connection	connection	NOUN
admet-331	294	21	between	between	ADP
admet-331	294	22	rhoa	rhoa	PROPN
admet-331	294	23	pathways	pathway	NOUN
admet-331	294	24	and	and	CCONJ
admet-331	294	25	vegf	vegf	NOUN
admet-331	294	26	effects	effect	NOUN
admet-331	294	27	[	[	X
admet-331	294	28	78	78	NUM
admet-331	294	29	]	]	PUNCT
admet-331	294	30	.	.	PUNCT
admet-331	295	1	in	in	ADP
admet-331	295	2	2014	2014	NUM
admet-331	295	3	,	,	PUNCT
admet-331	295	4	in	in	ADP
admet-331	295	5	an	an	DET
admet-331	295	6	experimental	experimental	ADJ
admet-331	295	7	diabetes	diabetes	NOUN
admet-331	295	8	rabbit	rabbit	NOUN
admet-331	295	9	model	model	NOUN
admet-331	295	10	,	,	PUNCT
admet-331	295	11	the	the	DET
admet-331	295	12	effect	effect	NOUN
admet-331	295	13	of	of	ADP
admet-331	295	14	a	a	DET
admet-331	295	15	éva	éva	ADJ
admet-331	295	16	halász	halász	NOUN
admet-331	295	17	,	,	PUNCT
admet-331	295	18	ellen	ellen	PROPN
admet-331	295	19	townes	townes	PROPN
admet-331	295	20	-	-	PUNCT
admet-331	295	21	anderson	anderson	PROPN
admet-331	295	22	admet	admet	PROPN
admet-331	295	23	&	&	CCONJ
admet-331	295	24	dmpk	dmpk	PROPN
admet-331	295	25	4(4	4(4	NUM
admet-331	295	26	)	)	PUNCT
admet-331	295	27	(	(	PUNCT
admet-331	295	28	2016	2016	NUM
admet-331	295	29	)	)	PUNCT
admet-331	295	30	280	280	NUM
admet-331	295	31	-	-	SYM
admet-331	295	32	301	301	NUM
admet-331	295	33	292	292	NUM
admet-331	295	34	single	single	ADJ
admet-331	295	35	intravitreal	intravitreal	ADJ
admet-331	295	36	injection	injection	NOUN
admet-331	295	37	of	of	ADP
admet-331	295	38	fasudil	fasudil	NOUN
admet-331	295	39	or	or	CCONJ
admet-331	295	40	bevacizumab	bevacizumab	NOUN
admet-331	295	41	on	on	ADP
admet-331	295	42	vegf	vegf	PROPN
admet-331	295	43	levels	level	NOUN
admet-331	295	44	was	be	AUX
admet-331	295	45	evaluated	evaluate	VERB
admet-331	295	46	.	.	PUNCT
admet-331	296	1	according	accord	VERB
admet-331	296	2	to	to	PART
admet-331	296	3	celik	celik	VERB
admet-331	296	4	et	et	PROPN
admet-331	296	5	al	al	PROPN
admet-331	296	6	.	.	PUNCT
admet-331	297	1	[	[	X
admet-331	297	2	79	79	NUM
admet-331	297	3	]	]	PUNCT
admet-331	297	4	,	,	PUNCT
admet-331	297	5	fasudil	fasudil	NOUN
admet-331	297	6	reduced	reduce	VERB
admet-331	297	7	the	the	DET
admet-331	297	8	vegf	vegf	PROPN
admet-331	297	9	levels	level	NOUN
admet-331	297	10	,	,	PUNCT
admet-331	297	11	however	however	ADV
admet-331	297	12	not	not	PART
admet-331	297	13	as	as	ADV
admet-331	297	14	efficiently	efficiently	ADV
admet-331	297	15	as	as	ADP
admet-331	297	16	bevacizumab	bevacizumab	NOUN
admet-331	297	17	.	.	PUNCT
admet-331	298	1	there	there	PRON
admet-331	298	2	are	be	VERB
admet-331	298	3	pilot	pilot	NOUN
admet-331	298	4	clinical	clinical	ADJ
admet-331	298	5	studies	study	NOUN
admet-331	298	6	which	which	PRON
admet-331	298	7	have	have	AUX
admet-331	298	8	evaluated	evaluate	VERB
admet-331	298	9	the	the	DET
admet-331	298	10	feasibility	feasibility	NOUN
admet-331	298	11	of	of	ADP
admet-331	298	12	fasudil	fasudil	NOUN
admet-331	298	13	combined	combine	VERB
admet-331	298	14	with	with	ADP
admet-331	298	15	bevacizumab	bevacizumab	NOUN
admet-331	298	16	as	as	ADP
admet-331	298	17	an	an	DET
admet-331	298	18	intravitreal	intravitreal	ADJ
admet-331	298	19	injection	injection	NOUN
admet-331	298	20	in	in	ADP
admet-331	298	21	diabetic	diabetic	ADJ
admet-331	298	22	macular	macular	ADJ
admet-331	298	23	edema	edema	NOUN
admet-331	298	24	.	.	PUNCT
admet-331	299	1	during	during	ADP
admet-331	299	2	one	one	NUM
admet-331	299	3	short	short	ADJ
admet-331	299	4	-	-	PUNCT
admet-331	299	5	term	term	NOUN
admet-331	299	6	study	study	NOUN
admet-331	299	7	,	,	PUNCT
admet-331	299	8	15	15	NUM
admet-331	299	9	patients	patient	NOUN
admet-331	299	10	suffering	suffer	VERB
admet-331	299	11	from	from	ADP
admet-331	299	12	diabetic	diabetic	ADJ
admet-331	299	13	macular	macular	ADJ
admet-331	299	14	edema	edema	NOUN
admet-331	299	15	received	receive	VERB
admet-331	299	16	an	an	DET
admet-331	299	17	intravitreal	intravitreal	ADJ
admet-331	299	18	injection	injection	NOUN
admet-331	299	19	of	of	ADP
admet-331	299	20	0.025	0.025	NUM
admet-331	299	21	mg	mg	PROPN
admet-331	299	22	fasudil	fasudil	NOUN
admet-331	299	23	combined	combine	VERB
admet-331	299	24	with	with	ADP
admet-331	299	25	1.25	1.25	NUM
admet-331	299	26	mg	mg	PROPN
admet-331	299	27	bevacizumab	bevacizumab	NOUN
admet-331	299	28	;	;	PUNCT
admet-331	299	29	the	the	DET
admet-331	299	30	targeted	target	VERB
admet-331	299	31	intraocular	intraocular	ADJ
admet-331	299	32	concentration	concentration	NOUN
admet-331	299	33	of	of	ADP
admet-331	299	34	the	the	DET
admet-331	299	35	drug	drug	NOUN
admet-331	299	36	was	be	AUX
admet-331	299	37	10	10	NUM
admet-331	299	38	µm	µm	NUM
admet-331	299	39	/	/	SYM
admet-331	299	40	l.	l.	NOUN
admet-331	299	41	one	one	NUM
admet-331	299	42	month	month	NOUN
admet-331	299	43	later	later	ADV
admet-331	299	44	visual	visual	ADJ
admet-331	299	45	acuity	acuity	NOUN
admet-331	299	46	and	and	CCONJ
admet-331	299	47	central	central	ADJ
admet-331	299	48	macular	macular	ADJ
admet-331	299	49	thickness	thickness	NOUN
admet-331	299	50	were	be	AUX
admet-331	299	51	measured	measure	VERB
admet-331	299	52	.	.	PUNCT
admet-331	300	1	the	the	DET
admet-331	300	2	best	well	ADV
admet-331	300	3	corrected	correct	VERB
admet-331	300	4	visual	visual	ADJ
admet-331	300	5	acuity	acuity	NOUN
admet-331	300	6	improved	improve	VERB
admet-331	300	7	on	on	ADP
admet-331	300	8	average	average	ADJ
admet-331	300	9	by	by	ADP
admet-331	300	10	40	40	NUM
admet-331	300	11	%	%	NOUN
admet-331	300	12	,	,	PUNCT
admet-331	300	13	and	and	CCONJ
admet-331	300	14	the	the	DET
admet-331	300	15	central	central	ADJ
admet-331	300	16	macular	macular	ADJ
admet-331	300	17	thickness	thickness	NOUN
admet-331	300	18	decreased	decrease	VERB
admet-331	300	19	by	by	ADP
admet-331	300	20	approximately	approximately	ADV
admet-331	300	21	20	20	NUM
admet-331	300	22	%	%	NOUN
admet-331	300	23	,	,	PUNCT
admet-331	300	24	without	without	ADP
admet-331	300	25	any	any	DET
admet-331	300	26	adverse	adverse	ADJ
admet-331	300	27	complications	complication	NOUN
admet-331	300	28	[	[	X
admet-331	300	29	80	80	NUM
admet-331	300	30	]	]	PUNCT
admet-331	300	31	.	.	PUNCT
admet-331	301	1	these	these	DET
admet-331	301	2	results	result	NOUN
admet-331	301	3	confirmed	confirm	VERB
admet-331	301	4	findings	finding	NOUN
admet-331	301	5	shown	show	VERB
admet-331	301	6	in	in	ADP
admet-331	301	7	a	a	DET
admet-331	301	8	previous	previous	ADJ
admet-331	301	9	smaller	small	ADJ
admet-331	301	10	trial	trial	NOUN
admet-331	301	11	[	[	X
admet-331	301	12	81	81	NUM
admet-331	301	13	]	]	PUNCT
admet-331	301	14	.	.	PUNCT
admet-331	302	1	moreover	moreover	ADV
admet-331	302	2	,	,	PUNCT
admet-331	302	3	0.4	0.4	NUM
admet-331	302	4	%	%	NOUN
admet-331	302	5	and	and	CCONJ
admet-331	302	6	0.8	0.8	NUM
admet-331	302	7	%	%	NOUN
admet-331	302	8	ripasudil	ripasudil	NOUN
admet-331	302	9	eye	eye	NOUN
admet-331	302	10	drops	drop	NOUN
admet-331	302	11	applied	apply	VERB
admet-331	302	12	topically	topically	ADV
admet-331	302	13	3	3	NUM
admet-331	302	14	times	time	NOUN
admet-331	302	15	daily	daily	ADV
admet-331	302	16	for	for	ADP
admet-331	302	17	5	5	NUM
admet-331	302	18	days	day	NOUN
admet-331	302	19	decreased	decrease	VERB
admet-331	302	20	not	not	PART
admet-331	302	21	just	just	ADV
admet-331	302	22	the	the	DET
admet-331	302	23	neovascular	neovascular	PROPN
admet-331	302	24	area	area	NOUN
admet-331	302	25	,	,	PUNCT
admet-331	302	26	but	but	CCONJ
admet-331	302	27	the	the	DET
admet-331	302	28	avascular	avascular	ADJ
admet-331	302	29	area	area	NOUN
admet-331	302	30	also	also	ADV
admet-331	302	31	,	,	PUNCT
admet-331	302	32	in	in	ADP
admet-331	302	33	a	a	DET
admet-331	302	34	hypoxia	hypoxia	NOUN
admet-331	302	35	-	-	PUNCT
admet-331	302	36	induced	induce	VERB
admet-331	302	37	diabetic	diabetic	ADJ
admet-331	302	38	retinopathy	retinopathy	ADJ
admet-331	302	39	mice	mouse	NOUN
admet-331	302	40	model	model	NOUN
admet-331	302	41	.	.	PUNCT
admet-331	303	1	in	in	ADP
admet-331	303	2	contrast	contrast	NOUN
admet-331	303	3	,	,	PUNCT
admet-331	303	4	0.4	0.4	NUM
admet-331	303	5	%	%	NOUN
admet-331	303	6	fasudil	fasudil	NOUN
admet-331	303	7	eye	eye	NOUN
admet-331	303	8	drops	drop	NOUN
admet-331	303	9	did	do	AUX
admet-331	303	10	not	not	PART
admet-331	303	11	show	show	VERB
admet-331	303	12	any	any	DET
admet-331	303	13	effect	effect	NOUN
admet-331	303	14	.	.	PUNCT
admet-331	304	1	additional	additional	ADJ
admet-331	304	2	experiments	experiment	NOUN
admet-331	304	3	which	which	PRON
admet-331	304	4	tested	test	VERB
admet-331	304	5	normal	normal	ADJ
admet-331	304	6	vascularization	vascularization	NOUN
admet-331	304	7	found	find	VERB
admet-331	304	8	that	that	SCONJ
admet-331	304	9	rock	rock	NOUN
admet-331	304	10	inhibitors	inhibitor	NOUN
admet-331	304	11	did	do	AUX
admet-331	304	12	not	not	PART
admet-331	304	13	affect	affect	VERB
admet-331	304	14	physiological	physiological	ADJ
admet-331	304	15	angiogenesis	angiogenesis	NOUN
admet-331	304	16	,	,	PUNCT
admet-331	304	17	although	although	SCONJ
admet-331	304	18	they	they	PRON
admet-331	304	19	did	do	AUX
admet-331	304	20	modify	modify	VERB
admet-331	304	21	pathological	pathological	ADJ
admet-331	304	22	vascular	vascular	ADJ
admet-331	304	23	growth	growth	NOUN
admet-331	304	24	in	in	ADP
admet-331	304	25	a	a	DET
admet-331	304	26	retinopathy	retinopathy	ADJ
admet-331	304	27	model	model	NOUN
admet-331	304	28	[	[	X
admet-331	304	29	10	10	NUM
admet-331	304	30	]	]	PUNCT
admet-331	304	31	.	.	PUNCT
admet-331	305	1	figure	figure	NOUN
admet-331	305	2	3	3	NUM
admet-331	305	3	.	.	PUNCT
admet-331	305	4	proposed	propose	VERB
admet-331	305	5	rho	rho	ADJ
admet-331	305	6	-	-	ADJ
admet-331	305	7	rock	rock	NOUN
admet-331	305	8	pathway	pathway	NOUN
admet-331	305	9	in	in	ADP
admet-331	305	10	the	the	DET
admet-331	305	11	pathogenesis	pathogenesis	NOUN
admet-331	305	12	of	of	ADP
admet-331	305	13	diabetic	diabetic	ADJ
admet-331	305	14	retinopathy	retinopathy	ADJ
admet-331	305	15	age	age	NOUN
admet-331	305	16	-	-	PUNCT
admet-331	305	17	related	relate	VERB
admet-331	305	18	macular	macular	ADJ
admet-331	305	19	degeneration	degeneration	NOUN
admet-331	305	20	(	(	PUNCT
admet-331	305	21	amd	amd	NOUN
admet-331	305	22	)	)	PUNCT
admet-331	305	23	age	age	NOUN
admet-331	305	24	-	-	PUNCT
admet-331	305	25	related	relate	VERB
admet-331	305	26	macular	macular	ADJ
admet-331	305	27	degeneration	degeneration	NOUN
admet-331	305	28	(	(	PUNCT
admet-331	305	29	amd	amd	PROPN
admet-331	305	30	)	)	PUNCT
admet-331	305	31	is	be	AUX
admet-331	305	32	a	a	DET
admet-331	305	33	degenerative	degenerative	ADJ
admet-331	305	34	disorder	disorder	NOUN
admet-331	305	35	and	and	CCONJ
admet-331	305	36	one	one	NUM
admet-331	305	37	of	of	ADP
admet-331	305	38	the	the	DET
admet-331	305	39	most	most	ADV
admet-331	305	40	frequent	frequent	ADJ
admet-331	305	41	causes	cause	NOUN
admet-331	305	42	of	of	ADP
admet-331	305	43	irreversible	irreversible	ADJ
admet-331	305	44	visual	visual	ADJ
admet-331	305	45	loss	loss	NOUN
admet-331	305	46	in	in	ADP
admet-331	305	47	industrialized	industrialized	ADJ
admet-331	305	48	countries	country	NOUN
admet-331	305	49	.	.	PUNCT
admet-331	306	1	the	the	DET
admet-331	306	2	etiology	etiology	NOUN
admet-331	306	3	of	of	ADP
admet-331	306	4	the	the	DET
admet-331	306	5	disease	disease	NOUN
admet-331	306	6	has	have	AUX
admet-331	306	7	been	be	AUX
admet-331	306	8	extensively	extensively	ADV
admet-331	306	9	investigated	investigate	VERB
admet-331	306	10	over	over	ADP
admet-331	306	11	the	the	DET
admet-331	306	12	last	last	ADJ
admet-331	306	13	decades	decade	NOUN
admet-331	306	14	,	,	PUNCT
admet-331	306	15	however	however	ADV
admet-331	306	16	we	we	PRON
admet-331	306	17	are	be	AUX
admet-331	306	18	still	still	ADV
admet-331	306	19	far	far	ADV
admet-331	306	20	from	from	ADP
admet-331	306	21	a	a	DET
admet-331	306	22	complete	complete	ADJ
admet-331	306	23	understanding	understanding	NOUN
admet-331	306	24	.	.	PUNCT
admet-331	307	1	the	the	DET
admet-331	307	2	conventional	conventional	ADJ
admet-331	307	3	classification	classification	NOUN
admet-331	307	4	distinguishes	distinguish	VERB
admet-331	307	5	two	two	NUM
admet-331	307	6	different	different	ADJ
admet-331	307	7	subtypes	subtype	NOUN
admet-331	307	8	:	:	PUNCT
admet-331	307	9	dry	dry	ADJ
admet-331	307	10	amd	amd	NOUN
admet-331	307	11	with	with	ADP
admet-331	307	12	atrophic	atrophic	ADJ
admet-331	307	13	lesions	lesion	NOUN
admet-331	307	14	and	and	CCONJ
admet-331	307	15	an	an	DET
admet-331	307	16	exudative	exudative	ADJ
admet-331	307	17	,	,	PUNCT
admet-331	307	18	wet	wet	ADJ
admet-331	307	19	form	form	NOUN
admet-331	307	20	with	with	ADP
admet-331	307	21	neovascularization	neovascularization	NOUN
admet-331	307	22	.	.	PUNCT
admet-331	308	1	the	the	DET
admet-331	308	2	crucial	crucial	ADJ
admet-331	308	3	difference	difference	NOUN
admet-331	308	4	between	between	ADP
admet-331	308	5	the	the	DET
admet-331	308	6	two	two	NUM
admet-331	308	7	subtypes	subtype	NOUN
admet-331	308	8	is	be	AUX
admet-331	308	9	the	the	DET
admet-331	308	10	development	development	NOUN
admet-331	308	11	of	of	ADP
admet-331	308	12	choroidal	choroidal	ADJ
admet-331	308	13	neovascularization	neovascularization	NOUN
admet-331	308	14	(	(	PUNCT
admet-331	308	15	cnv	cnv	PROPN
admet-331	308	16	)	)	PUNCT
admet-331	308	17	,	,	PUNCT
admet-331	308	18	the	the	DET
admet-331	308	19	formation	formation	NOUN
admet-331	308	20	of	of	ADP
admet-331	308	21	new	new	ADJ
admet-331	308	22	vessels	vessel	NOUN
admet-331	308	23	characterized	characterize	VERB
admet-331	308	24	by	by	ADP
admet-331	308	25	inflammation	inflammation	NOUN
admet-331	308	26	and	and	CCONJ
admet-331	308	27	fibrosis	fibrosis	NOUN
admet-331	308	28	,	,	PUNCT
admet-331	308	29	in	in	ADP
admet-331	308	30	wet	wet	ADJ
admet-331	308	31	amd	amd	NOUN
admet-331	308	32	.	.	PUNCT
admet-331	309	1	zandi	zandi	PROPN
admet-331	309	2	et	et	PROPN
admet-331	309	3	al	al	PROPN
admet-331	309	4	.	.	PUNCT
admet-331	310	1	[	[	X
admet-331	310	2	82	82	NUM
admet-331	310	3	]	]	PUNCT
admet-331	310	4	suggest	suggest	VERB
admet-331	310	5	that	that	SCONJ
admet-331	310	6	rocks	rock	NOUN
admet-331	310	7	may	may	AUX
admet-331	310	8	contribute	contribute	VERB
admet-331	310	9	to	to	ADP
admet-331	310	10	the	the	DET
admet-331	310	11	amd	amd	ADJ
admet-331	310	12	pathomechanism	pathomechanism	NOUN
admet-331	310	13	through	through	ADP
admet-331	310	14	macrophage	macrophage	ADJ
admet-331	310	15	differentiation	differentiation	NOUN
admet-331	310	16	in	in	ADP
admet-331	310	17	the	the	DET
admet-331	310	18	aging	age	VERB
admet-331	310	19	eye	eye	NOUN
admet-331	310	20	.	.	PUNCT
admet-331	311	1	their	their	PRON
admet-331	311	2	theory	theory	NOUN
admet-331	311	3	is	be	AUX
admet-331	311	4	supported	support	VERB
admet-331	311	5	by	by	ADP
admet-331	311	6	the	the	DET
admet-331	311	7	following	follow	VERB
admet-331	311	8	results	result	NOUN
admet-331	311	9	.	.	PUNCT
admet-331	312	1	intravitreally	intravitreally	ADV
admet-331	312	2	injected	inject	VERB
admet-331	312	3	undifferentiated	undifferentiated	ADJ
admet-331	312	4	m0	m0	NOUN
admet-331	312	5	macrophages	macrophage	NOUN
admet-331	312	6	did	do	AUX
admet-331	312	7	not	not	PART
admet-331	312	8	affect	affect	VERB
admet-331	312	9	the	the	DET
admet-331	312	10	area	area	NOUN
admet-331	312	11	of	of	ADP
admet-331	312	12	neovascularization	neovascularization	NOUN
admet-331	312	13	(	(	PUNCT
admet-331	312	14	cnv	cnv	NOUN
admet-331	312	15	)	)	PUNCT
admet-331	312	16	in	in	ADP
admet-331	312	17	mice	mice	NOUN
admet-331	312	18	eyes	eye	NOUN
admet-331	312	19	,	,	PUNCT
admet-331	312	20	however	however	ADV
admet-331	312	21	m1	m1	PROPN
admet-331	312	22	macrophages	macrophage	NOUN
admet-331	312	23	decreased	decrease	VERB
admet-331	312	24	the	the	DET
admet-331	312	25	area	area	NOUN
admet-331	312	26	of	of	ADP
admet-331	312	27	the	the	DET
admet-331	312	28	cnv	cnv	NOUN
admet-331	312	29	whereas	whereas	SCONJ
admet-331	312	30	m2	m2	PROPN
admet-331	312	31	macrophages	macrophage	NOUN
admet-331	312	32	increased	increase	VERB
admet-331	312	33	the	the	DET
admet-331	312	34	size	size	NOUN
admet-331	312	35	of	of	ADP
admet-331	312	36	the	the	DET
admet-331	312	37	lesion	lesion	NOUN
admet-331	312	38	.	.	PUNCT
admet-331	313	1	in	in	ADP
admet-331	313	2	these	these	DET
admet-331	313	3	animals	animal	NOUN
admet-331	313	4	repeated	repeat	VERB
admet-331	313	5	intravitreal	intravitreal	ADJ
admet-331	313	6	injections	injection	NOUN
admet-331	313	7	of	of	ADP
admet-331	313	8	fasudil	fasudil	NOUN
admet-331	313	9	(	(	PUNCT
admet-331	313	10	rock	rock	NOUN
admet-331	313	11	i	i	PROPN
admet-331	313	12	and	and	CCONJ
admet-331	313	13	rock	rock	PROPN
admet-331	313	14	ii	ii	PROPN
admet-331	313	15	inhibitor	inhibitor	NOUN
admet-331	313	16	)	)	PUNCT
admet-331	313	17	or	or	CCONJ
admet-331	313	18	kd025	kd025	ADJ
admet-331	313	19	(	(	PUNCT
admet-331	313	20	specific	specific	ADJ
admet-331	313	21	rock	rock	NOUN
admet-331	313	22	ii	ii	PROPN
admet-331	313	23	inhibitor	inhibitor	NOUN
admet-331	313	24	)	)	PUNCT
admet-331	313	25	decreased	decrease	VERB
admet-331	313	26	the	the	DET
admet-331	313	27	area	area	NOUN
admet-331	313	28	of	of	ADP
admet-331	313	29	the	the	DET
admet-331	313	30	cnv	cnv	NOUN
admet-331	313	31	,	,	PUNCT
admet-331	313	32	however	however	ADV
admet-331	313	33	only	only	ADV
admet-331	313	34	the	the	DET
admet-331	313	35	selective	selective	ADJ
admet-331	313	36	rock	rock	PROPN
admet-331	313	37	ii	ii	PROPN
admet-331	313	38	inhibitor	inhibitor	NOUN
admet-331	313	39	increased	increase	VERB
admet-331	313	40	markers	marker	NOUN
admet-331	313	41	of	of	ADP
admet-331	313	42	m1	m1	NOUN
admet-331	313	43	-	-	PUNCT
admet-331	313	44	type	type	NOUN
admet-331	313	45	macrophages	macrophage	NOUN
admet-331	313	46	.	.	PUNCT
admet-331	314	1	taken	take	VERB
admet-331	314	2	together	together	ADV
admet-331	314	3	the	the	DET
admet-331	314	4	authors	author	NOUN
admet-331	314	5	assume	assume	VERB
admet-331	314	6	that	that	SCONJ
admet-331	314	7	with	with	ADP
admet-331	314	8	aging	age	VERB
admet-331	314	9	the	the	DET
admet-331	314	10	fundus	fundus	NOUN
admet-331	314	11	cytokine	cytokine	NOUN
admet-331	314	12	environment	environment	NOUN
admet-331	314	13	changes	change	NOUN
admet-331	314	14	stimulated	stimulate	VERB
admet-331	314	15	by	by	ADP
admet-331	314	16	increased	increase	VERB
admet-331	314	17	rock	rock	NOUN
admet-331	314	18	ii	ii	PROPN
admet-331	314	19	signaling	signaling	NOUN
admet-331	314	20	,	,	PUNCT
admet-331	314	21	which	which	PRON
admet-331	314	22	may	may	AUX
admet-331	314	23	shift	shift	VERB
admet-331	314	24	the	the	DET
admet-331	314	25	admet	admet	PROPN
admet-331	314	26	&	&	CCONJ
admet-331	314	27	dmpk	dmpk	PROPN
admet-331	314	28	4(4	4(4	NUM
admet-331	314	29	)	)	PUNCT
admet-331	314	30	(	(	PUNCT
admet-331	314	31	2016	2016	NUM
admet-331	314	32	)	)	PUNCT
admet-331	314	33	280	280	NUM
admet-331	314	34	-	-	SYM
admet-331	314	35	301	301	NUM
admet-331	314	36	rock	rock	NOUN
admet-331	314	37	inhibitors	inhibitor	NOUN
admet-331	314	38	in	in	ADP
admet-331	314	39	ocular	ocular	ADJ
admet-331	314	40	disease	disease	NOUN
admet-331	314	41	doi	doi	NOUN
admet-331	314	42	:	:	PUNCT
admet-331	314	43	10.5599	10.5599	NUM
admet-331	314	44	/	/	SYM
admet-331	314	45	admet.4.4.331	admet.4.4.331	PROPN
admet-331	314	46	293	293	NUM
admet-331	314	47	macrophage	macrophage	ADJ
admet-331	314	48	transformation	transformation	NOUN
admet-331	314	49	towards	towards	ADP
admet-331	314	50	the	the	DET
admet-331	314	51	m2	m2	PROPN
admet-331	314	52	subtype	subtype	NOUN
admet-331	314	53	,	,	PUNCT
admet-331	314	54	also	also	ADV
admet-331	314	55	called	call	VERB
admet-331	314	56	proangiogenic	proangiogenic	ADJ
admet-331	314	57	madams	madam	NOUN
admet-331	314	58	(	(	PUNCT
admet-331	314	59	macular	macular	ADJ
admet-331	314	60	degeneration	degeneration	NOUN
admet-331	314	61	associated	associate	VERB
admet-331	314	62	macrophages	macrophage	NOUN
admet-331	314	63	)	)	PUNCT
admet-331	314	64	.	.	PUNCT
admet-331	315	1	selective	selective	ADJ
admet-331	315	2	rock	rock	PROPN
admet-331	315	3	ii	ii	PROPN
admet-331	315	4	inhibitors	inhibitor	NOUN
admet-331	315	5	may	may	AUX
admet-331	315	6	help	help	VERB
admet-331	315	7	to	to	PART
admet-331	315	8	restore	restore	VERB
admet-331	315	9	the	the	DET
admet-331	315	10	macrophage	macrophage	ADJ
admet-331	315	11	balance	balance	NOUN
admet-331	315	12	to	to	ADP
admet-331	315	13	that	that	PRON
admet-331	315	14	found	find	VERB
admet-331	315	15	in	in	ADP
admet-331	315	16	healthy	healthy	ADJ
admet-331	315	17	,	,	PUNCT
admet-331	315	18	young	young	ADJ
admet-331	315	19	eyes	eye	NOUN
admet-331	315	20	and	and	CCONJ
admet-331	315	21	reduce	reduce	VERB
admet-331	315	22	cnv	cnv	PROPN
admet-331	315	23	.	.	PUNCT
admet-331	316	1	on	on	ADP
admet-331	316	2	the	the	DET
admet-331	316	3	other	other	ADJ
admet-331	316	4	hand	hand	NOUN
admet-331	316	5	,	,	PUNCT
admet-331	316	6	in	in	ADP
admet-331	316	7	monkeys	monkey	NOUN
admet-331	316	8	,	,	PUNCT
admet-331	316	9	intravitreal	intravitreal	ADJ
admet-331	316	10	injection	injection	NOUN
admet-331	316	11	of	of	ADP
admet-331	316	12	fasudil	fasudil	NOUN
admet-331	316	13	(	(	PUNCT
admet-331	316	14	30	30	NUM
admet-331	316	15	µm	µm	NOUN
admet-331	316	16	/	/	SYM
admet-331	316	17	l	l	NOUN
admet-331	316	18	3	3	NUM
admet-331	316	19	times	time	NOUN
admet-331	316	20	per	per	ADP
admet-331	316	21	week	week	NOUN
admet-331	316	22	)	)	PUNCT
admet-331	316	23	still	still	ADV
admet-331	316	24	significantly	significantly	ADV
admet-331	316	25	decreased	decrease	VERB
admet-331	316	26	the	the	DET
admet-331	316	27	thickness	thickness	NOUN
admet-331	316	28	of	of	ADP
admet-331	316	29	and	and	CCONJ
admet-331	316	30	vascular	vascular	ADJ
admet-331	316	31	leakage	leakage	NOUN
admet-331	316	32	from	from	ADP
admet-331	316	33	the	the	DET
admet-331	316	34	cnv	cnv	NOUN
admet-331	316	35	membrane	membrane	NOUN
admet-331	316	36	[	[	X
admet-331	316	37	82	82	NUM
admet-331	316	38	]	]	PUNCT
admet-331	316	39	.	.	PUNCT
admet-331	317	1	a	a	DET
admet-331	317	2	novel	novel	NOUN
admet-331	317	3	and	and	CCONJ
admet-331	317	4	potent	potent	ADJ
admet-331	317	5	rock	rock	NOUN
admet-331	317	6	inhibitor	inhibitor	NOUN
admet-331	317	7	ama0428	ama0428	NOUN
admet-331	317	8	,	,	PUNCT
admet-331	317	9	from	from	ADP
admet-331	317	10	amakem	amakem	PROPN
admet-331	317	11	therapeutics	therapeutic	NOUN
admet-331	317	12	,	,	PUNCT
admet-331	317	13	has	have	AUX
admet-331	317	14	been	be	AUX
admet-331	317	15	shown	show	VERB
admet-331	317	16	to	to	PART
admet-331	317	17	not	not	PART
admet-331	317	18	only	only	ADV
admet-331	317	19	reduce	reduce	VERB
admet-331	317	20	the	the	DET
admet-331	317	21	angiogenesis	angiogenesis	NOUN
admet-331	317	22	,	,	PUNCT
admet-331	317	23	but	but	CCONJ
admet-331	317	24	also	also	ADV
admet-331	317	25	inhibit	inhibit	VERB
admet-331	317	26	inflammation	inflammation	NOUN
admet-331	317	27	and	and	CCONJ
admet-331	317	28	fibrosis	fibrosis	NOUN
admet-331	317	29	in	in	ADP
admet-331	317	30	a	a	DET
admet-331	317	31	mouse	mouse	NOUN
admet-331	317	32	neovascular	neovascular	NOUN
admet-331	317	33	amd	amd	PROPN
admet-331	317	34	model	model	NOUN
admet-331	317	35	.	.	PUNCT
admet-331	318	1	in	in	ADP
admet-331	318	2	various	various	ADJ
admet-331	318	3	human	human	ADJ
admet-331	318	4	cell	cell	NOUN
admet-331	318	5	cultures	culture	NOUN
admet-331	318	6	(	(	PUNCT
admet-331	318	7	human	human	ADJ
admet-331	318	8	umbilical	umbilical	ADJ
admet-331	318	9	vein	vein	ADJ
admet-331	318	10	endothelial	endothelial	ADJ
admet-331	318	11	cells	cell	NOUN
admet-331	318	12	=	=	SYM
admet-331	318	13	huvecs	huvec	NOUN
admet-331	318	14	,	,	PUNCT
admet-331	318	15	human	human	ADJ
admet-331	318	16	brain	brain	NOUN
admet-331	318	17	microvascular	microvascular	NOUN
admet-331	318	18	endothelial	endothelial	ADJ
admet-331	318	19	cells	cell	NOUN
admet-331	318	20	=	=	NOUN
admet-331	318	21	hbmecs	hbmec	NOUN
admet-331	318	22	,	,	PUNCT
admet-331	318	23	human	human	ADJ
admet-331	318	24	brain	brain	NOUN
admet-331	318	25	vascular	vascular	ADJ
admet-331	318	26	pericytes	pericyte	NOUN
admet-331	318	27	=	=	NOUN
admet-331	318	28	hbvps	hbvps	PROPN
admet-331	318	29	)	)	PUNCT
admet-331	318	30	administration	administration	NOUN
admet-331	318	31	of	of	ADP
admet-331	318	32	ama0428	ama0428	PROPN
admet-331	318	33	inhibited	inhibit	VERB
admet-331	318	34	the	the	DET
admet-331	318	35	vegf	vegf	NOUN
admet-331	318	36	-	-	PUNCT
admet-331	318	37	stimulated	stimulate	VERB
admet-331	318	38	migration	migration	NOUN
admet-331	318	39	of	of	ADP
admet-331	318	40	endothelial	endothelial	ADJ
admet-331	318	41	cells	cell	NOUN
admet-331	318	42	(	(	PUNCT
admet-331	318	43	huvecs	huvec	NOUN
admet-331	318	44	,	,	PUNCT
admet-331	318	45	hbmecs	hbmec	NOUN
admet-331	318	46	)	)	PUNCT
admet-331	318	47	and	and	CCONJ
admet-331	318	48	stimulated	stimulate	VERB
admet-331	318	49	pericyte	pericyte	NOUN
admet-331	318	50	recruitment	recruitment	NOUN
admet-331	318	51	.	.	PUNCT
admet-331	319	1	these	these	PRON
admet-331	319	2	in	in	ADP
admet-331	319	3	vitro	vitro	X
admet-331	319	4	data	datum	NOUN
admet-331	319	5	support	support	VERB
admet-331	319	6	the	the	DET
admet-331	319	7	concept	concept	NOUN
admet-331	319	8	that	that	SCONJ
admet-331	319	9	rock	rock	NOUN
admet-331	319	10	inhibition	inhibition	NOUN
admet-331	319	11	contributes	contribute	VERB
admet-331	319	12	to	to	ADP
admet-331	319	13	the	the	DET
admet-331	319	14	maturation	maturation	NOUN
admet-331	319	15	of	of	ADP
admet-331	319	16	blood	blood	NOUN
admet-331	319	17	vessels	vessel	NOUN
admet-331	319	18	,	,	PUNCT
admet-331	319	19	and	and	CCONJ
admet-331	319	20	might	might	AUX
admet-331	319	21	be	be	AUX
admet-331	319	22	able	able	ADJ
admet-331	319	23	to	to	PART
admet-331	319	24	reduce	reduce	VERB
admet-331	319	25	new	new	ADJ
admet-331	319	26	blood	blood	NOUN
admet-331	319	27	vessel	vessel	NOUN
admet-331	319	28	formation	formation	NOUN
admet-331	319	29	.	.	PUNCT
admet-331	320	1	in	in	ADP
admet-331	320	2	a	a	DET
admet-331	320	3	mouse	mouse	NOUN
admet-331	320	4	laser	laser	NOUN
admet-331	320	5	-	-	PUNCT
admet-331	320	6	induced	induce	VERB
admet-331	320	7	cnv	cnv	PROPN
admet-331	320	8	model	model	NOUN
admet-331	320	9	,	,	PUNCT
admet-331	320	10	a	a	DET
admet-331	320	11	single	single	ADJ
admet-331	320	12	intravitreal	intravitreal	ADJ
admet-331	320	13	injection	injection	NOUN
admet-331	320	14	of	of	ADP
admet-331	320	15	ama0428	ama0428	PROPN
admet-331	320	16	(	(	PUNCT
admet-331	320	17	100	100	NUM
admet-331	320	18	,	,	PUNCT
admet-331	320	19	1000	1000	NUM
admet-331	320	20	ng	ng	NOUN
admet-331	320	21	)	)	PUNCT
admet-331	320	22	administered	administer	VERB
admet-331	320	23	either	either	CCONJ
admet-331	320	24	at	at	ADP
admet-331	320	25	time	time	NOUN
admet-331	320	26	0	0	NUM
admet-331	320	27	or	or	CCONJ
admet-331	320	28	day	day	NOUN
admet-331	320	29	3	3	NUM
admet-331	320	30	significantly	significantly	ADV
admet-331	320	31	reduced	reduce	VERB
admet-331	320	32	the	the	DET
admet-331	320	33	inflammation	inflammation	NOUN
admet-331	320	34	examined	examine	VERB
admet-331	320	35	on	on	ADP
admet-331	320	36	day	day	NOUN
admet-331	320	37	5	5	NUM
admet-331	320	38	,	,	PUNCT
admet-331	320	39	while	while	SCONJ
admet-331	320	40	the	the	DET
admet-331	320	41	vegf-2	vegf-2	NUM
admet-331	320	42	receptor	receptor	NOUN
admet-331	320	43	inhibitor	inhibitor	NOUN
admet-331	320	44	(	(	PUNCT
admet-331	320	45	dc101	dc101	PROPN
admet-331	320	46	)	)	PUNCT
admet-331	320	47	had	have	VERB
admet-331	320	48	no	no	DET
admet-331	320	49	effect	effect	NOUN
admet-331	320	50	.	.	PUNCT
admet-331	321	1	fourteen	fourteen	NUM
admet-331	321	2	days	day	NOUN
admet-331	321	3	after	after	ADP
admet-331	321	4	cnv	cnv	PROPN
admet-331	321	5	induction	induction	NOUN
admet-331	321	6	,	,	PUNCT
admet-331	321	7	repeated	repeat	VERB
admet-331	321	8	intravitreal	intravitreal	ADJ
admet-331	321	9	injections	injection	NOUN
admet-331	321	10	of	of	ADP
admet-331	321	11	ama0428	ama0428	NOUN
admet-331	321	12	(	(	PUNCT
admet-331	321	13	100	100	NUM
admet-331	321	14	or	or	CCONJ
admet-331	321	15	1000ng	1000ng	PROPN
admet-331	321	16	on	on	ADP
admet-331	321	17	days	day	NOUN
admet-331	321	18	0	0	NUM
admet-331	321	19	,	,	PUNCT
admet-331	321	20	4	4	NUM
admet-331	321	21	,	,	PUNCT
admet-331	321	22	10	10	NUM
admet-331	321	23	)	)	PUNCT
admet-331	321	24	had	have	VERB
admet-331	321	25	a	a	DET
admet-331	321	26	remarkable	remarkable	ADJ
admet-331	321	27	inhibitory	inhibitory	ADJ
admet-331	321	28	effect	effect	NOUN
admet-331	321	29	on	on	ADP
admet-331	321	30	angiogenesis	angiogenesis	NOUN
admet-331	321	31	and	and	CCONJ
admet-331	321	32	vessel	vessel	NOUN
admet-331	321	33	leakage	leakage	NOUN
admet-331	321	34	similar	similar	ADJ
admet-331	321	35	to	to	ADP
admet-331	321	36	anti	anti	ADJ
admet-331	321	37	-	-	NOUN
admet-331	321	38	vegf	vegf	NOUN
admet-331	321	39	(	(	PUNCT
admet-331	321	40	dc101	dc101	PROPN
admet-331	321	41	)	)	PUNCT
admet-331	321	42	treatment	treatment	NOUN
admet-331	321	43	.	.	PUNCT
admet-331	322	1	moreover	moreover	ADV
admet-331	322	2	,	,	PUNCT
admet-331	322	3	one	one	NUM
admet-331	322	4	month	month	NOUN
admet-331	322	5	after	after	ADP
admet-331	322	6	the	the	DET
admet-331	322	7	laser	laser	NOUN
admet-331	322	8	injury	injury	NOUN
admet-331	322	9	,	,	PUNCT
admet-331	322	10	multiple	multiple	ADJ
admet-331	322	11	intravitreal	intravitreal	ADJ
admet-331	322	12	administrations	administration	NOUN
admet-331	322	13	of	of	ADP
admet-331	322	14	this	this	DET
admet-331	322	15	rock	rock	NOUN
admet-331	322	16	inhibitor	inhibitor	NOUN
admet-331	322	17	(	(	PUNCT
admet-331	322	18	100	100	NUM
admet-331	322	19	or	or	CCONJ
admet-331	322	20	1000	1000	NUM
admet-331	322	21	ng	ng	PROPN
admet-331	322	22	,	,	PUNCT
admet-331	322	23	on	on	ADP
admet-331	322	24	days	day	NOUN
admet-331	322	25	0	0	NUM
admet-331	322	26	,	,	PUNCT
admet-331	322	27	4	4	NUM
admet-331	322	28	,	,	PUNCT
admet-331	322	29	10	10	NUM
admet-331	322	30	,	,	PUNCT
admet-331	322	31	20	20	NUM
admet-331	322	32	)	)	PUNCT
admet-331	322	33	significantly	significantly	ADV
admet-331	322	34	reduced	reduce	VERB
admet-331	322	35	fibrosis	fibrosis	NOUN
admet-331	322	36	in	in	ADP
admet-331	322	37	the	the	DET
admet-331	322	38	mouse	mouse	PROPN
admet-331	322	39	cnv	cnv	PROPN
admet-331	322	40	model	model	NOUN
admet-331	322	41	whereas	whereas	SCONJ
admet-331	322	42	the	the	DET
admet-331	322	43	vegf	vegf	NOUN
admet-331	322	44	-	-	PUNCT
admet-331	322	45	receptor	receptor	NOUN
admet-331	322	46	2	2	NUM
admet-331	322	47	inhibitor	inhibitor	NOUN
admet-331	322	48	(	(	PUNCT
admet-331	322	49	dc101	dc101	PROPN
admet-331	322	50	)	)	PUNCT
admet-331	322	51	had	have	VERB
admet-331	322	52	no	no	DET
admet-331	322	53	effect	effect	NOUN
admet-331	322	54	[	[	X
admet-331	322	55	16	16	NUM
admet-331	322	56	]	]	PUNCT
admet-331	322	57	.	.	PUNCT
admet-331	323	1	ar13154	ar13154	PROPN
admet-331	323	2	is	be	AUX
admet-331	323	3	a	a	DET
admet-331	323	4	selective	selective	ADJ
admet-331	323	5	multi	multi	ADJ
admet-331	323	6	-	-	ADJ
admet-331	323	7	kinase	kinase	ADJ
admet-331	323	8	inhibitor	inhibitor	NOUN
admet-331	323	9	,	,	PUNCT
admet-331	323	10	which	which	PRON
admet-331	323	11	inhibits	inhibit	VERB
admet-331	323	12	rock	rock	NOUN
admet-331	323	13	,	,	PUNCT
admet-331	323	14	janus	janus	PROPN
admet-331	323	15	kinase	kinase	PROPN
admet-331	323	16	(	(	PUNCT
admet-331	323	17	jak	jak	PROPN
admet-331	323	18	)	)	PUNCT
admet-331	323	19	and	and	CCONJ
admet-331	323	20	plateletderived	plateletderive	VERB
admet-331	323	21	growth	growth	NOUN
admet-331	323	22	factor	factor	NOUN
admet-331	323	23	-	-	PUNCT
admet-331	323	24	ß	ß	NOUN
admet-331	323	25	(	(	PUNCT
admet-331	323	26	pdgf	pdgf	NOUN
admet-331	323	27	-	-	PUNCT
admet-331	323	28	ß	ß	NOUN
admet-331	323	29	)	)	PUNCT
admet-331	323	30	.	.	PUNCT
admet-331	324	1	this	this	DET
admet-331	324	2	compound	compound	NOUN
admet-331	324	3	significantly	significantly	ADV
admet-331	324	4	decreased	decrease	VERB
admet-331	324	5	neovascularization	neovascularization	NOUN
admet-331	324	6	in	in	ADP
admet-331	324	7	laserinduced	laserinduced	ADJ
admet-331	324	8	rat	rat	NOUN
admet-331	324	9	and	and	CCONJ
admet-331	324	10	hypoxia	hypoxia	NOUN
admet-331	324	11	-	-	PUNCT
admet-331	324	12	induced	induce	VERB
admet-331	324	13	mouse	mouse	NOUN
admet-331	324	14	models	model	NOUN
admet-331	324	15	.	.	PUNCT
admet-331	325	1	in	in	ADP
admet-331	325	2	rats	rat	NOUN
admet-331	325	3	,	,	PUNCT
admet-331	325	4	cnv	cnv	PROPN
admet-331	325	5	was	be	AUX
admet-331	325	6	induced	induce	VERB
admet-331	325	7	on	on	ADP
admet-331	325	8	day	day	NOUN
admet-331	325	9	0	0	NUM
admet-331	325	10	,	,	PUNCT
admet-331	325	11	and	and	CCONJ
admet-331	325	12	then	then	ADV
admet-331	325	13	ar13154	ar13154	VERB
admet-331	325	14	or	or	CCONJ
admet-331	325	15	vehicle	vehicle	NOUN
admet-331	325	16	was	be	AUX
admet-331	325	17	injected	inject	VERB
admet-331	325	18	intravitreally	intravitreally	ADV
admet-331	325	19	on	on	ADP
admet-331	325	20	days	day	NOUN
admet-331	325	21	1	1	NUM
admet-331	325	22	,	,	PUNCT
admet-331	325	23	4	4	NUM
admet-331	325	24	,	,	PUNCT
admet-331	325	25	10	10	NUM
admet-331	325	26	;	;	PUNCT
admet-331	325	27	aflibercept	aflibercept	X
admet-331	325	28	(	(	PUNCT
admet-331	325	29	800	800	NUM
admet-331	325	30	ug	ug	ADP
admet-331	325	31	/	/	SYM
admet-331	325	32	ml	ml	NOUN
admet-331	325	33	)	)	PUNCT
admet-331	325	34	was	be	AUX
admet-331	325	35	used	use	VERB
admet-331	325	36	as	as	ADP
admet-331	325	37	a	a	DET
admet-331	325	38	positive	positive	ADJ
admet-331	325	39	control	control	NOUN
admet-331	325	40	and	and	CCONJ
admet-331	325	41	injected	inject	VERB
admet-331	325	42	into	into	ADP
admet-331	325	43	the	the	DET
admet-331	325	44	vitreous	vitreous	ADJ
admet-331	325	45	cavity	cavity	NOUN
admet-331	325	46	only	only	ADV
admet-331	325	47	on	on	ADP
admet-331	325	48	the	the	DET
admet-331	325	49	first	first	ADJ
admet-331	325	50	day	day	NOUN
admet-331	325	51	.	.	PUNCT
admet-331	326	1	ar13154	ar13154	NOUN
admet-331	326	2	reduced	reduce	VERB
admet-331	326	3	the	the	DET
admet-331	326	4	mean	mean	ADJ
admet-331	326	5	lesion	lesion	NOUN
admet-331	326	6	size	size	NOUN
admet-331	326	7	by	by	ADP
admet-331	326	8	35	35	NUM
admet-331	326	9	%	%	NOUN
admet-331	326	10	,	,	PUNCT
admet-331	326	11	whereas	whereas	SCONJ
admet-331	326	12	the	the	DET
admet-331	326	13	aflibercept	aflibercept	PROPN
admet-331	326	14	administration	administration	NOUN
admet-331	326	15	achieved	achieve	VERB
admet-331	326	16	a	a	DET
admet-331	326	17	23	23	NUM
admet-331	326	18	%	%	NOUN
admet-331	326	19	reduction	reduction	NOUN
admet-331	326	20	.	.	PUNCT
admet-331	327	1	in	in	ADP
admet-331	327	2	a	a	DET
admet-331	327	3	mouse	mouse	NOUN
admet-331	327	4	hypoxia	hypoxia	NOUN
admet-331	327	5	-	-	PUNCT
admet-331	327	6	induced	induce	VERB
admet-331	327	7	optic	optic	ADJ
admet-331	327	8	retinopathy	retinopathy	ADJ
admet-331	327	9	model	model	NOUN
admet-331	327	10	,	,	PUNCT
admet-331	327	11	topical	topical	ADJ
admet-331	327	12	administration	administration	NOUN
admet-331	327	13	of	of	ADP
admet-331	327	14	0.06	0.06	NUM
admet-331	327	15	%	%	NOUN
admet-331	327	16	ar13154	ar13154	NOUN
admet-331	327	17	decreased	decrease	VERB
admet-331	327	18	the	the	DET
admet-331	327	19	area	area	NOUN
admet-331	327	20	of	of	ADP
admet-331	327	21	neovascularization	neovascularization	NOUN
admet-331	327	22	by	by	ADP
admet-331	327	23	37	37	NUM
admet-331	327	24	%	%	NOUN
admet-331	327	25	,	,	PUNCT
admet-331	327	26	a	a	DET
admet-331	327	27	level	level	NOUN
admet-331	327	28	similar	similar	ADJ
admet-331	327	29	to	to	ADP
admet-331	327	30	the	the	DET
admet-331	327	31	intraperitoneally	intraperitoneally	ADV
admet-331	327	32	applied	apply	VERB
admet-331	327	33	aflibercept	aflibercept	NOUN
admet-331	327	34	.	.	PUNCT
admet-331	328	1	the	the	DET
admet-331	328	2	combination	combination	NOUN
admet-331	328	3	of	of	ADP
admet-331	328	4	the	the	DET
admet-331	328	5	two	two	NUM
admet-331	328	6	drugs	drug	NOUN
admet-331	328	7	resulted	result	VERB
admet-331	328	8	in	in	ADP
admet-331	328	9	a	a	DET
admet-331	328	10	57	57	NUM
admet-331	328	11	%	%	NOUN
admet-331	328	12	reduction	reduction	NOUN
admet-331	328	13	of	of	ADP
admet-331	328	14	lesion	lesion	NOUN
admet-331	328	15	[	[	X
admet-331	328	16	83	83	NUM
admet-331	328	17	]	]	PUNCT
admet-331	328	18	.	.	PUNCT
admet-331	329	1	additional	additional	ADJ
admet-331	329	2	combinations	combination	NOUN
admet-331	329	3	of	of	ADP
admet-331	329	4	drugs	drug	NOUN
admet-331	329	5	,	,	PUNCT
admet-331	329	6	including	include	VERB
admet-331	329	7	selective	selective	ADJ
admet-331	329	8	rock	rock	NOUN
admet-331	329	9	ii	ii	PROPN
admet-331	329	10	inhibitors	inhibitor	NOUN
admet-331	329	11	,	,	PUNCT
admet-331	329	12	may	may	AUX
admet-331	329	13	be	be	AUX
admet-331	329	14	of	of	ADP
admet-331	329	15	interest	interest	NOUN
admet-331	329	16	in	in	ADP
admet-331	329	17	the	the	DET
admet-331	329	18	future	future	NOUN
admet-331	329	19	.	.	PUNCT
admet-331	330	1	optic	optic	ADJ
admet-331	330	2	nerve	nerve	NOUN
admet-331	330	3	blood	blood	NOUN
admet-331	330	4	flow	flow	NOUN
admet-331	330	5	,	,	PUNCT
admet-331	330	6	neuroprotection	neuroprotection	NOUN
admet-331	330	7	,	,	PUNCT
admet-331	330	8	retinal	retinal	ADJ
admet-331	330	9	detachment	detachment	NOUN
admet-331	330	10	besides	besides	SCONJ
admet-331	330	11	the	the	DET
admet-331	330	12	previously	previously	ADV
admet-331	330	13	described	describe	VERB
admet-331	330	14	mechanisms	mechanism	NOUN
admet-331	330	15	,	,	PUNCT
admet-331	330	16	clinical	clinical	ADJ
admet-331	330	17	application	application	NOUN
admet-331	330	18	of	of	ADP
admet-331	330	19	rock	rock	NOUN
admet-331	330	20	inhibitors	inhibitor	NOUN
admet-331	330	21	has	have	VERB
admet-331	330	22	other	other	ADJ
admet-331	330	23	potential	potential	ADJ
admet-331	330	24	benefits	benefit	NOUN
admet-331	330	25	.	.	PUNCT
admet-331	331	1	for	for	ADP
admet-331	331	2	instance	instance	NOUN
admet-331	331	3	,	,	PUNCT
admet-331	331	4	rock	rock	NOUN
admet-331	331	5	inhibitors	inhibitor	NOUN
admet-331	331	6	cause	cause	VERB
admet-331	331	7	vasodilatation	vasodilatation	NOUN
admet-331	331	8	through	through	ADP
admet-331	331	9	smooth	smooth	ADJ
admet-331	331	10	muscle	muscle	NOUN
admet-331	331	11	relaxation	relaxation	NOUN
admet-331	331	12	and	and	CCONJ
admet-331	331	13	regulation	regulation	NOUN
admet-331	331	14	of	of	ADP
admet-331	331	15	endothelial	endothelial	ADJ
admet-331	331	16	nitric	nitric	ADJ
admet-331	331	17	oxide	oxide	NOUN
admet-331	331	18	synthase	synthase	NOUN
admet-331	331	19	(	(	PUNCT
admet-331	331	20	enos	enos	PROPN
admet-331	331	21	)	)	PUNCT
admet-331	331	22	.	.	PUNCT
admet-331	332	1	impaired	impaired	ADJ
admet-331	332	2	blood	blood	NOUN
admet-331	332	3	flow	flow	NOUN
admet-331	332	4	around	around	ADP
admet-331	332	5	the	the	DET
admet-331	332	6	optic	optic	NOUN
admet-331	332	7	disc	disc	NOUN
admet-331	332	8	and	and	CCONJ
admet-331	332	9	in	in	ADP
admet-331	332	10	the	the	DET
admet-331	332	11	posterior	posterior	ADJ
admet-331	332	12	segment	segment	NOUN
admet-331	332	13	has	have	AUX
admet-331	332	14	been	be	AUX
admet-331	332	15	reported	report	VERB
admet-331	332	16	in	in	ADP
admet-331	332	17	several	several	ADJ
admet-331	332	18	conditions	condition	NOUN
admet-331	332	19	such	such	ADJ
admet-331	332	20	as	as	ADP
admet-331	332	21	glaucoma	glaucoma	NOUN
admet-331	332	22	,	,	PUNCT
admet-331	332	23	non	non	ADJ
admet-331	332	24	-	-	ADJ
admet-331	332	25	arteritic	arteritic	ADJ
admet-331	332	26	anterior	anterior	ADJ
admet-331	332	27	ischemic	ischemic	ADJ
admet-331	332	28	optic	optic	ADJ
admet-331	332	29	neuropathy	neuropathy	ADJ
admet-331	332	30	(	(	PUNCT
admet-331	332	31	naion	naion	NOUN
admet-331	332	32	)	)	PUNCT
admet-331	332	33	and	and	CCONJ
admet-331	332	34	diabetic	diabetic	ADJ
admet-331	332	35	retinopathy	retinopathy	NOUN
admet-331	332	36	.	.	PUNCT
admet-331	333	1	the	the	DET
admet-331	333	2	optic	optic	NOUN
admet-331	333	3	disc	disc	NOUN
admet-331	333	4	blood	blood	NOUN
admet-331	333	5	flow	flow	NOUN
admet-331	333	6	is	be	AUX
admet-331	333	7	mainly	mainly	ADV
admet-331	333	8	supplied	supply	VERB
admet-331	333	9	by	by	ADP
admet-331	333	10	the	the	DET
admet-331	333	11	posterior	posterior	ADJ
admet-331	333	12	ciliary	ciliary	ADJ
admet-331	333	13	arteries	artery	NOUN
admet-331	333	14	.	.	PUNCT
admet-331	334	1	topical	topical	ADJ
admet-331	334	2	and	and	CCONJ
admet-331	334	3	intravenously	intravenously	ADV
admet-331	334	4	applied	apply	VERB
admet-331	334	5	fasudil	fasudil	NOUN
admet-331	334	6	ameliorated	ameliorate	VERB
admet-331	334	7	the	the	DET
admet-331	334	8	enos	eno	NOUN
admet-331	334	9	inhibitorinduced	inhibitorinduce	VERB
admet-331	334	10	optic	optic	ADJ
admet-331	334	11	nerve	nerve	NOUN
admet-331	334	12	blood	blood	NOUN
admet-331	334	13	flow	flow	NOUN
admet-331	334	14	impairment	impairment	NOUN
admet-331	334	15	in	in	ADP
admet-331	334	16	rabbits	rabbit	NOUN
admet-331	334	17	,	,	PUNCT
admet-331	334	18	while	while	SCONJ
admet-331	334	19	no	no	DET
admet-331	334	20	significant	significant	ADJ
admet-331	334	21	effect	effect	NOUN
admet-331	334	22	on	on	ADP
admet-331	334	23	normal	normal	ADJ
admet-331	334	24	blood	blood	NOUN
admet-331	334	25	flow	flow	NOUN
admet-331	334	26	was	be	AUX
admet-331	334	27	detected	detect	VERB
admet-331	334	28	[	[	X
admet-331	334	29	84	84	NUM
admet-331	334	30	]	]	PUNCT
admet-331	334	31	.	.	PUNCT
admet-331	335	1	also	also	ADV
admet-331	335	2	in	in	ADP
admet-331	335	3	rabbits	rabbit	NOUN
admet-331	335	4	,	,	PUNCT
admet-331	335	5	rock	rock	NOUN
admet-331	335	6	inhibitors	inhibitor	NOUN
admet-331	335	7	(	(	PUNCT
admet-331	335	8	y27632	y27632	PROPN
admet-331	335	9	,	,	PUNCT
admet-331	335	10	y39983	y39983	PROPN
admet-331	335	11	)	)	PUNCT
admet-331	335	12	showed	show	VERB
admet-331	335	13	a	a	DET
admet-331	335	14	vasodilatatory	vasodilatatory	ADJ
admet-331	335	15	effect	effect	NOUN
admet-331	335	16	on	on	ADP
admet-331	335	17	ciliary	ciliary	ADJ
admet-331	335	18	artery	artery	NOUN
admet-331	335	19	segments	segment	NOUN
admet-331	335	20	,	,	PUNCT
admet-331	335	21	even	even	ADV
admet-331	335	22	when	when	SCONJ
admet-331	335	23	the	the	DET
admet-331	335	24	no	no	DET
admet-331	335	25	mediated	mediate	VERB
admet-331	335	26	route	route	NOUN
admet-331	335	27	of	of	ADP
admet-331	335	28	vasodilatation	vasodilatation	NOUN
admet-331	335	29	was	be	AUX
admet-331	335	30	blocked	block	VERB
admet-331	335	31	[	[	PUNCT
admet-331	335	32	85	85	NUM
admet-331	335	33	]	]	PUNCT
admet-331	335	34	.	.	PUNCT
admet-331	336	1	naion	naion	NOUN
admet-331	336	2	affects	affect	VERB
admet-331	336	3	the	the	DET
admet-331	336	4	anterior	anterior	ADJ
admet-331	336	5	part	part	NOUN
admet-331	336	6	of	of	ADP
admet-331	336	7	the	the	DET
admet-331	336	8	optic	optic	NOUN
admet-331	336	9	nerve	nerve	NOUN
admet-331	336	10	and	and	CCONJ
admet-331	336	11	is	be	AUX
admet-331	336	12	related	relate	VERB
admet-331	336	13	to	to	ADP
admet-331	336	14	an	an	DET
admet-331	336	15	altered	altered	ADJ
admet-331	336	16	blood	blood	NOUN
admet-331	336	17	supply	supply	NOUN
admet-331	336	18	of	of	ADP
admet-331	336	19	this	this	DET
admet-331	336	20	area	area	NOUN
admet-331	336	21	.	.	PUNCT
admet-331	337	1	intravitreal	intravitreal	ADJ
admet-331	337	2	fasudil	fasudil	NOUN
admet-331	337	3	(	(	PUNCT
admet-331	337	4	0.025	0.025	NUM
admet-331	337	5	mg/0.05	mg/0.05	NOUN
admet-331	337	6	ml	ml	ADP
admet-331	337	7	,	,	PUNCT
admet-331	337	8	calculated	calculate	VERB
admet-331	337	9	to	to	PART
admet-331	337	10	be	be	AUX
admet-331	337	11	equivalent	equivalent	ADJ
admet-331	337	12	to	to	ADP
admet-331	337	13	10	10	NUM
admet-331	337	14	µm	µm	NUM
admet-331	337	15	/	/	SYM
admet-331	337	16	l	l	NOUN
admet-331	337	17	)	)	PUNCT
admet-331	337	18	was	be	AUX
admet-331	337	19	used	use	VERB
admet-331	337	20	in	in	ADP
admet-331	337	21	a	a	DET
admet-331	337	22	pilot	pilot	NOUN
admet-331	337	23	study	study	NOUN
admet-331	337	24	with	with	ADP
admet-331	337	25	13	13	NUM
admet-331	337	26	recent	recent	ADJ
admet-331	337	27	-	-	PUNCT
admet-331	337	28	onset	onset	NOUN
admet-331	337	29	naion	naion	NOUN
admet-331	337	30	patients	patient	NOUN
admet-331	337	31	and	and	CCONJ
admet-331	337	32	seemed	seem	VERB
admet-331	337	33	to	to	PART
admet-331	337	34	facilitate	facilitate	VERB
admet-331	337	35	a	a	DET
admet-331	337	36	cure	cure	NOUN
admet-331	337	37	from	from	ADP
admet-331	337	38	the	the	DET
admet-331	337	39	disease	disease	NOUN
admet-331	337	40	.	.	PUNCT
admet-331	338	1	more	more	ADJ
admet-331	338	2	than	than	ADP
admet-331	338	3	70	70	NUM
admet-331	338	4	%	%	NOUN
admet-331	338	5	of	of	ADP
admet-331	338	6	the	the	DET
admet-331	338	7	patients	patient	NOUN
admet-331	338	8	showed	show	VERB
admet-331	338	9	significant	significant	ADJ
admet-331	338	10	recovery	recovery	NOUN
admet-331	338	11	of	of	ADP
admet-331	338	12	visual	visual	ADJ
admet-331	338	13	acuity	acuity	NOUN
admet-331	338	14	within	within	ADP
admet-331	338	15	one	one	NUM
admet-331	338	16	month	month	NOUN
admet-331	338	17	after	after	ADP
admet-331	338	18	the	the	DET
admet-331	338	19	injection	injection	NOUN
admet-331	338	20	,	,	PUNCT
admet-331	338	21	which	which	PRON
admet-331	338	22	is	be	AUX
admet-331	338	23	an	an	DET
admet-331	338	24	outstanding	outstanding	ADJ
admet-331	338	25	result	result	NOUN
admet-331	338	26	éva	éva	PROPN
admet-331	338	27	halász	halász	NOUN
admet-331	338	28	,	,	PUNCT
admet-331	338	29	ellen	ellen	PROPN
admet-331	338	30	townes	townes	PROPN
admet-331	338	31	-	-	PUNCT
admet-331	338	32	anderson	anderson	PROPN
admet-331	338	33	admet	admet	PROPN
admet-331	338	34	&	&	CCONJ
admet-331	338	35	dmpk	dmpk	PROPN
admet-331	338	36	4(4	4(4	NUM
admet-331	338	37	)	)	PUNCT
admet-331	338	38	(	(	PUNCT
admet-331	338	39	2016	2016	NUM
admet-331	338	40	)	)	PUNCT
admet-331	338	41	280	280	NUM
admet-331	338	42	-	-	SYM
admet-331	338	43	301	301	NUM
admet-331	338	44	294	294	NUM
admet-331	338	45	compared	compare	VERB
admet-331	338	46	to	to	ADP
admet-331	338	47	previous	previous	ADJ
admet-331	338	48	reports	report	NOUN
admet-331	338	49	of	of	ADP
admet-331	338	50	other	other	ADJ
admet-331	338	51	treatment	treatment	NOUN
admet-331	338	52	options	option	NOUN
admet-331	338	53	for	for	ADP
admet-331	338	54	naion	naion	NOUN
admet-331	338	55	.	.	PUNCT
admet-331	339	1	the	the	DET
admet-331	339	2	small	small	ADJ
admet-331	339	3	sample	sample	NOUN
admet-331	339	4	size	size	NOUN
admet-331	339	5	and	and	CCONJ
admet-331	339	6	the	the	DET
admet-331	339	7	lack	lack	NOUN
admet-331	339	8	of	of	ADP
admet-331	339	9	a	a	DET
admet-331	339	10	control	control	NOUN
admet-331	339	11	group	group	NOUN
admet-331	339	12	is	be	AUX
admet-331	339	13	a	a	DET
admet-331	339	14	limitation	limitation	NOUN
admet-331	339	15	of	of	ADP
admet-331	339	16	this	this	DET
admet-331	339	17	study	study	NOUN
admet-331	339	18	,	,	PUNCT
admet-331	339	19	nonetheless	nonetheless	ADV
admet-331	339	20	,	,	PUNCT
admet-331	339	21	the	the	DET
admet-331	339	22	outcomes	outcome	NOUN
admet-331	339	23	are	be	AUX
admet-331	339	24	promising	promise	VERB
admet-331	339	25	and	and	CCONJ
admet-331	339	26	should	should	AUX
admet-331	339	27	encourage	encourage	VERB
admet-331	339	28	further	further	ADJ
admet-331	339	29	investigation	investigation	NOUN
admet-331	340	1	[	[	X
admet-331	340	2	86	86	NUM
admet-331	340	3	]	]	PUNCT
admet-331	340	4	.	.	PUNCT
admet-331	341	1	in	in	ADP
admet-331	341	2	the	the	DET
admet-331	341	3	posterior	posterior	ADJ
admet-331	341	4	segment	segment	NOUN
admet-331	341	5	,	,	PUNCT
admet-331	341	6	intravitreal	intravitreal	ADJ
admet-331	341	7	ripasudil	ripasudil	NOUN
admet-331	341	8	(	(	PUNCT
admet-331	341	9	calculated	calculate	VERB
admet-331	341	10	intravitreal	intravitreal	ADJ
admet-331	341	11	concentrations	concentration	NOUN
admet-331	341	12	were	be	AUX
admet-331	341	13	1	1	NUM
admet-331	341	14	and	and	CCONJ
admet-331	341	15	100	100	NUM
admet-331	341	16	µm	µm	NOUN
admet-331	341	17	)	)	PUNCT
admet-331	341	18	in	in	ADP
admet-331	341	19	cats	cat	NOUN
admet-331	341	20	increased	increase	VERB
admet-331	341	21	retinal	retinal	ADJ
admet-331	341	22	blood	blood	NOUN
admet-331	341	23	flow	flow	NOUN
admet-331	341	24	and	and	CCONJ
admet-331	341	25	blood	blood	NOUN
admet-331	341	26	velocity	velocity	NOUN
admet-331	341	27	without	without	ADP
admet-331	341	28	showing	show	VERB
admet-331	341	29	effect	effect	NOUN
admet-331	341	30	on	on	ADP
admet-331	341	31	vessel	vessel	NOUN
admet-331	341	32	diameter	diameter	NOUN
admet-331	342	1	[	[	X
admet-331	342	2	87	87	NUM
admet-331	342	3	]	]	PUNCT
admet-331	342	4	.	.	PUNCT
admet-331	343	1	neuroprotection	neuroprotection	NOUN
admet-331	343	2	:	:	PUNCT
admet-331	344	1	yang	yang	PROPN
admet-331	344	2	et	et	PROPN
admet-331	344	3	al	al	PROPN
admet-331	344	4	.	.	PUNCT
admet-331	345	1	[	[	X
admet-331	345	2	88	88	NUM
admet-331	345	3	]	]	PUNCT
admet-331	345	4	demonstrated	demonstrate	VERB
admet-331	345	5	in	in	ADP
admet-331	345	6	rats	rat	NOUN
admet-331	345	7	that	that	SCONJ
admet-331	345	8	two	two	NUM
admet-331	345	9	weeks	week	NOUN
admet-331	345	10	after	after	SCONJ
admet-331	345	11	optic	optic	ADJ
admet-331	345	12	nerve	nerve	NOUN
admet-331	345	13	injury	injury	NOUN
admet-331	345	14	rhoa	rhoa	PROPN
admet-331	345	15	,	,	PUNCT
admet-331	345	16	rock	rock	NOUN
admet-331	345	17	i	i	PROPN
admet-331	345	18	and	and	CCONJ
admet-331	345	19	rock	rock	PROPN
admet-331	345	20	ii	ii	PROPN
admet-331	345	21	expression	expression	NOUN
admet-331	345	22	were	be	AUX
admet-331	345	23	increased	increase	VERB
admet-331	345	24	.	.	PUNCT
admet-331	346	1	these	these	DET
admet-331	346	2	increases	increase	NOUN
admet-331	346	3	were	be	AUX
admet-331	346	4	diminished	diminish	VERB
admet-331	346	5	by	by	ADP
admet-331	346	6	y39983	y39983	PROPN
admet-331	346	7	(	(	PUNCT
admet-331	346	8	applied	apply	VERB
admet-331	346	9	intravitreally	intravitreally	ADV
admet-331	346	10	20	20	NUM
admet-331	346	11	µm	µm	NOUN
admet-331	346	12	on	on	ADP
admet-331	346	13	day	day	NOUN
admet-331	346	14	0	0	NUM
admet-331	346	15	and	and	CCONJ
admet-331	346	16	7	7	NUM
admet-331	346	17	)	)	PUNCT
admet-331	346	18	.	.	PUNCT
admet-331	347	1	but	but	CCONJ
admet-331	347	2	in	in	ADP
admet-331	347	3	addition	addition	NOUN
admet-331	347	4	,	,	PUNCT
admet-331	347	5	the	the	DET
admet-331	347	6	rock	rock	NOUN
admet-331	347	7	inhibitor	inhibitor	NOUN
admet-331	347	8	enhanced	enhance	VERB
admet-331	347	9	the	the	DET
admet-331	347	10	number	number	NOUN
admet-331	347	11	of	of	ADP
admet-331	347	12	surviving	survive	VERB
admet-331	347	13	retinal	retinal	ADJ
admet-331	347	14	ganglion	ganglion	NOUN
admet-331	347	15	cells	cell	NOUN
admet-331	347	16	,	,	PUNCT
admet-331	347	17	thereby	thereby	ADV
admet-331	347	18	preventing	prevent	VERB
admet-331	347	19	axonal	axonal	ADJ
admet-331	347	20	degeneration	degeneration	NOUN
admet-331	347	21	500	500	NUM
admet-331	347	22	µm	µm	NOUN
admet-331	347	23	from	from	ADP
admet-331	347	24	the	the	DET
admet-331	347	25	crush	crush	NOUN
admet-331	347	26	site	site	NOUN
admet-331	347	27	.	.	PUNCT
admet-331	348	1	in	in	ADP
admet-331	348	2	2007	2007	NUM
admet-331	348	3	,	,	PUNCT
admet-331	348	4	sagawa	sagawa	PROPN
admet-331	348	5	et	et	NOUN
admet-331	348	6	al.[89	al.[89	PROPN
admet-331	348	7	]	]	PUNCT
admet-331	348	8	compared	compare	VERB
admet-331	348	9	two	two	NUM
admet-331	348	10	rock	rock	NOUN
admet-331	348	11	inhibitors	inhibitor	NOUN
admet-331	348	12	in	in	ADP
admet-331	348	13	feline	feline	ADJ
admet-331	348	14	retinal	retinal	ADJ
admet-331	348	15	cultures	culture	NOUN
admet-331	348	16	.	.	PUNCT
admet-331	349	1	whereas	whereas	SCONJ
admet-331	349	2	10	10	NUM
admet-331	349	3	µm	µm	ADP
admet-331	349	4	y39983	y39983	PROPN
admet-331	349	5	facilitated	facilitate	VERB
admet-331	349	6	the	the	DET
admet-331	349	7	extension	extension	NOUN
admet-331	349	8	of	of	ADP
admet-331	349	9	neurites	neurite	NOUN
admet-331	349	10	and	and	CCONJ
admet-331	349	11	glial	glial	ADJ
admet-331	349	12	processes	process	NOUN
admet-331	349	13	,	,	PUNCT
admet-331	349	14	y27632	y27632	PROPN
admet-331	349	15	had	have	VERB
admet-331	349	16	a	a	DET
admet-331	349	17	similar	similar	ADJ
admet-331	349	18	effect	effect	NOUN
admet-331	349	19	only	only	ADV
admet-331	349	20	when	when	SCONJ
admet-331	349	21	the	the	DET
admet-331	349	22	dose	dose	NOUN
admet-331	349	23	was	be	AUX
admet-331	349	24	increased	increase	VERB
admet-331	349	25	to	to	ADP
admet-331	349	26	100	100	NUM
admet-331	349	27	µm	µm	NOUN
admet-331	349	28	.	.	PROPN
admet-331	350	1	based	base	VERB
admet-331	350	2	on	on	ADP
admet-331	350	3	their	their	PRON
admet-331	350	4	in	in	X
admet-331	350	5	vitro	vitro	X
admet-331	350	6	results	result	NOUN
admet-331	350	7	they	they	PRON
admet-331	350	8	continued	continue	VERB
admet-331	350	9	the	the	DET
admet-331	350	10	experiment	experiment	NOUN
admet-331	350	11	in	in	ADP
admet-331	350	12	an	an	DET
admet-331	350	13	in	in	ADP
admet-331	350	14	vivo	vivo	ADJ
admet-331	350	15	cat	cat	NOUN
admet-331	350	16	optic	optic	PROPN
admet-331	350	17	nerve	nerve	NOUN
admet-331	350	18	crush	crush	NOUN
admet-331	350	19	model	model	NOUN
admet-331	350	20	in	in	ADP
admet-331	350	21	which	which	PRON
admet-331	350	22	10	10	NUM
admet-331	350	23	µm	µm	NOUN
admet-331	350	24	y39983	y39983	PROPN
admet-331	350	25	was	be	AUX
admet-331	350	26	injected	inject	VERB
admet-331	350	27	intravitreally	intravitreally	ADV
admet-331	350	28	.	.	PUNCT
admet-331	351	1	not	not	PART
admet-331	351	2	only	only	ADV
admet-331	351	3	the	the	DET
admet-331	351	4	immediate	immediate	ADJ
admet-331	351	5	injection	injection	NOUN
admet-331	351	6	,	,	PUNCT
admet-331	351	7	but	but	CCONJ
admet-331	351	8	also	also	ADV
admet-331	351	9	the	the	DET
admet-331	351	10	repeated	repeat	VERB
admet-331	351	11	intravitreal	intravitreal	ADJ
admet-331	351	12	administration	administration	NOUN
admet-331	351	13	on	on	ADP
admet-331	351	14	day	day	NOUN
admet-331	351	15	seven	seven	NUM
admet-331	351	16	significantly	significantly	ADV
admet-331	351	17	increased	increase	VERB
admet-331	351	18	(	(	PUNCT
admet-331	351	19	at	at	ADP
admet-331	351	20	least	least	ADJ
admet-331	351	21	doubled	double	VERB
admet-331	351	22	)	)	PUNCT
admet-331	351	23	the	the	DET
admet-331	351	24	number	number	NOUN
admet-331	351	25	of	of	ADP
admet-331	351	26	regenerated	regenerated	ADJ
admet-331	351	27	axons	axon	NOUN
admet-331	351	28	which	which	PRON
admet-331	351	29	were	be	AUX
admet-331	351	30	able	able	ADJ
admet-331	351	31	to	to	PART
admet-331	351	32	grow	grow	VERB
admet-331	351	33	through	through	ADP
admet-331	351	34	the	the	DET
admet-331	351	35	crush	crush	NOUN
admet-331	351	36	site	site	NOUN
admet-331	351	37	.	.	PUNCT
admet-331	352	1	on	on	ADP
admet-331	352	2	the	the	DET
admet-331	352	3	other	other	ADJ
admet-331	352	4	hand	hand	NOUN
admet-331	352	5	,	,	PUNCT
admet-331	352	6	at	at	ADP
admet-331	352	7	week	week	NOUN
admet-331	352	8	six	six	NUM
admet-331	352	9	,	,	PUNCT
admet-331	352	10	the	the	DET
admet-331	352	11	number	number	NOUN
admet-331	352	12	of	of	ADP
admet-331	352	13	axon	axon	ADJ
admet-331	352	14	fibers	fiber	NOUN
admet-331	352	15	at	at	ADP
admet-331	352	16	the	the	DET
admet-331	352	17	crush	crush	NOUN
admet-331	352	18	site	site	NOUN
admet-331	352	19	was	be	AUX
admet-331	352	20	almost	almost	ADV
admet-331	352	21	the	the	DET
admet-331	352	22	same	same	ADJ
admet-331	352	23	as	as	SCONJ
admet-331	352	24	that	that	PRON
admet-331	352	25	observed	observe	VERB
admet-331	352	26	at	at	ADP
admet-331	352	27	week	week	NOUN
admet-331	352	28	two	two	NUM
admet-331	352	29	.	.	PUNCT
admet-331	353	1	thus	thus	ADV
admet-331	353	2	repeated	repeat	VERB
admet-331	353	3	injections	injection	NOUN
admet-331	353	4	of	of	ADP
admet-331	353	5	y39983	y39983	PROPN
admet-331	353	6	seemed	seem	VERB
admet-331	353	7	to	to	PART
admet-331	353	8	facilitate	facilitate	VERB
admet-331	353	9	axon	axon	NOUN
admet-331	353	10	regeneration	regeneration	NOUN
admet-331	353	11	in	in	ADP
admet-331	353	12	the	the	DET
admet-331	353	13	first	first	ADJ
admet-331	353	14	two	two	NUM
admet-331	353	15	weeks	week	NOUN
admet-331	353	16	after	after	ADP
admet-331	353	17	the	the	DET
admet-331	353	18	nerve	nerve	NOUN
admet-331	353	19	trauma	trauma	NOUN
admet-331	353	20	;	;	PUNCT
admet-331	353	21	perhaps	perhaps	ADV
admet-331	353	22	additional	additional	ADJ
admet-331	353	23	administration	administration	NOUN
admet-331	353	24	of	of	ADP
admet-331	353	25	the	the	DET
admet-331	353	26	rock	rock	NOUN
admet-331	353	27	inhibitor	inhibitor	NOUN
admet-331	353	28	would	would	AUX
admet-331	353	29	have	have	AUX
admet-331	353	30	been	be	AUX
admet-331	353	31	beneficial	beneficial	ADJ
admet-331	353	32	.	.	PUNCT
admet-331	354	1	however	however	ADV
admet-331	354	2	,	,	PUNCT
admet-331	354	3	reduction	reduction	NOUN
admet-331	354	4	in	in	ADP
admet-331	354	5	activated	activate	VERB
admet-331	354	6	rhoa	rhoa	PROPN
admet-331	354	7	levels	level	NOUN
admet-331	354	8	[	[	X
admet-331	354	9	89	89	NUM
admet-331	354	10	]	]	PUNCT
admet-331	354	11	may	may	AUX
admet-331	354	12	reduce	reduce	VERB
admet-331	354	13	the	the	DET
admet-331	354	14	protection	protection	NOUN
admet-331	354	15	to	to	ADP
admet-331	354	16	neurons	neuron	NOUN
admet-331	354	17	of	of	ADP
admet-331	354	18	longer	long	ADJ
admet-331	354	19	treatments	treatment	NOUN
admet-331	354	20	.	.	PUNCT
admet-331	355	1	ichikawa	ichikawa	NOUN
admet-331	355	2	et	et	PROPN
admet-331	355	3	al	al	PROPN
admet-331	355	4	.	.	PUNCT
admet-331	356	1	[	[	X
admet-331	356	2	90	90	NUM
admet-331	356	3	]	]	PUNCT
admet-331	356	4	conducted	conduct	VERB
admet-331	356	5	similar	similar	ADJ
admet-331	356	6	experiments	experiment	NOUN
admet-331	356	7	comparing	compare	VERB
admet-331	356	8	the	the	DET
admet-331	356	9	effect	effect	NOUN
admet-331	356	10	of	of	ADP
admet-331	356	11	different	different	ADJ
admet-331	356	12	doses	dose	NOUN
admet-331	356	13	of	of	ADP
admet-331	356	14	y27632	y27632	PROPN
admet-331	356	15	and	and	CCONJ
admet-331	356	16	fasudil	fasudil	NOUN
admet-331	356	17	in	in	ADP
admet-331	356	18	in	in	ADP
admet-331	356	19	vitro	vitro	X
admet-331	356	20	and	and	CCONJ
admet-331	356	21	in	in	ADP
admet-331	356	22	vivo	vivo	ADJ
admet-331	356	23	cat	cat	NOUN
admet-331	356	24	optic	optic	PROPN
admet-331	356	25	nerve	nerve	NOUN
admet-331	356	26	injury	injury	NOUN
admet-331	356	27	models	model	NOUN
admet-331	356	28	.	.	PUNCT
admet-331	357	1	interestingly	interestingly	ADV
admet-331	357	2	,	,	PUNCT
admet-331	357	3	in	in	ADP
admet-331	357	4	culture	culture	NOUN
admet-331	357	5	conditions	condition	NOUN
admet-331	357	6	both	both	PRON
admet-331	357	7	10	10	NUM
admet-331	357	8	µm	µm	NOUN
admet-331	357	9	and	and	CCONJ
admet-331	357	10	30	30	NUM
admet-331	357	11	µm	µm	NOUN
admet-331	357	12	fasudil	fasudil	NOUN
admet-331	357	13	or	or	CCONJ
admet-331	357	14	y27632	y27632	PROPN
admet-331	357	15	enhanced	enhance	VERB
admet-331	357	16	neurite	neurite	NOUN
admet-331	357	17	extension	extension	NOUN
admet-331	357	18	,	,	PUNCT
admet-331	357	19	however	however	ADV
admet-331	357	20	100	100	NUM
admet-331	357	21	µm	µm	ADP
admet-331	357	22	fasudil	fasudil	NOUN
admet-331	357	23	application	application	NOUN
admet-331	357	24	resulted	result	VERB
admet-331	357	25	in	in	ADP
admet-331	357	26	neurite	neurite	ADJ
admet-331	357	27	outgrowth	outgrowth	NOUN
admet-331	357	28	inhibition	inhibition	NOUN
admet-331	357	29	,	,	PUNCT
admet-331	357	30	while	while	SCONJ
admet-331	357	31	100	100	NUM
admet-331	357	32	µm	µm	NUM
admet-331	357	33	y27632	y27632	PROPN
admet-331	357	34	exhibited	exhibit	VERB
admet-331	357	35	the	the	DET
admet-331	357	36	highest	high	ADJ
admet-331	357	37	number	number	NOUN
admet-331	357	38	of	of	ADP
admet-331	357	39	processes	process	NOUN
admet-331	357	40	.	.	PUNCT
admet-331	358	1	in	in	ADP
admet-331	358	2	in	in	ADP
admet-331	358	3	vivo	vivo	ADJ
admet-331	358	4	experiments	experiment	NOUN
admet-331	358	5	,	,	PUNCT
admet-331	358	6	fasudil	fasudil	NOUN
admet-331	358	7	treated	treat	VERB
admet-331	358	8	eyes	eye	NOUN
admet-331	358	9	did	do	AUX
admet-331	358	10	not	not	PART
admet-331	358	11	show	show	VERB
admet-331	358	12	newly	newly	ADV
admet-331	358	13	regenerated	regenerate	VERB
admet-331	358	14	axon	axon	ADJ
admet-331	358	15	fibers	fiber	NOUN
admet-331	358	16	in	in	ADP
admet-331	358	17	the	the	DET
admet-331	358	18	crush	crush	NOUN
admet-331	358	19	site	site	NOUN
admet-331	358	20	,	,	PUNCT
admet-331	358	21	whereas	whereas	SCONJ
admet-331	358	22	10	10	NUM
admet-331	358	23	and	and	CCONJ
admet-331	358	24	100	100	NUM
admet-331	358	25	µm	µm	NUM
admet-331	358	26	y27632	y27632	PROPN
admet-331	358	27	significantly	significantly	ADV
admet-331	358	28	facilitated	facilitate	VERB
admet-331	358	29	neurite	neurite	NOUN
admet-331	358	30	outgrowth	outgrowth	NOUN
admet-331	358	31	beyond	beyond	ADP
admet-331	358	32	the	the	DET
admet-331	358	33	crush	crush	NOUN
admet-331	358	34	site	site	NOUN
admet-331	358	35	.	.	PUNCT
admet-331	359	1	in	in	ADP
admet-331	359	2	rabbits	rabbit	NOUN
admet-331	359	3	intravenous	intravenous	ADJ
admet-331	359	4	fasudil	fasudil	NOUN
admet-331	359	5	ameliorated	ameliorate	VERB
admet-331	359	6	optic	optic	NOUN
admet-331	359	7	nerve	nerve	NOUN
admet-331	359	8	injury	injury	NOUN
admet-331	359	9	related	relate	VERB
admet-331	359	10	degenerative	degenerative	ADJ
admet-331	359	11	molecular	molecular	ADJ
admet-331	359	12	and	and	CCONJ
admet-331	359	13	morphological	morphological	ADJ
admet-331	359	14	changes	change	NOUN
admet-331	359	15	compared	compare	VERB
admet-331	359	16	to	to	ADP
admet-331	359	17	the	the	DET
admet-331	359	18	dexamethasone	dexamethasone	NOUN
admet-331	359	19	and	and	CCONJ
admet-331	359	20	saline	saline	ADJ
admet-331	359	21	treated	treat	VERB
admet-331	359	22	group	group	NOUN
admet-331	359	23	.	.	PUNCT
admet-331	360	1	in	in	ADP
admet-331	360	2	this	this	DET
admet-331	360	3	experiment	experiment	NOUN
admet-331	360	4	,	,	PUNCT
admet-331	360	5	nogoa	nogoa	PROPN
admet-331	360	6	(	(	PUNCT
admet-331	360	7	known	know	VERB
admet-331	360	8	as	as	ADP
admet-331	360	9	a	a	DET
admet-331	360	10	nerve	nerve	NOUN
admet-331	360	11	growth	growth	NOUN
admet-331	360	12	inhibitor	inhibitor	NOUN
admet-331	360	13	)	)	PUNCT
admet-331	360	14	and	and	CCONJ
admet-331	360	15	caspase	caspase	PROPN
admet-331	360	16	3	3	NUM
admet-331	360	17	(	(	PUNCT
admet-331	360	18	known	know	VERB
admet-331	360	19	to	to	PART
admet-331	360	20	take	take	VERB
admet-331	360	21	part	part	NOUN
admet-331	360	22	in	in	ADP
admet-331	360	23	apoptosis	apoptosis	NOUN
admet-331	360	24	)	)	PUNCT
admet-331	360	25	levels	level	NOUN
admet-331	360	26	were	be	AUX
admet-331	360	27	measured	measure	VERB
admet-331	360	28	;	;	PUNCT
admet-331	360	29	expression	expression	NOUN
admet-331	360	30	of	of	ADP
admet-331	360	31	both	both	DET
admet-331	360	32	factors	factor	NOUN
admet-331	360	33	was	be	AUX
admet-331	360	34	decreased	decrease	VERB
admet-331	360	35	by	by	ADP
admet-331	360	36	fasudil	fasudil	NOUN
admet-331	360	37	along	along	ADP
admet-331	360	38	with	with	ADP
admet-331	360	39	rhoa	rhoa	PROPN
admet-331	360	40	and	and	CCONJ
admet-331	360	41	rock	rock	NOUN
admet-331	360	42	ii	ii	PROPN
admet-331	360	43	levels	level	NOUN
admet-331	360	44	.	.	PUNCT
admet-331	361	1	moreover	moreover	ADV
admet-331	361	2	,	,	PUNCT
admet-331	361	3	at	at	ADP
admet-331	361	4	every	every	DET
admet-331	361	5	time	time	NOUN
admet-331	361	6	point	point	NOUN
admet-331	361	7	,	,	PUNCT
admet-331	361	8	(	(	PUNCT
admet-331	361	9	on	on	ADP
admet-331	361	10	day	day	NOUN
admet-331	361	11	3	3	NUM
admet-331	361	12	,	,	PUNCT
admet-331	361	13	7	7	NUM
admet-331	361	14	,	,	PUNCT
admet-331	361	15	14	14	NUM
admet-331	361	16	,	,	PUNCT
admet-331	361	17	21	21	NUM
admet-331	361	18	)	)	PUNCT
admet-331	361	19	but	but	CCONJ
admet-331	361	20	especially	especially	ADV
admet-331	361	21	after	after	ADP
admet-331	361	22	one	one	NUM
admet-331	361	23	week	week	NOUN
admet-331	361	24	,	,	PUNCT
admet-331	361	25	the	the	DET
admet-331	361	26	optic	optic	ADJ
admet-331	361	27	nerve	nerve	NOUN
admet-331	361	28	trauma	trauma	NOUN
admet-331	361	29	related	relate	VERB
admet-331	361	30	changes	change	NOUN
admet-331	361	31	,	,	PUNCT
admet-331	361	32	such	such	ADJ
admet-331	361	33	as	as	ADP
admet-331	361	34	retinal	retinal	ADJ
admet-331	361	35	ganglion	ganglion	NOUN
admet-331	361	36	cell	cell	NOUN
admet-331	361	37	nuclei	nucleus	NOUN
admet-331	361	38	degeneration	degeneration	NOUN
admet-331	361	39	and	and	CCONJ
admet-331	361	40	cell	cell	NOUN
admet-331	361	41	loss	loss	NOUN
admet-331	361	42	and	and	CCONJ
admet-331	361	43	thinning	thinning	NOUN
admet-331	361	44	of	of	ADP
admet-331	361	45	the	the	DET
admet-331	361	46	retina	retina	NOUN
admet-331	361	47	,	,	PUNCT
admet-331	361	48	were	be	AUX
admet-331	361	49	less	less	ADV
admet-331	361	50	severe	severe	ADJ
admet-331	361	51	in	in	ADP
admet-331	361	52	the	the	DET
admet-331	361	53	fasudiltreated	fasudiltreated	ADJ
admet-331	361	54	group	group	NOUN
admet-331	361	55	[	[	X
admet-331	361	56	91	91	NUM
admet-331	361	57	]	]	PUNCT
admet-331	361	58	.	.	PUNCT
admet-331	362	1	in	in	ADP
admet-331	362	2	salamander	salamander	NOUN
admet-331	362	3	retinal	retinal	ADJ
admet-331	362	4	cultures	culture	NOUN
admet-331	362	5	100	100	NUM
admet-331	362	6	µm	µm	ADP
admet-331	362	7	y27632	y27632	PROPN
admet-331	362	8	had	have	VERB
admet-331	362	9	different	different	ADJ
admet-331	362	10	effects	effect	NOUN
admet-331	362	11	on	on	ADP
admet-331	362	12	photoreceptors	photoreceptor	NOUN
admet-331	362	13	depending	depend	VERB
admet-331	362	14	on	on	ADP
admet-331	362	15	cell	cell	NOUN
admet-331	362	16	type	type	NOUN
admet-331	362	17	[	[	X
admet-331	362	18	92	92	NUM
admet-331	362	19	]	]	PUNCT
admet-331	362	20	.	.	PUNCT
admet-331	363	1	for	for	ADP
admet-331	363	2	rods	rod	NOUN
admet-331	363	3	,	,	PUNCT
admet-331	363	4	it	it	PRON
admet-331	363	5	inhibited	inhibit	VERB
admet-331	363	6	axonal	axonal	ADJ
admet-331	363	7	retraction	retraction	NOUN
admet-331	363	8	and	and	CCONJ
admet-331	363	9	slightly	slightly	ADV
admet-331	363	10	enhanced	enhance	VERB
admet-331	363	11	the	the	DET
admet-331	363	12	rod	rod	NOUN
admet-331	363	13	process	process	NOUN
admet-331	363	14	outgrowth	outgrowth	NOUN
admet-331	363	15	;	;	PUNCT
admet-331	363	16	but	but	CCONJ
admet-331	363	17	for	for	ADP
admet-331	363	18	cones	cone	NOUN
admet-331	363	19	,	,	PUNCT
admet-331	363	20	it	it	PRON
admet-331	363	21	significantly	significantly	ADV
admet-331	363	22	increased	increase	VERB
admet-331	363	23	the	the	DET
admet-331	363	24	number	number	NOUN
admet-331	363	25	of	of	ADP
admet-331	363	26	new	new	ADJ
admet-331	363	27	process	process	NOUN
admet-331	363	28	and	and	CCONJ
admet-331	363	29	the	the	DET
admet-331	363	30	development	development	NOUN
admet-331	363	31	of	of	ADP
admet-331	363	32	presynaptic	presynaptic	ADJ
admet-331	363	33	varicosities	varicosity	NOUN
admet-331	363	34	.	.	PUNCT
admet-331	364	1	temporary	temporary	ADJ
admet-331	364	2	or	or	CCONJ
admet-331	364	3	permanent	permanent	ADJ
admet-331	364	4	ischemia	ischemia	NOUN
admet-331	364	5	or	or	CCONJ
admet-331	364	6	trauma	trauma	NOUN
admet-331	364	7	to	to	ADP
admet-331	364	8	the	the	DET
admet-331	364	9	optic	optic	ADJ
admet-331	364	10	nerve	nerve	NOUN
admet-331	364	11	leads	lead	VERB
admet-331	364	12	to	to	PART
admet-331	364	13	oxidative	oxidative	VERB
admet-331	364	14	stress	stress	NOUN
admet-331	364	15	with	with	ADP
admet-331	364	16	elevated	elevated	ADJ
admet-331	364	17	levels	level	NOUN
admet-331	364	18	of	of	ADP
admet-331	364	19	reactive	reactive	ADJ
admet-331	364	20	oxygen	oxygen	NOUN
admet-331	364	21	species	specie	NOUN
admet-331	364	22	contributing	contribute	VERB
admet-331	364	23	to	to	ADP
admet-331	364	24	neurodegeneration	neurodegeneration	NOUN
admet-331	364	25	.	.	PUNCT
admet-331	365	1	yamamoto	yamamoto	PROPN
admet-331	365	2	et	et	PROPN
admet-331	365	3	al	al	PROPN
admet-331	365	4	.	.	PUNCT
admet-331	366	1	[	[	X
admet-331	366	2	93	93	NUM
admet-331	366	3	]	]	PUNCT
admet-331	366	4	described	describe	VERB
admet-331	366	5	,	,	PUNCT
admet-331	366	6	in	in	ADP
admet-331	366	7	a	a	DET
admet-331	366	8	mouse	mouse	NOUN
admet-331	366	9	optic	optic	ADJ
admet-331	366	10	nerve	nerve	NOUN
admet-331	366	11	crush	crush	NOUN
admet-331	366	12	model	model	NOUN
admet-331	366	13	using	use	VERB
admet-331	366	14	orally	orally	ADV
admet-331	366	15	administered	administer	VERB
admet-331	366	16	(	(	PUNCT
admet-331	366	17	1	1	NUM
admet-331	366	18	mg	mg	PROPN
admet-331	366	19	/	/	SYM
admet-331	366	20	kg	kg	PROPN
admet-331	366	21	/	/	SYM
admet-331	366	22	day	day	NOUN
admet-331	366	23	)	)	PUNCT
admet-331	366	24	fasudil	fasudil	NOUN
admet-331	366	25	or	or	CCONJ
admet-331	366	26	ripasudil	ripasudil	VERB
admet-331	366	27	,	,	PUNCT
admet-331	366	28	the	the	DET
admet-331	366	29	amelioration	amelioration	NOUN
admet-331	366	30	of	of	ADP
admet-331	366	31	retinal	retinal	ADJ
admet-331	366	32	ganglion	ganglion	NOUN
admet-331	366	33	cell	cell	NOUN
admet-331	366	34	death	death	NOUN
admet-331	366	35	.	.	PUNCT
admet-331	367	1	the	the	DET
admet-331	367	2	specificity	specificity	NOUN
admet-331	367	3	of	of	ADP
admet-331	367	4	ripasudil	ripasudil	NOUN
admet-331	367	5	for	for	ADP
admet-331	367	6	rock	rock	NOUN
admet-331	367	7	was	be	AUX
admet-331	367	8	found	find	VERB
admet-331	367	9	to	to	PART
admet-331	367	10	be	be	AUX
admet-331	367	11	2	2	NUM
admet-331	367	12	-	-	SYM
admet-331	367	13	18	18	NUM
admet-331	367	14	times	time	NOUN
admet-331	367	15	higher	high	ADJ
admet-331	367	16	than	than	ADP
admet-331	367	17	fasudil	fasudil	NOUN
admet-331	367	18	.	.	PUNCT
admet-331	368	1	on	on	ADP
admet-331	368	2	the	the	DET
admet-331	368	3	basis	basis	NOUN
admet-331	368	4	of	of	ADP
admet-331	368	5	their	their	PRON
admet-331	368	6	results	result	NOUN
admet-331	368	7	,	,	PUNCT
admet-331	368	8	they	they	PRON
admet-331	368	9	proposed	propose	VERB
admet-331	368	10	a	a	DET
admet-331	368	11	pathway	pathway	NOUN
admet-331	368	12	leading	lead	VERB
admet-331	368	13	to	to	ADP
admet-331	368	14	retinal	retinal	ADJ
admet-331	368	15	ganglion	ganglion	NOUN
admet-331	368	16	cell	cell	NOUN
admet-331	368	17	death	death	NOUN
admet-331	368	18	prevention	prevention	NOUN
admet-331	368	19	which	which	PRON
admet-331	368	20	started	start	VERB
admet-331	368	21	with	with	ADP
admet-331	368	22	suppression	suppression	NOUN
admet-331	368	23	of	of	ADP
admet-331	368	24	nox1	nox1	PROPN
admet-331	368	25	(	(	PUNCT
admet-331	368	26	nadph	nadph	ADJ
admet-331	368	27	oxidase	oxidase	NOUN
admet-331	368	28	)	)	PUNCT
admet-331	368	29	expression	expression	NOUN
admet-331	368	30	by	by	ADP
admet-331	368	31	rock	rock	NOUN
admet-331	368	32	inhibition	inhibition	NOUN
admet-331	368	33	and	and	CCONJ
admet-331	368	34	resulted	result	VERB
admet-331	368	35	in	in	ADP
admet-331	368	36	decreased	decreased	ADJ
admet-331	368	37	synthesis	synthesis	NOUN
admet-331	368	38	of	of	ADP
admet-331	368	39	reactive	reactive	ADJ
admet-331	368	40	oxygen	oxygen	NOUN
admet-331	368	41	species	specie	NOUN
admet-331	368	42	,	,	PUNCT
admet-331	368	43	and	and	CCONJ
admet-331	368	44	thereby	thereby	ADV
admet-331	368	45	,	,	PUNCT
admet-331	368	46	neuroprotection	neuroprotection	NOUN
admet-331	368	47	.	.	PUNCT
admet-331	369	1	retinal	retinal	ADJ
admet-331	369	2	detachment	detachment	NOUN
admet-331	369	3	:	:	PUNCT
admet-331	369	4	in	in	ADP
admet-331	369	5	the	the	DET
admet-331	369	6	above	above	ADJ
admet-331	369	7	examples	example	NOUN
admet-331	369	8	the	the	DET
admet-331	369	9	purpose	purpose	NOUN
admet-331	369	10	of	of	ADP
admet-331	369	11	using	use	VERB
admet-331	369	12	rock	rock	NOUN
admet-331	369	13	inhibitors	inhibitor	NOUN
admet-331	369	14	was	be	AUX
admet-331	369	15	to	to	PART
admet-331	369	16	increase	increase	VERB
admet-331	369	17	the	the	DET
admet-331	369	18	admet	admet	NOUN
admet-331	369	19	&	&	CCONJ
admet-331	369	20	dmpk	dmpk	PROPN
admet-331	369	21	4(4	4(4	NUM
admet-331	369	22	)	)	PUNCT
admet-331	369	23	(	(	PUNCT
admet-331	369	24	2016	2016	NUM
admet-331	369	25	)	)	PUNCT
admet-331	369	26	280	280	NUM
admet-331	369	27	-	-	SYM
admet-331	369	28	301	301	NUM
admet-331	369	29	rock	rock	NOUN
admet-331	369	30	inhibitors	inhibitor	NOUN
admet-331	369	31	in	in	ADP
admet-331	369	32	ocular	ocular	ADJ
admet-331	369	33	disease	disease	NOUN
admet-331	369	34	doi	doi	NOUN
admet-331	369	35	:	:	PUNCT
admet-331	369	36	10.5599	10.5599	NUM
admet-331	369	37	/	/	SYM
admet-331	369	38	admet.4.4.331	admet.4.4.331	PROPN
admet-331	369	39	295	295	NUM
admet-331	369	40	plasticity	plasticity	NOUN
admet-331	369	41	and	and	CCONJ
admet-331	369	42	growth	growth	NOUN
admet-331	369	43	of	of	ADP
admet-331	369	44	axons	axon	NOUN
admet-331	369	45	after	after	ADP
admet-331	369	46	the	the	DET
admet-331	369	47	injury	injury	NOUN
admet-331	369	48	.	.	PUNCT
admet-331	370	1	for	for	ADP
admet-331	370	2	retinal	retinal	ADJ
admet-331	370	3	detachment	detachment	NOUN
admet-331	370	4	the	the	DET
admet-331	370	5	goal	goal	NOUN
admet-331	370	6	is	be	AUX
admet-331	370	7	to	to	PART
admet-331	370	8	prevent	prevent	VERB
admet-331	370	9	structural	structural	ADJ
admet-331	370	10	remodeling	remodeling	NOUN
admet-331	370	11	and	and	CCONJ
admet-331	370	12	plasticity	plasticity	NOUN
admet-331	370	13	in	in	ADP
admet-331	370	14	order	order	NOUN
admet-331	370	15	to	to	PART
admet-331	370	16	decrease	decrease	VERB
admet-331	370	17	disruption	disruption	NOUN
admet-331	370	18	of	of	ADP
admet-331	370	19	synapses	synapsis	NOUN
admet-331	370	20	[	[	X
admet-331	370	21	94	94	NUM
admet-331	370	22	]	]	PUNCT
admet-331	370	23	.	.	PUNCT
admet-331	371	1	photoreceptor	photoreceptor	NOUN
admet-331	371	2	degeneration	degeneration	NOUN
admet-331	371	3	was	be	AUX
admet-331	371	4	shown	show	VERB
admet-331	371	5	to	to	PART
admet-331	371	6	be	be	AUX
admet-331	371	7	one	one	NUM
admet-331	371	8	of	of	ADP
admet-331	371	9	the	the	DET
admet-331	371	10	early	early	ADJ
admet-331	371	11	changes	change	NOUN
admet-331	371	12	after	after	ADP
admet-331	371	13	detachment	detachment	NOUN
admet-331	371	14	in	in	ADP
admet-331	371	15	the	the	DET
admet-331	371	16	feline	feline	ADJ
admet-331	371	17	retina	retina	NOUN
admet-331	372	1	[	[	X
admet-331	372	2	95	95	NUM
admet-331	372	3	]	]	PUNCT
admet-331	372	4	.	.	PUNCT
admet-331	373	1	however	however	ADV
admet-331	373	2	,	,	PUNCT
admet-331	373	3	all	all	DET
admet-331	373	4	photoreceptors	photoreceptor	NOUN
admet-331	373	5	did	do	AUX
admet-331	373	6	not	not	PART
admet-331	373	7	respond	respond	VERB
admet-331	373	8	in	in	ADP
admet-331	373	9	the	the	DET
admet-331	373	10	same	same	ADJ
admet-331	373	11	way	way	NOUN
admet-331	373	12	.	.	PUNCT
admet-331	374	1	while	while	SCONJ
admet-331	374	2	rods	rod	NOUN
admet-331	374	3	rapidly	rapidly	ADV
admet-331	374	4	started	start	VERB
admet-331	374	5	to	to	PART
admet-331	374	6	retract	retract	VERB
admet-331	374	7	their	their	PRON
admet-331	374	8	synaptic	synaptic	ADJ
admet-331	374	9	terminals	terminal	NOUN
admet-331	374	10	towards	towards	ADP
admet-331	374	11	their	their	PRON
admet-331	374	12	cell	cell	NOUN
admet-331	374	13	bodies	body	NOUN
admet-331	374	14	thereby	thereby	ADV
admet-331	374	15	breaking	break	VERB
admet-331	374	16	their	their	PRON
admet-331	374	17	synaptic	synaptic	ADJ
admet-331	374	18	connection	connection	NOUN
admet-331	374	19	to	to	ADP
admet-331	374	20	horizontal	horizontal	ADJ
admet-331	374	21	and	and	CCONJ
admet-331	374	22	bipolar	bipolar	ADJ
admet-331	374	23	cells	cell	NOUN
admet-331	374	24	,	,	PUNCT
admet-331	374	25	cones	cone	NOUN
admet-331	374	26	exhibited	exhibit	VERB
admet-331	374	27	degenerative	degenerative	ADJ
admet-331	374	28	signs	sign	NOUN
admet-331	374	29	later	later	ADV
admet-331	374	30	.	.	PUNCT
admet-331	375	1	cones	cone	NOUN
admet-331	375	2	did	do	AUX
admet-331	375	3	not	not	PART
admet-331	375	4	show	show	VERB
admet-331	375	5	retraction	retraction	NOUN
admet-331	375	6	[	[	X
admet-331	375	7	95	95	NUM
admet-331	375	8	]	]	PUNCT
admet-331	375	9	,	,	PUNCT
admet-331	375	10	but	but	CCONJ
admet-331	375	11	instead	instead	ADV
admet-331	375	12	changed	change	VERB
admet-331	375	13	the	the	DET
admet-331	375	14	shape	shape	NOUN
admet-331	375	15	of	of	ADP
admet-331	375	16	their	their	PRON
admet-331	375	17	terminals	terminal	NOUN
admet-331	375	18	[	[	X
admet-331	375	19	94	94	NUM
admet-331	375	20	]	]	PUNCT
admet-331	375	21	.	.	PUNCT
admet-331	376	1	similar	similar	ADJ
admet-331	376	2	changes	change	NOUN
admet-331	376	3	were	be	AUX
admet-331	376	4	described	describe	VERB
admet-331	376	5	in	in	ADP
admet-331	376	6	human	human	ADJ
admet-331	376	7	retina	retina	NOUN
admet-331	377	1	[	[	X
admet-331	377	2	96	96	NUM
admet-331	377	3	]	]	PUNCT
admet-331	377	4	.	.	PUNCT
admet-331	378	1	disruption	disruption	NOUN
admet-331	378	2	of	of	ADP
admet-331	378	3	the	the	DET
admet-331	378	4	first	first	ADJ
admet-331	378	5	synapse	synapse	NOUN
admet-331	378	6	in	in	ADP
admet-331	378	7	the	the	DET
admet-331	378	8	visual	visual	ADJ
admet-331	378	9	pathway	pathway	NOUN
admet-331	378	10	between	between	ADP
admet-331	378	11	the	the	DET
admet-331	378	12	photoreceptors	photoreceptor	NOUN
admet-331	378	13	and	and	CCONJ
admet-331	378	14	the	the	DET
admet-331	378	15	bipolar	bipolar	ADJ
admet-331	378	16	cells	cell	NOUN
admet-331	378	17	may	may	AUX
admet-331	378	18	be	be	AUX
admet-331	378	19	one	one	NUM
admet-331	378	20	reason	reason	NOUN
admet-331	378	21	for	for	ADP
admet-331	378	22	the	the	DET
admet-331	378	23	imperfect	imperfect	ADJ
admet-331	378	24	visual	visual	ADJ
admet-331	378	25	recovery	recovery	NOUN
admet-331	378	26	seen	see	VERB
admet-331	378	27	after	after	ADP
admet-331	378	28	successful	successful	ADJ
admet-331	378	29	reattachment	reattachment	NOUN
admet-331	378	30	surgery	surgery	NOUN
admet-331	378	31	.	.	PUNCT
admet-331	379	1	rhoa	rhoa	PROPN
admet-331	379	2	was	be	AUX
admet-331	379	3	shown	show	VERB
admet-331	379	4	to	to	PART
admet-331	379	5	be	be	AUX
admet-331	379	6	present	present	ADJ
admet-331	379	7	in	in	ADP
admet-331	379	8	the	the	DET
admet-331	379	9	inner	inner	NOUN
admet-331	379	10	and	and	CCONJ
admet-331	379	11	the	the	DET
admet-331	379	12	outer	outer	ADJ
admet-331	379	13	retina	retina	NOUN
admet-331	379	14	of	of	ADP
admet-331	379	15	salamanders	salamander	NOUN
admet-331	379	16	[	[	X
admet-331	379	17	97	97	NUM
admet-331	379	18	]	]	PUNCT
admet-331	379	19	,	,	PUNCT
admet-331	379	20	and	and	CCONJ
admet-331	379	21	pigs	pig	NOUN
admet-331	379	22	[	[	X
admet-331	379	23	94	94	NUM
admet-331	379	24	]	]	PUNCT
admet-331	379	25	.	.	PUNCT
admet-331	380	1	from	from	ADP
admet-331	380	2	both	both	PRON
admet-331	380	3	in	in	ADP
admet-331	380	4	vitro	vitro	X
admet-331	380	5	and	and	CCONJ
admet-331	380	6	in	in	ADP
admet-331	380	7	vivo	vivo	ADJ
admet-331	380	8	experiments	experiment	NOUN
admet-331	380	9	,	,	PUNCT
admet-331	380	10	the	the	DET
admet-331	380	11	rhoa	rhoa	NOUN
admet-331	380	12	-	-	PUNCT
admet-331	380	13	rock	rock	NOUN
admet-331	380	14	pathway	pathway	NOUN
admet-331	380	15	was	be	AUX
admet-331	380	16	shown	show	VERB
admet-331	380	17	to	to	PART
admet-331	380	18	take	take	VERB
admet-331	380	19	part	part	NOUN
admet-331	380	20	in	in	ADP
admet-331	380	21	structural	structural	ADJ
admet-331	380	22	remodeling	remodeling	NOUN
admet-331	380	23	of	of	ADP
admet-331	380	24	photoreceptors	photoreceptor	NOUN
admet-331	380	25	,	,	PUNCT
admet-331	380	26	including	include	VERB
admet-331	380	27	rod	rod	NOUN
admet-331	380	28	axon	axon	NOUN
admet-331	380	29	retraction	retraction	NOUN
admet-331	380	30	and	and	CCONJ
admet-331	380	31	cone	cone	NOUN
admet-331	380	32	neuritic	neuritic	ADJ
admet-331	380	33	outgrowth	outgrowth	NOUN
admet-331	380	34	.	.	PUNCT
admet-331	381	1	in	in	ADP
admet-331	381	2	salamander	salamander	NOUN
admet-331	381	3	retinal	retinal	ADJ
admet-331	381	4	cultures	culture	NOUN
admet-331	381	5	,	,	PUNCT
admet-331	381	6	rods	rod	NOUN
admet-331	381	7	retract	retract	VERB
admet-331	381	8	their	their	PRON
admet-331	381	9	axons	axon	NOUN
admet-331	381	10	by	by	ADP
admet-331	381	11	24	24	NUM
admet-331	381	12	hours	hour	NOUN
admet-331	381	13	.	.	PUNCT
admet-331	382	1	however	however	ADV
admet-331	382	2	,	,	PUNCT
admet-331	382	3	rods	rod	NOUN
admet-331	382	4	maintained	maintain	VERB
admet-331	382	5	their	their	PRON
admet-331	382	6	morphology	morphology	NOUN
admet-331	382	7	and	and	CCONJ
admet-331	382	8	showed	show	VERB
admet-331	382	9	no	no	DET
admet-331	382	10	axonal	axonal	ADJ
admet-331	382	11	retraction	retraction	NOUN
admet-331	382	12	with	with	ADP
admet-331	382	13	100	100	NUM
admet-331	382	14	µm	µm	ADP
admet-331	382	15	y27632	y27632	PROPN
admet-331	382	16	pretreatment	pretreatment	NOUN
admet-331	382	17	[	[	X
admet-331	382	18	97	97	NUM
admet-331	382	19	]	]	PUNCT
admet-331	382	20	and	and	CCONJ
admet-331	382	21	in	in	ADP
admet-331	382	22	similar	similar	ADJ
admet-331	382	23	conditions	condition	NOUN
admet-331	382	24	with	with	ADP
admet-331	382	25	even	even	ADV
admet-331	382	26	lower	low	ADJ
admet-331	382	27	concentrations	concentration	NOUN
admet-331	382	28	(	(	PUNCT
admet-331	382	29	10	10	NUM
admet-331	382	30	,	,	PUNCT
admet-331	382	31	30	30	NUM
admet-331	382	32	,	,	PUNCT
admet-331	382	33	100	100	NUM
admet-331	382	34	µm	µm	NOUN
admet-331	382	35	)	)	PUNCT
admet-331	382	36	in	in	ADP
admet-331	382	37	a	a	DET
admet-331	382	38	dose	dose	NOUN
admet-331	382	39	-	-	PUNCT
admet-331	382	40	dependent	dependent	ADJ
admet-331	382	41	manner	manner	NOUN
admet-331	383	1	[	[	X
admet-331	383	2	98	98	NUM
admet-331	383	3	]	]	PUNCT
admet-331	383	4	.	.	PUNCT
admet-331	384	1	an	an	DET
admet-331	384	2	in	in	ADP
admet-331	384	3	vitro	vitro	X
admet-331	384	4	retinal	retinal	ADJ
admet-331	384	5	detachment	detachment	NOUN
admet-331	384	6	model	model	NOUN
admet-331	384	7	in	in	ADP
admet-331	384	8	porcine	porcine	NOUN
admet-331	384	9	eyes	eye	NOUN
admet-331	384	10	demonstrated	demonstrate	VERB
admet-331	384	11	that	that	SCONJ
admet-331	384	12	rhoa	rhoa	PROPN
admet-331	384	13	activity	activity	NOUN
admet-331	384	14	increased	increase	VERB
admet-331	384	15	immediately	immediately	ADV
admet-331	384	16	after	after	ADP
admet-331	384	17	detachment	detachment	NOUN
admet-331	384	18	[	[	X
admet-331	384	19	94,99	94,99	NOUN
admet-331	384	20	]	]	X
admet-331	384	21	;	;	PUNCT
admet-331	384	22	recent	recent	ADJ
admet-331	384	23	experiments	experiment	NOUN
admet-331	384	24	,	,	PUNCT
admet-331	384	25	therefore	therefore	ADV
admet-331	384	26	,	,	PUNCT
admet-331	384	27	have	have	AUX
admet-331	384	28	explored	explore	VERB
admet-331	384	29	short	short	ADJ
admet-331	384	30	time	time	NOUN
admet-331	384	31	periods	period	NOUN
admet-331	384	32	after	after	ADP
admet-331	384	33	the	the	DET
admet-331	384	34	detachment	detachment	PROPN
admet-331	384	35	injury	injury	NOUN
admet-331	384	36	.	.	PUNCT
admet-331	385	1	porcine	porcine	NOUN
admet-331	385	2	retinal	retinal	ADJ
admet-331	385	3	explants	explant	NOUN
admet-331	385	4	treated	treat	VERB
admet-331	385	5	with	with	ADP
admet-331	385	6	1	1	NUM
admet-331	385	7	,	,	PUNCT
admet-331	385	8	10	10	NUM
admet-331	385	9	and	and	CCONJ
admet-331	385	10	100	100	NUM
admet-331	385	11	µm	µm	NOUN
admet-331	385	12	of	of	ADP
admet-331	385	13	y27632	y27632	PROPN
admet-331	385	14	significantly	significantly	ADV
admet-331	385	15	reduced	reduce	VERB
admet-331	385	16	the	the	DET
admet-331	385	17	number	number	NOUN
admet-331	385	18	of	of	ADP
admet-331	385	19	the	the	DET
admet-331	385	20	rod	rod	NOUN
admet-331	385	21	synaptic	synaptic	ADJ
admet-331	385	22	terminals	terminal	NOUN
admet-331	385	23	which	which	PRON
admet-331	385	24	retracted	retract	VERB
admet-331	385	25	into	into	ADP
admet-331	385	26	the	the	DET
admet-331	385	27	outer	outer	ADJ
admet-331	385	28	nuclear	nuclear	ADJ
admet-331	385	29	layer	layer	NOUN
admet-331	385	30	,	,	PUNCT
admet-331	385	31	moreover	moreover	ADV
admet-331	385	32	six	six	NUM
admet-331	385	33	hour	hour	NOUN
admet-331	385	34	-	-	PUNCT
admet-331	385	35	delayed	delay	VERB
admet-331	385	36	administrations	administration	NOUN
admet-331	385	37	of	of	ADP
admet-331	385	38	100	100	NUM
admet-331	385	39	µm	µm	ADP
admet-331	385	40	y27632	y27632	PROPN
admet-331	385	41	also	also	ADV
admet-331	385	42	reduced	reduce	VERB
admet-331	385	43	synaptic	synaptic	ADJ
admet-331	385	44	breakage	breakage	NOUN
admet-331	385	45	[	[	X
admet-331	385	46	94	94	NUM
admet-331	385	47	]	]	PUNCT
admet-331	385	48	.	.	PUNCT
admet-331	386	1	in	in	ADP
admet-331	386	2	a	a	DET
admet-331	386	3	live	live	ADJ
admet-331	386	4	pig	pig	NOUN
admet-331	386	5	model	model	NOUN
admet-331	386	6	of	of	ADP
admet-331	386	7	retinal	retinal	ADJ
admet-331	386	8	detachment	detachment	NOUN
admet-331	386	9	,	,	PUNCT
admet-331	386	10	y27632	y27632	PROPN
admet-331	386	11	or	or	CCONJ
admet-331	386	12	fasudil	fasudil	NOUN
admet-331	386	13	was	be	AUX
admet-331	386	14	injected	inject	VERB
admet-331	386	15	subretinally	subretinally	ADV
admet-331	386	16	.	.	PUNCT
admet-331	387	1	one	one	NUM
admet-331	387	2	and	and	CCONJ
admet-331	387	3	10	10	NUM
admet-331	387	4	mm	mm	NOUN
admet-331	387	5	of	of	ADP
admet-331	387	6	y27632	y27632	PROPN
admet-331	387	7	and	and	CCONJ
admet-331	387	8	10	10	NUM
admet-331	387	9	mm	mm	NOUN
admet-331	387	10	of	of	ADP
admet-331	387	11	fasudil	fasudil	NOUN
admet-331	387	12	achieved	achieve	VERB
admet-331	387	13	significant	significant	ADJ
admet-331	387	14	prevention	prevention	NOUN
admet-331	387	15	of	of	ADP
admet-331	387	16	rod	rod	NOUN
admet-331	387	17	axonal	axonal	ADJ
admet-331	387	18	remodeling	remodeling	NOUN
admet-331	387	19	in	in	ADP
admet-331	387	20	the	the	DET
admet-331	387	21	detached	detach	VERB
admet-331	387	22	area	area	NOUN
admet-331	387	23	of	of	ADP
admet-331	387	24	the	the	DET
admet-331	387	25	treated	treat	VERB
admet-331	387	26	eye	eye	NOUN
admet-331	387	27	compared	compare	VERB
admet-331	387	28	to	to	ADP
admet-331	387	29	the	the	DET
admet-331	387	30	detached	detach	VERB
admet-331	387	31	area	area	NOUN
admet-331	387	32	of	of	ADP
admet-331	387	33	the	the	DET
admet-331	387	34	fellow	fellow	ADJ
admet-331	387	35	non	non	ADJ
admet-331	387	36	-	-	ADJ
admet-331	387	37	treated	treat	VERB
admet-331	387	38	eye	eye	NOUN
admet-331	387	39	.	.	PUNCT
admet-331	388	1	in	in	ADP
admet-331	388	2	this	this	DET
admet-331	388	3	model	model	NOUN
admet-331	388	4	y27632	y27632	PROPN
admet-331	388	5	also	also	ADV
admet-331	388	6	seemed	seem	VERB
admet-331	388	7	to	to	PART
admet-331	388	8	be	be	AUX
admet-331	388	9	more	more	ADV
admet-331	388	10	effective	effective	ADJ
admet-331	388	11	than	than	ADP
admet-331	388	12	fasudil	fasudil	NOUN
admet-331	388	13	:	:	PUNCT
admet-331	388	14	10	10	NUM
admet-331	388	15	mm	mm	NOUN
admet-331	388	16	y27632	y27632	PROPN
admet-331	388	17	had	have	VERB
admet-331	388	18	significant	significant	ADJ
admet-331	388	19	effect	effect	NOUN
admet-331	388	20	on	on	ADP
admet-331	388	21	prevention	prevention	NOUN
admet-331	388	22	of	of	ADP
admet-331	388	23	synaptic	synaptic	ADJ
admet-331	388	24	changes	change	NOUN
admet-331	388	25	in	in	ADP
admet-331	388	26	both	both	CCONJ
admet-331	388	27	detached	detached	ADJ
admet-331	388	28	and	and	CCONJ
admet-331	388	29	non	non	ADJ
admet-331	388	30	-	-	ADJ
admet-331	388	31	detached	detach	VERB
admet-331	388	32	retinal	retinal	ADJ
admet-331	388	33	areas	area	NOUN
admet-331	388	34	,	,	PUNCT
admet-331	388	35	compared	compare	VERB
admet-331	388	36	to	to	ADP
admet-331	388	37	the	the	DET
admet-331	388	38	control	control	NOUN
admet-331	388	39	areas	area	NOUN
admet-331	388	40	from	from	ADP
admet-331	388	41	the	the	DET
admet-331	388	42	drug	drug	NOUN
admet-331	388	43	-	-	PUNCT
admet-331	388	44	free	free	ADJ
admet-331	388	45	eye	eye	NOUN
admet-331	388	46	,	,	PUNCT
admet-331	388	47	whereas	whereas	SCONJ
admet-331	388	48	fasudil	fasudil	NOUN
admet-331	388	49	prevented	prevent	VERB
admet-331	388	50	synaptic	synaptic	ADJ
admet-331	388	51	retraction	retraction	NOUN
admet-331	388	52	only	only	ADV
admet-331	388	53	in	in	ADP
admet-331	388	54	the	the	DET
admet-331	388	55	detached	detach	VERB
admet-331	388	56	area	area	NOUN
admet-331	388	57	of	of	ADP
admet-331	388	58	retina	retina	NOUN
admet-331	388	59	[	[	X
admet-331	388	60	99	99	NUM
admet-331	388	61	]	]	PUNCT
admet-331	388	62	,	,	PUNCT
admet-331	388	63	[	[	X
admet-331	388	64	unpublished	unpublished	ADJ
admet-331	388	65	data	datum	NOUN
admet-331	388	66	]	]	PUNCT
admet-331	388	67	.	.	PUNCT
admet-331	389	1	in	in	ADP
admet-331	389	2	vitro	vitro	X
admet-331	389	3	findings	finding	NOUN
admet-331	389	4	also	also	ADV
admet-331	389	5	suggest	suggest	VERB
admet-331	389	6	that	that	SCONJ
admet-331	389	7	other	other	ADJ
admet-331	389	8	kinases	kinase	NOUN
admet-331	389	9	in	in	ADP
admet-331	389	10	the	the	DET
admet-331	389	11	rhoa	rhoa	PROPN
admet-331	389	12	/	/	SYM
admet-331	389	13	rock	rock	NOUN
admet-331	389	14	pathway	pathway	NOUN
admet-331	389	15	,	,	PUNCT
admet-331	389	16	specifically	specifically	ADV
admet-331	389	17	lim	lim	PROPN
admet-331	389	18	kinase	kinase	PROPN
admet-331	389	19	(	(	PUNCT
admet-331	389	20	limk	limk	PROPN
admet-331	389	21	)	)	PUNCT
admet-331	389	22	,	,	PUNCT
admet-331	389	23	play	play	VERB
admet-331	389	24	a	a	DET
admet-331	389	25	role	role	NOUN
admet-331	389	26	in	in	ADP
admet-331	389	27	structural	structural	ADJ
admet-331	389	28	remodeling	remodeling	NOUN
admet-331	389	29	of	of	ADP
admet-331	389	30	photoreceptors	photoreceptor	NOUN
admet-331	389	31	and	and	CCONJ
admet-331	389	32	could	could	AUX
admet-331	389	33	be	be	AUX
admet-331	389	34	future	future	ADJ
admet-331	389	35	therapeutic	therapeutic	ADJ
admet-331	389	36	targets	target	NOUN
admet-331	389	37	after	after	ADP
admet-331	389	38	retinal	retinal	ADJ
admet-331	389	39	detachment	detachment	NOUN
admet-331	389	40	[	[	X
admet-331	389	41	98	98	NUM
admet-331	389	42	]	]	PUNCT
admet-331	389	43	.	.	PUNCT
admet-331	390	1	éva	éva	PROPN
admet-331	390	2	halász	halász	PROPN
admet-331	390	3	,	,	PUNCT
admet-331	390	4	ellen	ellen	PROPN
admet-331	390	5	townes	townes	PROPN
admet-331	390	6	-	-	PUNCT
admet-331	390	7	anderson	anderson	PROPN
admet-331	390	8	admet	admet	PROPN
admet-331	390	9	&	&	CCONJ
admet-331	390	10	dmpk	dmpk	PROPN
admet-331	390	11	4(4	4(4	NUM
admet-331	390	12	)	)	PUNCT
admet-331	390	13	(	(	PUNCT
admet-331	390	14	2016	2016	NUM
admet-331	390	15	)	)	PUNCT
admet-331	390	16	280	280	NUM
admet-331	390	17	-	-	SYM
admet-331	390	18	301	301	NUM
admet-331	390	19	296	296	NUM
admet-331	390	20	conclusions	conclusion	NOUN
admet-331	390	21	this	this	DET
admet-331	390	22	review	review	NOUN
admet-331	390	23	has	have	AUX
admet-331	390	24	collected	collect	VERB
admet-331	390	25	the	the	DET
admet-331	390	26	publications	publication	NOUN
admet-331	390	27	from	from	ADP
admet-331	390	28	the	the	DET
admet-331	390	29	last	last	ADJ
admet-331	390	30	few	few	ADJ
admet-331	390	31	years	year	NOUN
admet-331	390	32	related	relate	VERB
admet-331	390	33	to	to	ADP
admet-331	390	34	the	the	DET
admet-331	390	35	application	application	NOUN
admet-331	390	36	of	of	ADP
admet-331	390	37	rock	rock	NOUN
admet-331	390	38	inhibitors	inhibitor	NOUN
admet-331	390	39	in	in	ADP
admet-331	390	40	various	various	ADJ
admet-331	390	41	ocular	ocular	ADJ
admet-331	390	42	diseases	disease	NOUN
admet-331	390	43	.	.	PUNCT
admet-331	391	1	their	their	PRON
admet-331	391	2	potential	potential	ADJ
admet-331	391	3	beneficial	beneficial	ADJ
admet-331	391	4	effects	effect	NOUN
admet-331	391	5	are	be	AUX
admet-331	391	6	presented	present	VERB
admet-331	391	7	in	in	ADP
admet-331	391	8	table	table	NOUN
admet-331	391	9	2	2	NUM
admet-331	391	10	.	.	PUNCT
admet-331	391	11	table	table	NOUN
admet-331	391	12	2	2	NUM
admet-331	391	13	.	.	PUNCT
admet-331	391	14	beneficial	beneficial	ADJ
admet-331	391	15	effects	effect	NOUN
admet-331	391	16	of	of	ADP
admet-331	391	17	rock	rock	NOUN
admet-331	391	18	inhibitors	inhibitor	NOUN
admet-331	391	19	in	in	ADP
admet-331	391	20	various	various	ADJ
admet-331	391	21	ocular	ocular	ADJ
admet-331	391	22	disorders	disorder	NOUN
admet-331	391	23	.	.	PUNCT
admet-331	392	1	cornea	cornea	PROPN
admet-331	392	2	↑	↑	PROPN
admet-331	392	3	corneal	corneal	ADJ
admet-331	392	4	endothelial	endothelial	ADJ
admet-331	392	5	cell	cell	NOUN
admet-331	392	6	survival	survival	NOUN
admet-331	392	7	,	,	PUNCT
admet-331	392	8	migration	migration	NOUN
admet-331	392	9	,	,	PUNCT
admet-331	392	10	adhesion	adhesion	NOUN
admet-331	392	11	,	,	PUNCT
admet-331	392	12	proliferation	proliferation	NOUN
admet-331	392	13	↑	↑	NOUN
admet-331	392	14	endothelial	endothelial	PROPN
admet-331	392	15	markers	marker	NOUN
admet-331	392	16	related	relate	VERB
admet-331	392	17	to	to	PART
admet-331	392	18	pump	pump	VERB
admet-331	392	19	function	function	NOUN
admet-331	392	20	↓	↓	NOUN
admet-331	392	21	size	size	NOUN
admet-331	392	22	of	of	ADP
admet-331	392	23	corneal	corneal	ADJ
admet-331	392	24	endothelial	endothelial	ADJ
admet-331	392	25	wound	wound	NOUN
admet-331	392	26	↓	↓	NOUN
admet-331	392	27	corneal	corneal	ADJ
admet-331	392	28	edema	edema	NOUN
admet-331	392	29	(	(	PUNCT
admet-331	392	30	central	central	ADJ
admet-331	392	31	corneal	corneal	ADJ
admet-331	392	32	thickness	thickness	NOUN
admet-331	392	33	)	)	PUNCT
admet-331	392	34	↓	↓	NOUN
admet-331	392	35	cornea	cornea	PROPN
admet-331	392	36	neovascularization	neovascularization	NOUN
admet-331	392	37	↑	↑	NOUN
admet-331	392	38	healing	healing	NOUN
admet-331	392	39	of	of	ADP
admet-331	392	40	corneal	corneal	ADJ
admet-331	392	41	epithelial	epithelial	ADJ
admet-331	392	42	defect	defect	NOUN
admet-331	392	43	glaucoma	glaucoma	NOUN
admet-331	392	44	↓	↓	PROPN
admet-331	392	45	iop	iop	PROPN
admet-331	392	46	↑outflow	↑outflow	PROPN
admet-331	392	47	facility	facility	PROPN
admet-331	392	48	↑cross	↑cross	PROPN
admet-331	392	49	sectional	sectional	PROPN
admet-331	392	50	area	area	NOUN
admet-331	392	51	and	and	CCONJ
admet-331	392	52	permeability	permeability	NOUN
admet-331	392	53	of	of	ADP
admet-331	392	54	sclemm	sclemm	PROPN
admet-331	392	55	’s	’s	PART
admet-331	392	56	canal	canal	PROPN
admet-331	392	57	↓	↓	NOUN
admet-331	392	58	fibrosis	fibrosis	PROPN
admet-331	392	59	and	and	CCONJ
admet-331	392	60	postoperative	postoperative	ADJ
admet-331	392	61	scarring	scarring	NOUN
admet-331	392	62	at	at	ADP
admet-331	392	63	surgical	surgical	ADJ
admet-331	392	64	area	area	NOUN
admet-331	392	65	↑	↑	NOUN
admet-331	392	66	neuroprotection	neuroprotection	NOUN
admet-331	392	67	of	of	ADP
admet-331	392	68	retina	retina	NOUN
admet-331	392	69	retina	retina	NOUN
admet-331	392	70	diabetic	diabetic	ADJ
admet-331	392	71	retinopathy	retinopathy	ADJ
admet-331	392	72	↓	↓	NOUN
admet-331	392	73	leukocyte	leukocyte	NOUN
admet-331	392	74	adhesion	adhesion	NOUN
admet-331	392	75	,	,	PUNCT
admet-331	392	76	endothelial	endothelial	ADJ
admet-331	392	77	permeability	permeability	NOUN
admet-331	392	78	↑	↑	PROPN
admet-331	392	79	eno	eno	PROPN
admet-331	392	80	level	level	PROPN
admet-331	392	81	↓	↓	PROPN
admet-331	392	82	neovascularization	neovascularization	NOUN
admet-331	392	83	↓	↓	NOUN
admet-331	392	84	proliferative	proliferative	ADJ
admet-331	392	85	membrane	membrane	NOUN
admet-331	392	86	contraction	contraction	NOUN
admet-331	392	87	amd	amd	PRON
admet-331	392	88	↓	↓	PROPN
admet-331	392	89	angiogenesis	angiogenesis	PROPN
admet-331	392	90	,	,	PUNCT
admet-331	392	91	fibrosis	fibrosis	NOUN
admet-331	392	92	and	and	CCONJ
admet-331	392	93	inflammation	inflammation	NOUN
admet-331	392	94	optic	optic	ADJ
admet-331	392	95	nerve	nerve	NOUN
admet-331	392	96	injury	injury	NOUN
admet-331	392	97	↑	↑	NOUN
admet-331	392	98	increasing	increase	VERB
admet-331	392	99	optic	optic	ADJ
admet-331	392	100	nerve	nerve	NOUN
admet-331	392	101	blood	blood	NOUN
admet-331	392	102	flow	flow	NOUN
admet-331	392	103	↓	↓	NOUN
admet-331	392	104	degenerative	degenerative	NOUN
admet-331	392	105	and	and	CCONJ
admet-331	392	106	morphological	morphological	ADJ
admet-331	392	107	changes	change	NOUN
admet-331	392	108	↑	↑	NOUN
admet-331	392	109	axon	axon	PROPN
admet-331	392	110	regeneration	regeneration	VERB
admet-331	392	111	retinal	retinal	ADJ
admet-331	392	112	detachment	detachment	NOUN
admet-331	392	113	↑∕↓	↑∕↓	NOUN
admet-331	392	114	extension	extension	NOUN
admet-331	392	115	of	of	ADP
admet-331	392	116	neurite	neurite	NOUN
admet-331	392	117	and	and	CCONJ
admet-331	392	118	glial	glial	ADJ
admet-331	392	119	processes	process	NOUN
admet-331	392	120	∕	∕	NOUN
admet-331	392	121	neurite	neurite	VERB
admet-331	392	122	outgrowth	outgrowth	PROPN
admet-331	392	123	↑	↑	NOUN
admet-331	392	124	photoreceptor	photoreceptor	NOUN
admet-331	392	125	process	process	NOUN
admet-331	392	126	outgrowth	outgrowth	NOUN
admet-331	392	127	↓	↓	NOUN
admet-331	392	128	rod	rod	NOUN
admet-331	392	129	axon	axon	NOUN
admet-331	392	130	retraction	retraction	NOUN
admet-331	392	131	for	for	ADP
admet-331	392	132	corneal	corneal	ADJ
admet-331	392	133	endothelial	endothelial	ADJ
admet-331	392	134	wound	wound	NOUN
admet-331	392	135	healing	healing	NOUN
admet-331	392	136	and	and	CCONJ
admet-331	392	137	glaucoma	glaucoma	NOUN
admet-331	392	138	further	far	ADV
admet-331	392	139	/	/	PUNCT
admet-331	392	140	continued	continue	VERB
admet-331	392	141	investigation	investigation	NOUN
admet-331	392	142	is	be	AUX
admet-331	392	143	necessary	necessary	ADJ
admet-331	392	144	to	to	PART
admet-331	392	145	address	address	VERB
admet-331	392	146	pharmacodynamics	pharmacodynamic	NOUN
admet-331	392	147	,	,	PUNCT
admet-331	392	148	safety	safety	NOUN
admet-331	392	149	and	and	CCONJ
admet-331	392	150	tolerability	tolerability	NOUN
admet-331	392	151	.	.	PUNCT
admet-331	393	1	but	but	CCONJ
admet-331	393	2	already	already	ADV
admet-331	393	3	accumulating	accumulate	VERB
admet-331	393	4	evidence	evidence	NOUN
admet-331	393	5	from	from	ADP
admet-331	393	6	in	in	ADP
admet-331	393	7	vitro	vitro	X
admet-331	393	8	and	and	CCONJ
admet-331	393	9	in	in	ADP
admet-331	393	10	vivo	vivo	ADJ
admet-331	393	11	studies	study	NOUN
admet-331	393	12	shows	show	VERB
admet-331	393	13	that	that	SCONJ
admet-331	393	14	fasudil	fasudil	NOUN
admet-331	393	15	,	,	PUNCT
admet-331	393	16	ripasudil	ripasudil	VERB
admet-331	393	17	and	and	CCONJ
admet-331	393	18	other	other	ADJ
admet-331	393	19	rock	rock	NOUN
admet-331	393	20	inhibitors	inhibitor	NOUN
admet-331	393	21	may	may	AUX
admet-331	393	22	be	be	AUX
admet-331	393	23	promising	promise	VERB
admet-331	393	24	in	in	ADP
admet-331	393	25	prevention	prevention	NOUN
admet-331	393	26	or	or	CCONJ
admet-331	393	27	treatment	treatment	NOUN
admet-331	393	28	of	of	ADP
admet-331	393	29	these	these	PRON
admet-331	393	30	and	and	CCONJ
admet-331	393	31	other	other	ADJ
admet-331	393	32	retinal	retinal	ADJ
admet-331	393	33	disorders	disorder	NOUN
admet-331	393	34	(	(	PUNCT
admet-331	393	35	i.e.	i.e.	X
admet-331	393	36	,	,	PUNCT
admet-331	393	37	diabetic	diabetic	ADJ
admet-331	393	38	retinopathy	retinopathy	NOUN
admet-331	393	39	,	,	PUNCT
admet-331	393	40	amd	amd	ADJ
admet-331	393	41	)	)	PUNCT
admet-331	393	42	or	or	CCONJ
admet-331	393	43	injuries	injury	NOUN
admet-331	393	44	(	(	PUNCT
admet-331	393	45	e.g.	e.g.	ADV
admet-331	393	46	,	,	PUNCT
admet-331	393	47	retinal	retinal	ADJ
admet-331	393	48	detachment	detachment	NOUN
admet-331	393	49	)	)	PUNCT
admet-331	393	50	,	,	PUNCT
admet-331	393	51	in	in	ADP
admet-331	393	52	part	part	NOUN
admet-331	393	53	because	because	SCONJ
admet-331	393	54	the	the	DET
admet-331	393	55	rho	rho	ADJ
admet-331	393	56	/	/	SYM
admet-331	393	57	rock	rock	NOUN
admet-331	393	58	pathway	pathway	NOUN
admet-331	393	59	is	be	AUX
admet-331	393	60	deeply	deeply	ADV
admet-331	393	61	involved	involve	VERB
admet-331	393	62	in	in	ADP
admet-331	393	63	their	their	PRON
admet-331	393	64	pathogenesis	pathogenesis	NOUN
admet-331	393	65	.	.	PUNCT
admet-331	394	1	moreover	moreover	ADV
admet-331	394	2	,	,	PUNCT
admet-331	394	3	the	the	DET
admet-331	394	4	benefit	benefit	NOUN
admet-331	394	5	of	of	ADP
admet-331	394	6	rock	rock	NOUN
admet-331	394	7	inhibition	inhibition	NOUN
admet-331	394	8	may	may	AUX
admet-331	394	9	be	be	AUX
admet-331	394	10	increased	increase	VERB
admet-331	394	11	by	by	ADP
admet-331	394	12	the	the	DET
admet-331	394	13	fact	fact	NOUN
admet-331	394	14	that	that	SCONJ
admet-331	394	15	the	the	DET
admet-331	394	16	inhibitors	inhibitor	NOUN
admet-331	394	17	often	often	ADV
admet-331	394	18	target	target	VERB
admet-331	394	19	pathological	pathological	ADJ
admet-331	394	20	change	change	NOUN
admet-331	394	21	specifically	specifically	ADV
admet-331	394	22	and	and	CCONJ
admet-331	394	23	have	have	VERB
admet-331	394	24	no	no	DET
admet-331	394	25	effect	effect	NOUN
admet-331	394	26	on	on	ADP
admet-331	394	27	normal	normal	ADJ
admet-331	394	28	processes	process	NOUN
admet-331	394	29	.	.	PUNCT
admet-331	395	1	for	for	ADP
admet-331	395	2	instance	instance	NOUN
admet-331	395	3	,	,	PUNCT
admet-331	395	4	rock	rock	NOUN
admet-331	395	5	inhibition	inhibition	NOUN
admet-331	395	6	has	have	VERB
admet-331	395	7	no	no	DET
admet-331	395	8	effects	effect	NOUN
admet-331	395	9	on	on	ADP
admet-331	395	10	control	control	NOUN
admet-331	395	11	cornea	cornea	NOUN
admet-331	396	1	[	[	X
admet-331	396	2	37	37	NUM
admet-331	396	3	]	]	PUNCT
admet-331	396	4	,	,	PUNCT
admet-331	396	5	normal	normal	ADJ
admet-331	396	6	blood	blood	NOUN
admet-331	396	7	flow	flow	NOUN
admet-331	396	8	[	[	X
admet-331	396	9	84	84	NUM
admet-331	396	10	]	]	PUNCT
admet-331	396	11	and	and	CCONJ
admet-331	396	12	normal	normal	ADJ
admet-331	396	13	angiogenesis	angiogenesis	NOUN
admet-331	397	1	[	[	X
admet-331	397	2	10	10	NUM
admet-331	397	3	]	]	PUNCT
admet-331	397	4	.	.	PUNCT
admet-331	398	1	constitutive	constitutive	ADJ
admet-331	398	2	rock	rock	NOUN
admet-331	398	3	activity	activity	NOUN
admet-331	398	4	may	may	AUX
admet-331	398	5	be	be	AUX
admet-331	398	6	low	low	ADJ
admet-331	398	7	in	in	ADP
admet-331	398	8	many	many	ADJ
admet-331	398	9	ocular	ocular	ADJ
admet-331	398	10	tissues	tissue	NOUN
admet-331	398	11	.	.	PUNCT
admet-331	399	1	however	however	ADV
admet-331	399	2	,	,	PUNCT
admet-331	399	3	there	there	PRON
admet-331	399	4	are	be	VERB
admet-331	399	5	important	important	ADJ
admet-331	399	6	unanswered	unanswered	ADJ
admet-331	399	7	questions	question	NOUN
admet-331	399	8	.	.	PUNCT
admet-331	400	1	first	first	ADV
admet-331	400	2	of	of	ADP
admet-331	400	3	all	all	PRON
admet-331	400	4	,	,	PUNCT
admet-331	400	5	we	we	PRON
admet-331	400	6	need	need	VERB
admet-331	400	7	to	to	PART
admet-331	400	8	determine	determine	VERB
admet-331	400	9	the	the	DET
admet-331	400	10	optimal	optimal	ADJ
admet-331	400	11	therapeutic	therapeutic	ADJ
admet-331	400	12	intraocular	intraocular	ADJ
admet-331	400	13	concentration	concentration	NOUN
admet-331	400	14	of	of	ADP
admet-331	400	15	rock	rock	NOUN
admet-331	400	16	inhibitor	inhibitor	NOUN
admet-331	400	17	.	.	PUNCT
admet-331	401	1	then	then	ADV
admet-331	401	2	we	we	PRON
admet-331	401	3	must	must	AUX
admet-331	401	4	consider	consider	VERB
admet-331	401	5	the	the	DET
admet-331	401	6	best	good	ADJ
admet-331	401	7	and	and	CCONJ
admet-331	401	8	most	most	ADV
admet-331	401	9	feasible	feasible	ADJ
admet-331	401	10	method	method	NOUN
admet-331	401	11	of	of	ADP
admet-331	401	12	drug	drug	NOUN
admet-331	401	13	administration	administration	NOUN
admet-331	401	14	.	.	PUNCT
admet-331	402	1	because	because	SCONJ
admet-331	402	2	of	of	ADP
admet-331	402	3	the	the	DET
admet-331	402	4	short	short	ADJ
admet-331	402	5	biological	biological	ADJ
admet-331	402	6	half	half	ADJ
admet-331	402	7	-	-	PUNCT
admet-331	402	8	life	life	NOUN
admet-331	402	9	[	[	X
admet-331	402	10	2,7,100	2,7,100	NUM
admet-331	402	11	]	]	PUNCT
admet-331	402	12	of	of	ADP
admet-331	402	13	rock	rock	NOUN
admet-331	402	14	inhibitors	inhibitor	NOUN
admet-331	402	15	,	,	PUNCT
admet-331	402	16	repeated	repeat	VERB
admet-331	402	17	applications	application	NOUN
admet-331	402	18	of	of	ADP
admet-331	402	19	intravitreal	intravitreal	ADJ
admet-331	402	20	injections	injection	NOUN
admet-331	402	21	or	or	CCONJ
admet-331	402	22	eye	eye	NOUN
admet-331	402	23	drops	drop	NOUN
admet-331	402	24	will	will	AUX
admet-331	402	25	be	be	AUX
admet-331	402	26	necessary	necessary	ADJ
admet-331	402	27	.	.	PUNCT
admet-331	403	1	intravitreal	intravitreal	ADJ
admet-331	403	2	implantation	implantation	NOUN
admet-331	403	3	of	of	ADP
admet-331	403	4	a	a	DET
admet-331	403	5	slowly	slowly	ADV
admet-331	403	6	releasing	release	VERB
admet-331	403	7	drug	drug	NOUN
admet-331	403	8	delivery	delivery	NOUN
admet-331	403	9	system	system	NOUN
admet-331	403	10	may	may	AUX
admet-331	403	11	offer	offer	VERB
admet-331	403	12	an	an	DET
admet-331	403	13	admet	admet	PROPN
admet-331	403	14	&	&	CCONJ
admet-331	403	15	dmpk	dmpk	PROPN
admet-331	403	16	4(4	4(4	NUM
admet-331	403	17	)	)	PUNCT
admet-331	403	18	(	(	PUNCT
admet-331	403	19	2016	2016	NUM
admet-331	403	20	)	)	PUNCT
admet-331	403	21	280	280	NUM
admet-331	403	22	-	-	SYM
admet-331	403	23	301	301	NUM
admet-331	403	24	rock	rock	NOUN
admet-331	403	25	inhibitors	inhibitor	NOUN
admet-331	403	26	in	in	ADP
admet-331	403	27	ocular	ocular	ADJ
admet-331	403	28	disease	disease	NOUN
admet-331	403	29	doi	doi	NOUN
admet-331	403	30	:	:	PUNCT
admet-331	403	31	10.5599	10.5599	NUM
admet-331	403	32	/	/	SYM
admet-331	403	33	admet.4.4.331	admet.4.4.331	PROPN
admet-331	403	34	297	297	NUM
admet-331	403	35	alternative	alternative	ADJ
admet-331	403	36	solution	solution	NOUN
admet-331	403	37	.	.	PUNCT
admet-331	404	1	some	some	DET
admet-331	404	2	inhibitors	inhibitor	NOUN
admet-331	404	3	may	may	AUX
admet-331	404	4	prove	prove	VERB
admet-331	404	5	more	more	ADV
admet-331	404	6	useful	useful	ADJ
admet-331	404	7	than	than	ADP
admet-331	404	8	others	other	NOUN
admet-331	404	9	because	because	SCONJ
admet-331	404	10	of	of	ADP
admet-331	404	11	their	their	PRON
admet-331	404	12	tissue	tissue	NOUN
admet-331	404	13	interactions	interaction	NOUN
admet-331	404	14	.	.	PUNCT
admet-331	405	1	for	for	ADP
admet-331	405	2	instance	instance	NOUN
admet-331	405	3	,	,	PUNCT
admet-331	405	4	topically	topically	ADV
admet-331	405	5	instilled	instill	VERB
admet-331	405	6	0.4	0.4	NUM
admet-331	405	7	%	%	NOUN
admet-331	405	8	and	and	CCONJ
admet-331	405	9	0.8	0.8	NUM
admet-331	405	10	%	%	NOUN
admet-331	405	11	ripasudil	ripasudil	NOUN
admet-331	405	12	were	be	AUX
admet-331	405	13	shown	show	VERB
admet-331	405	14	to	to	PART
admet-331	405	15	reach	reach	VERB
admet-331	405	16	the	the	DET
admet-331	405	17	posterior	posterior	ADJ
admet-331	405	18	segment	segment	NOUN
admet-331	405	19	in	in	ADP
admet-331	405	20	sufficient	sufficient	ADJ
admet-331	405	21	concentration	concentration	NOUN
admet-331	405	22	to	to	PART
admet-331	405	23	affect	affect	VERB
admet-331	405	24	neovascularization	neovascularization	NOUN
admet-331	405	25	,	,	PUNCT
admet-331	405	26	whereas	whereas	SCONJ
admet-331	405	27	0.4	0.4	NUM
admet-331	405	28	%	%	NOUN
admet-331	405	29	fasudil	fasudil	NOUN
admet-331	405	30	did	do	VERB
admet-331	405	31	not	not	PART
admet-331	405	32	.	.	PUNCT
admet-331	406	1	preparation	preparation	NOUN
admet-331	406	2	of	of	ADP
admet-331	406	3	0.8	0.8	NUM
admet-331	406	4	%	%	NOUN
admet-331	406	5	fasudil	fasudil	NOUN
admet-331	406	6	eye	eye	NOUN
admet-331	406	7	drops	drop	NOUN
admet-331	406	8	was	be	AUX
admet-331	406	9	not	not	PART
admet-331	406	10	feasible	feasible	ADJ
admet-331	406	11	because	because	SCONJ
admet-331	406	12	of	of	ADP
admet-331	406	13	poor	poor	ADJ
admet-331	406	14	solubility	solubility	NOUN
admet-331	406	15	at	at	ADP
admet-331	406	16	this	this	DET
admet-331	406	17	concentration	concentration	NOUN
admet-331	406	18	[	[	X
admet-331	406	19	10	10	NUM
admet-331	406	20	]	]	PUNCT
admet-331	406	21	.	.	PUNCT
admet-331	407	1	further	further	ADJ
admet-331	407	2	chemical	chemical	PROPN
admet-331	407	3	modification	modification	NOUN
admet-331	407	4	of	of	ADP
admet-331	407	5	drugs	drug	NOUN
admet-331	407	6	such	such	ADJ
admet-331	407	7	as	as	ADP
admet-331	407	8	liposomal	liposomal	ADJ
admet-331	407	9	encapsulation	encapsulation	NOUN
admet-331	407	10	[	[	X
admet-331	407	11	101,102	101,102	NUM
admet-331	407	12	]	]	PUNCT
admet-331	407	13	,	,	PUNCT
admet-331	407	14	or	or	CCONJ
admet-331	407	15	other	other	ADJ
admet-331	407	16	types	type	NOUN
admet-331	407	17	of	of	ADP
admet-331	407	18	conjugations	conjugation	NOUN
admet-331	407	19	[	[	X
admet-331	407	20	103	103	NUM
admet-331	407	21	]	]	PUNCT
admet-331	407	22	,	,	PUNCT
admet-331	407	23	may	may	AUX
admet-331	407	24	be	be	AUX
admet-331	407	25	able	able	ADJ
admet-331	407	26	to	to	PART
admet-331	407	27	enhance	enhance	VERB
admet-331	407	28	in	in	ADP
admet-331	407	29	vivo	vivo	ADJ
admet-331	407	30	efficacy	efficacy	NOUN
admet-331	407	31	in	in	ADP
admet-331	407	32	the	the	DET
admet-331	407	33	future	future	NOUN
admet-331	407	34	.	.	PUNCT
admet-331	408	1	furthermore	furthermore	ADV
admet-331	408	2	,	,	PUNCT
admet-331	408	3	the	the	DET
admet-331	408	4	timing	timing	NOUN
admet-331	408	5	of	of	ADP
admet-331	408	6	the	the	DET
admet-331	408	7	treatment	treatment	NOUN
admet-331	408	8	may	may	AUX
admet-331	408	9	be	be	AUX
admet-331	408	10	important	important	ADJ
admet-331	408	11	.	.	PUNCT
admet-331	409	1	since	since	SCONJ
admet-331	409	2	anti	anti	ADJ
admet-331	409	3	-	-	ADJ
admet-331	409	4	vegf	vegf	ADJ
admet-331	409	5	therapy	therapy	NOUN
admet-331	409	6	is	be	AUX
admet-331	409	7	used	use	VERB
admet-331	409	8	in	in	ADP
admet-331	409	9	advanced	advanced	ADJ
admet-331	409	10	phases	phase	NOUN
admet-331	409	11	of	of	ADP
admet-331	409	12	neovascular	neovascular	NOUN
admet-331	409	13	disease	disease	NOUN
admet-331	409	14	,	,	PUNCT
admet-331	409	15	rock	rock	NOUN
admet-331	409	16	inhibitors	inhibitor	NOUN
admet-331	409	17	may	may	AUX
admet-331	409	18	be	be	AUX
admet-331	409	19	useful	useful	ADJ
admet-331	409	20	to	to	PART
admet-331	409	21	prevent	prevent	VERB
admet-331	409	22	structural	structural	ADJ
admet-331	409	23	changes	change	NOUN
admet-331	409	24	in	in	ADP
admet-331	409	25	earlier	early	ADJ
admet-331	409	26	stages	stage	NOUN
admet-331	409	27	and	and	CCONJ
admet-331	409	28	may	may	AUX
admet-331	409	29	affect	affect	VERB
admet-331	409	30	a	a	DET
admet-331	409	31	broader	broad	ADJ
admet-331	409	32	spectrum	spectrum	NOUN
admet-331	409	33	of	of	ADP
admet-331	409	34	viable	viable	ADJ
admet-331	409	35	targets	target	NOUN
admet-331	409	36	.	.	PUNCT
admet-331	410	1	in	in	ADP
admet-331	410	2	most	most	ADJ
admet-331	410	3	disease	disease	NOUN
admet-331	410	4	models	model	NOUN
admet-331	410	5	we	we	PRON
admet-331	410	6	also	also	ADV
admet-331	410	7	still	still	ADV
admet-331	410	8	need	need	VERB
admet-331	410	9	to	to	PART
admet-331	410	10	learn	learn	VERB
admet-331	410	11	about	about	ADP
admet-331	410	12	the	the	DET
admet-331	410	13	time	time	NOUN
admet-331	410	14	course	course	NOUN
admet-331	410	15	of	of	ADP
admet-331	410	16	rhoa	rhoa	PROPN
admet-331	410	17	and/or	and/or	CCONJ
admet-331	410	18	rock	rock	NOUN
admet-331	410	19	activity	activity	NOUN
admet-331	410	20	.	.	PUNCT
admet-331	411	1	in	in	ADP
admet-331	411	2	the	the	DET
admet-331	411	3	case	case	NOUN
admet-331	411	4	of	of	ADP
admet-331	411	5	our	our	PRON
admet-331	411	6	retinal	retinal	ADJ
admet-331	411	7	detachment	detachment	NOUN
admet-331	411	8	model	model	NOUN
admet-331	411	9	we	we	PRON
admet-331	411	10	are	be	AUX
admet-331	411	11	aiming	aim	VERB
admet-331	411	12	to	to	PART
admet-331	411	13	answer	answer	VERB
admet-331	411	14	similar	similar	ADJ
admet-331	411	15	questions	question	NOUN
admet-331	411	16	.	.	PUNCT
admet-331	412	1	although	although	SCONJ
admet-331	412	2	we	we	PRON
admet-331	412	3	know	know	VERB
admet-331	412	4	rhoa	rhoa	NOUN
admet-331	412	5	activation	activation	NOUN
admet-331	412	6	starts	start	VERB
admet-331	412	7	quickly	quickly	ADV
admet-331	412	8	we	we	PRON
admet-331	412	9	do	do	AUX
admet-331	412	10	not	not	PART
admet-331	412	11	know	know	VERB
admet-331	412	12	,	,	PUNCT
admet-331	412	13	for	for	ADP
admet-331	412	14	in	in	ADP
admet-331	412	15	vivo	vivo	ADJ
admet-331	412	16	injury	injury	NOUN
admet-331	412	17	,	,	PUNCT
admet-331	412	18	when	when	SCONJ
admet-331	412	19	it	it	PRON
admet-331	412	20	peaks	peak	VERB
admet-331	412	21	and	and	CCONJ
admet-331	412	22	how	how	SCONJ
admet-331	412	23	long	long	ADJ
admet-331	412	24	activity	activity	NOUN
admet-331	412	25	is	be	AUX
admet-331	412	26	above	above	ADP
admet-331	412	27	normal	normal	ADJ
admet-331	412	28	.	.	PUNCT
admet-331	413	1	for	for	ADP
admet-331	413	2	instance	instance	NOUN
admet-331	413	3	,	,	PUNCT
admet-331	413	4	how	how	SCONJ
admet-331	413	5	many	many	ADJ
admet-331	413	6	injections	injection	NOUN
admet-331	413	7	of	of	ADP
admet-331	413	8	a	a	DET
admet-331	413	9	rock	rock	NOUN
admet-331	413	10	inhibitor	inhibitor	NOUN
admet-331	413	11	will	will	AUX
admet-331	413	12	be	be	AUX
admet-331	413	13	necessary	necessary	ADJ
admet-331	413	14	to	to	PART
admet-331	413	15	not	not	PART
admet-331	413	16	only	only	ADV
admet-331	413	17	prevent	prevent	VERB
admet-331	413	18	photoreceptor	photoreceptor	NOUN
admet-331	413	19	synaptic	synaptic	ADJ
admet-331	413	20	remodeling	remodeling	NOUN
admet-331	413	21	but	but	CCONJ
admet-331	413	22	allow	allow	VERB
admet-331	413	23	restoration	restoration	NOUN
admet-331	413	24	of	of	ADP
admet-331	413	25	normal	normal	ADJ
admet-331	413	26	vision	vision	NOUN
admet-331	413	27	after	after	ADP
admet-331	413	28	detachment	detachment	NOUN
admet-331	413	29	and	and	CCONJ
admet-331	413	30	what	what	PRON
admet-331	413	31	is	be	AUX
admet-331	413	32	the	the	DET
admet-331	413	33	optimal	optimal	ADJ
admet-331	413	34	time	time	NOUN
admet-331	413	35	-	-	PUNCT
admet-331	413	36	window	window	NOUN
admet-331	413	37	and	and	CCONJ
admet-331	413	38	therapeutic	therapeutic	ADJ
admet-331	413	39	dose	dose	NOUN
admet-331	413	40	for	for	ADP
admet-331	413	41	treatment	treatment	NOUN
admet-331	413	42	.	.	PUNCT
admet-331	414	1	we	we	PRON
admet-331	414	2	also	also	ADV
admet-331	414	3	are	be	AUX
admet-331	414	4	investigating	investigate	VERB
admet-331	414	5	whether	whether	SCONJ
admet-331	414	6	more	more	ADJ
admet-331	414	7	than	than	ADP
admet-331	414	8	one	one	NUM
admet-331	414	9	component	component	NOUN
admet-331	414	10	of	of	ADP
admet-331	414	11	the	the	DET
admet-331	414	12	rhoa	rhoa	PROPN
admet-331	414	13	/	/	SYM
admet-331	414	14	rock	rock	NOUN
admet-331	414	15	pathway	pathway	NOUN
admet-331	414	16	can	can	AUX
admet-331	414	17	be	be	AUX
admet-331	414	18	targeted	target	VERB
admet-331	414	19	simultaneously	simultaneously	ADV
admet-331	414	20	and	and	CCONJ
admet-331	414	21	with	with	ADP
admet-331	414	22	what	what	DET
admet-331	414	23	effect	effect	NOUN
admet-331	414	24	.	.	PUNCT
admet-331	415	1	early	early	ADJ
admet-331	415	2	studies	study	NOUN
admet-331	415	3	indicate	indicate	VERB
admet-331	415	4	that	that	SCONJ
admet-331	415	5	a	a	DET
admet-331	415	6	combination	combination	NOUN
admet-331	415	7	of	of	ADP
admet-331	415	8	rock	rock	NOUN
admet-331	415	9	and	and	CCONJ
admet-331	415	10	limk	limk	NOUN
admet-331	415	11	inhibition	inhibition	NOUN
admet-331	415	12	may	may	AUX
admet-331	415	13	be	be	AUX
admet-331	415	14	a	a	DET
admet-331	415	15	more	more	ADV
admet-331	415	16	effective	effective	ADJ
admet-331	415	17	treatment	treatment	NOUN
admet-331	415	18	than	than	ADP
admet-331	415	19	either	either	CCONJ
admet-331	415	20	alone	alone	ADJ
admet-331	415	21	in	in	ADP
admet-331	415	22	our	our	PRON
admet-331	415	23	retinal	retinal	ADJ
admet-331	415	24	detachment	detachment	NOUN
admet-331	415	25	model	model	NOUN
admet-331	415	26	[	[	X
admet-331	415	27	98,104	98,104	X
admet-331	415	28	]	]	PUNCT
admet-331	415	29	.	.	PUNCT
admet-331	416	1	however	however	ADV
admet-331	416	2	,	,	PUNCT
admet-331	416	3	in	in	ADP
admet-331	416	4	spite	spite	NOUN
admet-331	416	5	of	of	ADP
admet-331	416	6	remaining	remain	VERB
admet-331	416	7	questions	question	NOUN
admet-331	416	8	,	,	PUNCT
admet-331	416	9	improvements	improvement	NOUN
admet-331	416	10	in	in	ADP
admet-331	416	11	treatment	treatment	NOUN
admet-331	416	12	of	of	ADP
admet-331	416	13	ocular	ocular	ADJ
admet-331	416	14	disease	disease	NOUN
admet-331	416	15	with	with	ADP
admet-331	416	16	rock	rock	NOUN
admet-331	416	17	inhibition	inhibition	NOUN
admet-331	416	18	seem	seem	VERB
admet-331	416	19	imminent	imminent	ADJ
admet-331	416	20	.	.	PUNCT
admet-331	417	1	acknowledgements	acknowledgement	NOUN
admet-331	417	2	:	:	PUNCT
admet-331	417	3	the	the	DET
admet-331	417	4	authors	author	NOUN
admet-331	417	5	gratefully	gratefully	ADV
admet-331	417	6	acknowledge	acknowledge	VERB
admet-331	417	7	support	support	NOUN
admet-331	417	8	from	from	ADP
admet-331	417	9	nih	nih	PROPN
admet-331	417	10	grant	grant	PROPN
admet-331	417	11	ey021542	ey021542	PROPN
admet-331	417	12	.	.	PUNCT
admet-331	418	1	references	reference	NOUN
admet-331	418	2	[	[	X
admet-331	418	3	1	1	NUM
admet-331	418	4	]	]	X
admet-331	418	5	y.	y.	PROPN
admet-331	418	6	feng	feng	PROPN
admet-331	418	7	,	,	PUNCT
admet-331	419	1	p.	p.	NOUN
admet-331	419	2	v.	v.	ADP
admet-331	419	3	lograsso	lograsso	NOUN
admet-331	419	4	,	,	PUNCT
admet-331	419	5	o.	o.	PROPN
admet-331	419	6	defert	defert	PROPN
admet-331	419	7	,	,	PUNCT
admet-331	419	8	r.	r.	PROPN
admet-331	419	9	li	li	PROPN
admet-331	419	10	,	,	PUNCT
admet-331	419	11	j.	j.	PROPN
admet-331	419	12	med	med	PROPN
admet-331	419	13	.	.	PROPN
admet-331	419	14	chem	chem	PROPN
admet-331	419	15	.	.	PUNCT
admet-331	420	1	59	59	NUM
admet-331	420	2	(	(	PUNCT
admet-331	420	3	2016	2016	NUM
admet-331	420	4	)	)	PUNCT
admet-331	420	5	2269–2300	2269–2300	NUM
admet-331	420	6	.	.	PUNCT
admet-331	421	1	[	[	X
admet-331	421	2	2	2	NUM
admet-331	421	3	]	]	PUNCT
admet-331	421	4	k.	k.	PROPN
admet-331	421	5	p.	p.	PROPN
admet-331	421	6	garnock	garnock	PROPN
admet-331	421	7	-	-	PUNCT
admet-331	421	8	jones	jones	NOUN
admet-331	421	9	,	,	PUNCT
admet-331	421	10	drugs	drug	NOUN
admet-331	421	11	74	74	NUM
admet-331	421	12	(	(	PUNCT
admet-331	421	13	2014	2014	NUM
admet-331	421	14	)	)	PUNCT
admet-331	421	15	2211–2215	2211–2215	NUM
admet-331	421	16	.	.	PUNCT
admet-331	422	1	[	[	X
admet-331	422	2	3	3	X
admet-331	422	3	]	]	PUNCT
admet-331	422	4	s.	s.	PROPN
admet-331	422	5	k.	k.	PROPN
admet-331	422	6	wang	wang	PROPN
admet-331	422	7	,	,	PUNCT
admet-331	422	8	r.	r.	PROPN
admet-331	422	9	t.	t.	PROPN
admet-331	422	10	chang	chang	PROPN
admet-331	422	11	,	,	PUNCT
admet-331	422	12	clin	clin	PROPN
admet-331	422	13	.	.	PUNCT
admet-331	423	1	ophthalmol	ophthalmol	PROPN
admet-331	423	2	.	.	PROPN
admet-331	424	1	8	8	NUM
admet-331	424	2	(	(	PUNCT
admet-331	424	3	2014	2014	NUM
admet-331	424	4	)	)	PUNCT
admet-331	425	1	883–890	883–890	NUM
admet-331	425	2	.	.	PUNCT
admet-331	426	1	[	[	X
admet-331	426	2	4	4	X
admet-331	426	3	]	]	X
admet-331	426	4	t.	t.	PROPN
admet-331	426	5	ishizaki	ishizaki	PROPN
admet-331	426	6	,	,	PUNCT
admet-331	426	7	m.	m.	NOUN
admet-331	426	8	uehata	uehata	PROPN
admet-331	426	9	,	,	PUNCT
admet-331	426	10	i.	i.	PROPN
admet-331	426	11	tamechika	tamechika	PROPN
admet-331	426	12	,	,	PUNCT
admet-331	426	13	j.	j.	PROPN
admet-331	426	14	keel	keel	PROPN
admet-331	426	15	,	,	PUNCT
admet-331	426	16	k.	k.	PROPN
admet-331	426	17	nonomura	nonomura	PROPN
admet-331	426	18	,	,	PUNCT
admet-331	426	19	m.	m.	NOUN
admet-331	426	20	maekawa	maekawa	PROPN
admet-331	426	21	,	,	PUNCT
admet-331	426	22	et	et	PROPN
admet-331	426	23	al	al	PROPN
admet-331	426	24	.	.	PROPN
admet-331	426	25	,	,	PUNCT
admet-331	426	26	mol	mol	PROPN
admet-331	426	27	.	.	PUNCT
admet-331	426	28	pharmacol	pharmacol	PROPN
admet-331	426	29	.	.	PUNCT
admet-331	427	1	57	57	NUM
admet-331	427	2	(	(	PUNCT
admet-331	427	3	2000	2000	NUM
admet-331	427	4	)	)	PUNCT
admet-331	428	1	976–983	976–983	NUM
admet-331	428	2	.	.	PUNCT
admet-331	429	1	[	[	X
admet-331	429	2	5	5	NUM
admet-331	429	3	]	]	PUNCT
admet-331	429	4	m.	m.	NOUN
admet-331	429	5	uehata	uehata	NOUN
admet-331	429	6	,	,	PUNCT
admet-331	429	7	t.	t.	PROPN
admet-331	429	8	ishizaki	ishizaki	PROPN
admet-331	429	9	,	,	PUNCT
admet-331	429	10	h.	h.	PROPN
admet-331	429	11	satoh	satoh	PROPN
admet-331	429	12	,	,	PUNCT
admet-331	429	13	t.	t.	PROPN
admet-331	429	14	ono	ono	PROPN
admet-331	429	15	,	,	PUNCT
admet-331	429	16	t.	t.	PROPN
admet-331	429	17	kawahara	kawahara	PROPN
admet-331	429	18	,	,	PUNCT
admet-331	429	19	t.	t.	PROPN
admet-331	429	20	morishita	morishita	PROPN
admet-331	429	21	,	,	PUNCT
admet-331	429	22	et	et	PROPN
admet-331	429	23	al	al	PROPN
admet-331	429	24	.	.	PROPN
admet-331	429	25	,	,	PUNCT
admet-331	429	26	nature	nature	NOUN
admet-331	429	27	389	389	NUM
admet-331	429	28	(	(	PUNCT
admet-331	429	29	1997	1997	NUM
admet-331	429	30	)	)	PUNCT
admet-331	430	1	990–4	990–4	X
admet-331	430	2	.	.	PUNCT
admet-331	431	1	[	[	X
admet-331	431	2	6	6	NUM
admet-331	431	3	]	]	X
admet-331	431	4	y.	y.	PROPN
admet-331	431	5	kaneko	kaneko	PROPN
admet-331	431	6	,	,	PUNCT
admet-331	431	7	m.	m.	NOUN
admet-331	431	8	ohta	ohta	PROPN
admet-331	431	9	,	,	PUNCT
admet-331	431	10	t.	t.	PROPN
admet-331	431	11	inoue	inoue	PROPN
admet-331	431	12	,	,	PUNCT
admet-331	431	13	k.	k.	PROPN
admet-331	431	14	mizuno	mizuno	PROPN
admet-331	431	15	,	,	PUNCT
admet-331	431	16	t.	t.	PROPN
admet-331	431	17	isobe	isobe	PROPN
admet-331	431	18	,	,	PUNCT
admet-331	431	19	s.	s.	PROPN
admet-331	431	20	tanabe	tanabe	PROPN
admet-331	431	21	,	,	PUNCT
admet-331	431	22	et	et	PROPN
admet-331	431	23	al	al	PROPN
admet-331	431	24	.	.	PROPN
admet-331	431	25	,	,	PUNCT
admet-331	431	26	sci	sci	PROPN
admet-331	431	27	.	.	PROPN
admet-331	431	28	rep	rep	PROPN
admet-331	431	29	.	.	PROPN
admet-331	431	30	6	6	NUM
admet-331	431	31	(	(	PUNCT
admet-331	431	32	2016	2016	NUM
admet-331	431	33	)	)	PUNCT
admet-331	431	34	19640	19640	NUM
admet-331	431	35	.	.	PUNCT
admet-331	432	1	[	[	X
admet-331	432	2	7	7	X
admet-331	432	3	]	]	PUNCT
admet-331	432	4	s.	s.	PROPN
admet-331	432	5	boland	boland	PROPN
admet-331	432	6	,	,	PUNCT
admet-331	432	7	o.	o.	PROPN
admet-331	432	8	defert	defert	PROPN
admet-331	432	9	,	,	PUNCT
admet-331	432	10	j.	j.	PROPN
admet-331	432	11	alen	alen	PROPN
admet-331	432	12	,	,	PUNCT
admet-331	432	13	a.	a.	NOUN
admet-331	432	14	bourin	bourin	PROPN
admet-331	432	15	,	,	PUNCT
admet-331	432	16	k.	k.	PROPN
admet-331	432	17	castermans	castermans	PROPN
admet-331	432	18	,	,	PUNCT
admet-331	432	19	n.	n.	PROPN
admet-331	432	20	kindt	kindt	PROPN
admet-331	432	21	,	,	PUNCT
admet-331	432	22	et	et	PROPN
admet-331	432	23	al	al	PROPN
admet-331	432	24	.	.	PROPN
admet-331	432	25	,	,	PUNCT
admet-331	432	26	bioorg	bioorg	PROPN
admet-331	432	27	.	.	PUNCT
admet-331	433	1	med	med	PROPN
admet-331	433	2	.	.	PROPN
admet-331	433	3	chem	chem	PROPN
admet-331	433	4	.	.	PUNCT
admet-331	434	1	lett	lett	PROPN
admet-331	434	2	.	.	PUNCT
admet-331	435	1	23	23	NUM
admet-331	435	2	(	(	PUNCT
admet-331	435	3	2013	2013	NUM
admet-331	435	4	)	)	PUNCT
admet-331	435	5	6442–6446	6442–6446	NOUN
admet-331	435	6	.	.	PUNCT
admet-331	436	1	[	[	X
admet-331	436	2	8	8	NUM
admet-331	436	3	]	]	PUNCT
admet-331	436	4	s.	s.	PROPN
admet-331	436	5	van	van	PROPN
admet-331	436	6	de	de	PROPN
admet-331	436	7	velde	velde	PROPN
admet-331	436	8	,	,	PUNCT
admet-331	436	9	t.	t.	PROPN
admet-331	436	10	van	van	PROPN
admet-331	436	11	bergen	bergen	PROPN
admet-331	436	12	,	,	PUNCT
admet-331	436	13	d.	d.	PROPN
admet-331	436	14	sijnave	sijnave	PROPN
admet-331	436	15	,	,	PUNCT
admet-331	436	16	k.	k.	PROPN
admet-331	436	17	hollanders	hollander	NOUN
admet-331	436	18	,	,	PUNCT
admet-331	436	19	k.	k.	PROPN
admet-331	436	20	castermans	castermans	PROPN
admet-331	436	21	,	,	PUNCT
admet-331	436	22	o.	o.	PROPN
admet-331	436	23	defert	defert	PROPN
admet-331	436	24	,	,	PUNCT
admet-331	436	25	et	et	PROPN
admet-331	436	26	al	al	PROPN
admet-331	436	27	.	.	PROPN
admet-331	436	28	,	,	PUNCT
admet-331	436	29	invest	invest	VERB
admet-331	436	30	.	.	PUNCT
admet-331	437	1	ophthalmol	ophthalmol	PROPN
admet-331	437	2	.	.	PUNCT
admet-331	438	1	vis	vis	X
admet-331	438	2	.	.	PUNCT
admet-331	439	1	sci	sci	PROPN
admet-331	439	2	.	.	PROPN
admet-331	440	1	55	55	NUM
admet-331	440	2	(	(	PUNCT
admet-331	440	3	2014	2014	NUM
admet-331	440	4	)	)	PUNCT
admet-331	440	5	1006–1016	1006–1016	NUM
admet-331	440	6	.	.	PUNCT
admet-331	441	1	[	[	X
admet-331	441	2	9	9	NUM
admet-331	441	3	]	]	X
admet-331	441	4	h.	h.	NOUN
admet-331	441	5	tokushige	tokushige	PROPN
admet-331	441	6	,	,	PUNCT
admet-331	441	7	m.	m.	NOUN
admet-331	441	8	inatani	inatani	PROPN
admet-331	441	9	,	,	PUNCT
admet-331	441	10	s.	s.	PROPN
admet-331	441	11	nemoto	nemoto	PROPN
admet-331	441	12	,	,	PUNCT
admet-331	441	13	h.	h.	PROPN
admet-331	441	14	sakaki	sakaki	PROPN
admet-331	441	15	,	,	PUNCT
admet-331	441	16	invest	invest	VERB
admet-331	441	17	.	.	PUNCT
admet-331	442	1	ophthalmol	ophthalmol	PROPN
admet-331	442	2	.	.	PUNCT
admet-331	443	1	vis	vis	X
admet-331	443	2	.	.	PUNCT
admet-331	444	1	sci	sci	PROPN
admet-331	444	2	.	.	PROPN
admet-331	445	1	48	48	NUM
admet-331	445	2	(	(	PUNCT
admet-331	445	3	2007	2007	NUM
admet-331	445	4	)	)	PUNCT
admet-331	445	5	3216–3222	3216–3222	NUM
admet-331	445	6	.	.	PUNCT
admet-331	446	1	[	[	X
admet-331	446	2	10	10	NUM
admet-331	446	3	]	]	PUNCT
admet-331	446	4	m.	m.	NOUN
admet-331	446	5	yamaguchi	yamaguchi	PROPN
admet-331	446	6	,	,	PUNCT
admet-331	446	7	s.	s.	PROPN
admet-331	446	8	nakao	nakao	PROPN
admet-331	446	9	,	,	PUNCT
admet-331	446	10	r.	r.	PROPN
admet-331	446	11	arita	arita	PROPN
admet-331	446	12	,	,	PUNCT
admet-331	446	13	y.	y.	PROPN
admet-331	446	14	kaizu	kaizu	PROPN
admet-331	446	15	,	,	PUNCT
admet-331	446	16	m.	m.	NOUN
admet-331	446	17	arima	arima	PROPN
admet-331	446	18	,	,	PUNCT
admet-331	446	19	y.	y.	PROPN
admet-331	446	20	zhou	zhou	PROPN
admet-331	446	21	,	,	PUNCT
admet-331	446	22	et	et	PROPN
admet-331	446	23	al	al	PROPN
admet-331	446	24	.	.	PROPN
admet-331	446	25	,	,	PUNCT
admet-331	446	26	invest	invest	VERB
admet-331	446	27	.	.	PUNCT
admet-331	447	1	ophthalmol	ophthalmol	PROPN
admet-331	447	2	.	.	PUNCT
admet-331	448	1	vis	vis	X
admet-331	448	2	.	.	PUNCT
admet-331	449	1	sci	sci	PROPN
admet-331	449	2	.	.	PROPN
admet-331	450	1	57	57	NUM
admet-331	450	2	(	(	PUNCT
admet-331	450	3	2016	2016	NUM
admet-331	450	4	)	)	PUNCT
admet-331	450	5	2264–2276	2264–2276	NUM
admet-331	450	6	.	.	PUNCT
admet-331	451	1	[	[	X
admet-331	451	2	11	11	NUM
admet-331	451	3	]	]	PUNCT
admet-331	451	4	t.	t.	PROPN
admet-331	451	5	inoue	inoue	PROPN
admet-331	451	6	,	,	PUNCT
admet-331	451	7	h.	h.	PROPN
admet-331	451	8	tanihara	tanihara	PROPN
admet-331	451	9	,	,	PUNCT
admet-331	451	10	h.	h.	PROPN
admet-331	451	11	tokushige	tokushige	PROPN
admet-331	451	12	,	,	PUNCT
admet-331	451	13	m.	m.	NOUN
admet-331	451	14	araie	araie	PROPN
admet-331	451	15	,	,	PUNCT
admet-331	451	16	acta	acta	PROPN
admet-331	451	17	ophthalmol	ophthalmol	PROPN
admet-331	451	18	.	.	PUNCT
admet-331	452	1	93	93	NUM
admet-331	452	2	(	(	PUNCT
admet-331	452	3	2015	2015	NUM
admet-331	452	4	)	)	PUNCT
admet-331	452	5	e393	e393	PROPN
admet-331	452	6	–	–	PUNCT
admet-331	452	7	e395	e395	PROPN
admet-331	452	8	.	.	PUNCT
admet-331	453	1	[	[	X
admet-331	453	2	12	12	NUM
admet-331	453	3	]	]	PUNCT
admet-331	453	4	j.	j.	PROPN
admet-331	453	5	h.	h.	PROPN
admet-331	453	6	lee	lee	PROPN
admet-331	453	7	,	,	PUNCT
admet-331	453	8	y.	y.	PROPN
admet-331	453	9	zheng	zheng	PROPN
admet-331	453	10	,	,	PUNCT
admet-331	453	11	d.	d.	PROPN
admet-331	453	12	von	von	PROPN
admet-331	453	13	bornstadt	bornstadt	PROPN
admet-331	453	14	,	,	PUNCT
admet-331	453	15	y.	y.	PROPN
admet-331	453	16	wei	wei	PROPN
admet-331	453	17	,	,	PUNCT
admet-331	453	18	a.	a.	NOUN
admet-331	453	19	balcioglu	balcioglu	PROPN
admet-331	453	20	,	,	PUNCT
admet-331	453	21	a.	a.	NOUN
admet-331	453	22	daneshmand	daneshmand	PROPN
admet-331	453	23	,	,	PUNCT
admet-331	453	24	et	et	PROPN
admet-331	453	25	al	al	PROPN
admet-331	453	26	.	.	PROPN
admet-331	453	27	,	,	PUNCT
admet-331	453	28	ann	ann	PROPN
admet-331	453	29	.	.	PUNCT
admet-331	454	1	clin	clin	PROPN
admet-331	454	2	.	.	PUNCT
admet-331	455	1	transl	transl	PROPN
admet-331	455	2	.	.	PUNCT
admet-331	456	1	neurol	neurol	NOUN
admet-331	456	2	.	.	PUNCT
admet-331	457	1	1	1	NUM
admet-331	457	2	(	(	PUNCT
admet-331	457	3	2014	2014	NUM
admet-331	457	4	)	)	PUNCT
admet-331	457	5	2–14	2–14	NOUN
admet-331	457	6	.	.	PUNCT
admet-331	458	1	[	[	X
admet-331	458	2	13	13	NUM
admet-331	458	3	]	]	PUNCT
admet-331	458	4	j.	j.	PROPN
admet-331	458	5	m.	m.	PROPN
admet-331	458	6	sturdivant	sturdivant	PROPN
admet-331	458	7	,	,	PUNCT
admet-331	458	8	s.	s.	PROPN
admet-331	458	9	m.	m.	PROPN
admet-331	458	10	royalty	royalty	PROPN
admet-331	458	11	,	,	PUNCT
admet-331	458	12	c.	c.	PROPN
admet-331	458	13	w.	w.	PROPN
admet-331	458	14	lin	lin	PROPN
admet-331	458	15	,	,	PUNCT
admet-331	458	16	l.	l.	PROPN
admet-331	458	17	a.	a.	PROPN
admet-331	458	18	moore	moore	PROPN
admet-331	458	19	,	,	PUNCT
admet-331	458	20	j.	j.	PROPN
admet-331	458	21	d.	d.	PROPN
admet-331	458	22	yingling	yingling	PROPN
admet-331	458	23	,	,	PUNCT
admet-331	458	24	c.	c.	PROPN
admet-331	458	25	l.	l.	PROPN
admet-331	458	26	laethem	laethem	PROPN
admet-331	458	27	,	,	PUNCT
admet-331	458	28	et	et	PROPN
admet-331	458	29	al	al	PROPN
admet-331	458	30	.	.	PROPN
admet-331	458	31	,	,	PUNCT
admet-331	458	32	bioorganic	bioorganic	PROPN
admet-331	458	33	med	med	PROPN
admet-331	458	34	.	.	PROPN
admet-331	458	35	chem	chem	PROPN
admet-331	458	36	.	.	PUNCT
admet-331	459	1	lett	lett	PROPN
admet-331	459	2	.	.	PUNCT
admet-331	460	1	26	26	NUM
admet-331	460	2	(	(	PUNCT
admet-331	460	3	2016	2016	NUM
admet-331	460	4	)	)	PUNCT
admet-331	460	5	2475–2480	2475–2480	NUM
admet-331	460	6	.	.	PUNCT
admet-331	461	1	[	[	X
admet-331	461	2	14	14	NUM
admet-331	461	3	]	]	X
admet-331	461	4	r.	r.	PROPN
admet-331	461	5	a.	a.	PROPN
admet-331	461	6	lewis	lewis	PROPN
admet-331	461	7	,	,	PUNCT
admet-331	461	8	b.	b.	PROPN
admet-331	461	9	levy	levy	PROPN
admet-331	461	10	,	,	PUNCT
admet-331	461	11	n.	n.	PROPN
admet-331	461	12	ramirez	ramirez	PROPN
admet-331	461	13	,	,	PUNCT
admet-331	461	14	c.	c.	PROPN
admet-331	461	15	c	c	PROPN
admet-331	461	16	kopczynski	kopczynski	PROPN
admet-331	461	17	,	,	PUNCT
admet-331	461	18	d.	d.	PROPN
admet-331	461	19	w.	w.	PROPN
admet-331	461	20	usner	usner	PROPN
admet-331	461	21	,	,	PUNCT
admet-331	461	22	g.	g.	PROPN
admet-331	461	23	d.	d.	PROPN
admet-331	461	24	novack	novack	PROPN
admet-331	461	25	,	,	PUNCT
admet-331	461	26	br	br	PROPN
admet-331	461	27	.	.	PUNCT
admet-331	462	1	j.	j.	PROPN
admet-331	462	2	ophthalmol	ophthalmol	PROPN
admet-331	462	3	.	.	PROPN
admet-331	463	1	100	100	NUM
admet-331	463	2	(	(	PUNCT
admet-331	463	3	2016	2016	NUM
admet-331	463	4	)	)	PUNCT
admet-331	464	1	339–344	339–344	NUM
admet-331	464	2	.	.	PUNCT
admet-331	465	1	[	[	X
admet-331	465	2	15	15	NUM
admet-331	465	3	]	]	X
admet-331	465	4	j.	j.	PROPN
admet-331	465	5	bacharach	bacharach	PROPN
admet-331	465	6	,	,	PUNCT
admet-331	465	7	glaucoma	glaucoma	NOUN
admet-331	465	8	today	today	NOUN
admet-331	465	9	(	(	PUNCT
admet-331	465	10	2016	2016	NUM
admet-331	465	11	)	)	PUNCT
admet-331	465	12	43–45	43–45	PROPN
admet-331	465	13	.	.	PUNCT
admet-331	465	14	éva	éva	PROPN
admet-331	465	15	halász	halász	PROPN
admet-331	465	16	,	,	PUNCT
admet-331	465	17	ellen	ellen	PROPN
admet-331	465	18	townes	townes	PROPN
admet-331	465	19	-	-	PUNCT
admet-331	465	20	anderson	anderson	PROPN
admet-331	465	21	admet	admet	PROPN
admet-331	465	22	&	&	CCONJ
admet-331	465	23	dmpk	dmpk	PROPN
admet-331	465	24	4(4	4(4	NUM
admet-331	465	25	)	)	PUNCT
admet-331	465	26	(	(	PUNCT
admet-331	465	27	2016	2016	NUM
admet-331	465	28	)	)	PUNCT
admet-331	465	29	280	280	NUM
admet-331	465	30	-	-	SYM
admet-331	465	31	301	301	NUM
admet-331	465	32	298	298	NUM
admet-331	466	1	[	[	X
admet-331	466	2	16	16	NUM
admet-331	466	3	]	]	PUNCT
admet-331	466	4	k.	k.	NOUN
admet-331	466	5	hollanders	hollander	NOUN
admet-331	466	6	,	,	PUNCT
admet-331	466	7	t.	t.	PROPN
admet-331	466	8	van	van	PROPN
admet-331	466	9	bergen	bergen	PROPN
admet-331	466	10	,	,	PUNCT
admet-331	466	11	n.	n.	PROPN
admet-331	466	12	kindt	kindt	PROPN
admet-331	466	13	,	,	PUNCT
admet-331	466	14	k.	k.	PROPN
admet-331	466	15	castermans	castermans	PROPN
admet-331	466	16	,	,	PUNCT
admet-331	466	17	d.	d.	PROPN
admet-331	466	18	leysen	leysen	PROPN
admet-331	466	19	,	,	PUNCT
admet-331	466	20	e.	e.	PROPN
admet-331	466	21	vandewalle	vandewalle	PROPN
admet-331	466	22	,	,	PUNCT
admet-331	466	23	et	et	PROPN
admet-331	466	24	al	al	PROPN
admet-331	466	25	.	.	PROPN
admet-331	466	26	,	,	PUNCT
admet-331	466	27	invest	invest	VERB
admet-331	466	28	.	.	PUNCT
admet-331	467	1	ophthalmol	ophthalmol	PROPN
admet-331	467	2	.	.	PUNCT
admet-331	468	1	vis	vis	X
admet-331	468	2	.	.	PUNCT
admet-331	469	1	sci	sci	PROPN
admet-331	469	2	.	.	PROPN
admet-331	470	1	56	56	NUM
admet-331	470	2	(	(	PUNCT
admet-331	470	3	2015	2015	NUM
admet-331	470	4	)	)	PUNCT
admet-331	470	5	1335–1348	1335–1348	NUM
admet-331	470	6	.	.	PUNCT
admet-331	471	1	[	[	X
admet-331	471	2	17	17	NUM
admet-331	471	3	]	]	PUNCT
admet-331	471	4	k.	k.	NOUN
admet-331	471	5	riento	riento	PROPN
admet-331	471	6	,	,	PUNCT
admet-331	471	7	a.	a.	PROPN
admet-331	471	8	j.	j.	PROPN
admet-331	471	9	ridley	ridley	PROPN
admet-331	471	10	,	,	PUNCT
admet-331	471	11	nat	nat	PROPN
admet-331	471	12	.	.	PUNCT
admet-331	472	1	rev	rev	PROPN
admet-331	472	2	.	.	PROPN
admet-331	473	1	mol	mol	ADP
admet-331	473	2	.cell	.cell	PROPN
admet-331	473	3	.	.	PUNCT
admet-331	474	1	biol	biol	PROPN
admet-331	474	2	.	.	PUNCT
admet-331	475	1	4	4	NUM
admet-331	475	2	(	(	PUNCT
admet-331	475	3	2003	2003	NUM
admet-331	475	4	)	)	PUNCT
admet-331	476	1	446–456	446–456	NUM
admet-331	476	2	.	.	PUNCT
admet-331	477	1	[	[	X
admet-331	477	2	18	18	NUM
admet-331	477	3	]	]	PUNCT
admet-331	477	4	t.	t.	PROPN
admet-331	477	5	leung	leung	PROPN
admet-331	477	6	,	,	PUNCT
admet-331	477	7	x.	x.	PROPN
admet-331	477	8	q.	q.	PROPN
admet-331	477	9	chen	chen	PROPN
admet-331	477	10	,	,	PUNCT
admet-331	477	11	e.	e.	PROPN
admet-331	477	12	manser	manser	PROPN
admet-331	477	13	,	,	PUNCT
admet-331	477	14	l.	l.	PROPN
admet-331	477	15	lim	lim	PROPN
admet-331	477	16	,	,	PUNCT
admet-331	477	17	mol	mol	PROPN
admet-331	477	18	.	.	PROPN
admet-331	477	19	cell	cell	NOUN
admet-331	477	20	.	.	PUNCT
admet-331	478	1	biol	biol	PROPN
admet-331	478	2	.	.	PUNCT
admet-331	479	1	16	16	NUM
admet-331	479	2	(	(	PUNCT
admet-331	479	3	1996	1996	NUM
admet-331	479	4	)	)	PUNCT
admet-331	479	5	5313–5327	5313–5327	NUM
admet-331	479	6	.	.	PUNCT
admet-331	480	1	[	[	X
admet-331	480	2	19	19	NUM
admet-331	480	3	]	]	PUNCT
admet-331	480	4	m.	m.	PROPN
admet-331	480	5	f.	f.	PROPN
admet-331	480	6	olson	olson	PROPN
admet-331	480	7	,	,	PUNCT
admet-331	480	8	curr	curr	PROPN
admet-331	480	9	.	.	PUNCT
admet-331	480	10	opin	opin	NOUN
admet-331	480	11	.	.	PUNCT
admet-331	481	1	cell	cell	NOUN
admet-331	481	2	biol	biol	PROPN
admet-331	481	3	.	.	PUNCT
admet-331	482	1	20	20	NUM
admet-331	482	2	(	(	PUNCT
admet-331	482	3	2008	2008	NUM
admet-331	482	4	)	)	PUNCT
admet-331	483	1	242–248	242–248	NUM
admet-331	483	2	.	.	PUNCT
admet-331	484	1	[	[	X
admet-331	484	2	20	20	NUM
admet-331	484	3	]	]	PUNCT
admet-331	484	4	a.	a.	NOUN
admet-331	484	5	p.	p.	NOUN
admet-331	484	6	somlyo	somlyo	PROPN
admet-331	484	7	,	,	PUNCT
admet-331	484	8	a.	a.	NOUN
admet-331	484	9	v	v	NOUN
admet-331	484	10	somlyo	somlyo	PROPN
admet-331	484	11	,	,	PUNCT
admet-331	484	12	j.	j.	PROPN
admet-331	484	13	physiol	physiol	PROPN
admet-331	484	14	.	.	PUNCT
admet-331	485	1	522	522	NUM
admet-331	485	2	pt	pt	NOUN
admet-331	485	3	2	2	NUM
admet-331	485	4	(	(	PUNCT
admet-331	485	5	2000	2000	NUM
admet-331	485	6	)	)	PUNCT
admet-331	485	7	177–85	177–85	NUM
admet-331	485	8	.	.	PUNCT
admet-331	486	1	[	[	X
admet-331	486	2	21	21	NUM
admet-331	486	3	]	]	X
admet-331	486	4	m.	m.	NOUN
admet-331	486	5	amano	amano	PROPN
admet-331	486	6	,	,	PUNCT
admet-331	486	7	m.	m.	PROPN
admet-331	486	8	ito	ito	PROPN
admet-331	486	9	,	,	PUNCT
admet-331	486	10	y.	y.	PROPN
admet-331	486	11	fukata	fukata	PROPN
admet-331	486	12	,	,	PUNCT
admet-331	486	13	k.	k.	PROPN
admet-331	486	14	chihara	chihara	PROPN
admet-331	486	15	,	,	PUNCT
admet-331	486	16	t.	t.	PROPN
admet-331	486	17	nakano	nakano	PROPN
admet-331	486	18	,	,	PUNCT
admet-331	486	19	y.	y.	PROPN
admet-331	486	20	matsuura	matsuura	PROPN
admet-331	486	21	,	,	PUNCT
admet-331	486	22	et	et	PROPN
admet-331	486	23	al	al	PROPN
admet-331	486	24	.	.	PROPN
admet-331	486	25	,	,	PUNCT
admet-331	486	26	j.	j.	PROPN
admet-331	486	27	biol	biol	PROPN
admet-331	486	28	.	.	PUNCT
admet-331	487	1	chem	chem	PROPN
admet-331	487	2	.	.	PUNCT
admet-331	488	1	271	271	NUM
admet-331	488	2	(	(	PUNCT
admet-331	488	3	1996	1996	NUM
admet-331	488	4	)	)	PUNCT
admet-331	488	5	20246–20249	20246–20249	NUM
admet-331	488	6	.	.	PUNCT
admet-331	489	1	[	[	X
admet-331	489	2	22	22	NUM
admet-331	489	3	]	]	PUNCT
admet-331	489	4	k.	k.	PROPN
admet-331	489	5	kimura	kimura	PROPN
admet-331	489	6	,	,	PUNCT
admet-331	489	7	m.	m.	PROPN
admet-331	489	8	ito	ito	PROPN
admet-331	489	9	,	,	PUNCT
admet-331	489	10	m.	m.	NOUN
admet-331	489	11	amano	amano	PROPN
admet-331	489	12	,	,	PUNCT
admet-331	489	13	k.	k.	PROPN
admet-331	489	14	chihara	chihara	PROPN
admet-331	489	15	,	,	PUNCT
admet-331	489	16	y.	y.	PROPN
admet-331	489	17	fukata	fukata	PROPN
admet-331	489	18	,	,	PUNCT
admet-331	489	19	m.	m.	NOUN
admet-331	489	20	nakafuku	nakafuku	NOUN
admet-331	489	21	,	,	PUNCT
admet-331	489	22	et	et	PROPN
admet-331	489	23	al	al	PROPN
admet-331	489	24	.	.	PROPN
admet-331	489	25	,	,	PUNCT
admet-331	489	26	science	science	NOUN
admet-331	489	27	273	273	NUM
admet-331	489	28	(	(	PUNCT
admet-331	489	29	1996	1996	NUM
admet-331	489	30	)	)	PUNCT
admet-331	490	1	245–248	245–248	NUM
admet-331	490	2	.	.	PUNCT
admet-331	491	1	[	[	X
admet-331	491	2	23	23	NUM
admet-331	491	3	]	]	PUNCT
admet-331	491	4	m.	m.	NOUN
admet-331	491	5	maekawa	maekawa	PROPN
admet-331	491	6	,	,	PUNCT
admet-331	491	7	science	science	NOUN
admet-331	491	8	(	(	PUNCT
admet-331	491	9	80-	80-	NUM
admet-331	491	10	.	.	NUM
admet-331	491	11	)	)	PUNCT
admet-331	491	12	.	.	PUNCT
admet-331	492	1	285	285	NUM
admet-331	492	2	(	(	PUNCT
admet-331	492	3	1999	1999	NUM
admet-331	492	4	)	)	PUNCT
admet-331	492	5	895–898	895–898	NUM
admet-331	492	6	.	.	PUNCT
admet-331	493	1	[	[	X
admet-331	493	2	24	24	NUM
admet-331	493	3	]	]	PUNCT
admet-331	493	4	m.	m.	NOUN
admet-331	493	5	amano	amano	PROPN
admet-331	493	6	,	,	PUNCT
admet-331	493	7	y.	y.	PROPN
admet-331	493	8	fukata	fukata	PROPN
admet-331	493	9	,	,	PUNCT
admet-331	493	10	k.	k.	PROPN
admet-331	493	11	kaibuchi	kaibuchi	PROPN
admet-331	493	12	,	,	PUNCT
admet-331	493	13	exp	exp	NOUN
admet-331	493	14	.	.	PROPN
admet-331	493	15	cell	cell	NOUN
admet-331	493	16	res	re	NOUN
admet-331	493	17	.	.	PUNCT
admet-331	494	1	261	261	NUM
admet-331	494	2	(	(	PUNCT
admet-331	494	3	2000	2000	NUM
admet-331	494	4	)	)	PUNCT
admet-331	494	5	44–51	44–51	NUM
admet-331	494	6	.	.	PUNCT
admet-331	495	1	[	[	X
admet-331	495	2	25	25	NUM
admet-331	495	3	]	]	X
admet-331	495	4	y.	y.	PROPN
admet-331	495	5	shimizu	shimizu	PROPN
admet-331	495	6	,	,	PUNCT
admet-331	495	7	d.	d.	PROPN
admet-331	495	8	thumkeo	thumkeo	PROPN
admet-331	495	9	,	,	PUNCT
admet-331	495	10	j.	j.	PROPN
admet-331	495	11	keel	keel	PROPN
admet-331	495	12	,	,	PUNCT
admet-331	495	13	t.	t.	PROPN
admet-331	495	14	ishizaki	ishizaki	PROPN
admet-331	495	15	,	,	PUNCT
admet-331	495	16	h.	h.	PROPN
admet-331	495	17	oshima	oshima	PROPN
admet-331	495	18	,	,	PUNCT
admet-331	495	19	m.	m.	NOUN
admet-331	495	20	oshima	oshima	PROPN
admet-331	495	21	,	,	PUNCT
admet-331	495	22	et	et	PROPN
admet-331	495	23	al	al	PROPN
admet-331	495	24	.	.	PROPN
admet-331	495	25	,	,	PUNCT
admet-331	495	26	j.	j.	PROPN
admet-331	495	27	cell	cell	PROPN
admet-331	495	28	biol	biol	PROPN
admet-331	495	29	.	.	PUNCT
admet-331	496	1	168	168	NUM
admet-331	496	2	(	(	PUNCT
admet-331	496	3	2005	2005	NUM
admet-331	496	4	)	)	PUNCT
admet-331	496	5	941	941	NUM
admet-331	496	6	–	–	PUNCT
admet-331	496	7	953	953	NUM
admet-331	496	8	.	.	PUNCT
admet-331	497	1	[	[	X
admet-331	497	2	26	26	NUM
admet-331	497	3	]	]	X
admet-331	497	4	d.	d.	PROPN
admet-331	497	5	thumkeo	thumkeo	PROPN
admet-331	497	6	,	,	PUNCT
admet-331	497	7	j.	j.	PROPN
admet-331	497	8	keel	keel	PROPN
admet-331	497	9	,	,	PUNCT
admet-331	497	10	t.	t.	PROPN
admet-331	497	11	ishizaki	ishizaki	PROPN
admet-331	497	12	,	,	PUNCT
admet-331	497	13	m.	m.	PROPN
admet-331	497	14	hirose	hirose	PROPN
admet-331	497	15	,	,	PUNCT
admet-331	497	16	k.	k.	PROPN
admet-331	497	17	nonomura	nonomura	PROPN
admet-331	497	18	,	,	PUNCT
admet-331	497	19	h.	h.	PROPN
admet-331	497	20	oshima	oshima	PROPN
admet-331	497	21	,	,	PUNCT
admet-331	497	22	et	et	PROPN
admet-331	497	23	al	al	PROPN
admet-331	497	24	.	.	PROPN
admet-331	497	25	,	,	PUNCT
admet-331	497	26	mol	mol	PROPN
admet-331	497	27	.	.	PROPN
admet-331	497	28	cell	cell	NOUN
admet-331	497	29	.	.	PUNCT
admet-331	498	1	biol	biol	PROPN
admet-331	498	2	.	.	PUNCT
admet-331	499	1	23	23	NUM
admet-331	499	2	(	(	PUNCT
admet-331	499	3	2003	2003	NUM
admet-331	499	4	)	)	PUNCT
admet-331	499	5	5043–55	5043–55	ADP
admet-331	499	6	.	.	PUNCT
admet-331	500	1	[	[	X
admet-331	500	2	27	27	NUM
admet-331	500	3	]	]	X
admet-331	500	4	d.	d.	PROPN
admet-331	500	5	thumkeo	thumkeo	PROPN
admet-331	500	6	,	,	PUNCT
admet-331	500	7	y.	y.	PROPN
admet-331	500	8	shimizu	shimizu	PROPN
admet-331	500	9	,	,	PUNCT
admet-331	500	10	s.	s.	PROPN
admet-331	500	11	sakamoto	sakamoto	PROPN
admet-331	500	12	,	,	PUNCT
admet-331	500	13	s.	s.	PROPN
admet-331	500	14	yamada	yamada	PROPN
admet-331	500	15	,	,	PUNCT
admet-331	500	16	s.	s.	PROPN
admet-331	500	17	narumiya	narumiya	PROPN
admet-331	500	18	,	,	PUNCT
admet-331	500	19	genes	gene	NOUN
admet-331	500	20	to	to	ADP
admet-331	500	21	cells	cell	NOUN
admet-331	500	22	10	10	NUM
admet-331	500	23	(	(	PUNCT
admet-331	500	24	2005	2005	NUM
admet-331	500	25	)	)	PUNCT
admet-331	500	26	825–834	825–834	NUM
admet-331	500	27	.	.	PUNCT
admet-331	501	1	[	[	X
admet-331	501	2	28	28	NUM
admet-331	501	3	]	]	X
admet-331	501	4	c.	c.	PROPN
admet-331	501	5	fukiage	fukiage	PROPN
admet-331	501	6	,	,	PUNCT
admet-331	501	7	k.	k.	PROPN
admet-331	501	8	mizutani	mizutani	PROPN
admet-331	501	9	,	,	PUNCT
admet-331	501	10	y.	y.	PROPN
admet-331	501	11	kawamoto	kawamoto	PROPN
admet-331	501	12	,	,	PUNCT
admet-331	501	13	m.	m.	NOUN
admet-331	501	14	azuma	azuma	PROPN
admet-331	501	15	,	,	PUNCT
admet-331	501	16	t.	t.	PROPN
admet-331	501	17	r.	r.	PROPN
admet-331	501	18	shearer	shearer	PROPN
admet-331	501	19	,	,	PUNCT
admet-331	501	20	biochem	biochem	PROPN
admet-331	501	21	.	.	PUNCT
admet-331	502	1	biophys	biophy	NOUN
admet-331	502	2	.	.	PUNCT
admet-331	503	1	res	re	NOUN
admet-331	503	2	.	.	PUNCT
admet-331	504	1	commun	commun	PROPN
admet-331	504	2	.	.	PUNCT
admet-331	505	1	288	288	NUM
admet-331	505	2	(	(	PUNCT
admet-331	505	3	2001	2001	NUM
admet-331	505	4	)	)	PUNCT
admet-331	505	5	296–300	296–300	NUM
admet-331	505	6	.	.	PUNCT
admet-331	506	1	[	[	X
admet-331	506	2	29	29	NUM
admet-331	506	3	]	]	X
admet-331	506	4	n.	n.	PROPN
admet-331	506	5	okumura	okumura	PROPN
admet-331	506	6	,	,	PUNCT
admet-331	506	7	m.	m.	PROPN
admet-331	506	8	ueno	ueno	PROPN
admet-331	506	9	,	,	PUNCT
admet-331	506	10	n.	n.	PROPN
admet-331	506	11	koizumi	koizumi	PROPN
admet-331	506	12	,	,	PUNCT
admet-331	506	13	y.	y.	PROPN
admet-331	506	14	sakamoto	sakamoto	PROPN
admet-331	506	15	,	,	PUNCT
admet-331	506	16	k.	k.	PROPN
admet-331	506	17	hirata	hirata	PROPN
admet-331	506	18	,	,	PUNCT
admet-331	506	19	j.	j.	PROPN
admet-331	506	20	hamuro	hamuro	PROPN
admet-331	506	21	,	,	PUNCT
admet-331	506	22	et	et	PROPN
admet-331	506	23	al	al	PROPN
admet-331	506	24	.	.	PROPN
admet-331	506	25	,	,	PUNCT
admet-331	506	26	invest	invest	VERB
admet-331	506	27	.	.	PUNCT
admet-331	507	1	ophthalmol	ophthalmol	PROPN
admet-331	507	2	.	.	PUNCT
admet-331	508	1	vis	vis	X
admet-331	508	2	.	.	PUNCT
admet-331	509	1	sci	sci	PROPN
admet-331	509	2	.	.	PROPN
admet-331	510	1	50	50	NUM
admet-331	510	2	(	(	PUNCT
admet-331	510	3	2009	2009	NUM
admet-331	510	4	)	)	PUNCT
admet-331	510	5	3680–3687	3680–3687	NUM
admet-331	510	6	.	.	PUNCT
admet-331	511	1	[	[	X
admet-331	511	2	30	30	NUM
admet-331	511	3	]	]	X
admet-331	511	4	n.	n.	NOUN
admet-331	511	5	okumura	okumura	PROPN
admet-331	511	6	,	,	PUNCT
admet-331	511	7	n.	n.	PROPN
admet-331	511	8	koizumi	koizumi	PROPN
admet-331	511	9	,	,	PUNCT
admet-331	511	10	e.	e.	PROPN
admet-331	511	11	p.	p.	PROPN
admet-331	511	12	kay	kay	PROPN
admet-331	511	13	,	,	PUNCT
admet-331	511	14	m.	m.	PROPN
admet-331	511	15	ueno	ueno	PROPN
admet-331	511	16	,	,	PUNCT
admet-331	511	17	y.	y.	PROPN
admet-331	511	18	sakamoto	sakamoto	PROPN
admet-331	511	19	,	,	PUNCT
admet-331	511	20	s.	s.	PROPN
admet-331	511	21	nakamura	nakamura	PROPN
admet-331	511	22	,	,	PUNCT
admet-331	511	23	et	et	PROPN
admet-331	511	24	al	al	PROPN
admet-331	511	25	.	.	PROPN
admet-331	511	26	,	,	PUNCT
admet-331	511	27	invest	invest	VERB
admet-331	511	28	.	.	PUNCT
admet-331	512	1	ophthalmol	ophthalmol	PROPN
admet-331	512	2	.	.	PUNCT
admet-331	513	1	vis	vis	X
admet-331	513	2	.	.	PUNCT
admet-331	514	1	sci	sci	PROPN
admet-331	514	2	.	.	PROPN
admet-331	514	3	54	54	NUM
admet-331	514	4	(	(	PUNCT
admet-331	514	5	2013	2013	NUM
admet-331	514	6	)	)	PUNCT
admet-331	514	7	2493–2502	2493–2502	NUM
admet-331	514	8	.	.	PUNCT
admet-331	515	1	[	[	X
admet-331	515	2	31	31	NUM
admet-331	515	3	]	]	X
admet-331	515	4	n.	n.	PROPN
admet-331	515	5	okumura	okumura	PROPN
admet-331	515	6	,	,	PUNCT
admet-331	515	7	r.	r.	PROPN
admet-331	515	8	inoue	inoue	PROPN
admet-331	515	9	,	,	PUNCT
admet-331	515	10	y.	y.	PROPN
admet-331	515	11	okazaki	okazaki	PROPN
admet-331	515	12	,	,	PUNCT
admet-331	515	13	s.	s.	PROPN
admet-331	515	14	nakano	nakano	PROPN
admet-331	515	15	,	,	PUNCT
admet-331	515	16	h.	h.	PROPN
admet-331	515	17	nakagawa	nakagawa	PROPN
admet-331	515	18	,	,	PUNCT
admet-331	515	19	s.	s.	PROPN
admet-331	515	20	kinoshita	kinoshita	PROPN
admet-331	515	21	,	,	PUNCT
admet-331	515	22	et	et	PROPN
admet-331	515	23	al	al	PROPN
admet-331	515	24	.	.	PROPN
admet-331	515	25	,	,	PUNCT
admet-331	515	26	invest	invest	VERB
admet-331	515	27	.	.	PUNCT
admet-331	516	1	ophthalmol	ophthalmol	PROPN
admet-331	516	2	.	.	PUNCT
admet-331	517	1	vis	vis	X
admet-331	517	2	.	.	PUNCT
admet-331	518	1	sci	sci	PROPN
admet-331	518	2	.	.	PROPN
admet-331	519	1	56	56	NUM
admet-331	519	2	(	(	PUNCT
admet-331	519	3	2015	2015	NUM
admet-331	519	4	)	)	PUNCT
admet-331	519	5	6067–6074	6067–6074	NUM
admet-331	519	6	.	.	PUNCT
admet-331	520	1	[	[	X
admet-331	520	2	32	32	NUM
admet-331	520	3	]	]	X
admet-331	520	4	y.	y.	PROPN
admet-331	520	5	q.	q.	PROPN
admet-331	520	6	soh	soh	PROPN
admet-331	520	7	,	,	PUNCT
admet-331	520	8	g.	g.	PROPN
admet-331	520	9	peh	peh	PROPN
admet-331	520	10	,	,	PUNCT
admet-331	520	11	b.	b.	PROPN
admet-331	520	12	l.	l.	PROPN
admet-331	520	13	george	george	PROPN
admet-331	520	14	,	,	PUNCT
admet-331	520	15	x.	x.	PROPN
admet-331	520	16	y.	y.	PROPN
admet-331	520	17	seah	seah	PROPN
admet-331	520	18	,	,	PUNCT
admet-331	520	19	n.	n.	PROPN
admet-331	520	20	k.	k.	PROPN
admet-331	520	21	primalani	primalani	PROPN
admet-331	520	22	,	,	PUNCT
admet-331	520	23	k.	k.	PROPN
admet-331	520	24	adnan	adnan	PROPN
admet-331	520	25	,	,	PUNCT
admet-331	520	26	et	et	PROPN
admet-331	520	27	al	al	PROPN
admet-331	520	28	.	.	PROPN
admet-331	520	29	,	,	PUNCT
admet-331	520	30	invest	invest	VERB
admet-331	520	31	.	.	PUNCT
admet-331	521	1	opthalmology	opthalmology	NOUN
admet-331	521	2	vis	vis	X
admet-331	521	3	.	.	PUNCT
admet-331	521	4	sci	sci	PROPN
admet-331	521	5	.	.	PROPN
admet-331	522	1	57	57	NUM
admet-331	522	2	(	(	PUNCT
admet-331	522	3	2016	2016	NUM
admet-331	522	4	)	)	PUNCT
admet-331	522	5	338	338	NUM
admet-331	522	6	-	-	SYM
admet-331	522	7	348	348	NUM
admet-331	522	8	.	.	PUNCT
admet-331	523	1	[	[	X
admet-331	523	2	33	33	NUM
admet-331	523	3	]	]	X
admet-331	523	4	n.	n.	PROPN
admet-331	523	5	okumura	okumura	PROPN
admet-331	523	6	,	,	PUNCT
admet-331	523	7	n.	n.	PROPN
admet-331	523	8	koizumi	koizumi	PROPN
admet-331	523	9	,	,	PUNCT
admet-331	523	10	m.	m.	PROPN
admet-331	523	11	ueno	ueno	PROPN
admet-331	523	12	,	,	PUNCT
admet-331	523	13	y.	y.	PROPN
admet-331	523	14	sakamoto	sakamoto	PROPN
admet-331	523	15	,	,	PUNCT
admet-331	523	16	h.	h.	PROPN
admet-331	523	17	takahashi	takahashi	PROPN
admet-331	523	18	,	,	PUNCT
admet-331	523	19	h.	h.	PROPN
admet-331	523	20	tsuchiya	tsuchiya	PROPN
admet-331	523	21	,	,	PUNCT
admet-331	523	22	et	et	PROPN
admet-331	523	23	al	al	PROPN
admet-331	523	24	.	.	PROPN
admet-331	523	25	,	,	PUNCT
admet-331	523	26	am	be	AUX
admet-331	523	27	.	.	PUNCT
admet-331	524	1	j.	j.	PROPN
admet-331	524	2	pathol	pathol	PROPN
admet-331	524	3	.	.	PUNCT
admet-331	525	1	181	181	NUM
admet-331	525	2	(	(	PUNCT
admet-331	525	3	2012	2012	NUM
admet-331	525	4	)	)	PUNCT
admet-331	526	1	268–277	268–277	NUM
admet-331	526	2	.	.	PUNCT
admet-331	527	1	[	[	X
admet-331	527	2	34	34	NUM
admet-331	527	3	]	]	X
admet-331	527	4	c.	c.	PROPN
admet-331	527	5	bostan	bostan	PROPN
admet-331	527	6	,	,	PUNCT
admet-331	527	7	m.	m.	NOUN
admet-331	527	8	thériault	thériault	NOUN
admet-331	527	9	,	,	PUNCT
admet-331	527	10	k.	k.	PROPN
admet-331	527	11	j.	j.	PROPN
admet-331	527	12	forget	forget	PROPN
admet-331	527	13	,	,	PUNCT
admet-331	527	14	c.	c.	PROPN
admet-331	527	15	doyon	doyon	PROPN
admet-331	527	16	,	,	PUNCT
admet-331	527	17	j.	j.	PROPN
admet-331	527	18	d.	d.	PROPN
admet-331	527	19	cameron	cameron	PROPN
admet-331	527	20	,	,	PUNCT
admet-331	527	21	s.	s.	PROPN
admet-331	527	22	proulx	proulx	PROPN
admet-331	527	23	,	,	PUNCT
admet-331	527	24	et	et	PROPN
admet-331	527	25	al	al	PROPN
admet-331	527	26	.	.	PROPN
admet-331	527	27	,	,	PUNCT
admet-331	527	28	invest	invest	VERB
admet-331	527	29	.	.	PUNCT
admet-331	528	1	ophthalmol	ophthalmol	PROPN
admet-331	528	2	.	.	PUNCT
admet-331	529	1	vis	vis	X
admet-331	529	2	.	.	PUNCT
admet-331	530	1	sci	sci	PROPN
admet-331	530	2	.	.	PROPN
admet-331	531	1	57	57	NUM
admet-331	531	2	(	(	PUNCT
admet-331	531	3	2016	2016	NUM
admet-331	531	4	)	)	PUNCT
admet-331	531	5	1620–34	1620–34	NUM
admet-331	531	6	.	.	PUNCT
admet-331	532	1	[	[	X
admet-331	532	2	35	35	NUM
admet-331	532	3	]	]	X
admet-331	532	4	n.	n.	PROPN
admet-331	532	5	koizumi	koizumi	PROPN
admet-331	532	6	,	,	PUNCT
admet-331	532	7	n.	n.	PROPN
admet-331	532	8	okumura	okumura	PROPN
admet-331	532	9	,	,	PUNCT
admet-331	532	10	m.	m.	PROPN
admet-331	532	11	ueno	ueno	PROPN
admet-331	532	12	,	,	PUNCT
admet-331	532	13	h.	h.	PROPN
admet-331	532	14	nakagawa	nakagawa	PROPN
admet-331	532	15	,	,	PUNCT
admet-331	532	16	j.	j.	PROPN
admet-331	532	17	hamuro	hamuro	PROPN
admet-331	532	18	,	,	PUNCT
admet-331	532	19	s.	s.	PROPN
admet-331	532	20	kinoshita	kinoshita	PROPN
admet-331	532	21	,	,	PUNCT
admet-331	532	22	cornea	cornea	NOUN
admet-331	532	23	32	32	NUM
admet-331	532	24	(	(	PUNCT
admet-331	532	25	2013	2013	NUM
admet-331	532	26	)	)	PUNCT
admet-331	532	27	1167	1167	NUM
admet-331	532	28	–	–	PUNCT
admet-331	532	29	1170	1170	NUM
admet-331	532	30	.	.	PUNCT
admet-331	533	1	[	[	X
admet-331	533	2	36	36	NUM
admet-331	533	3	]	]	X
admet-331	533	4	n.	n.	PROPN
admet-331	533	5	okumura	okumura	PROPN
admet-331	533	6	,	,	PUNCT
admet-331	533	7	s.	s.	PROPN
admet-331	533	8	nakano	nakano	PROPN
admet-331	533	9	,	,	PUNCT
admet-331	533	10	e.	e.	PROPN
admet-331	533	11	p.	p.	PROPN
admet-331	533	12	kay	kay	PROPN
admet-331	533	13	,	,	PUNCT
admet-331	533	14	r.	r.	PROPN
admet-331	533	15	numata	numata	PROPN
admet-331	533	16	,	,	PUNCT
admet-331	533	17	a.	a.	PROPN
admet-331	533	18	ota	ota	PROPN
admet-331	533	19	,	,	PUNCT
admet-331	533	20	y.	y.	PROPN
admet-331	533	21	sowa	sowa	PROPN
admet-331	533	22	,	,	PUNCT
admet-331	533	23	et	et	PROPN
admet-331	533	24	al	al	PROPN
admet-331	533	25	.	.	PROPN
admet-331	533	26	,	,	PUNCT
admet-331	533	27	invest	invest	VERB
admet-331	533	28	.	.	PUNCT
admet-331	534	1	ophthalmol	ophthalmol	PROPN
admet-331	534	2	.	.	PUNCT
admet-331	535	1	vis	vis	X
admet-331	535	2	.	.	PUNCT
admet-331	536	1	sci	sci	PROPN
admet-331	536	2	.	.	PROPN
admet-331	537	1	55	55	NUM
admet-331	537	2	(	(	PUNCT
admet-331	537	3	2014	2014	NUM
admet-331	537	4	)	)	PUNCT
admet-331	538	1	318–329	318–329	NUM
admet-331	538	2	.	.	PUNCT
admet-331	539	1	[	[	X
admet-331	539	2	37	37	NUM
admet-331	539	3	]	]	X
admet-331	539	4	n.	n.	NOUN
admet-331	539	5	okumura	okumura	PROPN
admet-331	539	6	,	,	PUNCT
admet-331	539	7	y.	y.	PROPN
admet-331	539	8	okazaki	okazaki	PROPN
admet-331	539	9	,	,	PUNCT
admet-331	539	10	r.	r.	PROPN
admet-331	539	11	inoue	inoue	PROPN
admet-331	539	12	,	,	PUNCT
admet-331	539	13	k.	k.	PROPN
admet-331	539	14	kakutani	kakutani	PROPN
admet-331	539	15	,	,	PUNCT
admet-331	539	16	s.	s.	PROPN
admet-331	539	17	nakano	nakano	PROPN
admet-331	539	18	,	,	PUNCT
admet-331	539	19	s.	s.	PROPN
admet-331	539	20	kinoshita	kinoshita	PROPN
admet-331	539	21	,	,	PUNCT
admet-331	539	22	et	et	PROPN
admet-331	539	23	al	al	PROPN
admet-331	539	24	.	.	PROPN
admet-331	539	25	,	,	PUNCT
admet-331	539	26	invest	invest	VERB
admet-331	539	27	.	.	PUNCT
admet-331	540	1	ophthalmol	ophthalmol	PROPN
admet-331	540	2	.	.	PUNCT
admet-331	541	1	vis	vis	X
admet-331	541	2	.	.	PUNCT
admet-331	542	1	sci	sci	PROPN
admet-331	542	2	.	.	PROPN
admet-331	543	1	57	57	NUM
admet-331	543	2	(	(	PUNCT
admet-331	543	3	2016	2016	NUM
admet-331	543	4	)	)	PUNCT
admet-331	543	5	1284–1292	1284–1292	NUM
admet-331	543	6	.	.	PUNCT
admet-331	544	1	[	[	X
admet-331	544	2	38	38	NUM
admet-331	544	3	]	]	X
admet-331	544	4	y.	y.	PROPN
admet-331	544	5	hata	hata	PROPN
admet-331	544	6	,	,	PUNCT
admet-331	544	7	m.	m.	NOUN
admet-331	544	8	miura	miura	PROPN
admet-331	544	9	,	,	PUNCT
admet-331	544	10	s.	s.	PROPN
admet-331	544	11	nakao	nakao	PROPN
admet-331	544	12	,	,	PUNCT
admet-331	544	13	s.	s.	PROPN
admet-331	544	14	kawahara	kawahara	PROPN
admet-331	544	15	,	,	PUNCT
admet-331	544	16	t.	t.	PROPN
admet-331	544	17	kita	kita	PROPN
admet-331	544	18	,	,	PUNCT
admet-331	544	19	t.	t.	PROPN
admet-331	544	20	ishibashi	ishibashi	PROPN
admet-331	544	21	,	,	PUNCT
admet-331	544	22	jpn	jpn	PROPN
admet-331	544	23	.	.	PUNCT
admet-331	545	1	j.	j.	PROPN
admet-331	545	2	ophthalmol	ophthalmol	PROPN
admet-331	545	3	.	.	PROPN
admet-331	546	1	52	52	NUM
admet-331	546	2	(	(	PUNCT
admet-331	546	3	2008	2008	NUM
admet-331	546	4	)	)	PUNCT
admet-331	547	1	16–23	16–23	NUM
admet-331	547	2	.	.	PUNCT
admet-331	548	1	[	[	X
admet-331	548	2	39	39	NUM
admet-331	548	3	]	]	PUNCT
admet-331	548	4	m.	m.	NOUN
admet-331	548	5	k.	k.	PROPN
admet-331	548	6	fink	fink	PROPN
admet-331	548	7	,	,	PUNCT
admet-331	548	8	r.	r.	PROPN
admet-331	548	9	r.	r.	PROPN
admet-331	548	10	mohan	mohan	PROPN
admet-331	548	11	,	,	PUNCT
admet-331	548	12	s.	s.	PROPN
admet-331	548	13	gupta	gupta	PROPN
admet-331	548	14	,	,	PUNCT
admet-331	548	15	s.	s.	PROPN
admet-331	548	16	ebers	ebers	PROPN
admet-331	548	17	,	,	PUNCT
admet-331	548	18	e.	e.	PROPN
admet-331	548	19	crider	crider	PROPN
admet-331	548	20	,	,	PUNCT
admet-331	548	21	m.	m.	NOUN
admet-331	548	22	possin	possin	PROPN
admet-331	548	23	,	,	PUNCT
admet-331	548	24	et	et	PROPN
admet-331	548	25	al	al	PROPN
admet-331	548	26	.	.	PROPN
admet-331	548	27	,	,	PUNCT
admet-331	548	28	rock	rock	NOUN
admet-331	548	29	inhibitor	inhibitor	NOUN
admet-331	548	30	ha1077	ha1077	PROPN
admet-331	548	31	:	:	PUNCT
admet-331	548	32	potently	potently	ADV
admet-331	548	33	inhibits	inhibit	VERB
admet-331	548	34	corneal	corneal	ADJ
admet-331	548	35	fibrosis	fibrosis	NOUN
admet-331	548	36	and	and	CCONJ
admet-331	548	37	neovascularization	neovascularization	NOUN
admet-331	548	38	.	.	PUNCT
admet-331	549	1	in	in	ADP
admet-331	549	2	annu	annu	NOUN
admet-331	549	3	.	.	PUNCT
admet-331	550	1	meet	meet	PROPN
admet-331	550	2	.	.	PUNCT
admet-331	551	1	assoc	assoc	PROPN
admet-331	551	2	.	.	PUNCT
admet-331	552	1	res	res	PROPN
admet-331	552	2	.	.	PUNCT
admet-331	553	1	vis	vis	X
admet-331	553	2	.	.	PROPN
admet-331	553	3	ophtalmol	ophtalmol	PROPN
admet-331	553	4	.	.	PROPN
admet-331	553	5	,	,	PUNCT
admet-331	553	6	seattle	seattle	PROPN
admet-331	553	7	,	,	PUNCT
admet-331	553	8	united	united	PROPN
admet-331	553	9	states	states	PROPN
admet-331	553	10	of	of	ADP
admet-331	553	11	america	america	PROPN
admet-331	553	12	,	,	PUNCT
admet-331	553	13	2016	2016	NUM
admet-331	553	14	,	,	PUNCT
admet-331	553	15	abstract	abstract	PROPN
admet-331	553	16	no.3481	no.3481	PROPN
admet-331	553	17	.	.	PUNCT
admet-331	554	1	[	[	X
admet-331	554	2	40	40	NUM
admet-331	554	3	]	]	PUNCT
admet-331	554	4	p.	p.	PROPN
admet-331	554	5	zeng	zeng	PROPN
admet-331	554	6	,	,	PUNCT
admet-331	554	7	r.	r.	PROPN
admet-331	554	8	pi	pi	PROPN
admet-331	554	9	,	,	PUNCT
admet-331	554	10	p.	p.	PROPN
admet-331	554	11	li	li	PROPN
admet-331	554	12	,	,	PUNCT
admet-331	554	13	r.	r.	PROPN
admet-331	554	14	chen	chen	PROPN
admet-331	554	15	,	,	PUNCT
admet-331	554	16	l.	l.	PROPN
admet-331	554	17	lin	lin	PROPN
admet-331	554	18	,	,	PUNCT
admet-331	554	19	h.	h.	PROPN
admet-331	554	20	he	he	PRON
admet-331	554	21	,	,	PUNCT
admet-331	554	22	et	et	PROPN
admet-331	554	23	al	al	PROPN
admet-331	554	24	.	.	PROPN
admet-331	554	25	,	,	PUNCT
admet-331	554	26	mol	mol	PROPN
admet-331	554	27	.	.	PUNCT
admet-331	554	28	vis	vis	X
admet-331	554	29	.	.	PROPN
admet-331	554	30	21	21	NUM
admet-331	554	31	(	(	PUNCT
admet-331	554	32	2015	2015	NUM
admet-331	554	33	)	)	PUNCT
admet-331	554	34	688–698	688–698	NUM
admet-331	554	35	.	.	PUNCT
admet-331	555	1	[	[	X
admet-331	555	2	41	41	NUM
admet-331	555	3	]	]	PUNCT
admet-331	555	4	p.	p.	NOUN
admet-331	555	5	vasantha	vasantha	PROPN
admet-331	555	6	rao	rao	PROPN
admet-331	555	7	,	,	PUNCT
admet-331	555	8	p.	p.	PROPN
admet-331	555	9	f.	f.	PROPN
admet-331	555	10	deng	deng	PROPN
admet-331	555	11	,	,	PUNCT
admet-331	555	12	j.	j.	PROPN
admet-331	555	13	kumar	kumar	PROPN
admet-331	555	14	,	,	PUNCT
admet-331	555	15	d.	d.	PROPN
admet-331	555	16	l.	l.	PROPN
admet-331	555	17	epstein	epstein	PROPN
admet-331	555	18	,	,	PUNCT
admet-331	555	19	invest	invest	VERB
admet-331	555	20	.	.	PUNCT
admet-331	556	1	ophthalmol	ophthalmol	PROPN
admet-331	556	2	.	.	PUNCT
admet-331	557	1	vis	vis	X
admet-331	557	2	.	.	PUNCT
admet-331	558	1	sci	sci	PROPN
admet-331	558	2	.	.	PROPN
admet-331	559	1	42	42	NUM
admet-331	559	2	(	(	PUNCT
admet-331	559	3	2001	2001	NUM
admet-331	559	4	)	)	PUNCT
admet-331	559	5	1029	1029	NUM
admet-331	559	6	–	–	PUNCT
admet-331	559	7	1037	1037	NUM
admet-331	559	8	.	.	PUNCT
admet-331	560	1	[	[	X
admet-331	560	2	42	42	NUM
admet-331	560	3	]	]	PUNCT
admet-331	560	4	b.	b.	PROPN
admet-331	560	5	a.	a.	PROPN
admet-331	560	6	harrison	harrison	PROPN
admet-331	560	7	,	,	PUNCT
admet-331	560	8	z.	z.	PROPN
admet-331	560	9	y.	y.	PROPN
admet-331	560	10	almstead	almstead	PROPN
admet-331	560	11	,	,	PUNCT
admet-331	560	12	h.	h.	PROPN
admet-331	560	13	burgoon	burgoon	PROPN
admet-331	560	14	,	,	PUNCT
admet-331	560	15	m.	m.	NOUN
admet-331	560	16	gardyan	gardyan	PROPN
admet-331	560	17	,	,	PUNCT
admet-331	560	18	n.	n.	PROPN
admet-331	560	19	c.	c.	PROPN
admet-331	560	20	goodwin	goodwin	PROPN
admet-331	560	21	,	,	PUNCT
admet-331	560	22	j.	j.	PROPN
admet-331	560	23	healy	healy	PROPN
admet-331	560	24	,	,	PUNCT
admet-331	560	25	et	et	PROPN
admet-331	560	26	al	al	PROPN
admet-331	560	27	.	.	PROPN
admet-331	560	28	,	,	PUNCT
admet-331	560	29	acs	acs	PROPN
admet-331	560	30	med	me	VERB
admet-331	560	31	.	.	PUNCT
admet-331	560	32	chem	chem	PROPN
admet-331	560	33	.	.	PUNCT
admet-331	561	1	lett	lett	PROPN
admet-331	561	2	.	.	PROPN
admet-331	562	1	6	6	NUM
admet-331	562	2	(	(	PUNCT
admet-331	562	3	2015	2015	NUM
admet-331	562	4	)	)	PUNCT
admet-331	562	5	84–88	84–88	NUM
admet-331	562	6	.	.	PUNCT
admet-331	563	1	[	[	X
admet-331	563	2	43	43	NUM
admet-331	563	3	]	]	X
admet-331	563	4	w.	w.	PROPN
admet-331	563	5	noske	noske	PROPN
admet-331	563	6	,	,	PUNCT
admet-331	563	7	graefe	graefe	PROPN
admet-331	563	8	’s	’s	PART
admet-331	563	9	arch	arch	NOUN
admet-331	563	10	.	.	PUNCT
admet-331	564	1	clin	clin	PROPN
admet-331	564	2	.	.	PUNCT
admet-331	565	1	exp	exp	PROPN
admet-331	565	2	.	.	PUNCT
admet-331	565	3	ophthalmol	ophthalmol	PROPN
admet-331	565	4	.	.	PUNCT
admet-331	566	1	235	235	NUM
admet-331	566	2	(	(	PUNCT
admet-331	566	3	1997	1997	NUM
admet-331	566	4	)	)	PUNCT
admet-331	567	1	551–552	551–552	NUM
admet-331	567	2	.	.	PUNCT
admet-331	568	1	[	[	X
admet-331	568	2	44	44	NUM
admet-331	568	3	]	]	PUNCT
admet-331	568	4	r.	r.	PROPN
admet-331	568	5	c.	c.	PROPN
admet-331	568	6	tripathi	tripathi	PROPN
admet-331	568	7	,	,	PUNCT
admet-331	568	8	j.	j.	PROPN
admet-331	568	9	li	li	PROPN
admet-331	568	10	,	,	PUNCT
admet-331	568	11	w.	w.	PROPN
admet-331	568	12	f.	f.	PROPN
admet-331	568	13	chan	chan	PROPN
admet-331	568	14	,	,	PUNCT
admet-331	568	15	b.	b.	PROPN
admet-331	568	16	j.	j.	PROPN
admet-331	568	17	tripathi	tripathi	PROPN
admet-331	568	18	,	,	PUNCT
admet-331	568	19	exp	exp	NOUN
admet-331	568	20	.	.	PUNCT
admet-331	568	21	eye	eye	NOUN
admet-331	568	22	res	re	NOUN
admet-331	568	23	.	.	PUNCT
admet-331	568	24	59	59	NUM
admet-331	568	25	(	(	PUNCT
admet-331	568	26	1994	1994	NUM
admet-331	568	27	)	)	PUNCT
admet-331	569	1	723–727	723–727	NUM
admet-331	569	2	.	.	PUNCT
admet-331	570	1	admet	admet	PROPN
admet-331	570	2	&	&	CCONJ
admet-331	570	3	dmpk	dmpk	PROPN
admet-331	570	4	4(4	4(4	NUM
admet-331	570	5	)	)	PUNCT
admet-331	570	6	(	(	PUNCT
admet-331	570	7	2016	2016	NUM
admet-331	570	8	)	)	PUNCT
admet-331	570	9	280	280	NUM
admet-331	570	10	-	-	SYM
admet-331	570	11	301	301	NUM
admet-331	570	12	rock	rock	NOUN
admet-331	570	13	inhibitors	inhibitor	NOUN
admet-331	570	14	in	in	ADP
admet-331	570	15	ocular	ocular	ADJ
admet-331	570	16	disease	disease	NOUN
admet-331	570	17	doi	doi	NOUN
admet-331	570	18	:	:	PUNCT
admet-331	570	19	10.5599	10.5599	NUM
admet-331	570	20	/	/	SYM
admet-331	570	21	admet.4.4.331	admet.4.4.331	NUM
admet-331	570	22	299	299	NUM
admet-331	571	1	[	[	X
admet-331	571	2	45	45	NUM
admet-331	571	3	]	]	PUNCT
admet-331	571	4	t.	t.	PROPN
admet-331	571	5	inoue	inoue	PROPN
admet-331	571	6	,	,	PUNCT
admet-331	571	7	h.	h.	PROPN
admet-331	571	8	tanihara	tanihara	PROPN
admet-331	571	9	,	,	PUNCT
admet-331	571	10	prog	prog	PROPN
admet-331	571	11	.	.	PUNCT
admet-331	572	1	retin	retin	PROPN
admet-331	572	2	.	.	PUNCT
admet-331	573	1	eye	eye	NOUN
admet-331	573	2	res	re	NOUN
admet-331	573	3	.	.	PUNCT
admet-331	574	1	37	37	NUM
admet-331	574	2	(	(	PUNCT
admet-331	574	3	2013	2013	NUM
admet-331	574	4	)	)	PUNCT
admet-331	574	5	1–12	1–12	NOUN
admet-331	574	6	.	.	PUNCT
admet-331	575	1	[	[	X
admet-331	575	2	46	46	NUM
admet-331	575	3	]	]	PUNCT
admet-331	575	4	r.	r.	PROPN
admet-331	575	5	wang	wang	PROPN
admet-331	575	6	,	,	PUNCT
admet-331	575	7	j.	j.	PROPN
admet-331	575	8	e.	e.	PROPN
admet-331	575	9	williamson	williamson	PROPN
admet-331	575	10	,	,	PUNCT
admet-331	575	11	c.	c.	PROPN
admet-331	575	12	kopczynski	kopczynski	PROPN
admet-331	575	13	,	,	PUNCT
admet-331	575	14	j.	j.	PROPN
admet-331	575	15	b.	b.	PROPN
admet-331	575	16	serle	serle	PROPN
admet-331	575	17	,	,	PUNCT
admet-331	575	18	j.	j.	PROPN
admet-331	575	19	glaucoma	glaucoma	PROPN
admet-331	575	20	24	24	NUM
admet-331	575	21	(	(	PUNCT
admet-331	575	22	2015	2015	NUM
admet-331	575	23	)	)	PUNCT
admet-331	575	24	51–54	51–54	NUM
admet-331	575	25	.	.	PUNCT
admet-331	576	1	[	[	X
admet-331	576	2	47	47	NUM
admet-331	576	3	]	]	PUNCT
admet-331	576	4	t.	t.	NOUN
admet-331	576	5	isobe	isobe	NOUN
admet-331	576	6	,	,	PUNCT
admet-331	576	7	k.	k.	PROPN
admet-331	576	8	mizuno	mizuno	PROPN
admet-331	576	9	,	,	PUNCT
admet-331	576	10	y.	y.	PROPN
admet-331	576	11	kaneko	kaneko	PROPN
admet-331	576	12	,	,	PUNCT
admet-331	576	13	m.	m.	NOUN
admet-331	576	14	ohta	ohta	PROPN
admet-331	576	15	,	,	PUNCT
admet-331	576	16	t.	t.	PROPN
admet-331	576	17	koide	koide	PROPN
admet-331	576	18	,	,	PUNCT
admet-331	576	19	s.	s.	PROPN
admet-331	576	20	tanabe	tanabe	PROPN
admet-331	576	21	,	,	PUNCT
admet-331	576	22	curr	curr	PROPN
admet-331	576	23	.	.	PUNCT
admet-331	577	1	eye	eye	NOUN
admet-331	577	2	res	re	NOUN
admet-331	577	3	.	.	PUNCT
admet-331	578	1	39	39	NUM
admet-331	578	2	(	(	PUNCT
admet-331	578	3	2014	2014	NUM
admet-331	578	4	)	)	PUNCT
admet-331	578	5	813–22	813–22	NOUN
admet-331	578	6	.	.	PUNCT
admet-331	579	1	[	[	X
admet-331	579	2	48	48	NUM
admet-331	579	3	]	]	PUNCT
admet-331	579	4	g.	g.	PROPN
admet-331	579	5	li	li	PROPN
admet-331	579	6	,	,	PUNCT
admet-331	579	7	d.	d.	PROPN
admet-331	579	8	mukherjee	mukherjee	PROPN
admet-331	579	9	,	,	PUNCT
admet-331	579	10	i.	i.	PROPN
admet-331	579	11	navarro	navarro	PROPN
admet-331	579	12	,	,	PUNCT
admet-331	579	13	n.	n.	PROPN
admet-331	579	14	e.	e.	PROPN
admet-331	579	15	ashpole	ashpole	PROPN
admet-331	579	16	,	,	PUNCT
admet-331	579	17	j.	j.	PROPN
admet-331	579	18	m.	m.	PROPN
admet-331	579	19	sherwood	sherwood	PROPN
admet-331	579	20	,	,	PUNCT
admet-331	579	21	j.	j.	PROPN
admet-331	579	22	chang	chang	PROPN
admet-331	579	23	,	,	PUNCT
admet-331	579	24	et	et	PROPN
admet-331	579	25	al	al	PROPN
admet-331	579	26	.	.	PROPN
admet-331	579	27	,	,	PUNCT
admet-331	579	28	eur	eur	PROPN
admet-331	579	29	.	.	PUNCT
admet-331	580	1	j.	j.	PROPN
admet-331	580	2	pharmacol	pharmacol	PROPN
admet-331	580	3	.	.	PUNCT
admet-331	581	1	(	(	PUNCT
admet-331	581	2	2016	2016	NUM
admet-331	581	3	)	)	PUNCT
admet-331	581	4	1–12	1–12	NOUN
admet-331	581	5	.	.	PUNCT
admet-331	582	1	[	[	X
admet-331	582	2	49	49	NUM
admet-331	582	3	]	]	PUNCT
admet-331	582	4	f.	f.	PROPN
admet-331	582	5	klingberg	klingberg	PROPN
admet-331	582	6	,	,	PUNCT
admet-331	582	7	b.	b.	PROPN
admet-331	582	8	hinz	hinz	PROPN
admet-331	582	9	,	,	PUNCT
admet-331	582	10	e.	e.	PROPN
admet-331	582	11	s.	s.	PROPN
admet-331	582	12	white	white	PROPN
admet-331	582	13	,	,	PUNCT
admet-331	582	14	j.	j.	PROPN
admet-331	582	15	pathol	pathol	PROPN
admet-331	582	16	.	.	PUNCT
admet-331	583	1	229	229	NUM
admet-331	583	2	(	(	PUNCT
admet-331	583	3	2013	2013	NUM
admet-331	583	4	)	)	PUNCT
admet-331	583	5	298–309	298–309	NUM
admet-331	583	6	.	.	PUNCT
admet-331	584	1	[	[	X
admet-331	584	2	50	50	NUM
admet-331	584	3	]	]	PUNCT
admet-331	584	4	m.	m.	NOUN
admet-331	584	5	honjo	honjo	PROPN
admet-331	584	6	,	,	PUNCT
admet-331	584	7	h.	h.	PROPN
admet-331	584	8	tanihara	tanihara	PROPN
admet-331	584	9	,	,	PUNCT
admet-331	584	10	t.	t.	PROPN
admet-331	584	11	kameda	kameda	PROPN
admet-331	584	12	,	,	PUNCT
admet-331	584	13	t.	t.	PROPN
admet-331	584	14	kawaji	kawaji	PROPN
admet-331	584	15	,	,	PUNCT
admet-331	584	16	n.	n.	PROPN
admet-331	584	17	yoshimura	yoshimura	PROPN
admet-331	584	18	,	,	PUNCT
admet-331	584	19	m.	m.	NOUN
admet-331	584	20	araie	araie	PROPN
admet-331	584	21	,	,	PUNCT
admet-331	584	22	invest	invest	VERB
admet-331	584	23	.	.	PUNCT
admet-331	585	1	ophthalmol	ophthalmol	PROPN
admet-331	585	2	.	.	PUNCT
admet-331	586	1	vis	vis	X
admet-331	586	2	.	.	PUNCT
admet-331	587	1	sci	sci	PROPN
admet-331	587	2	.	.	PROPN
admet-331	588	1	48	48	NUM
admet-331	588	2	(	(	PUNCT
admet-331	588	3	2007	2007	NUM
admet-331	588	4	)	)	PUNCT
admet-331	588	5	5549–5557	5549–5557	NUM
admet-331	588	6	.	.	PUNCT
admet-331	589	1	[	[	X
admet-331	589	2	51	51	NUM
admet-331	589	3	]	]	PUNCT
admet-331	589	4	a.	a.	NOUN
admet-331	589	5	futakuchi	futakuchi	PROPN
admet-331	589	6	,	,	PUNCT
admet-331	589	7	t.	t.	PROPN
admet-331	589	8	inoue	inoue	PROPN
admet-331	589	9	,	,	PUNCT
admet-331	589	10	t.	t.	PROPN
admet-331	589	11	fujimoto	fujimoto	PROPN
admet-331	589	12	,	,	PUNCT
admet-331	589	13	m.	m.	NOUN
admet-331	589	14	inoue	inoue	PROPN
admet-331	589	15	-	-	PUNCT
admet-331	589	16	mochita	mochita	PROPN
admet-331	589	17	,	,	PUNCT
admet-331	589	18	m.	m.	NOUN
admet-331	589	19	kawai	kawai	PROPN
admet-331	589	20	,	,	PUNCT
admet-331	589	21	h.	h.	PROPN
admet-331	589	22	tanihara	tanihara	PROPN
admet-331	589	23	,	,	PUNCT
admet-331	589	24	exp	exp	NOUN
admet-331	589	25	.	.	PUNCT
admet-331	589	26	eye	eye	NOUN
admet-331	589	27	res	re	NOUN
admet-331	589	28	.	.	PROPN
admet-331	589	29	149	149	NUM
admet-331	589	30	(	(	PUNCT
admet-331	589	31	2016	2016	NUM
admet-331	589	32	)	)	PUNCT
admet-331	589	33	107–115	107–115	NUM
admet-331	589	34	.	.	PUNCT
admet-331	590	1	[	[	X
admet-331	590	2	52	52	NUM
admet-331	590	3	]	]	PUNCT
admet-331	590	4	h.	h.	PROPN
admet-331	590	5	tanihara	tanihara	PROPN
admet-331	590	6	,	,	PUNCT
admet-331	590	7	t.	t.	PROPN
admet-331	590	8	inoue	inoue	PROPN
admet-331	590	9	,	,	PUNCT
admet-331	590	10	t.	t.	PROPN
admet-331	590	11	yamamoto	yamamoto	PROPN
admet-331	590	12	,	,	PUNCT
admet-331	590	13	y.	y.	PROPN
admet-331	590	14	kuwayama	kuwayama	PROPN
admet-331	590	15	,	,	PUNCT
admet-331	590	16	h.	h.	PROPN
admet-331	590	17	abe	abe	PROPN
admet-331	590	18	,	,	PUNCT
admet-331	590	19	m.	m.	PROPN
admet-331	590	20	araie	araie	PROPN
admet-331	590	21	,	,	PUNCT
admet-331	590	22	jama	jama	PROPN
admet-331	590	23	ophthalmol	ophthalmol	PROPN
admet-331	590	24	.	.	PUNCT
admet-331	591	1	131	131	NUM
admet-331	591	2	(	(	PUNCT
admet-331	591	3	2013	2013	NUM
admet-331	591	4	)	)	PUNCT
admet-331	591	5	1288–1295	1288–1295	NUM
admet-331	591	6	.	.	PUNCT
admet-331	592	1	[	[	X
admet-331	592	2	53	53	NUM
admet-331	592	3	]	]	PUNCT
admet-331	592	4	h.	h.	PROPN
admet-331	592	5	tanihara	tanihara	PROPN
admet-331	592	6	,	,	PUNCT
admet-331	592	7	t.	t.	PROPN
admet-331	592	8	inoue	inoue	PROPN
admet-331	592	9	,	,	PUNCT
admet-331	592	10	t.	t.	PROPN
admet-331	592	11	yamamoto	yamamoto	PROPN
admet-331	592	12	,	,	PUNCT
admet-331	592	13	y.	y.	PROPN
admet-331	592	14	kuwayama	kuwayama	PROPN
admet-331	592	15	,	,	PUNCT
admet-331	592	16	h.	h.	PROPN
admet-331	592	17	abe	abe	PROPN
admet-331	592	18	,	,	PUNCT
admet-331	592	19	m.	m.	PROPN
admet-331	592	20	araie	araie	PROPN
admet-331	592	21	,	,	PUNCT
admet-331	592	22	am	be	AUX
admet-331	592	23	.	.	PUNCT
admet-331	593	1	j.	j.	PROPN
admet-331	593	2	ophthalmol	ophthalmol	PROPN
admet-331	593	3	.	.	PUNCT
admet-331	594	1	156	156	NUM
admet-331	594	2	(	(	PUNCT
admet-331	594	3	2013	2013	NUM
admet-331	594	4	)	)	PUNCT
admet-331	594	5	731–736.e2	731–736.e2	NUM
admet-331	594	6	.	.	PUNCT
admet-331	595	1	[	[	X
admet-331	595	2	54	54	NUM
admet-331	595	3	]	]	PUNCT
admet-331	595	4	h.	h.	PROPN
admet-331	595	5	tanihara	tanihara	PROPN
admet-331	595	6	,	,	PUNCT
admet-331	595	7	t.	t.	PROPN
admet-331	595	8	inoue	inoue	PROPN
admet-331	595	9	,	,	PUNCT
admet-331	595	10	t.	t.	PROPN
admet-331	595	11	yamamoto	yamamoto	PROPN
admet-331	595	12	,	,	PUNCT
admet-331	595	13	y.	y.	PROPN
admet-331	595	14	kuwayama	kuwayama	PROPN
admet-331	595	15	,	,	PUNCT
admet-331	595	16	h.	h.	PROPN
admet-331	595	17	abe	abe	PROPN
admet-331	595	18	,	,	PUNCT
admet-331	595	19	h.	h.	PROPN
admet-331	595	20	suganami	suganami	PROPN
admet-331	595	21	,	,	PUNCT
admet-331	595	22	et	et	PROPN
admet-331	595	23	al	al	PROPN
admet-331	595	24	.	.	PROPN
admet-331	595	25	,	,	PUNCT
admet-331	595	26	acta	acta	PROPN
admet-331	595	27	ophthalmol	ophthalmol	PROPN
admet-331	595	28	.	.	PUNCT
admet-331	596	1	93	93	NUM
admet-331	596	2	(	(	PUNCT
admet-331	596	3	2015	2015	NUM
admet-331	596	4	)	)	PUNCT
admet-331	596	5	e254	e254	PROPN
admet-331	596	6	–	–	PUNCT
admet-331	596	7	e260	e260	PROPN
admet-331	596	8	.	.	PUNCT
admet-331	597	1	[	[	X
admet-331	597	2	55	55	NUM
admet-331	597	3	]	]	PUNCT
admet-331	597	4	h.	h.	PROPN
admet-331	597	5	tanihara	tanihara	PROPN
admet-331	597	6	,	,	PUNCT
admet-331	597	7	t.	t.	PROPN
admet-331	597	8	inoue	inoue	PROPN
admet-331	597	9	,	,	PUNCT
admet-331	597	10	t.	t.	PROPN
admet-331	597	11	yamamoto	yamamoto	PROPN
admet-331	597	12	,	,	PUNCT
admet-331	597	13	y.	y.	PROPN
admet-331	597	14	kuwayama	kuwayama	PROPN
admet-331	597	15	,	,	PUNCT
admet-331	597	16	h.	h.	PROPN
admet-331	597	17	abe	abe	PROPN
admet-331	597	18	,	,	PUNCT
admet-331	597	19	h.	h.	PROPN
admet-331	597	20	suganami	suganami	PROPN
admet-331	597	21	,	,	PUNCT
admet-331	597	22	et	et	PROPN
admet-331	597	23	al	al	PROPN
admet-331	597	24	.	.	PROPN
admet-331	597	25	,	,	PUNCT
admet-331	597	26	jama	jama	PROPN
admet-331	597	27	ophthalmol	ophthalmol	PROPN
admet-331	597	28	.	.	PUNCT
admet-331	598	1	133	133	NUM
admet-331	598	2	(	(	PUNCT
admet-331	598	3	2015	2015	NUM
admet-331	598	4	)	)	PUNCT
admet-331	599	1	755–761	755–761	NUM
admet-331	599	2	.	.	PUNCT
admet-331	600	1	[	[	X
admet-331	600	2	56	56	NUM
admet-331	600	3	]	]	X
admet-331	600	4	r.	r.	PROPN
admet-331	600	5	yamagishi	yamagishi	PROPN
admet-331	600	6	,	,	PUNCT
admet-331	600	7	m.	m.	NOUN
admet-331	600	8	honjo	honjo	PROPN
admet-331	600	9	,	,	PUNCT
admet-331	600	10	y.	y.	PROPN
admet-331	600	11	aoyama	aoyama	PROPN
admet-331	600	12	,	,	PUNCT
admet-331	600	13	t.	t.	PROPN
admet-331	600	14	uchida	uchida	PROPN
admet-331	600	15	,	,	PUNCT
admet-331	600	16	m.	m.	NOUN
admet-331	600	17	aihara	aihara	PROPN
admet-331	600	18	,	,	PUNCT
admet-331	600	19	alterered	alterered	ADJ
admet-331	600	20	interactions	interaction	NOUN
admet-331	600	21	of	of	ADP
admet-331	600	22	concomitant	concomitant	ADJ
admet-331	600	23	administrations	administration	NOUN
admet-331	600	24	of	of	ADP
admet-331	600	25	rock	rock	NOUN
admet-331	600	26	inhibitor	inhibitor	NOUN
admet-331	600	27	and	and	CCONJ
admet-331	600	28	parasympathetic	parasympathetic	ADJ
admet-331	600	29	agonist	agonist	NOUN
admet-331	600	30	in	in	ADP
admet-331	600	31	mouse	mouse	NOUN
admet-331	600	32	iop	iop	NOUN
admet-331	600	33	and	and	CCONJ
admet-331	600	34	outflow	outflow	NOUN
admet-331	600	35	dynamics	dynamic	NOUN
admet-331	600	36	,	,	PUNCT
admet-331	600	37	in	in	ADP
admet-331	600	38	annu	annu	NOUN
admet-331	600	39	.	.	PUNCT
admet-331	600	40	meet	meet	PROPN
admet-331	600	41	.	.	PUNCT
admet-331	601	1	assoc	assoc	PROPN
admet-331	601	2	.	.	PUNCT
admet-331	602	1	res	res	PROPN
admet-331	602	2	.	.	PUNCT
admet-331	603	1	vis	vis	X
admet-331	603	2	.	.	PUNCT
admet-331	603	3	ophthalmol	ophthalmol	PROPN
admet-331	603	4	.	.	PROPN
admet-331	603	5	,	,	PUNCT
admet-331	603	6	seattle	seattle	PROPN
admet-331	603	7	,	,	PUNCT
admet-331	603	8	united	united	PROPN
admet-331	603	9	states	states	PROPN
admet-331	603	10	of	of	ADP
admet-331	603	11	america	america	PROPN
admet-331	603	12	,	,	PUNCT
admet-331	603	13	2016	2016	NUM
admet-331	603	14	,	,	PUNCT
admet-331	603	15	abstract	abstract	ADJ
admet-331	603	16	no.3011	no.3011	PROPN
admet-331	603	17	-	-	PUNCT
admet-331	603	18	a0360	a0360	NOUN
admet-331	603	19	.	.	PUNCT
admet-331	604	1	[	[	X
admet-331	604	2	57	57	NUM
admet-331	604	3	]	]	PUNCT
admet-331	604	4	h.	h.	PROPN
admet-331	604	5	tanihara	tanihara	PROPN
admet-331	604	6	,	,	PUNCT
admet-331	604	7	t.	t.	PROPN
admet-331	604	8	inoue	inoue	PROPN
admet-331	604	9	,	,	PUNCT
admet-331	604	10	t.	t.	PROPN
admet-331	604	11	yamamoto	yamamoto	PROPN
admet-331	604	12	,	,	PUNCT
admet-331	604	13	y.	y.	PROPN
admet-331	604	14	kuwayama	kuwayama	PROPN
admet-331	604	15	,	,	PUNCT
admet-331	604	16	h.	h.	PROPN
admet-331	604	17	abe	abe	PROPN
admet-331	604	18	,	,	PUNCT
admet-331	604	19	a.	a.	PROPN
admet-331	604	20	fukushima	fukushima	PROPN
admet-331	604	21	,	,	PUNCT
admet-331	604	22	et	et	PROPN
admet-331	604	23	al	al	PROPN
admet-331	604	24	.	.	PROPN
admet-331	604	25	,	,	PUNCT
admet-331	604	26	acta	acta	PROPN
admet-331	604	27	ophthalmol	ophthalmol	PROPN
admet-331	604	28	.	.	PUNCT
admet-331	605	1	94	94	NUM
admet-331	605	2	(	(	PUNCT
admet-331	605	3	2016	2016	NUM
admet-331	605	4	)	)	PUNCT
admet-331	605	5	e26	e26	PROPN
admet-331	605	6	–	–	PUNCT
admet-331	605	7	e34	e34	NOUN
admet-331	605	8	.	.	PUNCT
admet-331	606	1	[	[	X
admet-331	606	2	58	58	NUM
admet-331	606	3	]	]	PUNCT
admet-331	606	4	h.	h.	PROPN
admet-331	606	5	nakagawa	nakagawa	PROPN
admet-331	606	6	,	,	PUNCT
admet-331	606	7	n.	n.	PROPN
admet-331	606	8	koizumi	koizumi	PROPN
admet-331	606	9	,	,	PUNCT
admet-331	606	10	n.	n.	PROPN
admet-331	606	11	okumura	okumura	PROPN
admet-331	606	12	,	,	PUNCT
admet-331	606	13	h.	h.	PROPN
admet-331	606	14	suganami	suganami	PROPN
admet-331	606	15	,	,	PUNCT
admet-331	606	16	s.	s.	PROPN
admet-331	606	17	kinoshita	kinoshita	PROPN
admet-331	606	18	,	,	PUNCT
admet-331	606	19	plos	plos	PROPN
admet-331	606	20	one	one	NUM
admet-331	606	21	10	10	NUM
admet-331	606	22	(	(	PUNCT
admet-331	606	23	2015	2015	NUM
admet-331	606	24	)	)	PUNCT
admet-331	606	25	1–15	1–15	PROPN
admet-331	606	26	.	.	PUNCT
admet-331	607	1	[	[	X
admet-331	607	2	59	59	NUM
admet-331	607	3	]	]	X
admet-331	607	4	n.	n.	PROPN
admet-331	607	5	okumura	okumura	PROPN
admet-331	607	6	,	,	PUNCT
admet-331	607	7	y.	y.	PROPN
admet-331	607	8	okazaki	okazaki	PROPN
admet-331	607	9	,	,	PUNCT
admet-331	607	10	r.	r.	PROPN
admet-331	607	11	inoue	inoue	PROPN
admet-331	607	12	,	,	PUNCT
admet-331	607	13	s.	s.	PROPN
admet-331	607	14	nakano	nakano	PROPN
admet-331	607	15	,	,	PUNCT
admet-331	607	16	n.	n.	PROPN
admet-331	607	17	j.	j.	PROPN
admet-331	607	18	fullwood	fullwood	PROPN
admet-331	607	19	,	,	PUNCT
admet-331	607	20	s.	s.	PROPN
admet-331	607	21	kinoshita	kinoshita	PROPN
admet-331	607	22	,	,	PUNCT
admet-331	607	23	et	et	PROPN
admet-331	607	24	al	al	PROPN
admet-331	607	25	.	.	PROPN
admet-331	607	26	,	,	PUNCT
admet-331	607	27	invest	invest	VERB
admet-331	607	28	.	.	PUNCT
admet-331	608	1	opthalmology	opthalmology	NOUN
admet-331	608	2	vis	vis	X
admet-331	608	3	.	.	PUNCT
admet-331	608	4	sci	sci	PROPN
admet-331	608	5	.	.	PROPN
admet-331	609	1	56	56	NUM
admet-331	609	2	(	(	PUNCT
admet-331	609	3	2015	2015	NUM
admet-331	609	4	)	)	PUNCT
admet-331	609	5	7560	7560	NUM
admet-331	609	6	.	.	PUNCT
admet-331	610	1	[	[	X
admet-331	610	2	60	60	NUM
admet-331	610	3	]	]	PUNCT
admet-331	610	4	j.	j.	PROPN
admet-331	610	5	w.	w.	PROPN
admet-331	610	6	kiel	kiel	PROPN
admet-331	610	7	,	,	PUNCT
admet-331	610	8	c.	c.	PROPN
admet-331	610	9	c.	c.	PROPN
admet-331	610	10	kopczynski	kopczynski	PROPN
admet-331	610	11	,	,	PUNCT
admet-331	610	12	j.	j.	PROPN
admet-331	610	13	ocul	ocul	PROPN
admet-331	610	14	.	.	PUNCT
admet-331	611	1	pharmacol	pharmacol	PROPN
admet-331	611	2	.	.	PUNCT
admet-331	612	1	ther	ther	PROPN
admet-331	612	2	.	.	PUNCT
admet-331	613	1	31	31	NUM
admet-331	613	2	(	(	PUNCT
admet-331	613	3	2015	2015	NUM
admet-331	613	4	)	)	PUNCT
admet-331	614	1	146–151	146–151	NUM
admet-331	614	2	.	.	PUNCT
admet-331	615	1	[	[	X
admet-331	615	2	61	61	NUM
admet-331	615	3	]	]	PUNCT
admet-331	615	4	m.	m.	NOUN
admet-331	615	5	weiss	weiss	PROPN
admet-331	615	6	,	,	PUNCT
admet-331	615	7	b.	b.	PROPN
admet-331	615	8	levy	levy	PROPN
admet-331	615	9	,	,	PUNCT
admet-331	615	10	c.	c.	PROPN
admet-331	615	11	kopczynski	kopczynski	PROPN
admet-331	615	12	,	,	PUNCT
admet-331	615	13	t.	t.	PROPN
admet-331	615	14	van	van	PROPN
admet-331	615	15	haarlem	haarlem	PROPN
admet-331	615	16	,	,	PUNCT
admet-331	615	17	g.	g.	PROPN
admet-331	615	18	novack	novack	PROPN
admet-331	615	19	,	,	PUNCT
admet-331	615	20	a.-c	a.-c	PROPN
admet-331	615	21	.	.	PUNCT
admet-331	616	1	study	study	NOUN
admet-331	616	2	group	group	NOUN
admet-331	616	3	,	,	PUNCT
admet-331	616	4	invest	inv	ADJ
admet-331	616	5	.	.	PUNCT
admet-331	617	1	ophthalmol	ophthalmol	PROPN
admet-331	617	2	.	.	PUNCT
admet-331	618	1	vis	vis	X
admet-331	618	2	.	.	PUNCT
admet-331	619	1	sci	sci	PROPN
admet-331	619	2	.	.	PROPN
admet-331	619	3	54	54	NUM
admet-331	619	4	(	(	PUNCT
admet-331	619	5	2013	2013	NUM
admet-331	619	6	)	)	PUNCT
admet-331	619	7	754	754	NUM
admet-331	619	8	.	.	PUNCT
admet-331	620	1	[	[	X
admet-331	620	2	62	62	NUM
admet-331	620	3	]	]	PUNCT
admet-331	620	4	b.	b.	NOUN
admet-331	620	5	levy	levy	PROPN
admet-331	620	6	,	,	PUNCT
admet-331	620	7	n.	n.	PROPN
admet-331	620	8	ramirez	ramirez	PROPN
admet-331	620	9	,	,	PUNCT
admet-331	620	10	g.	g.	PROPN
admet-331	620	11	d.	d.	PROPN
admet-331	620	12	novack	novack	PROPN
admet-331	620	13	,	,	PUNCT
admet-331	620	14	c.	c.	PROPN
admet-331	620	15	kopczynski	kopczynski	PROPN
admet-331	620	16	,	,	PUNCT
admet-331	620	17	am	be	AUX
admet-331	620	18	.	.	PUNCT
admet-331	621	1	j.	j.	PROPN
admet-331	621	2	ophthalmol	ophthalmol	PROPN
admet-331	621	3	.	.	PROPN
admet-331	622	1	159	159	NUM
admet-331	622	2	(	(	PUNCT
admet-331	622	3	2015	2015	NUM
admet-331	622	4	)	)	PUNCT
admet-331	623	1	980–985	980–985	NUM
admet-331	623	2	.	.	PUNCT
admet-331	624	1	[	[	X
admet-331	624	2	63	63	NUM
admet-331	624	3	]	]	PUNCT
admet-331	624	4	j.	j.	PROPN
admet-331	624	5	bacharach	bacharach	PROPN
admet-331	624	6	,	,	PUNCT
admet-331	624	7	h.	h.	PROPN
admet-331	624	8	b.	b.	PROPN
admet-331	624	9	dubiner	dubiner	PROPN
admet-331	624	10	,	,	PUNCT
admet-331	624	11	b.	b.	PROPN
admet-331	624	12	levy	levy	PROPN
admet-331	624	13	,	,	PUNCT
admet-331	624	14	c.	c.	PROPN
admet-331	624	15	c.	c.	PROPN
admet-331	624	16	kopczynski	kopczynski	PROPN
admet-331	624	17	,	,	PUNCT
admet-331	624	18	g.	g.	PROPN
admet-331	624	19	d.	d.	PROPN
admet-331	624	20	novack	novack	PROPN
admet-331	624	21	,	,	PUNCT
admet-331	624	22	ophthalmology	ophthalmology	NOUN
admet-331	624	23	122	122	NUM
admet-331	624	24	(	(	PUNCT
admet-331	624	25	2015	2015	NUM
admet-331	624	26	)	)	PUNCT
admet-331	624	27	302	302	NUM
admet-331	624	28	–	–	PUNCT
admet-331	624	29	307	307	NUM
admet-331	624	30	.	.	PUNCT
admet-331	625	1	[	[	X
admet-331	625	2	64	64	NUM
admet-331	625	3	]	]	PUNCT
admet-331	625	4	r.	r.	PROPN
admet-331	625	5	d.	d.	PROPN
admet-331	625	6	williams	williams	PROPN
admet-331	625	7	,	,	PUNCT
admet-331	625	8	g.	g.	PROPN
admet-331	625	9	d.	d.	PROPN
admet-331	625	10	novack	novack	PROPN
admet-331	625	11	,	,	PUNCT
admet-331	625	12	t.	t.	PROPN
admet-331	625	13	van	van	PROPN
admet-331	625	14	haarlem	haarlem	PROPN
admet-331	625	15	,	,	PUNCT
admet-331	625	16	c.	c.	PROPN
admet-331	625	17	kopczynski	kopczynski	PROPN
admet-331	625	18	,	,	PUNCT
admet-331	625	19	am	be	AUX
admet-331	625	20	.	.	PUNCT
admet-331	626	1	j.	j.	PROPN
admet-331	626	2	ophthalmol	ophthalmol	PROPN
admet-331	626	3	.	.	PUNCT
admet-331	627	1	152	152	NUM
admet-331	627	2	(	(	PUNCT
admet-331	627	3	2011	2011	NUM
admet-331	627	4	)	)	PUNCT
admet-331	627	5	834	834	NUM
admet-331	627	6	–	–	PUNCT
admet-331	627	7	841.e1	841.e1	NUM
admet-331	627	8	.	.	PUNCT
admet-331	628	1	[	[	X
admet-331	628	2	65	65	NUM
admet-331	628	3	]	]	X
admet-331	628	4	h.	h.	PROPN
admet-331	628	5	tanihara	tanihara	PROPN
admet-331	628	6	,	,	PUNCT
admet-331	628	7	m.	m.	NOUN
admet-331	628	8	inatani	inatani	PROPN
admet-331	628	9	,	,	PUNCT
admet-331	628	10	m.	m.	NOUN
admet-331	628	11	honjo	honjo	PROPN
admet-331	628	12	,	,	PUNCT
admet-331	628	13	h.	h.	PROPN
admet-331	628	14	tokushige	tokushige	PROPN
admet-331	628	15	,	,	PUNCT
admet-331	628	16	j.	j.	PROPN
admet-331	628	17	azuma	azuma	PROPN
admet-331	628	18	,	,	PUNCT
admet-331	628	19	m.	m.	NOUN
admet-331	628	20	araie	araie	PROPN
admet-331	628	21	,	,	PUNCT
admet-331	628	22	arch	arch	NOUN
admet-331	628	23	.	.	PUNCT
admet-331	629	1	ophthalmol	ophthalmol	PROPN
admet-331	629	2	.	.	PUNCT
admet-331	630	1	126	126	NUM
admet-331	630	2	(	(	PUNCT
admet-331	630	3	2008	2008	NUM
admet-331	630	4	)	)	PUNCT
admet-331	630	5	309–315	309–315	NUM
admet-331	630	6	.	.	PUNCT
admet-331	631	1	[	[	X
admet-331	631	2	66	66	NUM
admet-331	631	3	]	]	PUNCT
admet-331	631	4	j.	j.	PROPN
admet-331	631	5	chen	chen	PROPN
admet-331	631	6	,	,	PUNCT
admet-331	631	7	s.	s.	PROPN
admet-331	631	8	a.	a.	PROPN
admet-331	631	9	runyan	runyan	PROPN
admet-331	631	10	,	,	PUNCT
admet-331	631	11	m.	m.	PROPN
admet-331	631	12	r.	r.	PROPN
admet-331	631	13	robinson	robinson	PROPN
admet-331	631	14	,	,	PUNCT
admet-331	631	15	clin	clin	PROPN
admet-331	631	16	.	.	PUNCT
admet-331	632	1	ophthalmol	ophthalmol	PROPN
admet-331	632	2	.	.	PUNCT
admet-331	633	1	5	5	NUM
admet-331	633	2	(	(	PUNCT
admet-331	633	3	2011	2011	NUM
admet-331	633	4	)	)	PUNCT
admet-331	634	1	667–677	667–677	NUM
admet-331	634	2	.	.	PUNCT
admet-331	635	1	[	[	X
admet-331	635	2	67	67	NUM
admet-331	635	3	]	]	PUNCT
admet-331	635	4	q.-y	q.-y	NOUN
admet-331	635	5	.	.	PUNCT
admet-331	636	1	lu	lu	PROPN
admet-331	636	2	,	,	PUNCT
admet-331	636	3	w.	w.	PROPN
admet-331	636	4	chen	chen	PROPN
admet-331	636	5	,	,	PUNCT
admet-331	636	6	l.	l.	PROPN
admet-331	636	7	lu	lu	PROPN
admet-331	636	8	,	,	PUNCT
admet-331	636	9	z.	z.	PROPN
admet-331	636	10	zheng	zheng	PROPN
admet-331	636	11	,	,	PUNCT
admet-331	636	12	x.	x.	PROPN
admet-331	636	13	xu	xu	PROPN
admet-331	636	14	,	,	PUNCT
admet-331	636	15	int	int	PROPN
admet-331	636	16	.	.	PUNCT
admet-331	637	1	j.	j.	PROPN
admet-331	637	2	clin	clin	PROPN
admet-331	637	3	.	.	PUNCT
admet-331	638	1	exp	exp	PROPN
admet-331	638	2	.	.	PUNCT
admet-331	638	3	pathol	pathol	NOUN
admet-331	638	4	.	.	PUNCT
admet-331	639	1	7	7	NUM
admet-331	639	2	(	(	PUNCT
admet-331	639	3	2014	2014	NUM
admet-331	639	4	)	)	PUNCT
admet-331	639	5	7268–7277	7268–7277	NUM
admet-331	639	6	.	.	PUNCT
admet-331	640	1	[	[	X
admet-331	640	2	68	68	NUM
admet-331	640	3	]	]	PUNCT
admet-331	640	4	x.	x.	PROPN
admet-331	640	5	yang	yang	PROPN
admet-331	640	6	,	,	PUNCT
admet-331	640	7	a.	a.	NOUN
admet-331	640	8	bhaskaran	bhaskaran	NOUN
admet-331	640	9	,	,	PUNCT
admet-331	640	10	h.	h.	PROPN
admet-331	640	11	scott	scott	PROPN
admet-331	640	12	,	,	PUNCT
admet-331	640	13	s.	s.	PROPN
admet-331	640	14	ardekani	ardekani	PROPN
admet-331	640	15	,	,	PUNCT
admet-331	640	16	j.	j.	PROPN
admet-331	640	17	xu	xu	PROPN
admet-331	640	18	,	,	PUNCT
admet-331	640	19	u.	u.	PROPN
admet-331	640	20	mohideen	mohideen	PROPN
admet-331	640	21	,	,	PUNCT
admet-331	640	22	et	et	PROPN
admet-331	640	23	al	al	PROPN
admet-331	640	24	.	.	PROPN
admet-331	640	25	,	,	PUNCT
admet-331	640	26	rho	rho	ADJ
admet-331	640	27	/	/	SYM
admet-331	640	28	rock	rock	NOUN
admet-331	640	29	-	-	PUNCT
admet-331	640	30	mediated	mediate	VERB
admet-331	640	31	retinal	retinal	ADJ
admet-331	640	32	endothelial	endothelial	NOUN
admet-331	640	33	stiffening	stiffening	NOUN
admet-331	640	34	impairs	impair	VERB
admet-331	640	35	trpv4	trpv4	NOUN
admet-331	640	36	signaling	signal	VERB
admet-331	640	37	and	and	CCONJ
admet-331	640	38	promotes	promote	VERB
admet-331	640	39	diabetic	diabetic	ADJ
admet-331	640	40	retinal	retinal	ADJ
admet-331	640	41	inflammation	inflammation	NOUN
admet-331	640	42	,	,	PUNCT
admet-331	640	43	in	in	ADP
admet-331	640	44	annu	annu	NOUN
admet-331	640	45	.	.	PUNCT
admet-331	641	1	meet	meet	PROPN
admet-331	641	2	.	.	PUNCT
admet-331	642	1	assoc	assoc	PROPN
admet-331	642	2	.	.	PUNCT
admet-331	643	1	res	res	PROPN
admet-331	643	2	.	.	PUNCT
admet-331	644	1	vis	vis	X
admet-331	644	2	.	.	PUNCT
admet-331	644	3	ophthalmol	ophthalmol	PROPN
admet-331	644	4	.	.	PROPN
admet-331	644	5	,	,	PUNCT
admet-331	644	6	seattle	seattle	PROPN
admet-331	644	7	,	,	PUNCT
admet-331	644	8	united	united	PROPN
admet-331	644	9	states	states	PROPN
admet-331	644	10	of	of	ADP
admet-331	644	11	america	america	PROPN
admet-331	644	12	,	,	PUNCT
admet-331	644	13	2016	2016	NUM
admet-331	644	14	,	,	PUNCT
admet-331	644	15	abstract	abstract	ADJ
admet-331	644	16	no.3220	no.3220	PROPN
admet-331	644	17	-	-	PUNCT
admet-331	644	18	c0020	c0020	PROPN
admet-331	644	19	.	.	PUNCT
admet-331	645	1	[	[	X
admet-331	645	2	69	69	NUM
admet-331	645	3	]	]	PUNCT
admet-331	645	4	r.	r.	PROPN
admet-331	645	5	arita	arita	PROPN
admet-331	645	6	,	,	PUNCT
admet-331	645	7	y.	y.	PROPN
admet-331	645	8	hata	hata	PROPN
admet-331	645	9	,	,	PUNCT
admet-331	645	10	s.	s.	PROPN
admet-331	645	11	nakao	nakao	PROPN
admet-331	645	12	,	,	PUNCT
admet-331	645	13	t.	t.	PROPN
admet-331	645	14	kita	kita	PROPN
admet-331	645	15	,	,	PUNCT
admet-331	645	16	m.	m.	NOUN
admet-331	645	17	miura	miura	PROPN
admet-331	645	18	,	,	PUNCT
admet-331	645	19	s.	s.	PROPN
admet-331	645	20	kawahara	kawahara	PROPN
admet-331	645	21	,	,	PUNCT
admet-331	645	22	et	et	PROPN
admet-331	645	23	al	al	PROPN
admet-331	645	24	.	.	PROPN
admet-331	645	25	,	,	PUNCT
admet-331	645	26	diabetes	diabete	VERB
admet-331	645	27	58	58	NUM
admet-331	645	28	(	(	PUNCT
admet-331	645	29	2009	2009	NUM
admet-331	645	30	)	)	PUNCT
admet-331	645	31	215–226	215–226	NUM
admet-331	645	32	.	.	PUNCT
admet-331	646	1	[	[	X
admet-331	646	2	70	70	NUM
admet-331	646	3	]	]	X
admet-331	646	4	r.	r.	PROPN
admet-331	646	5	arita	arita	PROPN
admet-331	646	6	,	,	PUNCT
admet-331	646	7	s.	s.	PROPN
admet-331	646	8	nakao	nakao	PROPN
admet-331	646	9	,	,	PUNCT
admet-331	646	10	t.	t.	PROPN
admet-331	646	11	kita	kita	PROPN
admet-331	646	12	,	,	PUNCT
admet-331	646	13	s.	s.	PROPN
admet-331	646	14	kawahara	kawahara	PROPN
admet-331	646	15	,	,	PUNCT
admet-331	646	16	r.	r.	PROPN
admet-331	646	17	asato	asato	PROPN
admet-331	646	18	,	,	PUNCT
admet-331	646	19	s.	s.	PROPN
admet-331	646	20	yoshida	yoshida	PROPN
admet-331	646	21	,	,	PUNCT
admet-331	646	22	et	et	PROPN
admet-331	646	23	al	al	PROPN
admet-331	646	24	.	.	PROPN
admet-331	646	25	,	,	PUNCT
admet-331	646	26	invest	invest	VERB
admet-331	646	27	.	.	PUNCT
admet-331	647	1	ophthalmol	ophthalmol	PROPN
admet-331	647	2	.	.	PUNCT
admet-331	648	1	vis	vis	X
admet-331	648	2	.	.	PUNCT
admet-331	649	1	sci	sci	PROPN
admet-331	649	2	.	.	PROPN
admet-331	649	3	54	54	NUM
admet-331	649	4	(	(	PUNCT
admet-331	649	5	2013	2013	NUM
admet-331	649	6	)	)	PUNCT
admet-331	649	7	2373–2383	2373–2383	NUM
admet-331	649	8	.	.	PUNCT
admet-331	650	1	[	[	X
admet-331	650	2	71	71	NUM
admet-331	650	3	]	]	PUNCT
admet-331	650	4	a.	a.	NOUN
admet-331	650	5	bhaskaran	bhaskaran	NOUN
admet-331	650	6	,	,	PUNCT
admet-331	650	7	x.	x.	PROPN
admet-331	650	8	yang	yang	PROPN
admet-331	650	9	,	,	PUNCT
admet-331	650	10	h.	h.	PROPN
admet-331	650	11	scott	scott	PROPN
admet-331	650	12	,	,	PUNCT
admet-331	650	13	k.	k.	PROPN
admet-331	650	14	ghosh	ghosh	PROPN
admet-331	650	15	,	,	PUNCT
admet-331	650	16	activated	activate	VERB
admet-331	650	17	monocytes	monocyte	NOUN
admet-331	650	18	contribute	contribute	VERB
admet-331	650	19	to	to	ADP
admet-331	650	20	the	the	DET
admet-331	650	21	mechanical	mechanical	ADJ
admet-331	650	22	control	control	NOUN
admet-331	650	23	of	of	ADP
admet-331	650	24	diabetic	diabetic	ADJ
admet-331	650	25	retinal	retinal	ADJ
admet-331	650	26	endothelial	endothelial	ADJ
admet-331	650	27	activation	activation	NOUN
admet-331	650	28	,	,	PUNCT
admet-331	650	29	in	in	ADP
admet-331	650	30	annu	annu	NOUN
admet-331	650	31	.	.	PUNCT
admet-331	651	1	meet	meet	PROPN
admet-331	651	2	.	.	PUNCT
admet-331	652	1	assoc	assoc	PROPN
admet-331	652	2	.	.	PUNCT
admet-331	653	1	res	res	PROPN
admet-331	653	2	.	.	PUNCT
admet-331	654	1	vis	vis	X
admet-331	654	2	.	.	PROPN
admet-331	654	3	ophtalmol	ophtalmol	PROPN
admet-331	654	4	.	.	PROPN
admet-331	654	5	,	,	PUNCT
admet-331	654	6	seattle	seattle	PROPN
admet-331	654	7	,	,	PUNCT
admet-331	654	8	united	united	PROPN
admet-331	654	9	states	states	PROPN
admet-331	654	10	of	of	ADP
admet-331	654	11	america	america	PROPN
admet-331	654	12	,	,	PUNCT
admet-331	654	13	2016	2016	NUM
admet-331	654	14	,	,	PUNCT
admet-331	654	15	abstract	abstract	ADJ
admet-331	654	16	no.3219	no.3219	PROPN
admet-331	654	17	-	-	PUNCT
admet-331	654	18	c0019	c0019	PROPN
admet-331	654	19	.	.	PUNCT
admet-331	654	20	éva	éva	PROPN
admet-331	654	21	halász	halász	PROPN
admet-331	654	22	,	,	PUNCT
admet-331	654	23	ellen	ellen	PROPN
admet-331	654	24	townes	townes	PROPN
admet-331	654	25	-	-	PUNCT
admet-331	654	26	anderson	anderson	PROPN
admet-331	654	27	admet	admet	PROPN
admet-331	654	28	&	&	CCONJ
admet-331	654	29	dmpk	dmpk	PROPN
admet-331	654	30	4(4	4(4	NUM
admet-331	654	31	)	)	PUNCT
admet-331	654	32	(	(	PUNCT
admet-331	654	33	2016	2016	NUM
admet-331	654	34	)	)	PUNCT
admet-331	654	35	280	280	NUM
admet-331	654	36	-	-	SYM
admet-331	654	37	301	301	NUM
admet-331	654	38	300	300	NUM
admet-331	654	39	[	[	X
admet-331	654	40	72	72	NUM
admet-331	654	41	]	]	X
admet-331	654	42	f.	f.	PROPN
admet-331	654	43	monickaraj	monickaraj	PROPN
admet-331	654	44	,	,	PUNCT
admet-331	654	45	p.	p.	PROPN
admet-331	654	46	g.	g.	PROPN
admet-331	654	47	mcguire	mcguire	PROPN
admet-331	654	48	,	,	PUNCT
admet-331	654	49	c.	c.	PROPN
admet-331	654	50	franco	franco	PROPN
admet-331	654	51	nitta	nitta	PROPN
admet-331	654	52	,	,	PUNCT
admet-331	654	53	k.	k.	PROPN
admet-331	654	54	ghosh	ghosh	PROPN
admet-331	654	55	,	,	PUNCT
admet-331	654	56	a.	a.	PROPN
admet-331	654	57	das	das	PROPN
admet-331	654	58	,	,	PUNCT
admet-331	654	59	faseb	faseb	PROPN
admet-331	654	60	j.	j.	PROPN
admet-331	654	61	30	30	NUM
admet-331	654	62	(	(	PUNCT
admet-331	654	63	2016	2016	NUM
admet-331	654	64	)	)	PUNCT
admet-331	654	65	1670–1682	1670–1682	NOUN
admet-331	654	66	.	.	PUNCT
admet-331	655	1	[	[	X
admet-331	655	2	73	73	NUM
admet-331	655	3	]	]	PUNCT
admet-331	655	4	p.-r	p.-r	PROPN
admet-331	655	5	.	.	PUNCT
admet-331	656	1	rothschild	rothschild	PROPN
admet-331	656	2	,	,	PUNCT
admet-331	656	3	s.	s.	PROPN
admet-331	656	4	salah	salah	PROPN
admet-331	656	5	,	,	PUNCT
admet-331	656	6	e.	e.	PROPN
admet-331	656	7	gelize	gelize	PROPN
admet-331	656	8	,	,	PUNCT
admet-331	656	9	c.	c.	PROPN
admet-331	656	10	bergin	bergin	PROPN
admet-331	656	11	,	,	PUNCT
admet-331	656	12	m.	m.	NOUN
admet-331	656	13	berdugo	berdugo	PROPN
admet-331	656	14	,	,	PUNCT
admet-331	656	15	c.	c.	PROPN
admet-331	656	16	klein	klein	PROPN
admet-331	656	17	,	,	PUNCT
admet-331	656	18	et	et	PROPN
admet-331	656	19	al	al	PROPN
admet-331	656	20	.	.	PROPN
admet-331	656	21	,	,	PUNCT
admet-331	656	22	diabetes	diabetes	NOUN
admet-331	656	23	-	-	PUNCT
admet-331	656	24	induced	induce	VERB
admet-331	656	25	rock	rock	NOUN
admet-331	656	26	activation	activation	NOUN
admet-331	656	27	contributes	contribute	VERB
admet-331	656	28	to	to	ADP
admet-331	656	29	outer	outer	ADJ
admet-331	656	30	blood	blood	NOUN
admet-331	656	31	retinal	retinal	ADJ
admet-331	656	32	barrier	barrier	NOUN
admet-331	656	33	breakdown	breakdown	NOUN
admet-331	656	34	:	:	PUNCT
admet-331	656	35	implications	implication	NOUN
admet-331	656	36	for	for	ADP
admet-331	656	37	diabetic	diabetic	ADJ
admet-331	656	38	macular	macular	ADJ
admet-331	656	39	edema	edema	NOUN
admet-331	656	40	,	,	PUNCT
admet-331	656	41	in	in	ADP
admet-331	656	42	annu	annu	NOUN
admet-331	656	43	.	.	PUNCT
admet-331	657	1	meet	meet	PROPN
admet-331	657	2	.	.	PUNCT
admet-331	658	1	assoc	assoc	PROPN
admet-331	658	2	.	.	PUNCT
admet-331	659	1	res	res	PROPN
admet-331	659	2	.	.	PUNCT
admet-331	660	1	vis	vis	X
admet-331	660	2	.	.	PUNCT
admet-331	660	3	ophthalmol	ophthalmol	PROPN
admet-331	660	4	.	.	PROPN
admet-331	660	5	,	,	PUNCT
admet-331	660	6	seattle	seattle	PROPN
admet-331	660	7	,	,	PUNCT
admet-331	660	8	united	united	PROPN
admet-331	660	9	states	states	PROPN
admet-331	660	10	of	of	ADP
admet-331	660	11	america	america	PROPN
admet-331	660	12	,	,	PUNCT
admet-331	660	13	2016	2016	NUM
admet-331	660	14	,	,	PUNCT
admet-331	660	15	abstract	abstract	ADJ
admet-331	660	16	no	no	NOUN
admet-331	660	17	.	.	PUNCT
admet-331	660	18	6144	6144	NUM
admet-331	660	19	.	.	PUNCT
admet-331	661	1	[	[	X
admet-331	661	2	74	74	X
admet-331	661	3	]	]	PUNCT
admet-331	661	4	t.	t.	PROPN
admet-331	661	5	kita	kita	PROPN
admet-331	661	6	,	,	PUNCT
admet-331	661	7	y.	y.	PROPN
admet-331	661	8	hata	hata	PROPN
admet-331	661	9	,	,	PUNCT
admet-331	661	10	k.	k.	PROPN
admet-331	661	11	kano	kano	PROPN
admet-331	661	12	,	,	PUNCT
admet-331	661	13	m.	m.	PROPN
admet-331	661	14	miura	miura	PROPN
admet-331	661	15	,	,	PUNCT
admet-331	661	16	s.	s.	PROPN
admet-331	661	17	nakao	nakao	PROPN
admet-331	661	18	,	,	PUNCT
admet-331	661	19	y.	y.	PROPN
admet-331	661	20	noda	noda	PROPN
admet-331	661	21	,	,	PUNCT
admet-331	661	22	et	et	PROPN
admet-331	661	23	al	al	PROPN
admet-331	661	24	.	.	PROPN
admet-331	661	25	,	,	PUNCT
admet-331	661	26	diabetes	diabete	VERB
admet-331	661	27	56	56	NUM
admet-331	661	28	(	(	PUNCT
admet-331	661	29	2007	2007	NUM
admet-331	661	30	)	)	PUNCT
admet-331	661	31	231–238	231–238	NUM
admet-331	661	32	.	.	PUNCT
admet-331	662	1	[	[	X
admet-331	662	2	75	75	NUM
admet-331	662	3	]	]	PUNCT
admet-331	662	4	t.	t.	PROPN
admet-331	662	5	b.	b.	PROPN
admet-331	662	6	connor	connor	PROPN
admet-331	662	7	,	,	PUNCT
admet-331	662	8	a.	a.	PROPN
admet-331	662	9	b.	b.	PROPN
admet-331	662	10	roberts	roberts	PROPN
admet-331	662	11	,	,	PUNCT
admet-331	662	12	m.	m.	PROPN
admet-331	662	13	b.	b.	PROPN
admet-331	662	14	sporn	sporn	PROPN
admet-331	662	15	,	,	PUNCT
admet-331	662	16	d.	d.	PROPN
admet-331	662	17	danielpour	danielpour	PROPN
admet-331	662	18	,	,	PUNCT
admet-331	662	19	l.	l.	PROPN
admet-331	662	20	l.	l.	PROPN
admet-331	662	21	dart	dart	PROPN
admet-331	662	22	,	,	PUNCT
admet-331	662	23	r.	r.	PROPN
admet-331	662	24	g.	g.	PROPN
admet-331	662	25	michels	michels	PROPN
admet-331	662	26	,	,	PUNCT
admet-331	662	27	et	et	PROPN
admet-331	662	28	al	al	PROPN
admet-331	662	29	.	.	PROPN
admet-331	662	30	,	,	PUNCT
admet-331	662	31	j.	j.	PROPN
admet-331	662	32	clin	clin	PROPN
admet-331	662	33	.	.	PUNCT
admet-331	663	1	invest	invest	VERB
admet-331	663	2	.	.	PUNCT
admet-331	664	1	83	83	NUM
admet-331	664	2	(	(	PUNCT
admet-331	664	3	1989	1989	NUM
admet-331	664	4	)	)	PUNCT
admet-331	664	5	1661–6	1661–6	NUM
admet-331	664	6	.	.	PUNCT
admet-331	665	1	[	[	X
admet-331	665	2	76	76	X
admet-331	665	3	]	]	X
admet-331	665	4	t.	t.	PROPN
admet-331	665	5	kita	kita	PROPN
admet-331	665	6	,	,	PUNCT
admet-331	665	7	y.	y.	PROPN
admet-331	665	8	hata	hata	PROPN
admet-331	665	9	,	,	PUNCT
admet-331	665	10	r.	r.	PROPN
admet-331	665	11	arita	arita	PROPN
admet-331	665	12	,	,	PUNCT
admet-331	665	13	s.	s.	PROPN
admet-331	665	14	kawahara	kawahara	PROPN
admet-331	665	15	,	,	PUNCT
admet-331	665	16	m.	m.	PROPN
admet-331	665	17	miura	miura	PROPN
admet-331	665	18	,	,	PUNCT
admet-331	665	19	s.	s.	PROPN
admet-331	665	20	nakao	nakao	PROPN
admet-331	665	21	,	,	PUNCT
admet-331	665	22	et	et	PROPN
admet-331	665	23	al	al	PROPN
admet-331	665	24	.	.	PROPN
admet-331	665	25	,	,	PUNCT
admet-331	665	26	proc	proc	PROPN
admet-331	665	27	.	.	PUNCT
admet-331	666	1	natl	natl	PROPN
admet-331	666	2	.	.	PUNCT
admet-331	667	1	acad	acad	PROPN
admet-331	667	2	.	.	PUNCT
admet-331	668	1	sci	sci	PROPN
admet-331	668	2	.	.	PUNCT
admet-331	668	3	u.	u.	PROPN
admet-331	668	4	s.	s.	PROPN
admet-331	668	5	a.	a.	PROPN
admet-331	668	6	105	105	NUM
admet-331	668	7	(	(	PUNCT
admet-331	668	8	2008	2008	NUM
admet-331	668	9	)	)	PUNCT
admet-331	668	10	17504–9	17504–9	NUM
admet-331	668	11	.	.	PUNCT
admet-331	669	1	[	[	X
admet-331	669	2	77	77	X
admet-331	669	3	]	]	X
admet-331	669	4	y.	y.	PROPN
admet-331	669	5	zheng	zheng	PROPN
admet-331	669	6	,	,	PUNCT
admet-331	669	7	h.	h.	PROPN
admet-331	669	8	bando	bando	PROPN
admet-331	669	9	,	,	PUNCT
admet-331	669	10	y.	y.	PROPN
admet-331	669	11	ikuno	ikuno	PROPN
admet-331	669	12	,	,	PUNCT
admet-331	669	13	y.	y.	PROPN
admet-331	669	14	oshima	oshima	PROPN
admet-331	669	15	,	,	PUNCT
admet-331	669	16	m.	m.	PROPN
admet-331	669	17	sawa	sawa	PROPN
admet-331	669	18	,	,	PUNCT
admet-331	669	19	m.	m.	NOUN
admet-331	669	20	ohji	ohji	PROPN
admet-331	669	21	,	,	PUNCT
admet-331	669	22	et	et	PROPN
admet-331	669	23	al	al	PROPN
admet-331	669	24	.	.	PROPN
admet-331	669	25	,	,	PUNCT
admet-331	669	26	invest	invest	VERB
admet-331	669	27	.	.	PUNCT
admet-331	670	1	ophthalmol	ophthalmol	PROPN
admet-331	670	2	.	.	PUNCT
admet-331	671	1	vis	vis	X
admet-331	671	2	.	.	PUNCT
admet-331	672	1	sci	sci	PROPN
admet-331	672	2	.	.	PROPN
admet-331	673	1	45	45	NUM
admet-331	673	2	(	(	PUNCT
admet-331	673	3	2004	2004	NUM
admet-331	673	4	)	)	PUNCT
admet-331	674	1	668–674	668–674	NUM
admet-331	674	2	.	.	PUNCT
admet-331	675	1	[	[	X
admet-331	675	2	78	78	NUM
admet-331	675	3	]	]	X
admet-331	675	4	g.p	g.p	PROPN
admet-331	675	5	.	.	PROPN
admet-331	675	6	van	van	PROPN
admet-331	675	7	nieuw	nieuw	PROPN
admet-331	675	8	amerongen	amerongen	PROPN
admet-331	675	9	,	,	PUNCT
admet-331	675	10	p.	p.	NOUN
admet-331	675	11	koolwijk	koolwijk	PROPN
admet-331	675	12	,	,	PUNCT
admet-331	675	13	a.	a.	PROPN
admet-331	675	14	versteilen	versteilen	PROPN
admet-331	675	15	,	,	PUNCT
admet-331	675	16	v.	v.	PROPN
admet-331	675	17	w.	w.	PROPN
admet-331	675	18	m.	m.	PROPN
admet-331	675	19	van	van	PROPN
admet-331	675	20	hinsbergh	hinsbergh	PROPN
admet-331	675	21	,	,	PUNCT
admet-331	675	22	arterioscler	arterioscler	NOUN
admet-331	675	23	.	.	PUNCT
admet-331	676	1	thromb	thromb	PROPN
admet-331	676	2	.	.	PUNCT
admet-331	677	1	vasc	vasc	PROPN
admet-331	677	2	.	.	PUNCT
admet-331	678	1	biol	biol	PROPN
admet-331	678	2	.	.	PUNCT
admet-331	679	1	23	23	NUM
admet-331	679	2	(	(	PUNCT
admet-331	679	3	2003	2003	NUM
admet-331	679	4	)	)	PUNCT
admet-331	679	5	211–217	211–217	NUM
admet-331	679	6	.	.	PUNCT
admet-331	680	1	[	[	X
admet-331	680	2	79	79	NUM
admet-331	680	3	]	]	X
admet-331	680	4	f.	f.	PROPN
admet-331	680	5	celik	celik	PROPN
admet-331	680	6	,	,	PUNCT
admet-331	680	7	f.	f.	PROPN
admet-331	680	8	ulas	ulas	PROPN
admet-331	680	9	,	,	PUNCT
admet-331	680	10	z.	z.	PROPN
admet-331	680	11	g.	g.	PROPN
admet-331	680	12	ozunal	ozunal	PROPN
admet-331	680	13	,	,	PUNCT
admet-331	680	14	t.	t.	PROPN
admet-331	680	15	firat	firat	PROPN
admet-331	680	16	,	,	PUNCT
admet-331	680	17	s.	s.	PROPN
admet-331	680	18	celebi	celebi	PROPN
admet-331	680	19	,	,	PUNCT
admet-331	680	20	u.	u.	PROPN
admet-331	680	21	dogan	dogan	PROPN
admet-331	680	22	,	,	PUNCT
admet-331	680	23	int	int	PROPN
admet-331	680	24	.	.	PUNCT
admet-331	681	1	j.	j.	PROPN
admet-331	681	2	ophthalmol	ophthalmol	PROPN
admet-331	681	3	.	.	PROPN
admet-331	682	1	7	7	NUM
admet-331	682	2	(	(	PUNCT
admet-331	682	3	2014	2014	NUM
admet-331	682	4	)	)	PUNCT
admet-331	682	5	57–61	57–61	NUM
admet-331	682	6	.	.	PUNCT
admet-331	683	1	[	[	X
admet-331	683	2	80	80	NUM
admet-331	683	3	]	]	PUNCT
admet-331	683	4	r.	r.	PROPN
admet-331	683	5	nourinia	nourinia	PROPN
admet-331	683	6	,	,	PUNCT
admet-331	683	7	h.	h.	PROPN
admet-331	683	8	ahmadieh	ahmadieh	PROPN
admet-331	683	9	,	,	PUNCT
admet-331	683	10	m.	m.	NOUN
admet-331	683	11	h.	h.	PROPN
admet-331	683	12	shahheidari	shahheidari	PROPN
admet-331	683	13	,	,	PUNCT
admet-331	683	14	s.	s.	PROPN
admet-331	683	15	zandi	zandi	PROPN
admet-331	683	16	,	,	PUNCT
admet-331	683	17	s.	s.	PROPN
admet-331	683	18	nakao	nakao	PROPN
admet-331	683	19	,	,	PUNCT
admet-331	683	20	a.	a.	PROPN
admet-331	683	21	hafezi	hafezi	PROPN
admet-331	683	22	-	-	PUNCT
admet-331	683	23	moghadam	moghadam	PROPN
admet-331	683	24	,	,	PUNCT
admet-331	683	25	j.	j.	PROPN
admet-331	683	26	ophthalmic	ophthalmic	PROPN
admet-331	683	27	vis	vis	X
admet-331	683	28	.	.	PUNCT
admet-331	683	29	res	re	NOUN
admet-331	683	30	.	.	PROPN
admet-331	683	31	8	8	NUM
admet-331	683	32	(	(	PUNCT
admet-331	683	33	2013	2013	NUM
admet-331	683	34	)	)	PUNCT
admet-331	683	35	337–340	337–340	NUM
admet-331	683	36	.	.	PUNCT
admet-331	684	1	[	[	X
admet-331	684	2	81	81	NUM
admet-331	684	3	]	]	PUNCT
admet-331	684	4	h.	h.	PROPN
admet-331	684	5	ahmadieh	ahmadieh	PROPN
admet-331	684	6	,	,	PUNCT
admet-331	684	7	jama	jama	PROPN
admet-331	684	8	ophthalmol	ophthalmol	PROPN
admet-331	684	9	.	.	PUNCT
admet-331	685	1	131	131	NUM
admet-331	685	2	(	(	PUNCT
admet-331	685	3	2013	2013	NUM
admet-331	685	4	)	)	PUNCT
admet-331	685	5	923–924	923–924	NUM
admet-331	685	6	.	.	PUNCT
admet-331	686	1	[	[	X
admet-331	686	2	82	82	NUM
admet-331	686	3	]	]	X
admet-331	686	4	s.	s.	PROPN
admet-331	686	5	zandi	zandi	PROPN
admet-331	686	6	,	,	PUNCT
admet-331	686	7	s.	s.	PROPN
admet-331	686	8	nakao	nakao	PROPN
admet-331	686	9	,	,	PUNCT
admet-331	686	10	k.	k.	PROPN
admet-331	686	11	h.	h.	PROPN
admet-331	686	12	chun	chun	PROPN
admet-331	686	13	,	,	PUNCT
admet-331	686	14	p.	p.	PROPN
admet-331	686	15	fiorina	fiorina	PROPN
admet-331	686	16	,	,	PUNCT
admet-331	686	17	d.	d.	PROPN
admet-331	686	18	sun	sun	PROPN
admet-331	686	19	,	,	PUNCT
admet-331	686	20	r.	r.	PROPN
admet-331	686	21	arita	arita	PROPN
admet-331	686	22	,	,	PUNCT
admet-331	686	23	et	et	PROPN
admet-331	686	24	al	al	PROPN
admet-331	686	25	.	.	PROPN
admet-331	686	26	,	,	PUNCT
admet-331	686	27	cell	cell	PROPN
admet-331	686	28	rep	rep	PROPN
admet-331	686	29	.	.	PROPN
admet-331	686	30	10	10	NUM
admet-331	686	31	(	(	PUNCT
admet-331	686	32	2015	2015	NUM
admet-331	686	33	)	)	PUNCT
admet-331	686	34	1173–1186	1173–1186	NUM
admet-331	686	35	.	.	PUNCT
admet-331	687	1	[	[	X
admet-331	687	2	83	83	NUM
admet-331	687	3	]	]	PUNCT
admet-331	687	4	c.-w	c.-w	PROPN
admet-331	687	5	.	.	PUNCT
admet-331	688	1	lin	lin	PROPN
admet-331	688	2	,	,	PUNCT
admet-331	688	3	j.	j.	PROPN
admet-331	688	4	m.	m.	PROPN
admet-331	688	5	sturdivant	sturdivant	PROPN
admet-331	688	6	,	,	PUNCT
admet-331	688	7	m.	m.	NOUN
admet-331	688	8	a.	a.	PROPN
admet-331	688	9	delong	delong	PROPN
admet-331	688	10	,	,	PUNCT
admet-331	688	11	c.	c.	PROPN
admet-331	688	12	kopczynski	kopczynski	PROPN
admet-331	688	13	,	,	PUNCT
admet-331	688	14	effectiveness	effectiveness	NOUN
admet-331	688	15	of	of	ADP
admet-331	688	16	ar-13154	ar-13154	PROPN
admet-331	688	17	monotherapy	monotherapy	NOUN
admet-331	688	18	and	and	CCONJ
admet-331	688	19	combination	combination	NOUN
admet-331	688	20	therapy	therapy	NOUN
admet-331	688	21	in	in	ADP
admet-331	688	22	animal	animal	NOUN
admet-331	688	23	models	model	NOUN
admet-331	688	24	of	of	ADP
admet-331	688	25	wet	wet	ADJ
admet-331	688	26	age	age	NOUN
admet-331	688	27	-	-	PUNCT
admet-331	688	28	related	relate	VERB
admet-331	688	29	macular	macular	ADJ
admet-331	688	30	degeneration	degeneration	NOUN
admet-331	688	31	and	and	CCONJ
admet-331	688	32	proliferative	proliferative	ADJ
admet-331	688	33	diabetic	diabetic	ADJ
admet-331	688	34	retinopathy	retinopathy	NOUN
admet-331	688	35	,	,	PUNCT
admet-331	688	36	in	in	ADP
admet-331	688	37	annu	annu	NOUN
admet-331	688	38	.	.	PUNCT
admet-331	689	1	meet	meet	PROPN
admet-331	689	2	.	.	PUNCT
admet-331	690	1	assoc	assoc	PROPN
admet-331	690	2	.	.	PUNCT
admet-331	691	1	res	res	PROPN
admet-331	691	2	.	.	PUNCT
admet-331	692	1	vis	vis	X
admet-331	692	2	.	.	PUNCT
admet-331	692	3	ophthalmol	ophthalmol	PROPN
admet-331	692	4	.	.	PROPN
admet-331	692	5	,	,	PUNCT
admet-331	692	6	seattle	seattle	PROPN
admet-331	692	7	,	,	PUNCT
admet-331	692	8	united	united	PROPN
admet-331	692	9	states	states	PROPN
admet-331	692	10	of	of	ADP
admet-331	692	11	america	america	PROPN
admet-331	692	12	,	,	PUNCT
admet-331	692	13	2016	2016	NUM
admet-331	692	14	,	,	PUNCT
admet-331	692	15	abstract	abstract	ADJ
admet-331	692	16	no.287	no.287	NOUN
admet-331	692	17	-	-	PUNCT
admet-331	692	18	b0320	b0320	NOUN
admet-331	692	19	.	.	PUNCT
admet-331	693	1	[	[	X
admet-331	693	2	84	84	NUM
admet-331	693	3	]	]	PUNCT
admet-331	693	4	t.	t.	NOUN
admet-331	693	5	sugiyama	sugiyama	NOUN
admet-331	693	6	,	,	PUNCT
admet-331	693	7	m.	m.	NOUN
admet-331	693	8	shibata	shibata	PROPN
admet-331	693	9	,	,	PUNCT
admet-331	693	10	s.	s.	PROPN
admet-331	693	11	kajiura	kajiura	PROPN
admet-331	693	12	,	,	PUNCT
admet-331	693	13	t.	t.	PROPN
admet-331	693	14	okuno	okuno	PROPN
admet-331	693	15	,	,	PUNCT
admet-331	693	16	m.	m.	NOUN
admet-331	693	17	tonari	tonari	PROPN
admet-331	693	18	,	,	PUNCT
admet-331	693	19	h.	h.	PROPN
admet-331	693	20	oku	oku	PROPN
admet-331	693	21	,	,	PUNCT
admet-331	693	22	et	et	PROPN
admet-331	693	23	al	al	PROPN
admet-331	693	24	.	.	PROPN
admet-331	693	25	,	,	PUNCT
admet-331	693	26	invest	invest	VERB
admet-331	693	27	.	.	PUNCT
admet-331	694	1	ophthalmol	ophthalmol	PROPN
admet-331	694	2	.	.	PUNCT
admet-331	695	1	vis	vis	X
admet-331	695	2	.	.	PUNCT
admet-331	696	1	sci	sci	PROPN
admet-331	696	2	.	.	PROPN
admet-331	697	1	52	52	NUM
admet-331	697	2	(	(	PUNCT
admet-331	697	3	2011	2011	NUM
admet-331	697	4	)	)	PUNCT
admet-331	697	5	64–69	64–69	NOUN
admet-331	697	6	.	.	PUNCT
admet-331	698	1	[	[	X
admet-331	698	2	85	85	NUM
admet-331	698	3	]	]	X
admet-331	698	4	h.	h.	PROPN
admet-331	698	5	watabe	watabe	PROPN
admet-331	698	6	,	,	PUNCT
admet-331	698	7	s.	s.	PROPN
admet-331	698	8	abe	abe	PROPN
admet-331	698	9	,	,	PUNCT
admet-331	698	10	t.	t.	PROPN
admet-331	698	11	yoshitomi	yoshitomi	PROPN
admet-331	698	12	,	,	PUNCT
admet-331	698	13	jpn	jpn	PROPN
admet-331	698	14	.	.	PUNCT
admet-331	699	1	j.	j.	PROPN
admet-331	699	2	ophthalmol	ophthalmol	PROPN
admet-331	699	3	.	.	PUNCT
admet-331	700	1	55	55	NUM
admet-331	700	2	(	(	PUNCT
admet-331	700	3	2011	2011	NUM
admet-331	700	4	)	)	PUNCT
admet-331	700	5	411–417	411–417	NUM
admet-331	700	6	.	.	PUNCT
admet-331	701	1	[	[	X
admet-331	701	2	86	86	NUM
admet-331	701	3	]	]	X
admet-331	701	4	n.	n.	NOUN
admet-331	701	5	sanjari	sanjari	PROPN
admet-331	701	6	,	,	PUNCT
admet-331	701	7	m.	m.	NOUN
admet-331	701	8	pakravan	pakravan	PROPN
admet-331	701	9	,	,	PUNCT
admet-331	701	10	r.	r.	PROPN
admet-331	701	11	nourinia	nourinia	PROPN
admet-331	701	12	,	,	PUNCT
admet-331	701	13	h.	h.	PROPN
admet-331	701	14	esfandiari	esfandiari	PROPN
admet-331	701	15	,	,	PUNCT
admet-331	701	16	a.	a.	PROPN
admet-331	701	17	hafezi	hafezi	PROPN
admet-331	701	18	-	-	PUNCT
admet-331	701	19	moghadam	moghadam	PROPN
admet-331	701	20	,	,	PUNCT
admet-331	701	21	s.	s.	PROPN
admet-331	701	22	zandi	zandi	PROPN
admet-331	701	23	,	,	PUNCT
admet-331	701	24	et	et	PROPN
admet-331	701	25	al	al	PROPN
admet-331	701	26	.	.	PROPN
admet-331	701	27	,	,	PUNCT
admet-331	701	28	j.	j.	PROPN
admet-331	701	29	clin	clin	PROPN
admet-331	701	30	.	.	PUNCT
admet-331	702	1	pharmacol	pharmacol	PROPN
admet-331	702	2	.	.	PUNCT
admet-331	703	1	(	(	PUNCT
admet-331	703	2	2015	2015	NUM
admet-331	703	3	)	)	PUNCT
admet-331	703	4	1–5	1–5	NUM
admet-331	703	5	.	.	PUNCT
admet-331	704	1	[	[	X
admet-331	704	2	87	87	NUM
admet-331	704	3	]	]	PUNCT
admet-331	704	4	s.	s.	PROPN
admet-331	704	5	nakabayashi	nakabayashi	PROPN
admet-331	704	6	,	,	PUNCT
admet-331	704	7	m.	m.	NOUN
admet-331	704	8	kawai	kawai	PROPN
admet-331	704	9	,	,	PUNCT
admet-331	704	10	t.	t.	PROPN
admet-331	704	11	yoshioka	yoshioka	PROPN
admet-331	704	12	,	,	PUNCT
admet-331	704	13	y.	y.	PROPN
admet-331	704	14	s.	s.	PROPN
admet-331	704	15	song	song	PROPN
admet-331	704	16	,	,	PUNCT
admet-331	704	17	t.	t.	PROPN
admet-331	704	18	tani	tani	PROPN
admet-331	704	19	,	,	PUNCT
admet-331	704	20	a.	a.	PROPN
admet-331	704	21	yoshida	yoshida	PROPN
admet-331	704	22	,	,	PUNCT
admet-331	704	23	et	et	PROPN
admet-331	704	24	al	al	PROPN
admet-331	704	25	.	.	PROPN
admet-331	704	26	,	,	PUNCT
admet-331	704	27	exp	exp	PROPN
admet-331	704	28	.	.	PUNCT
admet-331	704	29	eye	eye	NOUN
admet-331	704	30	res	re	NOUN
admet-331	704	31	.	.	PUNCT
admet-331	705	1	139	139	NUM
admet-331	705	2	(	(	PUNCT
admet-331	705	3	2015	2015	NUM
admet-331	705	4	)	)	PUNCT
admet-331	705	5	132–135	132–135	NUM
admet-331	705	6	.	.	PUNCT
admet-331	706	1	[	[	X
admet-331	706	2	88	88	NUM
admet-331	706	3	]	]	PUNCT
admet-331	706	4	z.	z.	PROPN
admet-331	706	5	yang	yang	PROPN
admet-331	706	6	,	,	PUNCT
admet-331	706	7	j.	j.	PROPN
admet-331	706	8	wang	wang	PROPN
admet-331	706	9	,	,	PUNCT
admet-331	706	10	x.	x.	PROPN
admet-331	706	11	liu	liu	PROPN
admet-331	706	12	,	,	PUNCT
admet-331	706	13	y.	y.	PROPN
admet-331	706	14	cheng	cheng	PROPN
admet-331	706	15	,	,	PUNCT
admet-331	706	16	l.	l.	PROPN
admet-331	706	17	deng	deng	PROPN
admet-331	706	18	,	,	PUNCT
admet-331	706	19	y.	y.	PROPN
admet-331	706	20	zhong	zhong	PROPN
admet-331	706	21	,	,	PUNCT
admet-331	706	22	oncol	oncol	PROPN
admet-331	706	23	.	.	PUNCT
admet-331	707	1	rep	rep	PROPN
admet-331	707	2	.	.	PROPN
admet-331	707	3	29	29	NUM
admet-331	707	4	(	(	PUNCT
admet-331	707	5	2013	2013	NUM
admet-331	707	6	)	)	PUNCT
admet-331	707	7	1140–1146	1140–1146	NUM
admet-331	707	8	.	.	PUNCT
admet-331	708	1	[	[	X
admet-331	708	2	89	89	NUM
admet-331	708	3	]	]	X
admet-331	708	4	h.	h.	PROPN
admet-331	708	5	sagawa	sagawa	PROPN
admet-331	708	6	,	,	PUNCT
admet-331	708	7	h.	h.	PROPN
admet-331	708	8	terasaki	terasaki	PROPN
admet-331	708	9	,	,	PUNCT
admet-331	708	10	m.	m.	NOUN
admet-331	708	11	nakamura	nakamura	PROPN
admet-331	708	12	,	,	PUNCT
admet-331	708	13	m.	m.	NOUN
admet-331	708	14	ichikawa	ichikawa	PROPN
admet-331	708	15	,	,	PUNCT
admet-331	708	16	t.	t.	PROPN
admet-331	708	17	yata	yata	PROPN
admet-331	708	18	,	,	PUNCT
admet-331	708	19	y.	y.	PROPN
admet-331	708	20	tokita	tokita	PROPN
admet-331	708	21	,	,	PUNCT
admet-331	708	22	et	et	PROPN
admet-331	708	23	al	al	PROPN
admet-331	708	24	.	.	PROPN
admet-331	708	25	,	,	PUNCT
admet-331	708	26	exp	exp	PROPN
admet-331	708	27	.	.	PUNCT
admet-331	708	28	neurol	neurol	PROPN
admet-331	708	29	.	.	PUNCT
admet-331	709	1	205	205	NUM
admet-331	709	2	(	(	PUNCT
admet-331	709	3	2007	2007	NUM
admet-331	709	4	)	)	PUNCT
admet-331	709	5	230–240	230–240	NUM
admet-331	709	6	.	.	PUNCT
admet-331	710	1	[	[	X
admet-331	710	2	90	90	NUM
admet-331	710	3	]	]	PUNCT
admet-331	710	4	m.	m.	NOUN
admet-331	710	5	ichikawa	ichikawa	PROPN
admet-331	710	6	,	,	PUNCT
admet-331	710	7	j.	j.	PROPN
admet-331	710	8	yoshida	yoshida	PROPN
admet-331	710	9	,	,	PUNCT
admet-331	710	10	k.	k.	PROPN
admet-331	710	11	saito	saito	PROPN
admet-331	710	12	,	,	PUNCT
admet-331	710	13	h.	h.	PROPN
admet-331	710	14	sagawa	sagawa	PROPN
admet-331	710	15	,	,	PUNCT
admet-331	710	16	y.	y.	PROPN
admet-331	710	17	tokita	tokita	PROPN
admet-331	710	18	,	,	PUNCT
admet-331	710	19	m.	m.	PROPN
admet-331	710	20	watanabe	watanabe	PROPN
admet-331	710	21	,	,	PUNCT
admet-331	710	22	brain	brain	NOUN
admet-331	710	23	res	re	NOUN
admet-331	710	24	.	.	PUNCT
admet-331	711	1	1201	1201	NUM
admet-331	711	2	(	(	PUNCT
admet-331	711	3	2008	2008	NUM
admet-331	711	4	)	)	PUNCT
admet-331	711	5	23–33	23–33	NUM
admet-331	711	6	.	.	PUNCT
admet-331	712	1	[	[	X
admet-331	712	2	91	91	NUM
admet-331	712	3	]	]	X
admet-331	712	4	j.	j.	PROPN
admet-331	712	5	yu	yu	PROPN
admet-331	712	6	,	,	PUNCT
admet-331	712	7	l.	l.	PROPN
admet-331	712	8	lin	lin	PROPN
admet-331	712	9	,	,	PUNCT
admet-331	712	10	x.	x.	PROPN
admet-331	712	11	luan	luan	PROPN
admet-331	712	12	,	,	PUNCT
admet-331	712	13	x.	x.	PROPN
admet-331	712	14	jing	jing	PROPN
admet-331	712	15	,	,	PUNCT
admet-331	712	16	8	8	NUM
admet-331	712	17	(	(	PUNCT
admet-331	712	18	2015	2015	NUM
admet-331	712	19	)	)	PUNCT
admet-331	712	20	14717–14724	14717–14724	NUM
admet-331	712	21	.	.	PUNCT
admet-331	713	1	[	[	X
admet-331	713	2	92	92	NUM
admet-331	713	3	]	]	PUNCT
admet-331	713	4	a.	a.	NOUN
admet-331	713	5	m.	m.	NOUN
admet-331	713	6	fontainhas	fontainhas	PROPN
admet-331	713	7	,	,	PUNCT
admet-331	713	8	e.	e.	PROPN
admet-331	713	9	townes	townes	PROPN
admet-331	713	10	-	-	PUNCT
admet-331	713	11	anderson	anderson	PROPN
admet-331	713	12	,	,	PUNCT
admet-331	713	13	invest	invest	VERB
admet-331	713	14	.	.	PUNCT
admet-331	714	1	ophthalmol	ophthalmol	PROPN
admet-331	714	2	.	.	PUNCT
admet-331	715	1	vis	vis	X
admet-331	715	2	.	.	PUNCT
admet-331	716	1	sci	sci	PROPN
admet-331	716	2	.	.	PROPN
admet-331	716	3	49	49	NUM
admet-331	716	4	(	(	PUNCT
admet-331	716	5	2008	2008	NUM
admet-331	716	6	)	)	PUNCT
admet-331	716	7	4177–4187	4177–4187	NUM
admet-331	716	8	.	.	PUNCT
admet-331	717	1	[	[	X
admet-331	717	2	93	93	NUM
admet-331	717	3	]	]	PUNCT
admet-331	717	4	k.	k.	PROPN
admet-331	717	5	yamamoto	yamamoto	PROPN
admet-331	717	6	,	,	PUNCT
admet-331	717	7	k.	k.	PROPN
admet-331	717	8	maruyama	maruyama	PROPN
admet-331	717	9	,	,	PUNCT
admet-331	717	10	n.	n.	PROPN
admet-331	717	11	himori	himori	PROPN
admet-331	717	12	,	,	PUNCT
admet-331	717	13	k.	k.	PROPN
admet-331	717	14	omodaka	omodaka	PROPN
admet-331	717	15	,	,	PUNCT
admet-331	717	16	y.	y.	PROPN
admet-331	717	17	yokoyama	yokoyama	PROPN
admet-331	717	18	,	,	PUNCT
admet-331	717	19	y.	y.	PROPN
admet-331	717	20	shiga	shiga	PROPN
admet-331	717	21	,	,	PUNCT
admet-331	717	22	et	et	PROPN
admet-331	717	23	al	al	PROPN
admet-331	717	24	.	.	PROPN
admet-331	717	25	,	,	PUNCT
admet-331	717	26	invest	invest	VERB
admet-331	717	27	.	.	PUNCT
admet-331	718	1	ophthalmol	ophthalmol	PROPN
admet-331	718	2	.	.	PUNCT
admet-331	719	1	vis	vis	X
admet-331	719	2	.	.	PUNCT
admet-331	720	1	sci	sci	PROPN
admet-331	720	2	.	.	PROPN
admet-331	721	1	55	55	NUM
admet-331	721	2	(	(	PUNCT
admet-331	721	3	2014	2014	NUM
admet-331	721	4	)	)	PUNCT
admet-331	721	5	7126–7136	7126–7136	NUM
admet-331	721	6	.	.	PUNCT
admet-331	722	1	[	[	X
admet-331	722	2	94	94	NUM
admet-331	722	3	]	]	X
admet-331	722	4	a.	a.	NOUN
admet-331	722	5	m.	m.	NOUN
admet-331	722	6	fontainhas	fontainhas	PROPN
admet-331	722	7	,	,	PUNCT
admet-331	722	8	e.	e.	PROPN
admet-331	722	9	townes	townes	PROPN
admet-331	722	10	-	-	PUNCT
admet-331	722	11	anderson	anderson	PROPN
admet-331	722	12	,	,	PUNCT
admet-331	722	13	invest	invest	VERB
admet-331	722	14	.	.	PUNCT
admet-331	723	1	ophthalmol	ophthalmol	PROPN
admet-331	723	2	.	.	PUNCT
admet-331	724	1	vis	vis	X
admet-331	724	2	.	.	PUNCT
admet-331	725	1	sci	sci	PROPN
admet-331	725	2	.	.	PROPN
admet-331	726	1	52	52	NUM
admet-331	726	2	(	(	PUNCT
admet-331	726	3	2011	2011	NUM
admet-331	726	4	)	)	PUNCT
admet-331	727	1	579–587	579–587	NUM
admet-331	727	2	.	.	PUNCT
admet-331	728	1	[	[	X
admet-331	728	2	95	95	X
admet-331	728	3	]	]	PUNCT
admet-331	728	4	p.	p.	NOUN
admet-331	728	5	a.	a.	PROPN
admet-331	728	6	erickson	erickson	PROPN
admet-331	728	7	,	,	PUNCT
admet-331	728	8	s.	s.	PROPN
admet-331	728	9	k.	k.	PROPN
admet-331	728	10	fisher	fisher	PROPN
admet-331	728	11	,	,	PUNCT
admet-331	728	12	d.	d.	PROPN
admet-331	728	13	h.	h.	PROPN
admet-331	728	14	anderson	anderson	PROPN
admet-331	728	15	,	,	PUNCT
admet-331	728	16	w.	w.	PROPN
admet-331	728	17	h.	h.	PROPN
admet-331	728	18	stern	stern	PROPN
admet-331	728	19	,	,	PUNCT
admet-331	728	20	g.	g.	PROPN
admet-331	728	21	a.	a.	NOUN
admet-331	728	22	borgula	borgula	PROPN
admet-331	728	23	,	,	PUNCT
admet-331	728	24	invest	invest	VERB
admet-331	728	25	.	.	PUNCT
admet-331	729	1	ophthalmol	ophthalmol	PROPN
admet-331	729	2	.	.	PUNCT
admet-331	730	1	vis	vis	X
admet-331	730	2	.	.	PUNCT
admet-331	731	1	sci	sci	PROPN
admet-331	731	2	.	.	PROPN
admet-331	731	3	24	24	NUM
admet-331	731	4	(	(	PUNCT
admet-331	731	5	1983	1983	NUM
admet-331	731	6	)	)	PUNCT
admet-331	731	7	927–942	927–942	NUM
admet-331	731	8	.	.	PUNCT
admet-331	732	1	[	[	X
admet-331	732	2	96	96	NUM
admet-331	732	3	]	]	PUNCT
admet-331	732	4	s.	s.	PROPN
admet-331	732	5	k.	k.	PROPN
admet-331	732	6	fisher	fisher	PROPN
admet-331	732	7	,	,	PUNCT
admet-331	732	8	g.	g.	PROPN
admet-331	732	9	p.	p.	PROPN
admet-331	732	10	lewis	lewis	PROPN
admet-331	732	11	,	,	PUNCT
admet-331	732	12	vision	vision	NOUN
admet-331	732	13	res	re	NOUN
admet-331	732	14	.	.	PUNCT
admet-331	733	1	43	43	NUM
admet-331	733	2	(	(	PUNCT
admet-331	733	3	2003	2003	NUM
admet-331	733	4	)	)	PUNCT
admet-331	734	1	887–897	887–897	NUM
admet-331	734	2	.	.	PUNCT
admet-331	735	1	[	[	X
admet-331	735	2	97	97	NUM
admet-331	735	3	]	]	PUNCT
admet-331	735	4	a.	a.	NOUN
admet-331	735	5	m.	m.	NOUN
admet-331	735	6	fontainhas	fontainhas	PROPN
admet-331	735	7	,	,	PUNCT
admet-331	735	8	e.	e.	PROPN
admet-331	735	9	townes	townes	PROPN
admet-331	735	10	-	-	PUNCT
admet-331	735	11	anderson	anderson	PROPN
admet-331	735	12	,	,	PUNCT
admet-331	735	13	invest	invest	VERB
admet-331	735	14	.	.	PUNCT
admet-331	736	1	ophthalmol	ophthalmol	PROPN
admet-331	736	2	.	.	PUNCT
admet-331	737	1	vis	vis	X
admet-331	737	2	.	.	PUNCT
admet-331	738	1	sci	sci	PROPN
admet-331	738	2	.	.	PROPN
admet-331	738	3	49	49	NUM
admet-331	738	4	(	(	PUNCT
admet-331	738	5	2008	2008	NUM
admet-331	738	6	)	)	PUNCT
admet-331	738	7	4177–4187	4177–4187	NUM
admet-331	738	8	.	.	PUNCT
admet-331	739	1	[	[	X
admet-331	739	2	98	98	NUM
admet-331	739	3	]	]	X
admet-331	739	4	w.	w.	PROPN
admet-331	739	5	wang	wang	PROPN
admet-331	739	6	,	,	PUNCT
admet-331	739	7	e.	e.	PROPN
admet-331	739	8	townes	townes	PROPN
admet-331	739	9	-	-	PUNCT
admet-331	739	10	anderson	anderson	PROPN
admet-331	739	11	,	,	PUNCT
admet-331	739	12	invest	invest	VERB
admet-331	739	13	.	.	PUNCT
admet-331	740	1	ophthalmol	ophthalmol	PROPN
admet-331	740	2	.	.	PUNCT
admet-331	741	1	vis	vis	X
admet-331	741	2	.	.	PUNCT
admet-331	742	1	sci	sci	PROPN
admet-331	742	2	.	.	PROPN
admet-331	743	1	56	56	NUM
admet-331	743	2	(	(	PUNCT
admet-331	743	3	2015	2015	NUM
admet-331	743	4	)	)	PUNCT
admet-331	743	5	7847–7858	7847–7858	NUM
admet-331	743	6	.	.	PUNCT
admet-331	744	1	[	[	X
admet-331	744	2	99	99	NUM
admet-331	744	3	]	]	PUNCT
admet-331	744	4	j.	j.	PROPN
admet-331	744	5	wang	wang	PROPN
admet-331	744	6	,	,	PUNCT
admet-331	744	7	m.	m.	PROPN
admet-331	744	8	zarbin	zarbin	PROPN
admet-331	744	9	,	,	PUNCT
admet-331	744	10	i.	i.	PROPN
admet-331	744	11	sugino	sugino	PROPN
admet-331	744	12	,	,	PUNCT
admet-331	744	13	i.	i.	PROPN
admet-331	744	14	whitehead	whitehead	PROPN
admet-331	744	15	,	,	PUNCT
admet-331	744	16	e.	e.	PROPN
admet-331	744	17	townes	townes	PROPN
admet-331	744	18	-	-	PUNCT
admet-331	744	19	anderson	anderson	PROPN
admet-331	744	20	,	,	PUNCT
admet-331	744	21	invest	invest	VERB
admet-331	744	22	.	.	PUNCT
admet-331	745	1	ophthalmol	ophthalmol	PROPN
admet-331	745	2	.	.	PUNCT
admet-331	746	1	vis	vis	X
admet-331	746	2	.	.	PUNCT
admet-331	747	1	sci	sci	PROPN
admet-331	747	2	.	.	PROPN
admet-331	748	1	57	57	NUM
admet-331	748	2	(	(	PUNCT
admet-331	748	3	2016	2016	NUM
admet-331	748	4	)	)	PUNCT
admet-331	748	5	3892	3892	NUM
admet-331	748	6	-	-	SYM
admet-331	748	7	3906	3906	NUM
admet-331	748	8	.	.	PUNCT
admet-331	749	1	[	[	X
admet-331	749	2	100	100	NUM
admet-331	749	3	]	]	PUNCT
admet-331	749	4	m.	m.	NOUN
admet-331	749	5	li	li	PROPN
admet-331	749	6	,	,	PUNCT
admet-331	749	7	y.	y.	PROPN
admet-331	749	8	huang	huang	PROPN
admet-331	749	9	,	,	PUNCT
admet-331	749	10	a.	a.	PROPN
admet-331	749	11	a.	a.	PROPN
admet-331	749	12	k.	k.	PROPN
admet-331	749	13	ma	ma	PROPN
admet-331	749	14	,	,	PUNCT
admet-331	749	15	e.	e.	PROPN
admet-331	749	16	lin	lin	PROPN
admet-331	749	17	,	,	PUNCT
admet-331	749	18	m.	m.	NOUN
admet-331	749	19	i.	i.	PROPN
admet-331	749	20	diamond	diamond	PROPN
admet-331	749	21	,	,	PUNCT
admet-331	749	22	neurobiol	neurobiol	PROPN
admet-331	749	23	.	.	PUNCT
admet-331	750	1	dis	dis	PROPN
admet-331	750	2	.	.	PUNCT
admet-331	751	1	36	36	NUM
admet-331	751	2	(	(	PUNCT
admet-331	751	3	2009	2009	NUM
admet-331	751	4	)	)	PUNCT
admet-331	752	1	413–420	413–420	NUM
admet-331	752	2	.	.	PUNCT
admet-331	753	1	admet	admet	PROPN
admet-331	753	2	&	&	CCONJ
admet-331	753	3	dmpk	dmpk	PROPN
admet-331	753	4	4(4	4(4	NUM
admet-331	753	5	)	)	PUNCT
admet-331	753	6	(	(	PUNCT
admet-331	753	7	2016	2016	NUM
admet-331	753	8	)	)	PUNCT
admet-331	753	9	280	280	NUM
admet-331	753	10	-	-	SYM
admet-331	753	11	301	301	NUM
admet-331	753	12	rock	rock	NOUN
admet-331	753	13	inhibitors	inhibitor	NOUN
admet-331	753	14	in	in	ADP
admet-331	753	15	ocular	ocular	ADJ
admet-331	753	16	disease	disease	NOUN
admet-331	753	17	doi	doi	NOUN
admet-331	753	18	:	:	PUNCT
admet-331	753	19	10.5599	10.5599	NUM
admet-331	753	20	/	/	SYM
admet-331	753	21	admet.4.4.331	admet.4.4.331	PROPN
admet-331	753	22	301	301	NUM
admet-331	753	23	[	[	X
admet-331	753	24	101	101	NUM
admet-331	753	25	]	]	PUNCT
admet-331	753	26	m.	m.	NOUN
admet-331	753	27	li	li	PROPN
admet-331	753	28	,	,	PUNCT
admet-331	753	29	d.	d.	PROPN
admet-331	753	30	yasumura	yasumura	PROPN
admet-331	753	31	,	,	PUNCT
admet-331	753	32	a.	a.	NOUN
admet-331	753	33	a.	a.	PROPN
admet-331	753	34	k.	k.	PROPN
admet-331	753	35	ma	ma	PROPN
admet-331	753	36	,	,	PUNCT
admet-331	753	37	m.	m.	NOUN
admet-331	753	38	t.	t.	PROPN
admet-331	753	39	matthes	matthes	PROPN
admet-331	753	40	,	,	PUNCT
admet-331	753	41	h.	h.	PROPN
admet-331	753	42	yang	yang	PROPN
admet-331	753	43	,	,	PUNCT
admet-331	753	44	g.	g.	PROPN
admet-331	753	45	nielson	nielson	PROPN
admet-331	753	46	,	,	PUNCT
admet-331	753	47	et	et	PROPN
admet-331	753	48	al	al	PROPN
admet-331	753	49	.	.	PROPN
admet-331	753	50	,	,	PUNCT
admet-331	753	51	plos	plos	PROPN
admet-331	753	52	one	one	NUM
admet-331	753	53	8	8	NUM
admet-331	753	54	(	(	PUNCT
admet-331	753	55	2013	2013	NUM
admet-331	753	56	)	)	PUNCT
admet-331	753	57	1–8	1–8	X
admet-331	753	58	.	.	PUNCT
admet-331	754	1	[	[	X
admet-331	754	2	102	102	NUM
admet-331	754	3	]	]	X
admet-331	754	4	v.	v.	CCONJ
admet-331	754	5	gupta	gupta	PROPN
admet-331	754	6	,	,	PUNCT
admet-331	754	7	n.	n.	PROPN
admet-331	754	8	gupta	gupta	PROPN
admet-331	754	9	,	,	PUNCT
admet-331	754	10	i.	i.	PROPN
admet-331	754	11	h.	h.	PROPN
admet-331	754	12	shaik	shaik	PROPN
admet-331	754	13	,	,	PUNCT
admet-331	754	14	r.	r.	PROPN
admet-331	754	15	mehvar	mehvar	PROPN
admet-331	754	16	,	,	PUNCT
admet-331	754	17	i.	i.	PROPN
admet-331	754	18	f.	f.	PROPN
admet-331	754	19	mcmurtry	mcmurtry	PROPN
admet-331	754	20	,	,	PUNCT
admet-331	754	21	m.	m.	NOUN
admet-331	754	22	oka	oka	PROPN
admet-331	754	23	,	,	PUNCT
admet-331	754	24	et	et	PROPN
admet-331	754	25	al	al	PROPN
admet-331	754	26	.	.	PROPN
admet-331	754	27	,	,	PUNCT
admet-331	754	28	j.	j.	PROPN
admet-331	754	29	control	control	PROPN
admet-331	754	30	.	.	PUNCT
admet-331	755	1	release	release	VERB
admet-331	755	2	167	167	NUM
admet-331	755	3	(	(	PUNCT
admet-331	755	4	2013	2013	NUM
admet-331	755	5	)	)	PUNCT
admet-331	755	6	189–199	189–199	NUM
admet-331	755	7	.	.	PUNCT
admet-331	756	1	[	[	X
admet-331	756	2	103	103	NUM
admet-331	756	3	]	]	X
admet-331	756	4	k.	k.	PROPN
admet-331	756	5	nahar	nahar	PROPN
admet-331	756	6	,	,	PUNCT
admet-331	756	7	s.	s.	PROPN
admet-331	756	8	absar	absar	PROPN
admet-331	756	9	,	,	PUNCT
admet-331	756	10	n.	n.	PROPN
admet-331	756	11	gupta	gupta	PROPN
admet-331	756	12	,	,	PUNCT
admet-331	756	13	v.	v.	PROPN
admet-331	756	14	r.	r.	PROPN
admet-331	756	15	kotamraju	kotamraju	PROPN
admet-331	756	16	,	,	PUNCT
admet-331	756	17	i.	i.	PROPN
admet-331	756	18	f.	f.	PROPN
admet-331	756	19	mcmurtry	mcmurtry	PROPN
admet-331	756	20	,	,	PUNCT
admet-331	756	21	m.	m.	NOUN
admet-331	756	22	oka	oka	PROPN
admet-331	756	23	,	,	PUNCT
admet-331	756	24	et	et	PROPN
admet-331	756	25	al	al	PROPN
admet-331	756	26	.	.	PROPN
admet-331	756	27	,	,	PUNCT
admet-331	756	28	mol	mol	PROPN
admet-331	756	29	.	.	PUNCT
admet-331	756	30	pharm	pharm	PROPN
admet-331	756	31	.	.	PUNCT
admet-331	757	1	11	11	NUM
admet-331	757	2	(	(	PUNCT
admet-331	757	3	2014	2014	NUM
admet-331	757	4	)	)	PUNCT
admet-331	757	5	4374–4384	4374–4384	NUM
admet-331	757	6	.	.	PUNCT
admet-331	758	1	[	[	X
admet-331	758	2	104	104	X
admet-331	758	3	]	]	X
admet-331	758	4	w.	w.	PROPN
admet-331	758	5	wang	wang	PROPN
admet-331	758	6	,	,	PUNCT
admet-331	758	7	e.	e.	PROPN
admet-331	758	8	townes	townes	PROPN
admet-331	758	9	-	-	PUNCT
admet-331	758	10	anderson	anderson	PROPN
admet-331	758	11	,	,	PUNCT
admet-331	758	12	neural	neural	ADJ
admet-331	758	13	regen	regen	PROPN
admet-331	758	14	.	.	PUNCT
admet-331	759	1	res	re	NOUN
admet-331	759	2	.	.	PROPN
admet-331	760	1	11	11	NUM
admet-331	760	2	(	(	PUNCT
admet-331	760	3	2016	2016	NUM
admet-331	760	4	)	)	PUNCT
admet-331	760	5	1029	1029	NUM
admet-331	760	6	-	-	SYM
admet-331	760	7	1032	1032	NUM
admet-331	760	8	.	.	PUNCT
admet-331	761	1	©	©	PROPN
admet-331	761	2	2016	2016	NUM
admet-331	761	3	by	by	ADP
admet-331	761	4	the	the	DET
admet-331	761	5	authors	author	NOUN
admet-331	761	6	;	;	PUNCT
admet-331	761	7	licensee	licensee	PROPN
admet-331	761	8	iapc	iapc	PROPN
admet-331	761	9	,	,	PUNCT
admet-331	761	10	zagreb	zagreb	PROPN
admet-331	761	11	,	,	PUNCT
admet-331	761	12	croatia	croatia	PROPN
admet-331	761	13	.	.	PUNCT
admet-331	762	1	this	this	DET
admet-331	762	2	article	article	NOUN
admet-331	762	3	is	be	AUX
admet-331	762	4	an	an	DET
admet-331	762	5	open	open	ADJ
admet-331	762	6	-	-	PUNCT
admet-331	762	7	access	access	NOUN
admet-331	762	8	article	article	NOUN
admet-331	762	9	distributed	distribute	VERB
admet-331	762	10	under	under	ADP
admet-331	762	11	the	the	DET
admet-331	762	12	terms	term	NOUN
admet-331	762	13	and	and	CCONJ
admet-331	762	14	conditions	condition	NOUN
admet-331	762	15	of	of	ADP
admet-331	762	16	the	the	DET
admet-331	762	17	creative	creative	ADJ
admet-331	762	18	commons	common	NOUN
admet-331	762	19	attribution	attribution	NOUN
admet-331	762	20	license	license	NOUN
admet-331	762	21	(	(	PUNCT
admet-331	762	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-331	762	23	)	)	PUNCT
admet-331	762	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN